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Abstract 
Silicate ester prodrugs are a novel family of labile prodrugs by which both 
physical (i.e., solubility) and chemical (i.e., rates of hydrolysis back to the parent 
drug) characteristics may be easily tuned.  Block co-polymers of well-defined 
composition, namely poly(ethylene glycol)-b-poly(lactic-co-glycolic acid) (PEG-b-
PLGA), were synthesized to serve as the drug carrier.  These innovative drugs 
and FDA approved polymers have been effectively coupled with a formulation 
technique known as flash nanoprecipitation (FNP).  FNP of a selected silicate 
ester prodrug of paclitaxel and PEG-b-PLGA yields nanoparticles of ca. 120 nm 
diameter and consisting of ca. 50 wt% of the paclitaxel silicate prodrug.  An MDA-
MB-231 (breast cancer) cell culture assay was used to demonstrate in vitro 
efficacy of both taxane silicate prodrugs themselves as well as the loaded 
nanoparticles from FNP.  Upon administration to tumor-bearing mice the silicate 
prodrugs hydrolyze in the tumor microenvironment, thereby releasing the 
cytotoxic parent drug. Tumor size was monitored via bioluminescence, and the 
silicate prodrug-containing nanoparticles showed statistically equivalent efficacy 
(and minimal associated side effects) when compared to equivalent dosings of 
the commercially used Taxol® and Abraxane®. 
The silicate chemistry is not specific to the taxane family of drugs.  In the 
second part of thesis I will present recent findings on this front.  The scope of the 
functional groups selected was based upon the availability of the drugs and the 
novelty of the subsequent silicate functionalization.  The general background of 
each drug and utility will also be discussed.  Finally, in the last section of this 
thesis, efforts towards the utilization of silicates in the hexadehydro-Diels-Alder 
(HDDA) reaction are presented. 
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1.1. Cancer Patient Outlook and Statistics 
Cancer is the second most frequent cause of death in the United States, 
trailing heart disease by only 4%.1  Without belaboring the prevalence of the 
disease in a variety of tissues, an excerpt of a lengthy table from the American 
Cancer Society is shown in Table 1.1 below.  The estimated number of new 
cancer cases and the number of deaths for 2014 is broken down by sex and 
cancer type.  In the column next to the total number of cases and deaths, the 
percentage of the particular type of cancer is calculated in comparison to all sites.  
From this data, one can quickly see that breast cancer in women is the most 
prominent of all cancer types.  Fortunately, breast cancer is not the leading cause 
of deaths for patients with any form of cancer. Also highlighted in Table 1.1, lung 
cancer is the second most common cancer in both men and woman, and also the 
leading cause for cancer deaths. 
Table 1.1 | Cancer statistics [new cases and estimated deaths, US, 2014].1 
 
                                            
1  Siegel, R.; Naishadham, D. Cancer Statistics, 2014. CA Cancer J. Clin. 2014, 64, 9-29. 
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Estimated New Cases Estimated Deaths
Male
855,220
Female
810,320
Total
1,665,540
Male
310,010
Female
275,710
Total
585,720
Breast
Prostate
Lung & bronchus
Colon & rectum
Urinary bladder
Melanoma of the skin
Kidney & renal pelvis
Non-Hodgkin lymphoma
Oral cavity & pharynx
Thyroid
Leukemia
Pancreas
Liver & intrahepatic bile duct
Esophagus
Ovary
Uterine corpus
Brain & other nervous system
235,030
233,000
224,210
136,830
74,690
76,100
63,920
70,800
42,440
62,980
52,380
46,420
33,190
18,170
21,980
52,630
23,380
2,360
233,000
116,000
71,830
56,390
43,890
39,140
38,270
30,220
15,190
30,100
23,530
24,600
14,660
–
–
12,820
232,670
–
108,210
65,000
18,300
32,210
24,780
32,530
12,220
47,790
22,280
22,890
8,590
3,510
21,980
52,630
10,560
430
29,480
86,930
26,270
11,170
6,470
8,900
10,470
5,730
830
14,040
20,170
15,870
12,450
–
–
8,090
40,000
–
72,330
24,040
4,410
3,240
4,960
8,520
2,660
1,060
10,050
19,420
7,130
3,000
14,270
8,590
6,230
40,430
29,480
159,260
50,310
15,580
9,710
13,860
18,990
8,390
1,890
24,090
39,590
23,000
15,450
14,270
8,590
14,320
All Sites
0.3%
27%
14%
8%
7%
5%
5%
4%
4%
2%
4%
3%
3%
2%
–
–
1%
29%
–
13%
8%
2%
4%
3%
4%
2%
6%
3%
3%
1%
0%
3%
6%
1%
14%
14%
13%
8%
4%
5%
4%
4%
3%
4%
3%
3%
2%
1%
1%
3%
1%
0.1%
10%
28%
8%
4%
2%
3%
3%
2%
0%
5%
7%
5%
4%
–
–
3%
15%
–
26%
9%
2%
1%
2%
3%
1%
0.4%
4%
7%
3%
1%
5%
3%
2%
7%
5%
27%
9%
3%
2%
2%
3%
1%
0%
4%
7%
4%
3%
2%
1%
2%
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For the purpose of this thesis, we have chosen to focus our studies toward 
breast cancer unless otherwise noted.  It is of interest to us to determine the 
frequency an oncologist turns to chemotherapy when treating a breast cancer 
patient compared to other forms of treatment such as surgery or radiation 
therapy.  The main factor an oncologist is influenced by when prescribing 
treatment is the progression of the disease. 
There are different systems used to diagnose a stage of breast cancer, the 
most elaborate assesses cancers in three ways:  i.) the size of the tumor and its 
growth or incorporation into nearby areas (T), ii.) the occurrence of the tumor to 
regional lymph node (N), and iii.) the metastases (M) of the tumor to distant 
areas.  These three criteria make up the TNM staging system, the most 
commonly used system clinically.  Once each value is determined, collectively a 
stage is diagnosed as I-IV, where stage I is invasive breast cancer and IV is the 
most advanced of the disease.   
Table 1.2 | Female breast cancer treatment patterns by stage, 2008.2 
 
Table 1.2, shown below, describes the cases in which an oncologist turns 
to surgery, radiation therapy, and/or chemotherapy.   Interestingly, the first 
Early Stage
(I and II)
Late Stage
(III and IV)
BCS alone
BCS + RT
BCS + RT + chemo
Mastectomy alone
Mastectomy + chemo
Mastectomy + RT
Mastectomy + RT + chemo
Nonsurgical treatement
No treatment
Total surgical
Total RT
Total chemo
10 %
30 %
17 %
17 %
14 %
1 %
4 %
6 %
1 %
93 %
52 %
35 %
2 %
1 %
10 %
7 %
20 %
2 %
31 %
18 %
7 %
73 %
44 %
61 %
BCS = breast-conserving surgery, RT = radiation therapy, Chemo = chemotherapy and 
may include common targeted therapies.  Totals may not sum to 100 % due to rounding
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treatment prescribed is surgery but as the disease progresses the oncologist 
turns to chemotherapy in hopes to remedy any metastases.2 
Due to the necessity of chemotherapy to treat breast cancer, it is of great 
interest to develop brand new anticancer agents, to improve upon the outcome of 
chemotherapy.  Also, the development of sophisticated drug delivery vehicles of 
current chemotherapeutics has the potential to both mitigate side effects and 
enhance the therapeutic outcome. 
 
1.2. Challenges of Chemotherapeutic Drug Delivery 
Chemistry allows for the creation of “custom” small molecule drugs, which 
can be tuned at will to alter the physiochemical properties to achieve the desired 
biological effect.  The synthesis of a family of related drugs gives the chemist a 
clear picture of what can be altered on the pharmacophore of the drug while 
maintaining activity and gives an understanding of the structure activity 
relationship of the drug.  Through enough iterations of small changes on the drug 
an optimum candidate is developed, but some side effects can still linger.  It is 
worth mentioning that through an infinite number of small changes a discrete 
small molecule could be developed to achieve the desired biological effect 
without any undesirable side effects.  To mitigate some of the side effects 
associated, as well as bypassing a poor physical property with these drugs 
(water solubility), the notion of packing these toxic molecules in a well-defined 
delivery vehicle has come to the forefront of anti-cancer research.  
Developments in polymer chemistry allows for the synthesis of well-
defined macromolecules, which can be used as the drug delivery vehicle.  More 
specifically the polymerization of biocompatible polyesters from a water-soluble 
                                            
2  Siegel, R.; Naishadham, D. Cancer Statistics, 2012. CA Cancer J. Clin. 2012, 62, 10-29. 
[National Cancer Database, American College of Surgeons Commission on Cancer, 2008 Data 
Submission.] 
Part I: Anticancer Drug Delivery  Chapter 1 | 
 
 
4 
4 
polymer initiator is an excellent drug delivery system for many anti-cancer 
agents.  If the carrier macromolecule does not aid in the biological performance 
of the drug it is referred to as an excipient.  Recent advances in placing a tumor-
targeting agent on the delivery system has shown to enhance the effectiveness 
of the excipient performance, much a kin to the use of a zip code in our own mail 
delivery system.  Due to the arsenal of tools available to a chemist namely: i.) 
Synthesis of tailored small drug molecules, ii.) Polymerization of well defined 
macromolecular drug delivery vehicles, and iii.) Ability to analytically discern the 
effectiveness of combining the two materials, the chemistry is the key to create a 
novel general strategy for the delivery of drugs.  However the creation of the 
system is only one part to the process to birth a new drug formation. 
The creation a new formulation for the delivery of chemotherapeutics 
requires a broad range of expertise due to the monumental tasks of: i.) controlling 
the physical properties of the drug while maintaining the biochemical activitiy ii.) 
creating and optimizing the excipient used to allow for the delivery of the agent 
iii.) determining the efficacy and the overall safety of the formulation.  These 
three tasks require the interdisciplinary approach to make headway in the field of 
drug delivery.  The collaborative effort between chemistry, chemical engineering, 
and pharmaceutics allows for the design and evaluation of the new formulations 
discussed in this thesis. 
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1.3. The Development of Paclitaxel as the Gold Standard 
1.3.1 Paclitaxel Discovery 
The United States Department of Agriculture screened extracts of parts of 
the pacific yew tree, Taxus brevifolia, for anticancer activity against KB cancer 
cells in 1962.  Cytotoxicity was confirmed and expanded upon via in vivo studies 
of mouse leukemia by Wall in 1966.3  Pure paclitaxel (PTX) extracts were later 
isolated in 0.01% yield from the bark and found to be the cytotoxic agent.  
McPhail and co-workers elucidated the structure through degradation strategies 
to reveal the side chain and the 10-deacetylbaccatin III core, also found in a 
similar yew tree species.4  Interest dulled when poor in vivo studies came forth, 
but was revived with the discovery of the unprecedented binding properties of 
PTX by Horwitz in 1979.5  The agent binds to tubulin monomers to promote the 
assembly of microtubules, and this stabilization depletes the necessary tubulin 
concentration required for mitosis.  Eventually the restriction of mitosis leads to 
cell death.6  
Due to the discovery of microtubule stabilization, poor yields of paclitaxel 
obtained from the pacific yew, and promising phase I clinical trials the supply of 
paclitaxel dwindled and new methodology was required to meet the demand for 
paclitaxel.4 Both total and semi synthetic strategies were explored, below some 
notable synthesis are briefly mentioned. 
  
                                            
3 Kingston, D. G. I. Taxol, a Molecule for All Seasons. Chem. Commun.  2001, 10, 867–880. 
4 Kingston, D. G. I. The Shape of Things to Come: Structural and Synthetic Studies of Taxol and 
Related Compounds. Phytochemistry 2007, 68, 1844–1854. 
5 Rao, S.; Orr, G. A.; Chaudhary, A. G.; Kingston, D. G.; Horwitz, S. B. Characterization of the 
Taxol Binding Site on the Microtubule. 2-(M-Azidobenzoyl)Taxol Photolabels a Peptide (Amino 
Acids 217-231) of Beta-Tubulin. J. Biol. Chem. 1995, 270, 20235–20238. 
6 Schiff, P. B.; Fant, J.; Horwitz, S. B. Promotion of Microtubule Assembly in vitro by Taxol. Nature 
1979, 277, 1–3. 
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1.3.2 Notable Synthesis of Paclitaxel 
Potier and coworkers successfully isolated 10-deacetyl-baccatin III from 
the needles of the European yew, T. baccata which does not require harvesting 
the bark of the pacific yew tree. Holton’s semisynthesis from this renewable 
resource helped to create a commercially viable supply, but more research was 
required, to increase the efficiency of the synthesis.7,8 The final step of this 
synthesis protected the 7-hydroxyl of 102a as a triethylsilyl (TES) ether (102b), 
which was then coupled as the lithium alkoxide to the β-lactam 101 as shown in 
Scheme 1.1.7  
Scheme 1.1 | Holton’s semisynthesis from 10-deacetyl-baccatin III.3  
 
 
Holton also developed the first total synthesis of PTX from the natural 
product ß-patchoulene oxide.  His synthesis is relatively short (~37 steps) due to 
the wise choice of this complex starting material.9 
  
                                            
7 Holton, R. Semi-synthesis of Taxane Derivatives using Metal Alkoxides and Oxazinones. U.S. 
Patent 5, 254, 703, October 19, 1993. 
8 Patel, R. Tour De Paclitaxel: Biocatalysis for Semisynthesis. Annu. Rev. Microbiol. 1998, 98, 
361-395. 
9 Holton, R. A.; Kim, H. B.; Somoza, C.; Liang, F.; Biediger, R. J.; Boatman, P. D.; Shindo, M.; 
Smith, C. C.; Kim, S. First Total Synthesis of Taxol. 2. Completion of the C and D Rings. J. Am. 
Chem. Soc. 1994, 116, 1599–1600. 
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Nearly simultaneously, Nicolaou published an elegant total syntheis in 
1994 (highlights are shown in Scheme 1.2).10 This convergent synthesis utilizes 
the two advanced intermediates 104 and 107, both made via Diels-Alder 
transformations from starting materials 103 and 105/106 respecivielty.  These 
compounds underwent a Shapiro coupling to yield 108, followed by a McMurry 
coupling (108 to 109) to achieve the baccatin core 109, which was further 
derivitized to yield the baccatin III analogue.  From the baccatin III bioprecursor 
110, an allylic oxidation and sodium borohydride reduction gave compound 102.  
Holton’s semisynthetic approach (cf. Scheme 1.1) was then used to synthesize 
paclitaxel. 
Though both of these studies expanded the scope of synthetic 
methodology, neither was industrially useful to meet the current demand.  A plant 
cell fermentation (PCF) process developed by Bristol-Myers Squibb (BMS) along 
with the late stage semisynthetic methodology of Holton are utilized to create a 
large supply of the chemotherapeutic agent.11  
  
                                            
10 Nicolaou, K. C.; Yang, Z.; Liu, J. J.; Ueno, H.; Nantermet, P. G.; Guy, R. K.; Claiborne, C. F.; 
Renaud, J.; Couladouros, E. A.; Paulvannan, K. Total Synthesis of Taxol. Nature 1994, 367, 630–
634. 
11 Venkat, K. In Pure Appl. Chem., Proceedings of the International Conference on Biodiversity 
and Bioresources, (Phuket), Thialand, November 23-27, 1997. 
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Scheme 1.2 | Nicolaou’s key intermediates en route of the total synthesis of 
paclitaxel.3,10 
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1.3.3 Chemical Derivatization of Paclitaxel  
To generate analogues or prodrugs of PTX, a full understanding of the 
chemical reactivity of the molecules needs to be defined.  Kingston was the initial 
investigator to examine the reactivity of PTX to a variety of conditions, which is 
presented in a clockwise fashion in Scheme 1.3.  Kingston fist looked at the 
oxidation of the three alcohols present in PTX.12  Initial attempts to oxidize the C-
7 hydroxyl to the ketone, involved protecting the C-2’ hydroxyl as an ester, 
followed by deprotection.  However, when the C-2’ hydroxyl was successfully 
protected as the acetate ester, they had difficulty removing it following the 
oxidation at C-7.12 Instead of protecting the C-2’ hydroxyl; when PTX alone is 
reacted with Jones reagent, the C-7 hydroxyl oxidizes cleanly to the C-7 oxo-
derivative 111 shown in Scheme 1.3. The Kingston group could also oxidize the 
C-2’ position, however an excess of the Jones reagent and prolonged reaction 
times were required.  They ultimately conclude that the C-2’ secondary-alcohol is 
less reactive due to its alpha position to carbonyl (C-1’). 
Lastly, from the C-7 oxo-PTX 111 they were able to open up the oxetane 
ring by treatment with 1,8-diazabicyclo[5.4.0]-undec-7-ene (DBU) to form 112. 
Attempts were made with mild aqueous bases, however without the basicity of 
DBU the reactions lead to a mixture of products.12 The seco-PTX derivative 112 
was of great interest to probe the importance of the conformationally-rigid 
oxetane ring on the biological activity.  All attempts to reduce the C-7 ketone of 
112, provided complex mixtures due to the reactivity of the other functional 
groups present in 112. 
Derivatives at C-13 are desirable to probe the side chain bioactivity of 
PTX.  Researchers could capitalize on the semi-synthesis of Holton by reacting 
baccatin III with a variety of β-lactams (c.f. Scheme 1.1) to install different C-13 
side chains, however the baccatin III precursor is isolated in a low yield from the 
                                            
12 Magri, N. F.; Kingston, D. G. I. Modified Taxols. 2. Oxidation Products of Taxol. J. Org. Chem. 
1986, 51, 797–802. 
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pacific yew tree needles. 13  The Kingston group experimented with PTX to 
determine the lability of the C-13 ester linkage to obtain baccatin III (116, 
Scheme 1.3).  Initial attempts at solvolysis of PTX with sodium isopropoxide in 
isopropanol yielded a mixture of the desired baccatin III (116) and the epimer 
baccatin V (115) as well as the cleaved side chain to give carboxylic acid 113.  If 
the reaction was allowed to react for an extended time, more of the baccatin V 
(115) was obtained, so they abandoned this route.14 
Interestingly, the Kingston group showed that the C-13 side chain could be 
reductively cleaved when PTX is reacted with a borohydride reagent.  Upon 
further optimization of the reducing agent, they found that tetrabutylammonium 
borohydride produced a 97% yield of baccatin III (116), a minor amount of 115, 
and the diol 114.  Isolation of the diol 114 proved that the cleavage occurs 
reductively and not through hydrolysis of the ester.  They conclude that the C-2’ 
hydroxyl at the α position is required for the reductive cleavage, which also 
shows the enhanced lability compared to the C-2, C-4, and C-10 esters.  To 
further prove this assistance of the C-2’ hydroxyl, the reductive cleavage at C-13 
did not occur when the C-2’ was acetylated.  Lastly, baccatin III (116) was 
acetylated with excess acetic anhydride (AcO2), pyridine (py), and 4-
(dimethylamino)pyridine (DMAP) to give the C-7 mono-acetylated product 117 
first, followed by the C-13 and C-7 bis-acetylated product 118 when heat was 
applied to the reaction.  Not only did this experiment settle the contradictory 
reactivity differences that two different groups reported, it showed that the C-7 
hydroxyl is more nucleophilic than the C-13 hydroxyl and must be protected to 
install a different side chain at C-13.14 
Attempts at epimerization of the C-2’ methine of PTX proved challenging.13 
They first protected both of the reactive hydroxyls with 2,2,2-trichloroethyl 
                                            
13 Magri, N. F.; Kingston, D. G. Modified Taxols, 4. Synthesis and Biological Activity of Taxols 
Modified in the Side Chain. J. Nat. Prod. 1988, 51, 298–306. 
14 Magri, N. F.; Kingston, D. G. I.; Jitrangsri, C.; Piccariello, T. Modified Taxols. 3. Preparation and 
Acylation of Baccatin III. J. Org. Chem. 1986, 51, 3239–3242. 
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chloroformate (119) to give them the bis-trichloroethylcarbonates of PTX, namely 
PTX-2’,7-[COOCH2CCl3]2 (120).  Unfortunately, treatment of 120 with DBU did 
not epimerize the more reactive methine at C-2’, instead deprotonation of the 
amide at C-3’ occurred.  The resulting amide anion at C-3’ cyclized onto the 
carbonate and elimination of 2,2,2-trichloroethan-1-ol gave the oxazolidinone 
derivative of PTX.  Removal of the protecting group at C-7 with zinc dust and 
acetic acid afforded analogue 121.  Although interesting in structure, the 
compound was inactive in the KB cancer cells showing a cytotoxicity that was 
20,000 fold less potent when compared with PTX.13 
The Kingston lab also looked at the nuceophilic character of PTX by 
reacting it with four electrophilic reagents.15  When reacted with acetyl chloride, 
surprisingly they obtained drastically rearranged product.  To probe the structure, 
systematic studies were conducted. 
The bis-protection of PTX was achieved by reacting with excess 
triethylsilyl chloride (TES–Cl) and imidazole (imid.) to obtain the PTX-2’,7-
[Si(Et)3]2 compound (not shown).  After isolation, the C-1 hydroxyl was converted 
to the mesylate by the reaction with methanesulfonyl chloride (Ms–Cl) and 
triethylamine (TEA) at -15 ˚C.  Upon warming to 0 ˚C, an elimination occurred 
through a rearrangement of the A-ring of PTX which gave 122a. Deprotection of 
the silylethers using pyridinium floride gave the skeleton 122b. The 1H-NMR of 
this rearranged product matched with the A-ring protons when PTX was reacted 
with acetylchloride, however there was significant difference in the spectrum at 
the oxetane ring.  Interestingly, the tubulin depolymerization protein assay of 122 
showed only a 3-fold decrease in potency compared to PTX.  However like 121, 
when the compound was exposed to the entire cell (KB cell culture assay) it 
showed that rearranged product 122 was not cytotoxic.15 
                                            
15 Samaranayake, G.; Magri, N. F.; Jitrangsri, C.; Kingston, D. G. I. Modified Taxols. 5. Reaction 
of Taxol with Electrophilic Reagents and Preparation of a Rearranged Taxol Derivative with 
Tubulin Assembly Activity. J. Org. Chem. 1991, 56, 5114–5119. 
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Scheme 1.3 | Synthetic transformations of PTX from “modified taxols by David 
G. I. Kingston.”12,13,14,15 
 
To explore the fate of the oxetane ring under the acetyl chloride 
conditions, PTX was reacted with Meerwein’s salt (triethyloxonium 
tetrafluoroborate) to afford the ring opened and rearranged product 124.  They 
hypothesize the product arises through the alkylation of the oxetane ring to the 
oxonium ion, participation of the neighboring acetoxy group to form the ortho-
ester that upon hydrolysis in acidic media cleanly gives 124.  The 1H-NMR shifts 
matched closely with their acetyl chloride conditions. This ring opened derivative 
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124 showed essentially no activity in either the tubulin depolymerization or the in 
vitro assay.15 The mildest set of conditions for the reaction of PTX with an 
electrophilic reagent (zinc bromide in methanol) epimerized the C-7 hydroxyl and 
also deacetylated the C-10 position to gave 125 as the major compound (likely 
through solvolysis with methanol).  The epimer retained cytotoxicity when 
compared to PTX.15 
To understand the role of the C-7 hydroxyl for the biological activity of 
PTX, the Kingston group removed it.  A mono-protection at the C-2’ hydroxyl of 
PTX was quantitatively accomplished with TES-Cl and imidazole.  Treatment of 
the mono-silyl protected PTX with sodium hydride (NaH) followed by an excess 
of the carbon disulfide (CS2) and methyliodide (MeI) yielded a S-methyl xanthate 
which could be removed through radical chemistry pioneered by Barton.  The S-
methyl xanthate of PTX was removed by tributyltin initiated by azobis-
isobutyronitrile (AIBN) at 75 ˚C.  Deprotection of the C-2’ silyl ether with dilute 
acid yieled the C-7 deoxypaclitaxel 123.  The deoxy-PTX 123 was found to be 
more cytotoxic than that of the PTX by 40 fold in the P-388 leukemia cell assay.  
This suggests that the C-7 hydroxyl is not required to retain biological activity.16 
Kingston also explored the use of water soluble prodrugs,17 a method for 
seperating PTX from other Taxane analogues,18 the Deacylation and Reacylation 
of Baccatin III,19 and the use of 7-substituted photoaffinity analogues of PTX.20,21 
                                            
16 Chaudhary, A. G.; Rimoldi, J. M.; Kingston, D. G. I. Modified Taxols. 10. Preparation of 7-
Deoxytaxol, a Highly Bioactive Taxol Derivative, and Interconversion of Taxol and 7-Epi-Taxol. J. 
Org. Chem. 1993, 58, 3798–3799. 
17 Zhao, Z.; Kingston, D. G. I.; Crosswell, A. R. Modified Taxols, 6. Preparation of Water-Soluble 
Prodrugs of Taxol. J. Nat. Prod. 1991, 54, 1607–1611. 
18 Kingston, D. G.; Gunatilaka, A. A.; Ivey, C. A. Modified Taxols, 7. a Method for the Separation 
of Taxol and Cephalomannine. J. Nat. Prod. 1992, 55, 259–261. 
19 Samaranayake, G.; Neidigh, K. A.; Kingston, D. G. Modified Taxols, 8. Deacylation and 
Reacylation of Baccatin III. J. Nat. Prod. 1993, 56, 884–898. 
20 Rimoldi, J. M.; Kingston, D. G.; Chaudhary, A. G.; Samaranayake, G.; Grover, S.; Hamel, E. 
Modified Taxols, 9. Synthesis and Biological Evaluation of 7-Substituted Photoaffinity Analogues 
of Taxol. J. Nat. Prod. 1993, 56, 1313–1330. 
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All of which lead to a firm understanding of the structure activity relationship of 
PTX summarized below. 
1.3.4 Structure Activity Relationship 
The total synthesis of paclitaxel showed the power of synthetic organic 
chemistry and also provided intermediate compounds, which were evaluated for 
activity against cancer cells.  All of the insight gained from the total syntheses of 
PTX, derivatization studies, and activity studies of the intermediates led to an 
understanding of the drug’s structure activity relationship (SAR).3 The most 
relevant observations from the SAR studies are described in (Figure 1.1). 
The structure consists of a complex fused ring system and an amide tail, 
both of which are important for cytotoxicity.  The oxetane ring creates rigidity in 
the rest of the PTX structure and causes the C-4 position acetate to be in the 
proper orientation to serve as a hydrogen bond acceptor to the tubulin protein. 
The C-7 oxygen is not critical for activity, but swapping it for a larger atom greatly 
reduces the potency.3,16 A tight non-covalent binding of PTX to the protein is 
essential for any activity, the two accessible hydroxyl groups located at the 2’ and 
7 positions on the molecule have a varying tolerance for modification, due steric 
space available (C-7 hydroxyl) or for hydrogen bonding (C-2’ hydroxyl). Alteration 
of the 7-position hydroxyl has shown that the activity remains when esterified 
with a small group, epimerized, or even removed. The 2’-hydroxyl, the most 
reactive of the three hydroxyls, shows very little tolerance to retain activity once 
modified. Interestingly, acetylation of the 2’-hydroxyl shows similar activity to the 
parent suggesting that the small analogues at the 2’ position can be made as 
long as there is steric space and the electronics allow for hydrogen binding to the 
                                                                                                                                  
21 Kingston, D. G. I.; Jagtap, P. G.; Yuan, H.; Samala, L. The Chemistry of Taxol and Related 
Taxoids. Progress in the Chemistry of Organic Natural Products; Springer Vienna: Vienna, 2002, 
84, 53–225. 
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protein. 22  The functionalities highlighted in green can be altered without a 
significant loss in activity, and in many cases improves the potency.  By utilizing 
the SAR, derivatives have been created in attempts to boost or alter activity, 
stability, solubility, absorption, distribution, metabolism, and excretion. 
 
Figure 1.1 | The structure activity relationship of paclitaxel (adapted from ref. 3,4) 
 
1.3.5 Paclitaxel Analogues 
Many researches have developed analogues of paclitaxel by utilizing the 
information gained during the detailed the SAR experiments.  The most 
successful analogue is the closely related compound docetaxel (DTX).  Building 
off of Holton’s semisynthesis (cf., Scheme 1.1), 102 is protected and esterified 
with a highly functionalized side chain.  After the selective deprotection of both 
benzyl groups and subsequent Boc protection of the resulting free amine, DTX is 
synthesized in good yield (Figure 1.2).23 This synthetic analogue improves upon 
the poor hydrophilicity found in PTX by swapping the benzoyl group for the 
                                            
22 Snyder, J. P.; Nettles, J. H.; Cornett, B.; Downing, K. H.; Nogales, E. The Binding Conformation 
of Taxol in Beta-Tubulin: a Model Based on Electron Crystallographic Density. Proc. Natl. Acad. 
Sci. U.S.A. 2001, 98, 5312–5316. 
23 Sisti, N. Method for Docetaxel Synthesis. U.S. Patent 5,688,977, November 18, 1997. 
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butoxycarbonyl at the C-3’ nitrogen and removing the acetyl at C-10.24 This 
compound is currently formulated and given clinically as Taxotere® which will be 
discussed in Chapter 1.4. 
A less developed analogue of PTX, (BMS-184476) 126, utilizes a thio-
methyl ether at the C-7 hydroxyl position which has been shown to improve 
cytotoxicity and overcomes drug resistance in multiple cell lines.25 The derivative 
126 can be synthesized in three steps from PTX.  First a TES protection of the C-
2’ hydroxyl is required; then treatment with methylthiomethyl ether and 
deprotection of the TES ether provides BMS-184476 (126) in good yield.26  
 
Figure 1.2 | Synthetic taxane analogues that are in the clinic or in clinical trials. 
 
1.3.6 Second Generation and Beyond: Derivatives of Paclitaxel 
The brief set of paclitaxel analogues shown in chapter 1.3.4 contain minor 
variations to the paclitaxel pharmacophore and are currently used in the clinic or 
are in clinical trials.  Later generations of PTX derivatives have been developed 
                                            
24 Sparreboom, A.; van Tellingen, O.; Nooijen, W. J.; Beijnen, J. H. Preclinical Pharmacokinetics 
of Paclitaxel and Docetaxel. Anti-cancer Drugs 1998, 9, 1-17. 
25 Rose, W.; Fairchild, C.; Lee, F. Y. F. Preclinical Antitumor Activity of Two Novel Taxanes. 
Cancer Chemoth. and Pharm. 2001, 47, 97-105. 
26 Altstadt, T. J.; Fairchild, C. R.; Golik, J.; Johnston, K. A.; Kadow, J. F.; Lee, F. Y.; Long, B. H.; 
Rose, W. C.; Vyas, D. M.; Wong, H.; Wu, M.-J.; Wittman, M. D. Synthesis and Antitumor Activity 
of Novel C-7 Paclitaxel Ethers:  Discovery of BMS-184476. J. Med. Chem. 2001, 44, 4577–4583. 
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for the potential of a drastic increase in potency accompanied with better 
biophysical properties.27  Most notably, the work of both Ojima28 and Georg29 
capitalizes on the SAR studies to synthesize molecules that have cytotoxicity 
against cancer lines that have a resistance to PTX. 
 
 
Figure 1.3 | Second and third generation PTX analogues. 
 
Although these compounds have significantly improved the shortcomings 
of PTX in some aspects, the biophysical properties are not ideal and further the 
need for excipients to effectively solubilize the drug for in vivo studies.  More 
importantly the lack of specificity for tumor cells as opposed to healthy cells, 
requires further modification.  Creating prodrugs from PTX is a different approach 
for the safe delivery of PTX to cancer cells.  Instead of optimizing analogues to 
give the ideal biophysical properties, one makes a temporary modification to the 
drug. 
                                            
27 Kingston, D. G. I. A Natural Love of Natural Products. J. Org. Chem. 2008, 73, 3975–3984. 
28 Ojima, I.; Das, M. Recent Advances in the Chemistry and Biology of New Generation Taxoids 
J. Nat. Prod. 2009, 72, 554–565. 
29 Rice, A.; Liu, Y.; Michaelis, M. L.; Himes, R. H.; Georg, G. I.; Audus, K. L. Chemical 
Modification of Paclitaxel (Taxol) Reduces P-Glycoprotein Interactions and Increases Permeation 
Across the Blood-Brain Barrier in Vitro and in Situ. J. Med. Chem 2005, 48, 832–838. 
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1.4. Common strategies used to make PTX prodrugs 
Prodrugs are derivatives of a compound that temporarily change the 
physical and biological properties of the parent drug.  Upon exposure to an 
external stimulus such as enzymatic degradation, metabolism, near infrared light 
(NIR), or simple water hydrolysis, the bioactive parent drug is released. 30 
Specifically, PTX is typically modified at either the 2’- or the 7- hydroxyl due to 
synthetic accessibility.  The prodrugs most commonly created from the 
derivatization of PTX aim to improve upon the poor water solubility of the parent 
drug; thus the major focus in this area of research has been to attach hydrophilic 
groups to PTX. 
A less common prodrug approach is to improve the specificity of PTX 
towards cancer cells.  To meet this broad goal, researchers have made prodrugs 
of PTX by functionalization with tumor targeting agents31 or antibodies.32 The 
targeting agents used serve the purpose to either i.) guide the therapeutic agent 
(PTX) to the cancer sight, thereby localizing a large concentration of the drug, or 
ii.) to provide a transport mechanism across the cancer cell wall, for the selective 
uptake to tumor tissues. 
Figure 1.4 below summarizes strategies used to temporarily alter the 
chemical and biological properties of PTX until chemical cleavage occurs.33 The 
general Figure is read in a clockwise fashion as the molecular increases from 
small molecule prodrugs, isomer conjugates, small molecule tumor targeting 
                                            
30 Sinkula, A. A.; Yalkowsky, S. H. Rationale for Design of Biologically Reversible Drug 
Derivatives: Prodrugs. J. Pharm. Sci. 1975, 64, 181–210. 
31 Majumdar, S.; Duvvuri, S.; Mitra, A. K. Membrane transporter/ receptor-targeted prodrug 
design: strategies for human and veterinary drug development. Adv. Drug Delivery Rev. 2004, 56, 
1437-1452.   
32 Schmidt, F.; Ungureanu, I.; Duval, R.; Pompon, A.; Monneret, C. Cancer Chemotherapy: a 
Paclitaxel Prodrug for ADEPT (Antibody-Directed Enzyme Prodrug Therapy). Eur. J. Org. Chem. 
2001, 2001, 2129–2134. 
33 Skwarczynski, M.; Hayashi, Y.; Kiso, Y. Paclitaxel Prodrugs:  Toward Smarter Delivery of 
Anticancer Agents. J. Med. Chem. 2006, 49, 7253–7269. 
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agents, macromolecule (peptide, polymer, and protein) conjugates, and lastly the 
up and coming field of antibody-drug conjugates.34 
 
Figure 1.4 | Prodrug chart shows 5 prodrug strategies of paclitaxel (modified 
from ref. 33).  
 
Many different prodrugs have capitalized on the reactivity of the 2’ and 7   
hydroxyls of PTX with the common goal to deliver the drug exclusively to tumor 
cells thereby reducing problematic side effects. Keeping the SAR (cf., Figure 1.1) 
in mind, it has been observed that R1 (Figure 1.1) must be cleaved under 
physiological conditions to return the free hydroxyl and to maintain biological 
activity.  This 2’-OH is critical for the potency of the drug due to hydrogen 
bonding with the amino acid residues of the α- and β-tubulin.35  The R2 group can 
                                            
34 Yewale, C.; Baradia, D.; Vhora, I.; Misra, A. Proteins: Emerging Carrier for Delivery of Cancer 
Therapeutics. Expert. Opin. Drug Deliv. 2013, 10, 1429–1448. 
35 Xiao, H.; Verdier-Pinard, P.; Fernandez-Fuentes, N.; Burd, B.; Angeletti, R.; Fiser, A.; Horwitz, 
S. B.; Orr, G. A. Insights Into the Mechanism of Microtubule Stabilization by Taxol. Proc. Natl. 
Acad. Sci. U.S.A. 2006, 103, 10166–10173. 
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be varied and does not necessarily need to be cleaved.3 Examples of derivatives 
at these positions include phosphate esters,36 amino acids,37 sugars,38 bioactive 
precursors, 39  tumor tissue targeting agents, 40 , 41  antibodies, 42  and polymer 
conjugates.43  
To render hydrophobic drugs water soluble, phosphate salts serve as 
exceptional prodrugs.  Specifically, synthesis of the prodrug is achieved through 
the treatment of PTX with LDA at -30 °C to form the dianion followed by addition 
of dibenzyl pyrophosphate.  Hydrogenolysis of the benzyl group to afford the 
corresponding acids and conversion into the sodium salts gave compounds 129 
or 129’ (Figure 1.5). This approach was taken to acquire the phosphate at the 2’ 
or 7 hydroxyl group, after initial attempts using standard phosphorylation 
conditions such as using POCl3 failed.45 The phosphate esters are thought to be 
cleaved enzymatically by endogenous phosphatases that revert the prodrug to 
the parent compound and the corresponding benign byproducts.  Although the 
water solubility increased for 129, phosphatases could not cleave the phosphate 
esters, presumably due to the steric hindrance of PTX, resulting in decreased 
                                            
36 Vyas, D. M.; Wong, H.; Crosswell, A. R.; Casazza, A. M.; Knipe, J. O.; Mamber, S. W.; Doyle, 
T. W. Synthesis and Antitumor Evaluation of Water Soluble Taxol Phosphates. Bioorg. Med. 
Chem. Lett. 1993, 3, 1357–1360. 
37 Paradis, R.; Pagé, M. New Active Paclitaxel Amino Acids Derivatives with Improved Water 
Solubility. Anticancer Res. 1998, 18, 2711–2716. 
38 de Bont, D. B. A.; Leenders, R. G. G.; Haisma, H. J.; van der Meulen-Muileman, I.; Scheeren, 
H. W. Synthesis and Biological Activity of β-glucuronyl Carbamate-based Prodrugs of Paclitaxel 
as Potential Candidates for ADEPT. Bioorg. Med. Chem. Lett. 1997, 5, 405–414. 
39 Hayashi, Y.; Skwarczynski, M.; Hamada, Y.; Sohma, Y.; Kimura, T.; Kiso, Y. A Novel Approach 
of Water-soluble Paclitaxel Prodrug with No Auxiliary and No Byproduct: Design and Synthesis of 
Isotaxel. J. Med. Chem. 2003, 46, 3782–3784. 
40 Hemamalini, S.; Chander, M.; Baker, S.; He, L. Tumor Targeting by Covalent Conjugation of a 
Natural Fatty Acid to Paclitaxel. Clin. Cancer Res. 2001, 7, 3229–3238. 
41 Bradley, M.; Swindell, C.; Anthony, F.  Tumor targeting by Conjugation of DHA to Paclitaxel. J. 
Control. Release 2001, 74, 233-236. 
42 Dubowchik, G.; Mosure, K.; Knipe, J. Cathepsin B-sensitive Dipeptide Prodrugs. 2. Models of 
Anticancer Drugs Paclitaxel (Taxol®), Mitomycin C and Doxorubicin. Bioorg. Med. Chem. Lett. 
1998, 8, 3347-3352. 
43 Greenwald, R.; Choe, Y.; McGuire, J. Effective Drug Delivery by PEGylated Drug Conjugates. 
Adv. Drug Deliver. Rev. 2003, 55, 217-250. 
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efficacy.36 To combat these issues Bristol-Myers Squibb (BMS) is researching 
conjugation of phosphate esters to paclitaxel via long hydrocarbon linkers, in 
hopes that greater steric accessibility will allow the enzymes to cleave the 
prodrug.44 
 
Figure 1.5 | Prodrug conjugates of paclitaxel corresponding to the 5 different 
categories (small molecule, isomers, tumor targeting, macromolecules, antibody). 
                                            
44 Vyas, D. M.; Ueda, Y.; Wong, H.; Matiskella, J. D.; Hauck, S.; Mikkilineni, A. B.; Farina, V.; 
Rose, W. C.; Casazza, A. M. ACS Symposium Series; Georg, G. I.; Chen, T. T.; Ojima, I.; Vyas, 
D. M., Eds. ACS Symposium Series, 1947 American Chemical Society: Washington, DC, 2009; 
Vol. 583, pp. 124–137. 
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Isotaxel (130, Figure 1.5) uses a very clever approach to prodrug strategy, 
in that it avoids additional functionalization of the parent drug all-together.  To 
accomplish the temporary change in physical properties without adding in 
additional moieties on the drug, Isotaxel 130 utilizes isomerization chemistry.  
The taxane is an isomer of paclitaxel with the benzoyl group linked to the 2’-
hydroxyl instead of the amine at the 3’ position.  The free amine is then converted 
to the hydrochloride salt so that it is much more water-soluble.  Upon in vivo 
administration, the Isotaxel is isomerized back to PTX through an O-N 
intramolecular acyl migration.45 The efficacy of 130 is dependent on the rate of 
re-isomerization, which is pH dependent.39 
To capitalize on the temporary functionalization of the prodrugs, research 
has focused on biasing PTX to accumulate in tumor tissue preferentially over 
healthy tissue.  For example, the covalent binding of PTX to a tumor-targeting 
agents such as biotin 429 or folic acid has been developed.46  These targeting 
agents exploit the minor yet real differences between healthy cells and cancer 
cells. It has been shown that cancer cells over-express many different enzymes 
and receptors, and passively uptake macromolecules more easily than healthy 
cells.47  Also cancer cells have lower concentrations of oxygen and a lower 
pH.48 ,49 These differences can be taken advantage of to allow for selective 
delivery of the prodrug.  Since tumor tissues require a large energy supply to 
                                            
45 Skwarczynski, M.; Sohma, Y.; Kimura, M.; Hayashi, Y.; Kimura, T.; Kiso, Y. O–N Intramolecular 
Acyl Migration Strategy in Water-soluble Prodrugs of Taxoids. Bioorg. Med. Chem. Lett.  2003, 
13, 4441–4444. 
46 Yashveer Singh, M. P. P. J. S. Recent Trends in Targeted Anticancer Prodrug and Conjugate 
Design. Curr. Med. Chem. 2008, 15, 1802. 
47 Carvalho, I.; Milanezi, F.; Martins, A.; Reis, R. M.; Schmitt, F. Overexpression of Platelet-
Derived Growth Factor Receptor Alpha in Breast Cancer Is Associated with Tumour Progression. 
Breast Cancer Res. 2005, 7, R788–R795. 
48 Jin, S.; Wan, J.; Meng, L.; Huang, X.; Guo, J.; Liu, L.; Wang, C. Biodegradation and Toxicity of 
Protease/Redox/pH Stimuli-Responsive PEGlated PMAA Nanohydrogels for Targeting Drug 
Delivery. ACS Appl. Mater. Interfaces 2015, ASAP. 
49 Xiong, M.-H.; Bao, Y.; Du, X.-J.; Tan, Z.-B.; Jiang, Q.; Wang, H.-X.; Zhu, Y.-H.; Wang, J. 
Differential Anticancer Drug Delivery with a Nanogel Sensitive to Bacteria-Accumulated Tumor 
Artificial Environment. ACS Nano 2013, 7, 10636–10645. 
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keep up with rapidly growing vasculature and size,50 conjugating PTX with a fatty 
acid side chain has proved very useful.  The prodrug 131 (Figure 1.5) shows the 
lengthy hydrophobic docosahexaenoic acid appended to the 2’-hydroxyl position 
of PTX, which is hydrolytically cleaved during the metabolism of the fatty acid.40 
Interestingly, this prodrug has an improved solubility in plasma; therefore, less 
surfactant is needed to administer the drug, which will be discussed further in 
Chapter 1.4. 
The prodrug that has shown the most significant improvement in water 
solubility of PTX is the covalent linkage to a hydrophilic macromolecule, a 
poly(ethyleneglycol) (PEG), which yields prodrug 132 (Figure 1.5). When the 2’ 
hydroxyl is bonded to a 5 kDa PEG-polymer, the solubility increases significantly.  
An impressive 660 mg of the conjugate can dissolve in 1 mL of water, which is 
ca. 95 mg/mL PTX.43 This clearly shows the utility of conjugation of PTX to a 
PEG polymer, since the typical water solubility of PTX is merely 0.25 - 0.56 
mg/mL.44,51 In vitro studies also showed great promise, with an IC50 of 15 nM 
and 17 nM in the P388/O and L1210/O cancer cell lines respectively, compared 
with free PTX (6 nM, 6 nM).52 However, in vivo testing showed less efficacy than 
the commercial paclitaxel formulation. 
Currently being explored is the linkage of prodrug 133 (Figure 5) with 
mono clonal antibodies (mAbs).42 To develop these large antibody complexes, 
the benzyl protected short amino acid linker 133 has been conjugated to PTX.  
After deprotection and reductive amination of 133 with a mono-clonal antibody, 
the complex targeting agent is formed.  When the antibody cytotoxic agent binds 
to the antigen, the drug is actively transported into the cell where, upon 
                                            
50 Garber, K. Energy Deregulation: Licensing Tumors to Grow. Science 2006, 312, 1158–1159. 
51 Damen, E. W. P.; Wigerinck, P. H. G.; Braamer, L.; Sperling, D.; de Vos, D.; Scheeren, H. W. 
Paclitaxel Esters of Malic Acid as Prodrugs with Improved Water Solubility. Bioorg. Med. Chem. 
Lett. 2000, 8, 427–432. 
52 Greenwald, R. B.; Pendri, A.; Bolikal, D. Highly Water Soluble Taxol Derivatives: 2′-
Polyethyleneglycol Esters as Potential Prodrugs. Bioorg. Med. Chem. Lett. 1994, 4, 2465–2470. 
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hydrolysis, the parent drug is released.53 This strategy gives good insight into the 
development of polypeptide/antibody polymer conjugates that we plan to explore 
for delivery of our formulation (Chapter 4, Future Outlook). 
Although these prodrugs serve as a guide for developing hydrophilic 
prodrugs of PTX, it should be noted that the main topic of this thesis is to create 
prodrugs that are more hydrophobic than the parent compound (Chapter 2) for 
formulation into nanoparticles. The development of small molecule hydrophobic 
and hydrolytically labile silicate prodrugs of PTX will be discussed in Chapter 3 of 
this thesis. Extrapolating from the traditional prodrug research suggests that the 
modification may occur on either or both the 2’ and/or 7 positions can be 
functionalized to yield a hydrophobic prodrug.  Although creating a prodrug that is 
less water-soluble may seem counter productive, it is advantageous in the 
context of nanoparticle drug delivery. Current clinical formulations discussed 
below, show the need for better formulations of PTX. 
1.4 Clinically Relevant Taxane Formulations 
Taxane chemotherapeutics are formulated using a variety of techniques 
with the common goal of delivering the chemotherapeutic drug to the tumor tissue 
without causing side effects to the patient.  The current, commercially available 
formulations are summarized in Table 1.3.54 From this comparison, it is possible 
to envision an advanced formulation that maximizes the amount of taxane in the 
formulation with minimal adverse effects on a patient. 
The administration technique of PTX or its analogues most relevant to this 
thesis is intravenous delivery.  This technique can be quite time consuming, 
painful, and cause life threating reactions at the injection site, mainly due to the 
excipient used to solubilize the taxane. The method of administration also has 
                                            
53 Smith, T. A. D.; Cheyne, R. W. Predicting Tumour Response to Anti-HER1 Therapy using 
Medical Imaging: a Literature Review and in vitro Study of [18F]-FDG Incorporation by Breast 
Cancer Cells Responding to Cetuximab. J. Biomed. Sci. 2011, 68, 158–166. 
54 Hennenfent, K. L. Novel Formulations of Taxanes: a Review. Old Wine in a New Bottle? Ann. 
Oncol. 2006, 17, 735–749. 
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significant benefits in contrast to oral delivery. If adverse side effects begin to 
develop in a patient, the dosage of the pharmaceutical can be reduced or the 
treatment can be aborted instantly.  I.V. injection has benefits resulting from 
bypassing the gastrointestinal tract: a lower toxicity in the stomach and intestines 
is observed, the drug is not forced to pass through a barrier into the blood 
stream, and first-pass liver metabolism is avoided.55  
Paclitaxel chemotherapy is routinely and most commonly prescribed as 
the Taxol® formulation.  Specifically, the medication consists of 6 mg of paclitaxel 
per mL of CrEL®.  A single dose is around 156 mg of paclitaxel.  CrEL® consists 
of a 50:50 mixture of poly-oxyethyleneglycerol triricinoleate castor oil (ca. 3 kDa) 
and dehydrated ethanol.  This ion-free solution is not unique to paclitaxel; it is a 
well-studied solubilizer developed for the delivery of hydrophobic drugs via the 
self-assembly of micellular structures in which the hydrophobic components are 
contained in the center.  Unfortunately the poor water solubility of paclitaxel 
requires oncologists to use an exorbitant amount of CrEL® to administer the drug.  
This formulation (Taxol®) is very problematic due to the inherent bioactivity of 
CrEL®.  The most notable side effect due to high levels of CrEL is acute 
hypersensitivity (rash) at the injection site.56 Although this effect can be reduced 
with pretreatment of corticosteroids and antihistamines, 40% of patients still 
experience this effect and 1.5%-3% have life threatening reactions.57,58 Additional 
attempts to remedy this side effect include longer infusion times. However, 
neurotoxicity has been seen in peripheral neurons due to the solubilizer and the 
                                            
55 Sparreboom, A.; Van Asperen, J.; Mayer, U.; Schinkel, A. H.; Smit, J. W.; Meijer, D. K. F.; 
Borst, P.; Nooijen, W. J.; Beijnen, J. H.; Van Tellingen, O. Limited Oral Bioavailability and Active 
Epithelial Excretion of Paclitaxel (Taxol) caused by P-glycoprotein in the Intestine P. Natl. Acad. 
Sci. USA 1997, 94, 2031-2035. 
56 Gelderblom, H.; Verweij, J.; Nooter, K.; Sparreboom, A. Cremophor EL: the Drawbacks and 
Advantages of Vehicle Selection for Drug Formulation. Eur. J. Cancer. 2001, 37, 1590–1598. 
57 Weiss, R.; Donehower, R.; Wiernik, P. Hypersensitivity Reactions from Taxol. J. Clin. Oncol. 
1990, 8, 1263-1268. 
58 Friedland, D.; Gorman, G.; Treat, J. Hypersensitivity Reactions From Taxol and Etoposide. J. 
Natl. Cancer I. 1993, 85, 2036.i 
Part I: Anticancer Drug Delivery  Chapter 1 | 
 
 
26 
26 
longer infusion times. Another disappointing result associated with the 
administration of Taxol® is a distorted pharmacokinetic profile.59  Specifically, 
paclitaxel binds to serum lipoproteins and leads to poor biodistribution and 
clearance.60 All these downfalls in Taxol® have led researchers to study better 
formulations. 
Docetaxel (DTX) is inherently less hydrophobic than PTX, which results in 
a formulation containing a different solubilizer known as polysorbate 80 (Tween® 
80). 61 , 62  Although this formulation (Taxotere®) overcomes some of the 
shortcomings of Taxol® by alleviating the frequency of hypersensitivity and 
decreasing neurotoxicity slightly, problems still persist with drug disposition.63 
Poor clearance and distribution of the drug is still observed.64,65Since Taxotere® 
only moderately improved upon the Taxol® formulation and the therapeutic 
outcome of patients was the same, other delivery agents were explored. 
Tumor targeting agents are very useful tools to selectively deliver PTX.  
The Taxoprexin® formulation contains 8 milligrams of 131 (cf., Figure 1.5) per 
milliliter of CrEL® and 5% dextrose.54 Having the targeting agent allows for 80% 
less CrEL® to be used, but, again, hypersensitivity and neurotoxicity is still 
                                            
59 van Tellingen, O.; Huizing, M. Cremophor EL Causes (Pseudo-) Non-linear Pharmacokinetics 
of Paclitaxel in Patients. Brit. J. Cancer 1999, 81, 330-335. 
60 Schwartz, E.; Einzig, A.; Strauman, J. Phase I trial of taxol Given as a 24-hour Infusion every 
21 Days: Responses Observed in Metastatic Melanoma. J. Clin. Oncol. 1987, 5, 1232-1239. 
61 Crown, J. Docetaxel and Paclitaxel in the Treatment of Breast Cancer: A Review of Clinical 
Experience. Oncologist 2004, 9, 24–32. 
62 Bernstein, B. Docetaxel as an Alternative to Paclitaxel After Acute Hypersensitivity Reactions. 
Ann. Pharmacother. 2000, 34, 1332-1335. 
63 Norris, L. B.; Qureshi, Z. P.; Bookstaver, P. B.; Raisch, D. W.; Sartor, O.; Chen, H.; Bennet C.L. 
Polysorbate 80 Hypersensitivity Reactions: a Renewed Call to Action. J. Community Support. 
Oncol. 2010, 7, 425–428. 
64 Eckhoff, L.; Nielsen, M.; Moeller, S.; Knoop, A. TAXTOX - a Retrospective Study Regarding the 
Side Effects of Docetaxel Given as Part of the Adjuvant Treatment to Patients with Primary Breast 
Cancer in Denmark from 2007 to 2009. Acta Oncologica. 2011, 50, 1075–1082. 
65 Sparreboom, A.; van Tellingen, O.; Nooijen, W. J.; Beijnen, J. H. Tissue Distribution, 
Metabolism and Excretion of Paclitaxel in Mice. Anti-cancer Drugs 1996, 7, 78–86. 
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observed in patients.66 Even though the lipophilic group of 131 has a higher 
affinity for plasma proteins than PTX, it has been shown that Taxoprexin® 
delivers more paclitaxel to tumor tissue than the Taxol® formulation.40,41 Due to 
the persisting acute toxicity associated with the use of emulsification agents, 
research has been focused on formulating PTX into a biocompatible excipient. 
To completely avoid the use of a surfactant to deliver paclitaxel to tumor 
tissues, the Abraxis company has developed a bio-based formulation dubbed 
Abraxane®.  Abraxane® consists of 900 mg of human serum albumin (HSA, a 
natural plasma protein) and 100 mg of PTX.  When the lyophilized powder of 
HSA/PTX is resuspended into 20 mL of 0.9% NaCl, stable nanoparticles are 
formed.67,68,69 The nanoparticles have a size range of 130-150 nm.  The HSA is 
believed to protect the drug and deliver it by the gp60 receptor.  The gp60 
receptor is albumin specific and abundantly expressed on tumor cells. 70 
Abraxane® delivers more active drug than the Taxol® formulation due to active 
transport across endothelial cells and the use of dosages containing 5-10 times 
greater amounts of paclitaxel.4 However, in terms of patients receiving taxane-
based chemotherapy for the first time, Abraxane® did not significantly improve 
upon the survival time when compared against Taxol®.  Second-line 
administration (patients who have received treatment before) of this formulation 
improves the survival time by approximately 10 weeks.  “Abraxane's wholesale 
cost is $5,100 a dose every 3 weeks, which is 16 times as much as generic 
                                            
66 Harries, M.; O'Donnell, A.; Scurr, M.; Reade, S. Phase I/II Study of DHA–paclitaxel in 
Combination with Carboplatin in Patients with Advanced Malignant Solid Tumours. Brit. J. Cancer 
2004, 91, 1651-1655. 
67 Desai, N. Methods for in vivo delivery of Substantially Water Insoluble Pharmacologically Active 
Agents and Compositions Useful Therefor. U.S. Patent 5,439,686, August 8, 1995. 
68 U.S. FDA approved leaflet Abraxane Package Insert Version 12. 2005, 1–26. 
69 Dosio, F.; Arpicco, S.; Brusa, P.; Stella, B.; Cattel, L. Poly(ethylene glycol)–human serum 
albumin–paclitaxel Conjugates: Preparation, Characterization and Pharmacokinetics. J. Control. 
Release 2001, 1–11. 
70 Nyman, D. W. Phase I and Pharmacokinetics Trial of ABI-007, a Novel Nanoparticle 
Formulation of Paclitaxel in Patients With Advanced Nonhematologic Malignancies. J. Clin. 
Oncol. 2005, 23, 7785–7793. 
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paclitaxel.”71 The significant difference seen in second-line administration, led to 
the FDA approval of Abraxane® for treatment of metastatic breast cancer after 
relapse or chemotherapy failure.  Abraxane® still does not show a great benefit in 
first-line patients and the sheer cost of the drug makes other formulations more 
appealing.69, 72 
Genexol-PM is a micellular formulation consisting of many low molecular 
weight block-copolymers.  The amphiphilic block copolymer monomethoxy-
poly(ethylene glycol)-poly(D,L-lactide) (mPEG-D,L-PLA) solubilizes the paclitaxel 
into micelles of 20-50 nm.73 The ca. 75% polymer particles are redispersed in a 
5% dextrose solution and administered to patients. Genexol-PM is currently in 
clinical trials, despite a slight hypersensitivity in patients like the other 
formulations based on PTX.74,75 Unfortunately, all of the formulations based on 
the PTX and DTX are poly-glycoprotein (P-gp) substrates.  The P-gp transporter 
removes the drug out of the tumor cells by way of an efflux pump.  This removal 
of the drug creates a resistance to the taxane class in many cancers. 
  
                                            
71 Herper, M. Cancer Man. Forbes 2009, 1–2. 
72 Sparreboom, A. Comparative Preclinical and Clinical Pharmacokinetics of a Cremophor-Free, 
Nanoparticle Albumin-Bound Paclitaxel (ABI-007) and Paclitaxel Formulated in Cremophor 
(Taxol). Clin. Cancer Res. 2005, 11, 4136–4143. 
73 Joshi-Hangal, R. Paclitaxel Formulation. U.S. Patent, 6,538,020, March 25, 2011. 
74 Kim, T. Y. Phase I and Pharmacokinetic Study of Genexol-PM, a Cremophor-Free, Polymeric 
Micelle-Formulated Paclitaxel, in Patients with Advanced Malignancies. Clin. Cancer Res. 2004, 
10, 3708–3716. 
75 Lee, K. S.; Chung, H. C.; Im, S. A.; Park, Y. H.; Kim, C. S.; Kim, S.-B.; Rha, S. Y.; Lee, M. Y.; 
Ro, J. Multicenter Phase II trial of Genexol-PM, a Cremophor-free, Polymeric Micelle Formulation 
of Paclitaxel, in Patients with Metastatic Breast Cancer. Breast Cancer Res. Tr. 2007, 108, 241–
250. 
Part I: Anticancer Drug Delivery  Chapter 1 | 
 
 
29 
29 
Table 1.3 | Comparison of paclitaxel formulations (adapted from Ref. 54).  
 Pharmaceutical Taxol® Taxotere® Taxoprexin® Abraxane® Genexol® 
 Active Agent PTX DTX 10 PTX PTX 
 % Active Agent 1.1% 3.6% 73% 10% 16.7% 
 Delivery Agent CrEL Tween® 80 CrEL Albumin PEG-PLA 
 I.V. inj. Time 1, 3, or 24 h 1 h 2 h 30 min 3 h 
 Pre-Medication Required Required Required Not Needed Not Needed 
 P-gp substrate Yes Yes Yes Yes Yes 
 Dose (mg/m2)a 200-390  70-275 200–1100 135–375 135–390 
 MTD 3 weeksb 250 mg/m2 275 mg/m2 1100 mg/m2 300 mg/m2 390 mg/m2 
 aDosage varied based upon cancer type and severity. 
 bMaximum tolerated dose (MTD), beneficial dose with minimal side effects 
patient varies with patients 
 
One should note that, although these formulations are used clinically, 
serious limitations are present due to the amount of drug present in comparison 
to the excipient used.  It would be beneficial to have a formulation with a large 
loading of the drug that will release in a controlled fashion.  To achieve this large 
dose formulation, one can envision a nanoparticle formulation consisting of an 
amphiphilic block copolymer (BCP) and a hydrophobic drug.  The larger sized 
nanoparticle would resemble the self-assembled micelles, Genexol®.4 The drug 
and the hydrophobic portion of the BCP resides in the core of the particle and the 
hydrophilic portion of the BCP is displayed on the corona.  More of the particle 
design and will be discussed in Chapter 2. 
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2.1 Flash Nanoprecipitation 
2.1.1 Confined Impingement Jet Mixer with Dilution  
To effectively formulate PTX or DTX with minimal excipient, which we refer 
to as high loading of the drug, the technique of flash nanoprecipitation (FNP), 
pioneered by Prud’homme showed that stable nanoparticles can be formed even 
at drug loadings past 50 wt%. 76   FNP can produce kinetically trapped 
nanoparticles of ca. 100 nm in size and not the thermodynamic micelles typically 
produced through self-assembly of a drug and amphiphilic block copolymers.  
Self-assembled micelles made through an oil/water emulsion have a much lower 
loading level of the organic solute ca. 1-10 wt% (uncommon up to 25 wt%) and a 
diameter of 50-80 nm.77 Although the sizes are dependant on the MW of the two 
blocks in the block copolymer used in their formulations. Due to the low loading 
of micelles, we turned to the FNP process to achieve our nanoparticle 
formulations. 
The FNP process overcomes low aqueous solubility via encapsulation of 
hydrophobic organic molecules (e.g., drugs) in the core of a particle comprising 
of amphiphilic block copolymers.78 In this technique, rapid impingement mixing of 
water and a miscible organic solvent  (in which the hydrophobic drug and block 
copolymer are co-dissolved) results in encapsulation of the hydrophobic portion 
                                            
76 Prud'homme, R.; Saad, W. Paclitaxel Conjugate Block Copolymer Nanoparticle Formation by 
Flash Nanoprecipitation. Nanotech. 2006, 2, 824-826. 
77 Kataoka, K.; Matsumoto, T.; Yokoyama, M.; Okano, T. Doxorubicin-Loaded Poly (Ethylene 
Glycol)–Poly (Β-Benzyl-L-Aspartate) Copolymer Micelles: Their Pharmaceutical Characteristics 
and Biological Significance. J. Control. Release 2000, 64, 143–153. 
78 Ansell, S. M.; Johnstone, S. A.; Tardi, P. G.; Lo, L.; Xie, S.; Shu, Y.; Harasym, T. O.; Harasym, 
N. L.; Williams, L.; Bermudes, D.; Liboiron, B. D.; Saad, W.; Prud'homme, R. K.; Mayer, L. D. 
Modulating the Therapeutic Activity of Nanoparticle Delivered Paclitaxel by Manipulating the 
Hydrophobicity of Prodrug Conjugates. J. Med. Chem. 2008, 51, 3288–3296. 
Chapter 2. Nanoparticle Drug Delivery
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of the polymer and the hydrophobic solute.79,80 The hydrophilic block of the 
copolymer ensures that the particles are soluble in the water as shown in Figure 
2.1. 
2.1.2 FNP Mixer Designs 
Different mixers have been developed to maximize the utility of the FNP 
process.  The confined impingement jet (CIJ) mixer uses equal volumes of 
organic and aqueous solvents at equal speeds (Figure 2.1, panel a).  This is the 
most straightforward process, but it is restricted by the need for equal amounts of 
solvent to work properly.79 The ease of use of the CIJ mixer is realized with the 
use of hand-operated syringes to press the two streams in < 1 second. Without 
access to different solvent ratios, supersaturated concentrations cannot be 
achieved in all cases, and only highly hydrophobic solutes can be efficiently 
captured and retained in the nanoparticle core. 
The confined tangential flow (CTF) mixer offsets the two solvent streams 
instead of meeting orthogonally like the CIJ mixer. This offset allows the user to 
prepare a sample in which different volumes of solvent and anti-solvent are used, 
and ultimately sufficient entrapment of moderately hydrophobic drugs (Figure 2.1, 
panel b).81,82 By introducing more inlet streams, the process can be customized 
for different organic solutes, co-encapsulation of two different drugs, and 
independent control of each stream. The multi-inlet vortex (MIV) mixer (Figure 
2.1, panel c) allows for the greatest control in achieving uniform 
                                            
79 Zhu, Z.; Anacker, J. L.; Ji, S.; Hoye, T. R.; Macosko, C. W.; Prud'homme, R. K. Formation of 
Block Copolymer-Protected Nanoparticles via Reactive Impingement Mixing. Langmuir 2007, 23, 
10499–10504. 
80 Zhu, Z. Polymer Stabilized Nanosuspensions Formed via Flash Nanoprecipitation: Nanoparticle 
Formulation, Formulation, and Stability. Ph.D. Dissertation, University of MN, Minneapolis, MN, 
2010. 1‐240. 
81 Johnson, B. K. Flash NanoPrecipitation of Organic Actives via Confined Micromixing and Block 
Copolymer Stabilization. Ph.D. Dissertation, Princeton University, Princeton, NJ, 2003. 1‐337. 
82 Saad, W. S. Drug Nanoparticle Formation via Flash Nanoprecipitation: Conjugation to 
Encapsulate and Control the Release of Paclitaxel. Ph.D. Dissertation, Princeton University, 
Princeton, NJ, 2007. 1‐198. 
Part I: Anticancer Drug Delivery  Chapter 2 | 
 
 
32 
32 
nanoparticles.83,84 Both of these the latter, more sophisticated mixers are typically 
run with syringe pumps for consistent flow rates of each stream and optimum 
mixing of each component. 
 
Figure 2.1 | Mixers used for flash nanoprecipitation (FNP) a.) confined 
impingement jet (CIJ) b.) confined tangential flow (CTF) c.) multi-inlet vortex 
(MIV) [adapted from ref 81,83,84].  
 
                                            
83 Shen, H.; Hong, S.; Prud'homme, R. K.; Liu, Y. Self-assembling Process of Flash 
Nanoprecipitation in a Multi-inlet Vortex mixer to Produce Drug-loaded Polymeric Nanoparticles. 
J. Nanopart. Res. 2011, 13, 4109–4120. 
84 Liu, Y.; Prudhomme, R. Optimized Descriptive Model for Micromixing in a Vortex Mixer. Chem. 
Eng. Commun. 2010, 197, 1068-1075. 
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The confined impingement jet mixer with a dilution (CIJ-D) stage is 
presented in Figure 2.2. For this design two solvent streams enter the mixing 
chambers at right angles and at the same rate.  This is commonly done with two 
hand-operated syringes at the top of the mixer.  Since the total volume in each 
syringe must be the same, the final nanoparticle formulation contains a large 
amount of the organic solvent.  A dilution tank containing water was utilized to 
reduce the vol% of the organic medium, which leads to nanoparticles that are 
kinetically trapped and have a better stability profile. 85,86 Due to the ease of 
operation, the CIJ-D mixer was used for all of our experiments unless otherwise 
noted. Unfortunately the flow rates of the two mixing solvents are fixed due to the 
backpressure of each stream on the other, so other mixers would need to be 
used to optimize the loading and to reduce the amount of organic solvent used 
(cf. 2.1). 
                                            
85 Han, J.; Zhu, Z.; Qian, H.; Wohl, A. R.; Beaman, C. J.; Hoye, T. R.; Macosko, C. W. A Simple 
confined impingement jets mixer for flash nanoprecipitation. J. Pharm. Sci. 2012, 101, 4018–
4023. 
86 Pustulka, K. M.; Wohl, A. R.; Lee, H. S.; Michel, A. R.; Han, J.; Hoye, T. R.; McCormick, A. V.; 
Panyam, J.; Macosko, C. W. Flash nanoprecipitation: Particle structure and stability. Mol. 
Pharmaceut. 2013, 10, 4367–4377. 
Part I: Anticancer Drug Delivery  Chapter 2 | 
 
 
34 
34 
 
Figure 2.2 | Flash nanoprecipitation (adapted from ref. 85,86). 
 
2.2 Flash Nanoprecipitation Experiments 
2.2.1 Initial Model Drug Experiments 
Due to the hydrophobic nature of β-carotene and its bright color, it was 
chosen as a model for a hydrophobic drug for the CIJ mixer experimentation.78 
The solute, β-carotene, and block polymer, poly(ethylene oxide)-b-poly(styrene) 
(PEO-b-PS), were impingement mixed in the CIJ mixer to achieve an impressive 
87% β-carotene wt/wt formulation that was fully encapsulated by the polymer.  
The size regime associated with this formulation varied between ~80-400 nm in 
diameter. These sizes are typical values from multiple runs. Although the 
variation was not ideal, all particles were considered as an acceptable size for 
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passive uptake of cancer cells by the enhanced permiation and retention (EPR) 
effect (Chapter 2.4).79  
Although this model study showed the proof of concept, the choice of the 
solute and block polymer has some downsides. β-Carotene has no 
chemotherapeutic properties and its hydrophobicity is much higher than typical 
drugs we envisioned using.  Also the block polymer used (PEO-b-PS) is not 
biodegradable and not FDA approved, which forbids its use in formulations for 
use in humans.  From these restrictions on the formulation, the solute or drug 
was changed to a chemotherapeutic and the polymer was changed to a 
biodegradable block polymer. 
 
2.2.2 FNP of Paclitaxel  
Paclitaxel was chosen for its hydrophobicity and track record of 
chemotherapeutic properties. The first experiment with the desired substrate, 
paclitaxel, and block polymer, poly(ethylene glycol)-block-poly(lactic-co-glycolic 
acid) [(PEG-b-PLGA), 2k-10k] was attempted using the CIJ mixer.79 The particles 
formed displayed sizes ranging from 90-285 nm, and were 34 wt% PTX. This 
loading level is a great improvement when compared to the clinically relevent 
formulations described in Chapter 1.  Unforunately, after 15 minutes, PTX 
crystallized out of the particle core through a phenomenon known as Ostwald 
ripening. 87  Zhu confirmed the formation of crystal growth after 90 mins by 
spraying the suspension on a silicon wafer for scanning electron microscopy 
(SEM) shown in Figure 2.3, panel a.80 I repeated the experiment with the CIJ-D 
mixer and a different block polymer (mPEG-b-PLGA, 5k-10k) and observed 
crystal growth within an hour visible to the naked eye (Figure 2.3, b).  This 
showed that although the PEG-b-PLGA polymer is biocompatable, when used in 
conjunction with PTX the FNP process was troublesome.  Other polymers need 
                                            
87 Voorhees, P. W. The Theory of Ostwald Ripening. J. Stat. Phys. 1985, 38, 231–252. 
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to be explored in hopes to improve the stability of PTX nanoparticles formed by 
FNP.88 
Despite the ease and reliability of FNP to form stable nanoparticles in the 
case of model studies, attempts to formulate PTX in nanoparticles via this 
methodology were unsuccessful.89 In this case, paclitaxel was not hydrophobic 
enough to stay in the core; instead “leaking out” and crystallizing within minutes 
after FNP of PTX with a PEG-b-PLGA polymer.86,89 
  
Figure 2.3 | Experiments showing the Ostwald ripening of PTX from 
nanoparticles a.) SEM image taken by Zhu et al. b.) Photo of nanoparticle 
suspension with PTX 
 
To remedy this shortcoming, a prodrug that is more hydrophobic than that 
of the parent was envisioned to stay in the core of the particle and release out 
PTX in a controlled fashion.  As mentioned before, prodrugs are typically created 
to temporally increase the hydrophilicity of a drug.  The following chapter gives a 
detailed overview on the strategies used to make hydrophobic prodrugs of PTX 
for the possible use as nanoparticle formulations by way of the FNP process. 
                                            
88 Zhu, Z. Effects of amphiphilic diblock copolymer on drug nanoparticle formulation and stability. 
Biomaterials 2013, 34, 10238–10248. 
89 Zhu, Z. Flash Nanoprecipitation: Prediction and Enhancement of Particle Stability via Drug 
Structure. Mol. Pharm. 2014, 11, 776–786. 
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2.3 Hydrophobic Esters of PTX and DTX 
Ironically, PTX is too hydrophobic to be administered to patients in a saline 
solution without complication, but not hydrophobic enough to stay in 
nanoparticles.  While most research has focused on increasing the water 
solubility of PTX, hydrophobic modification has been minimally studied. 
Prud’homme and co-workers prepared a suite of hydrophobic ester 
prodrugs of PTX shown in Scheme 2.1. Appended to the 2’-position of PTX, the 
linkers 206-208 provided conjugation of PTX to the very lipophilic alcohols 201a-
203a.  To form these linkers cyclic anhydrides 204 and 205 were opened under 
basic conditions by alcohols 201a-203a.  The lipophilic linkers 206-208 were then 
conjugated with PTX using diisopropylcarboiimide (DIPC) and 
dimethylaminopyridine (DMAP) to yield the hydrophobic PTX conjugates 209-
211. 
Unfortunately, when the prodrugs are tested for in vitro efficacy, 3 to 60 
times the concentration of PTX was required to achieve the same therapeutic 
outcome.78 This suggests that the prodrugs are not hydrolyzing back to PTX in an 
adequate time frame. In addition, precipitation of these hydrophobic prodrugs in 
aqueous media can occur, which can compromise the cytotoxicity study. 
Interestingly, those derived from cyclic anhydride 205 have an increased potency 
due to a proposed inclination for the 3-oxa group to hydrolyze quicker than the 
204 derivatives. Thus, to make effective hydrophobic prodrugs, the ease of 
hydrolysis is a critical issue.  In the case of 211b it was noted that, although a 
decent IC50 value was found, the prodrug-loaded nanoparticle was not stable 
after 1–2 weeks when stored as a solution. 
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Scheme 2.1 | Conjugation of PTX to form hydrophobic prodrugs: summary of 
structure and in vitro activity (altered from ref. 78). 
 
a IC50 values in triplicate of MCF-7 breast cancer cell line.  IC50 of PTX is 3.8 ± 
0.6. 
b Value not applicable to in vivo studies due to particle stability over time. 
 
The nanoparticle formulations were examined by different pharmaceutics 
experiments such as: circulation and plasma elimination, partitioning kinetics, 
and efficacy.  Ansell and coworkers strongly encourage the necessity of in vivo 
testing early on in the formulation process to distinguish the subtle differences in 
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each formulation.  Although they obtained varied results for the in vitro and in 
vivo studies, they concluded that the chemical properties of each prodrug 
dictated its performance and not the delivery vehicle itself.  More specifically, the 
rate at which the parent compound is released is governed by the nature of the 
covalent bond between the hydroxyl of PTX and the hydrophobic functionality.  
This research provided the insight that a delicate balance is needed when 
creating hydrophobic prodrugs of PTX for particle formulation. To be formulated 
into nanoparticles or micelles the conjugating bond needs to be stable enough to 
keep the prodrug in the core of the particle for storage and administration and yet 
needs to be labile for efficient hydrolysis and release to return the cytotoxicity of 
the parent drug. 
A few other research groups have developed hydrophobic ester prodrugs 
of PTX.90,91,92 Instead of utilizing FNP to make nanoparticles, they chose to allow 
the hydrophobic constructs of PTX to self-assemble into either micelles or 
nanoparticles when mixed with an amphiphilic block polymer.  A select set of 
prodrugs is shown in Figure 2.4 below, with examples chosen from reports in 
which the particles created with these prodrugs were tested in vivo. 
Forrest and co-workers synthesized a suite of hydrophobic esters 
following a previous protocol developed by Ali.91 They could functionalize the 2’-
hydroxyl with a fatty acid (217) by performing a DCC and DMAP esterification.  
Alternatively, they accessed the less reactive 7-hydroxyl by first protecting the 2’-
hydroxyl with a TBS ether (214), then esterifying to yield compounds like 215.  
Following the deprotection of the silylether with TBAF, the desired R2-derivatives 
                                            
90 Mura, S.; Zouhiri, F.; Lerondel, S.; Maksimenko, A.; Mougin, J.; Gueutin, C.; Brambilla, D.; 
Caron, J.; Sliwinski, E.; LePape, A.; et al. Novel Isoprenoyl Nanoassembled Prodrug for Paclitaxel 
Delivery. Bioconjugate Chem. 2013, 24, 1840–1849. 
91 Ali, S.; Ahmad, I.; Peters, A.; Masters, G.; Minchey, S.; Janoff, A.; Mayhew, E. Hydrolyzable 
Hydrophobic Taxanes: Synthesis and Anti-Cancer Activities. Anti-cancer Drugs 2001, 12, 117–
128. 
92 Ma, P.; Rahima Benhabbour, S.; Feng, L.; Mumper, R. J. 2′-Behenoyl-Paclitaxel Conjugate 
Containing Lipid Nanoparticles for the Treatment of Metastatic Breast Cancer. Cancer Lett. 2013, 
334, 253–262. 
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(216) were synthesized.  The six (216a-217c) prodrugs, shown in Figure 2.4, 
were then formulated into micelles.93 
 
Figure 2.4 | Hydrophobic prodrug esters developed by Forrest et al. Figure 
adapted from reference (93). a Compound synthesized and tested by Mura et al.90 
 
Each prodrug (216a-217c) was dissolved in acetone with a 5k-10k PEG-b-
PCL polymer, and added with a syringe pump dropwise into vigorously stirred 
water over 15 minutes.  The organic solvent was removed by blowing air over the 
contents, which also reduced the overall volume of the suspension.  Finally, they 
passed the micelle mixture through a porous filter to remove any unincorporated 
solid prodrug and polymer. Particle diameters were measured by dynamic light 
                                            
93 Forrest, M. L.; Yáñez, J. A.; Remsberg, C. M.; Ohgami, Y.; Kwon, G. S.; Davies, N. M. 
Paclitaxel Prodrugs with Sustained Release and High Solubility in Poly(Ethylene Glycol)-B-
Poly(Ε-Caprolactone) Micelle Nanocarriers: Pharmacokinetic Disposition, Tolerability, and 
Cytotoxicity. Pharm. Res. 2007, 25, 194–206. 
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scattering (DLS) and gave sizes ranging from 27-44 nm.  They also determined 
the loading levels of the micelles, to be approximately 20 wt% of the prodrug to 
the polymer.  Yet, once again, like the ester prodrugs made by Prud’homme, only 
the 216a prodrug showed cytotoxicity comparable to free drug. Further 
investigations into the pharmacokinetic parameters and the biodistribution of the 
216a micelle formulation via a jugular vein injection into a rat model, led these 
workers to conclude that the formulation had benefits when compared to the 
clinical Taxol® formulation.93 They attributed these benefits to the enhanced 
permeation and retention (EPR) effect, which will be discussed in detail in 
Chapter 2.4. 
The Couvreur group from France has also explored the use of 
hydrophobic ester prodrugs of PTX. Described a recent publication, they used an 
isoprenoid (212d) ester of PTX (218) as shown in Figure 2.4.90 The ester is 
formed by the use of EDCI and DMAP with the desired acid; this methodology 
analogues to their previous report of the esterification of a squalene fatty 
acid. 94 , 95  The squalene ester of PTX showed a poor cytotoxicity profile in 
comparison to the free PTX, which subsquantely changed to a smaller ester 
chain present in 218 to improve the IC50 value.90 
Nanoparticles were prepared with a PEG-SQ [MePEG-Trisnorsqualene, 
(2k)] polymer [made by the O-alkylation of the sodium alkoxide of 
polyethelyeneglycol (PEG-O-Na+) with 1,1’,2-trisnorsqualene methanesulfonate 
(SQ-Ms)].90 To form the particles the isoprenoid prodrug 218 and the polymer 
were dissolved in ethanol and added dropwise under rapid stirring into water.  
The organic solvent was removed by rotary evaporation and the resulting 
suspension stored at 4 ˚C.  The nanoparticles formed rapidly with a diameter of 
                                            
94 Desmaële, D.; Gref, R.; Couvreur, P. Squalenoylation: a Generic Platform for Nanoparticular 
Drug Delivery. J. Control. Release 2012, 161, 609–618. 
95 Reddy, L. H.; Marque, P. E.; Dubernet, C.; Mouelhi, S. L.; Desmaele, D.; Couvreur, P. 
Preclinical Toxicology (Subacute and Acute) and Efficacy of a New Squalenoyl Gemcitabine 
Anticancer Nanomedicine. J. Pharmacol. Exp. Ther. 2008, 325, 484–490. 
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200 nm measured by DLS, and interestingly showed a very high loading level of 
82 wt% of the PTX derivative. An In vitro assay showed the particles to be less 
potent than the free drug by 10 fold.  In vivo bioluminence imaging of the particles 
showed an improvement in comparison to the Taxol® formulation when given as 
a tail vein injection to a balb/c mouse model.  Also the tail (injection site) showed 
healthy tissue even after five consecutive injections of their nanoparticle 
formulation. This was in a stark contrast to the highly necrotic (dead) tails found 
in the Taxol® treated mice.90 
Although these formulations did not achieve the desired therapeutic 
outcome, they serve as precedence for the development of hydrophobic prodrugs 
of PTX that are capable of forming stable particles of various sizes.  As noted by 
the groups, esters of PTX containing large hydrophobic esters that do not quickly 
hydrolyze back to the parent drug limit their utility.  It presents the opportunity to 
create a more liable prodrug with sufficient hydrophobicity. 
2.4 The Enhanced Permeation and Retention (EPR) Effect  
The enhanced permeation and retention (EPR) effect serves as a primary 
basis for considering the use of nanotherapeutics in cancer therapy. In contrast 
to the blood vessels supplying most normal organs, tumor blood vessels lack a 
continuous endothelial cell coverage and basement membrane. Delivery vehicles 
in the colloidal size range (including polymeric nanoparticles, liposomes, and 
micellar systems) are typically excluded from normal organs but are able to 
passively accumulate in tumors because of this leaky vasculature. Lack of well-
developed lymphatic drainage enhances retention of these vehicles once in the 
tumors. The EPR effect can result in decreased toxicity and increased efficacy of 
an encapsulated drug.96 
                                            
96 Swindell, C. S.; Krauss, N. E.; Horwitz, S. B.; Ringel, I. Biologically active taxol analogs with 
deleted A-ring side chain substituents and variable C-2' configurations. J. Med. Chem. 1991, 34, 
1176–1184. 
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The physiological differences between that of healthy tissue and diseased 
tissue (cancerous, inflamed, infected) allows for the passive uptake of 
macromolecules into the diseased tissues. Depicted in Figure 2.5, the enhanced 
permeation and retention (EPR) effect shows the selectivity for the accumulation 
of macromolecules into tumor tissue. Small molecules can pass through the tight 
junctures of the blood capillaries in the endothelial cell layer (green, Figure 2.5). 
 
Figure 2.5 | Enhanced permeation and retention (EPR) effect (adapted from 
Haag et al.).97 
Macromolecules (large molecules, cells) on the other hand are too large to 
fit through the narrow passages; they can however enter through the “leaky” 
endothelial layer present in cancer tissue. The blood capillaries of the cancerous 
tissue are widened to allow for maximum blood and nutrient flow to the fast 
growing tissue.  Also, this diseased tissue has a poor lymphatic drainage system 
compared to healthy tissue. Due to the poor waste drainage, once 
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macromolecules enter the tumor cell matrix they tend to remain inside and are 
not readily cleared out.97 
The optimal size of macromolecules or nanoparticles to allow for size 
selectivity in the passive uptake of macromolecules into the tumor tissue 
compared to the healthy tissue is still debated.98,99 Many research groups claim 
that the smaller the particle size the better for the uptake. However there is a 
lower limit to allow for the differentiation from small molecules of <1 kDa.  Also a 
longer blood circulation time is required for the accumulation of the 
macromolecules into the tumor tissue.  Most healthy organisms have a renal 
clearance cutoff of ca. 30-50 kDa to restrict the loss of body proteins into the 
bladder.100 This molecular weight converts to a volume of ca. 2-5 nm.101 Having a 
hydrodynamic radius larger than 5 nm allows for a prolonged circulation and, 
therefore, greater accumulation into tumor tissue. 
Due to the “person-specific” nature of cancer, possessing a variety of 
phenotypes, a generic size of particle or macromolecule is not important. The 
optimal drug delivery system is simply one that works by taking advantage of the 
weak points like the EPR effect expressed by diseased tissues.  In addition to the 
EPR effect, tumor tissues are also hypoxic, which leads to a lower pH value 
(shown in Figure 2.5). 102   The lower pH can be advantageous for the 
development of acid labile prodrugs, which will be discussed more in Chapter 3. 
                                            
97 Haag, R.; Kratz, F. Polymer Therapeutics: Concepts and Applications. Angew. Chem. Int. Ed. 
2006, 45, 1198–1215. 
98 Fang, J.; Nakamura, H.; Maeda, H. The EPR Effect: Unique Features of Tumor Blood Vessels 
for Drug Delivery, Factors Involved, and Limitations and Augmentation of the Effect. Adv. Drug 
Deliv. Rev. 2011, 63, 136–151. 
99 Tang, L.; Yang, X.; Yin, Q.; Cai, K.; Wang, H.; Chaudhury, I.; Yao, C.; Zhou, Q.; Kwon, M.; 
Hartman, J. A.; et al. Investigating the Optimal Size of Anticancer Nanomedicine. Proc. Natl. 
Acad. Sci. U.S.A. 2014, 111, 15344–15349. 
100 P. Caliceti, F. M. Veronese, Pharmacokinetic and biodistribution properties of poly(ethylene 
glycol)-protein conjugates Drug Deliv. Rev. 2003, 55, 1261–1277. 
101 Erickson, H. P. Size and Shape of Protein Molecules at the Nanometer Level Determined by 
Sedimentation, Gel Filtration, and Electron Microscopy. Biol. Proced. Online 2009, 11, 32–51. 
102 Harris, A. L. Hypoxia—a Key Regulatory Factor in Tumour Growth. Nat. Rev. Cancer. 2002, 2, 
38–47. 
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2.5 Introduction to Silicon Chemistry 
Although the functionality of orthosilicates {Si(OR1)4, Si(OR1)3(OR2), 
Si(OR1)2(OR2)2, Si(OR1)2(OR2)(OR3), Si(OR1)(OR2)(OR3)(OR4)}  has been 
studied before and is an old chemistry,103 the use in the context of prodrug 
formulation is quite novel.  By varying the nature of the R-groups, great control of 
the physical and chemical properties of the silicates can be obtained.  This 
strategy is very attractive due to straightforward synthesis to access an array of 
radically different prodrugs.  More specifically the hydrophobicity of the prodrug 
(cLogP) can be tuned by choosing an alkyl-R of varying carbon chain length or 
“greasiness”.  Also the hydrolytic lability can be selected by the steric bulk 
surrounding the silicon center.  Since this approach to prodrugs is unexplored, 
there is a void in covered chemistries within patent literature, which can be 
capitalized upon.  
To start the discussion of the orthosilicate chemistry described in this 
thesis, a little nomenclature is needed to clarify the compounds.  Historically the 
names have been derived from the simplest parent compound SiH4 (silane).  As 
heavier atoms replace the hydrogens the name is adjusted to reflect the new 
compound as shown in the five examples below.  The nomenclature changes 
when four oxygen atoms are bound to the silicon to reflect the simplest parent 
compound Si(OH)4 (orthosilicic acid).  This naming is shown in the three 
examples below. When one hydrogen is replaced with a hydroxyl the compound 
is a silanol.  Uniquely when there are four Si-O bonds the compound is denoted 
as a silicate as shown with tetraethyl orthosilicate or tetraethyl silicate (TEOS).104 
                                            
103 Ebelmen, M. Ann. Chim. Phys. 1845 15, 319. 
104 Arkles, B. Silicon Esters. In Kirk-Othmer Encyclopedia of Chemical Technology, Fourth 
Edition, Volume 22; Kroschwitz, J. I.; Howe-Grant, M., ed. John Wiley & Sons, Inc: New York, 
1997, 69–81. 
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Figure 2.6 | Silane nomenclature used for the distinction between silicate esters 
and silanes. 
 
The naming of Si(OEt)4 and related compounds (4 Si-O bonds) is further 
complicated by multiple references citing them as a silicon or silicate esters. In 
discussion the “ester” is typically dropped and the compounds are referred to as 
“silicates”.  This creates confusion with the inorganic chemistry and geology 
communities because silicate anions (SiO4-4) are frequently encountered.105  The 
use of silicates or silicate esters in this thesis will always describe a compound 
with the formula of {Si(OR1)4, Si(OR1)3(OR2), Si(OR1)2(OR2)2, 
Si(OR1)2(OR2)(OR3), Si(OR1)(OR2)(OR3)(OR4)} and not the anion common in 
inorganic chemistry. 
 
Figure 2.7 | Silanol nomenclature used for the distinction between silicate esters 
and silanols. 
  
                                            
105 Wright, J. R. Bolt, R. O.; Goldschmidt, A.; Abbott, A. D. Silicate Esters and Related 
Compounds. I. Synthesis of Certain Tetraalkoxysilanes, Polyalkoxysilanes, Bis-(trialkoxysilyl)-
alkanes, and Related Intermediates. J. Am. Chem. Soc. 1957, 80, 1733–1737. 
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2.6 Prior Research using Silicon for Biomaterial Nanoparticles 
Although the use of hydrophobic silicon-based prodrugs envisioned to 
form stable nanoparticles was novel and an innovative strategy developed in the 
Hoye labs, recent published work shows the strategy of silicon functionalization 
of drugs can be applied to a variety of systems (Chapters 3, 6-7). During the 
development of this technology, there was a lack of direct precedent for the use 
of tetraalkoxysilanes as prodrug constructs. 
The Cheng group from the University of Illinois at Urbana-Champaign 
published their work with trialkoxyalkylsilane derivatives of known drugs for the 
incorporation into silica nanoparticles with well-defined architecture. The basic 
strategy employed by Cheng is to derivative the drug through a thioether ester 
linkage to form the trimethoxysilyl camptothecin (Figure 2.8, 227) or 
trimethoxysilyl paclitaxel (Figure 2.8, 228).106,107 The trialkoxyalkylsilane is used 
to anchor the prodrug into a nanoparticle composed of bulk silica (TEOS).  By 
using a modified Stöber process they are able to make monodisperse particles 
that can be adorned with PEG.  One should note that this strategy is different 
from the simple silicate promoiety and precipitation with a block copolymer 
discussed in this thesis.  Nanoparticles prepared by the Cheng and coworkers 
showed desirable biocompatibility and biodistribution; however due to the in vivo 
stability of the thioether ester linkage a modification to the linker was required.108 
                                            
106 Tang, L.; Yang, X.; Dobrucki, L. W.; Chaudhury, I.; Yin, Q.; Yao, C.; Lezmi, S.; Helferich, W. 
G.; Fan, T. M.; Cheng, J. Aptamer-Functionalized, Ultra-Small, Monodisperse Silica 
Nanoconjugates for Targeted Dual-Modal Imaging of Lymph Nodes with Metastatic Tumors. 
Angew. Chem. Int. Ed. 2012, 51, 12721–12726. 
107 Tang, L.; Fan, T. M.; Borst, L. B.; Cheng, J. Synthesis and Biological Response of Size-
Specific, Monodisperse Drug–Silica Nanoconjugates. ACS Nano 2012, 6, 3954–3966. 
108 Tang, L.; Gabrielson, N. P.; Uckun, F. M.; Fan, T. M.; Cheng, J. Size-Dependent Tumor 
Penetration and in VivoEfficacy of Monodisperse Drug–Silica Nanoconjugates. Mol. Pharm. 2013, 
10, 883–892. 
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Figure 2.8 | The structures of the thioether ester linked silicon-based prodrugs 
and nanoparticle strategy reported by Cheng.106,107,108,109  
 
Wang took advantage of Cheng’s design, 109  the development of two 
modified linkers, one of which is shown in Figure 2.9, allow for the facile cleavage 
of the drug from the silicon anchor and the linker.  Wang et. al report that the 
higher levels of glutathione in cancer cells allow for the cleavage of the disulfide 
bond shown in the camptothecin conjugate 229.  This cleavage allows for the 
molecule to be released from the silicon particle (made by in the same fashion as 
Cheng et. al) as the free thiol 230.  Finally, by way of a cyclization onto 
carbamate, the parent drug 232 is exposed along with the cyclic byproduct 231.  
Wang and co-workers also have developed a hydrazine-based linker (not shown) 
that is responsive toward pH.  By utilizing these labile linkers, the in vitro 
anticancer cytotoxicity indicated that the nanoparticle formulations were 
comparable to the parent drugs after 72 hours of incubation with cancer cells.110 
                                            
109 Tang, L.; Cheng, J. Nonporous Silica Nanoparticles for Nanomedicine Application. Nano 
Today 2013, 8, 290–312. 
110 Xu, Z.; Liu, S.; Kang, Y.; Wang, M. Glutathione- and pH-Responsive Nonporous Silica Prodrug 
Nanoparticles for Controlled Release and Cancer Therapy. Nanoscale 2015, 7, 5859–5868. 
N
N
O
O
O
O
S
O
Et
Si(OMe)3
O
AcO OH
OH
O
OAc
OBz
O
O
O
NH
H
Bz
S
Si(OMe)3
OCamptothecin
Conjugate
227 PTX Conjugate
228
90-80 wt% Si(OEt)4
TEOS Based Particles
Anchor
Thioether Ester
Anchor
Thioether Ester
mPEG-Link-Anchor
10-20 wt%
227 -or- 228
PEGylated
Nanoparticles
Part I: Anticancer Drug Delivery  Chapter 2 | 
 
 
49 
49 
 
Figure 2.9 | Modified linker structure to increase the bio-lability reported by 
Wang.110 
 
The DeSimone group has also utilized silyl ethers as hydrolytically labile 
linkers on biomaterials. Instead of using an ester or carbonate as the proximal 
functional group and the silicon at the distil site on the prodrug, DeSimone 
reversed the positions for his prodrug system.  This is very beneficial due to the 
inherit lability of the silyl ether compared to an ester, disulfide, or carbonate.  
Under acidic conditions the dialkyldialkoxysilanes cleaved the drug from the 
biomaterials. With DeSimone’s engineering expertise the group has successfully 
fashioned a variety of bio-devices (e.g. sutures, stents) and drug delivery 
systems (e.g. nanoparticles). The silyl ether bond stability towards acidic 
conditions can be modified by the choice of alkyl group as shown in Figure 2.10.  
More specifically, they modified the steric bulk around the silicon using diethyl, 
diisopropyl, and di-tert-butyl groups. When a model non-toxic drug was attached 
to the dialkyldialkoxysilane linker, they observed nontoxic biological properties of 
the compound as a whole or from byproducts resulting from the hydrolysis.111,112  
                                            
111 Parrott, M. C.; Luft, J. C.; Byrne, J. D.; Fain, J. H.; Napier, M. E.; DeSimone, J. M. Tunable 
Bifunctional Silyl Ether Cross-Linkers for the Design of Acid-Sensitive Biomaterials. J. Am. Chem. 
Soc. 2010, 132, 17928–17932. 
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Moving from the model systems that demonstrated the proof of principle 
and in vitro benign behavior of the silyl ether link, DeSimone and coworkers 
reported the use of dialkoxydialkysilanes as prodrugs of camptothecin (233), 
gemcitabine (234), and dasatinib (235) shown in Figure 2.10.  A suite of three 
different dialkyl groups was examined to determine the effect of steric bulk on the 
release rates of their prodrugs. Namely the [(ethyl, 233a, 234a, 235a), (isopropyl, 
233b, 234b, 235b), and (tert-buyl, 233c, 234c, 235c)] versions of the prodrugs 
along with hydroxyethyl acrylate were cross-linked with PEG-diacrylate 236 
through the acrylate moiety to form a polymer network. 
 
Figure 2.10 | Structures of all dialkoxydialkyl silane drug derivatives 233-235 
reported by DeSimone.112 
                                                                                                                                  
112 Parrott, M. C.; Finniss, M.; Luft, J. C.; Pandya, A.; Gullapalli, A.; Napier, M. E.; DeSimone, J. 
M. Incorporation and Controlled Release of Silyl Ether Prodrugs From PRINT Nanoparticles. J. 
Am. Chem. Soc. 2012, 134, 7978–7982. 
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The PEG-diacrylate (MW=1000) served as the hydrophilic portion, so that 
the macromolecule could be formulated into nanoparticles.  Interestingly, they 
determined that the hydrolysis and subsequent release of the parent drug was 
influenced by the steric bulk of the two alkyl units around the silicon.  This report 
gives encouraging results and precedent for the use of silicon as a prodrug 
construct that we will discuss in Chapter 3. 
Instead of incorporating dual functionality into the prodrug, we envisioned 
utilizing the silicon atom as both the labile moiety and anchoring into the 
nanoparticle through FNP.113  More specifically, Cheng used an ester as the 
labile link to release the drug and the silane as the anchor into nanoparticles, 
Wang utilized a disulfide and carbonate as the labile linker and silane as the 
anchor, and lastly DeSimone used the silane as the labile link and a cross linked 
polymer ester as the anchor.  We hypothesize that a silane of an appropriate 
hydrophobicity can serve as both the labile linker and the anchor to release the 
drug from nanoparticle.  This can be accomplished by the encapsulation of a 
drug-silicon-conjugate into a block copolymer through FNP. 
Before embarking on the design and synthesis of silanes or silicates for 
use as prodrug constructs, I performed a series of Reaxys® searches to 
determine the prevalence of functionalization at each hydroxyl in PTX. 114 Reaxys 
allows for wild cards to serve as any group (G*).  Initial substance searches using 
G* at C-1,C-2’, or C-7 quickly show that functionalization at the C-2’ position is 
the most common (721 vs 370 vs 2) and of those the silanes/silicates of PTX are 
shown in grey. The 2’,7-functionalized PTX is also quite prevalent. The number of 
reactions that generated a generic G* functionalized product 237-243 from PTX 
is shown in the fourth column from the right.  Again the 2’-monofunctionalized 
PTX (238) is dominate. However the 2’,7-bis functionalized (242) has 113 hits 
                                            
113 Hoye, T. R.; Wohl, A. W.; Macosko, C. W.; Panyam, J. Silicate prodrugs and nanoparticles. 
U.S. Patent Application PCT/US2012/040247, May 31, 2012. 
114 Reaxys, version 2.19790.2; Elsevier; 2015; RRN 969209 (accessed July 13, 2015). 
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compared with the 90 hits of the 7-monofunctionalized PTX compound (239).  
This suggests that the bis-derivative is typically made first followed by cleavage 
of the 2’-group.  This is further confirmed in the second column from the right.  
The bis-functionalized 242 is made from 238 considerably more than from 239. 
Also 239 arises from the bis-functionalized 242 more frequently than from PTX 
itself (184 hits vs. 91 hits). There is little to no reactivity at the C-1 hydroxyl (237, 
240, 241, 243). These searches match well with the literature reactivity 
differences of the hydroxyls of PTX, namely C-2’ > C-7 >> C-1. 
 
Figure 2.11 | Reaxys® searches showing the prevalence of hydroxyl 
functionalization of PTX. Reaction searches were run from every compound to 
the others and contained 0 hits unless otherwise noted in columns 12 and 13. 
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3.1 Silicate Ester Prodrug Hypothesis 
Below is a summary of the lengthy background information found in 
chapters 1 and 2, used to refresh and orient the reader to our hypothesis.  
Paclitaxel (PTX) is a potent antimitotic antitumor compound. It is the active agent 
in front-line chemotherapeutic drugs used for treatment of a variety of 
cancers.115,, 54 Because it is only minimally water-soluble, PTX is administered to 
humans as a drug formulation that is formed by its solubilization with  an 
emulsifier (a 1:1 (v/v) mixture of polyethoxylated castor oil and absolute ethanol), 
with human serum albumin, or with PEG-PLA. These formulations comprise a 
significant advance in chemotherapeutics, but the drug loading is relatively low 
(1.1, 10, and 16.7 wt% PTX, respectively), and in the case of the first significant 
undesirable side effects of the emulsifier are experienced by some patients. 
Similarly, the closely related taxane docetaxel (DTX) is administered as an 
ethanolic suspension of 4 wt/vol% DTX in polysorbate 80.  
Because these taxanes are such effective cytotoxins, new conceptual and 
practical strategies for improving the administration of PTX and DTX remain 
desirable. In particular, drug delivery vehicles containing higher drug loading 
levels than currently in the front-line drug formulations mentioned above have the 
potential to be quite advantageous. Accordingly, we envision that proper 
matching of the physicochemical properties of a taxane derivative with a suitable 
polymer-based drug carrier might allow for formulation of an effective 
nanoparticle drug delivery entity. One potentially attractive strategy is the 
incorporation of drugs into block-copolymer(BCP)-based nanoparticles (NPs) by 
rapid co-precipitation of the drug and the BCP in a process known as flash 
                                            
115 Ismael, G. F. V.; Rosa, D. D.; Mano; M. S., Awada, A. Novel cytotoxic drugs: Old challenges, 
new solutions. Cancer Treat. Rev. 2008, 34, 81–91. 
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nanoprecipitation (FNP).116,117  This can provide NPs with dimensions attractive 
from a drug delivery perspective and that are highly loaded (to ≥50 wt%) with the 
small molecule drug agent. FNP has been used to prepare NPs comprising PTX 
and various BCPs–in particular, the biocompatible poly(ethylene glycol)-b-
poly(ester) amphiphilic block polymers PEG-PCL, PEG-PLA, or PEG-PLGA 
[where the poly(ester) is poly(caprolactone), poly(lactic acid), or 
poly(lactic/glycolic acid), respectively].85,86 However, the resulting aqueous 
dispersions of these PTX-loaded NPs were kinetically unstable; the PTX exited 
the hydrophobic core of the particle and crystallized in the exterior in a matter of 
minutes, presumably via the mechanism of Ostwald ripening.82,80 We envision 
that this undesirable process could be arrested by use of a modified taxane 
derivative that is more hydrophobic than the parent drug molecule. Moreover, if 
that derivative is susceptible to reversion back to the parent taxane, say by 
simple hydrolysis, then it could serve as a taxane prodrug.118 
We hypothesize that silicate esters, tetra-alkoxy silanes [(RO)4Si], 
comprise a class of prodrugs that are well suited for the encapsulation into 
nanoparticles.  The general concept is portrayed in Figure 3.1. A parent drug 
molecule containing a reactive hydroxyl group is converted to its 
tetraalkoxysilane (the silicate derivative) by reaction with a 
trialkoxychlorosilane119 derivatizing agent.120 Eventual hydrolytic cleavage returns 
                                            
116 Johnson, B. K.; Prud’homme, R. K. Chemical processing and micromixing in confined 
impinging jets. AIChE. 2003, 49, 2264–2282. 
117 Johnson, B. K.; Prud’homme, R. K. Flash nanoprecipitation of organic actives and block 
copolymers using a confined impinging jets mixer. Aust. J. Chem. 2003, 56, 1021–1024. 
118 Wohl, A. R.; Michel, A. R.; Kalscheuer, S.; Macosko, C. W.; Panyam, J.; Hoye, T. R. Silicate 
esters of paclitaxel and docetaxel: synthesis, hydrophobicity, hydrolytic stability, cytotoxicity, and 
prodrug potential. J. Med. Chem. 2014, 57, 2368–2379. 
119 Corriu, R. J. P.; Granier, M.; Lanneau, G. F. Synthesis and reactivity of 
bis(triethoxysilyl)methane, tris(triethoxysilyl)methane and some derivatives. J. Organomet. Chem. 
1998, 562, 79–88. 
120 Wohl, A. R. Synthesis and characterization of silicate esters prodrugs and poly(ethylene 
glycol)-b-poly(lactic-co-glycolic acid) block copolymers for formulation into prodrug-loaded 
nanoparticles. Ph.D. Dissertation, University of Minnesota, Minneapolis, 2012. 
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the parent drug. Note that a number of studies imply that orthosilicic acid 
[Si(OH)4], the ultimate stoichiometric byproduct of silicate ester cleavage, does 
not pose any significant toxicity issues.121, 122, 123  The nature of the three auxiliary 
R groups in the silicate prodrug (Figure 3.1) would provide considerable flexibility 
in allowing for adjustment of the degree of hydrophobicity as well as the 
hydrolytic stability of the derivative.118 
 
Figure 3.1 | Potential silicate prodrug strategy. Modification of a hydroxyl group 
in the drug with a trialkoxychlorosilane generates the (labile) silicate derivative, 
which following administration under- goes hydrolysis to return the free drug 
along with benign alcohol and orthosilicic acid byproducts. 
 
After the appropriate model studies using simple alcohols were 
established some of which are presented in Part II: Chapter VI of this thesis, 
attention was devoted to PTX and DTX.  In this chapter the synthesis and 
selected properties of the desired taxane based silicates are reported.  Also the 
inherit lability: i.) rates of hydrolysis of the silicates back to the parent drugs, ii.) 
stability in biologically relevant media, and iii.) prodrug form after cell uptake are 
shown. 
  
                                            
121 Gitelman, H. J.; Alderman, F.; Perry, S. J. Renal handling of silicon in normals and patients 
with renal insufficiency. Kidney Int. 1992, 42, 957–959. 
122 Marco-Franco, J. E.; Torres, V. E.; Nixon, D. E.; Wilson, D. M.; James, E. M.; Bergstrahl, E. J.; 
McCarthy, J. T. Oxalate, silicon, and vanadium in acquired cystic kidney disease. Clin. Nephrol. 
1991, 35, 52–58. 
123 Anglin, E. J.; Cheng, L.; Freeman, W. R.; Sailor, M. J. Porous silicon in drug delivery devices 
and materials. Adv. Drug Deliv. Rev. 2008, 60, 1266–1277. 
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3.2 Silicate Ester Prodrugs of PTX and DTX 
From the extensive reactivity studies of PTX presented in Chapters 1 and 
2, we were confident that the reactions of chlorosilanes with PTX or DTX would 
occur smoothly.  We were however worried about the inherit lability associated 
with the silicate esters and whether purification on silica gel would cleave the 
functionality and return it back to the parent drug.  A suite of 
chlorotrialkoxysilanes was synthesized from silicon tetrachloride and aliphatic 
alcohols with a varying degree of steric hindrance at the silicon center, which will 
be described in detail in Chapter 3.3.  Gratifyingly, the initial model studies 
showed that silicates survived column chromatography and likewise the taxane-
based silicates could also be purified.120 
When describing the silicate esters of either PTX or DTX, we chose to 
name them according to the extent of functionalization.  When the C-2’ hydroxyl 
was modified the 2’-mono description shown in Figure 3.2 was used, namely 
mono PTX-2’-Si(OR)3.  Likewise the C-7 position was named as a 7-mono 
silicate, PTX-7-Si(OR)3.  Lastly the 2’,7-bis descriptor is used when both 
positions are modified with a silicate.  Although functionalization at the C-10 
hydroxyl of DTX is achievable, we opted to simply test the reaction, but refrained 
from taking these compounds on for sake of reducing the complexity.  
Nevertheless, when referring to a near exhaustive derivatization of DTX the 
2’,7,10-tris designation refers to DTX-2’,7,10-[Si(OR)3]3. 
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Figure 3.2 | Paclitaxel silicate conjugation at either the 2’-hydroxyl or the 7-
hydroxyl renders the drug highly hydrophobic. 
 
3.3 Synthesis of Silicate Ester Prodrugs of PTX and DTX 
To functionalize each taxane with a silicate ester, we took advantage of 
the known reactivity difference of the free hydroxyl groups in either PTX or DTX 
(Scheme 4). The reactivity rates are gleaned from the total synthesis and 
analogue synthesis presented in Chapter 1. In PTX the three hydroxyl groups are 
derivativized in a relative rate of C2' > C7 > C1,124, 3 which reflects, principally, the 
relative steric hindrance among the three.   In DTX the order of reactivity is C-2’ > 
C-7 > C-10 > C-1.  Selective mono-silylation at C2' in PTX to give the silicates 
301a-c was best achieved when a trialkylamine (e.g. triethylamine) was used as 
the base to promote reaction with the appropriate chlorosilane reagent (305a-c). 
The preparation of the requisite chlorosilanes 305b,125 305c,126 305d,127 
and 306 128 , 129  is indicated in Scheme 3.1 (panel c); 305a and 305e are 
                                            
124 Skwarczynski, M.; Hayashi, Y.; Kiso, Y. Paclitaxel prodrugs: Toward smarter delivery of 
anticancer agents. J. Med. Chem. 2006, 49, 7253–7269. 
125 Gerrard, W.; Howe, B. K. The behaviour of 1,1,1,3,3,3-hexachloropropan-2-ol with inorganic 
non-metal halides. J. Chem. Soc. 1955, 505–510.   
126 Chappelow, C. C.; Elliot, R. L.; Goodwin, J. T. The phenylation and methylation of 
alkoxychlorosilanes. J. Org. Chem. 1960, 25, 435–439.  
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commercially available. Use of the hindered tertiary alkylamine rather than 
pyridine showed greater selectivity for C2'-mono-silicate ester production with 
minimal formation of the C2',C7-bis-silicate esters.  
In the case of the hindered trimenthyloxychlorosilane reagent (301d), the 
second silylation at C7 was very slow. Accordingly, we experienced little difficulty 
in using the less selective catalyst, pyridine for the preparation of trimenthyl 
silicate derivatives. The mixed, tert-butoxy-containing silicates 301f-h were 
prepared using an excess of the bulky electrophile (tBuO)2SiCl2 (306) and 
pyridine as the base. As with the menthyl-containing reagent 301d, we again did 
not observe competitive reaction at C7. Addition of an excess of ethanol (for 
301f) or acetic acid (for 301g) to substitute the second chloride (as well as 
consume the excess of 306 still present) allowed isolation of the mixed silicates 
301f-h, respectively, albeit in overall modest to low yields. On one occasion a 
small amount of the tri(tert)butyl silicate 301e was isolated from an experiment 
using an in situ-generated (and less pristine) lot of the chlorosilane reagent 306. 
Attempts to prepare 301e using a commercial sample of (t-BuO)3SiCl (305e) and 
pyridine, even at elevated temperatures, gave no evidence of reaction. We 
presume that 301e was produced by way of the intermediate PTX-Si(O-tBu)2Cl 
followed by subsequent reaction with t-BuOH.  
The PTX C2',C7-bis-silicate esters 302a-d were best prepared using the 
less hindered pyridine as the base and a larger excess (3-4 equiv) of the 
(RO)3SiCl 305a-c. The C7-mono-silicate 303a-c derivative of PTX was accessed 
by selective hydrolytic cleavage [trifluoroacetic acid (TFA), H2O, acetone] of the 
more labile C2'-silicate ester present in the bis-derivative 302a-c, respectively. 
                                                                                                                                  
127 Beckman, J.; Daketernieks, D.; Tiekink, E. R. T. Chiral trialkoxysilanols derived from terpene 
alcohols. Molecular structures of tris([(1S)-endo]-(−)-bornoxy)silanol and tetrakis((−)-
menthoxy)silane. J. Organomet. Chem. 2002, 648, 188-192.  
128 Gerrard, W.; Woodhead, A. H. Interaction of alcohols with silicon tetrachloride. J. Chem. Soc. 
1951, 519–522. 
129 Miner, C. S., Jr.; Bryan, L. A.; Holysz, R. P., Jr.; Pedlow, G. W., Jr. tert-Alkoxyaminosilanes. 
Indust. Engin. Chem. 1947, 39, 1368–1371 
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Similarly, the DTX 2'-monosilicate esters 304a-e (Scheme 3.1, panel b) 
were prepared. In these experiments we chose to use a different tertiary amine, 
n-butyl(dimethyl)amine, and, as we conjectured, it showed comparably good C2' 
vs. C7 selectivity as triethylamine but a faster reaction rate under otherwise 
identical conditions.118 
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Scheme 3.1 | a Synthesis of silicate ester derivatives of PTX (301a-h, 302a-d, 
and 303a-b, panel a) and DTX (304a-e, panel b) and of the necessary 
chlorosilane derivatizing agents (305 and 306, panel c).  
 
a Conditions: (i) SiCl(OR)3 (305a-d), NEt3 (for 301a-c) or py (for 301d), THF. (ii) 
SiCl2(OtBu)2 (306), py, THF; then EtOH (for 301f or 301e) or AcOH (for 301g) or 
PivOH (for 301h).  (iii) SiCl(OR)3 (305a-c), py, THF. (iv) acetone, water, TFA 
(90/9/1, v/v/v). (v) SiCl(OR)3 (305a-d), n-BuNMe2 (for 304a-c) or py (for 304d), 
THF. (vi) alcohol, rt, pentane. (vii) t-BuOH (2.1 equiv), py, THF.  Yield of 
chromatographed taxane silicate: 301a (91%); 301b (81%); 301c (65%); 301d 
(62%); 301e (18%); 301f (93%); 301g (66%); 301h (12%); 302a (85%); 302b 
(77%); 302c (67%); 302d (35%); 303a (91%, brsm); 303b (66%, brsm); 303c 
(77% brsm); 304a (65%); 304b (64%); 304c (85%); 304d (44%); 404e (60%). 
brsm = based on recovered starting material. 
O
AcO OH
OH
O
OAc
OBz
O
O
OH
Ph
BzHN
2'
7
O
AcO O
OH
O
OAc
OBz
O
O
O
Ph
BzHN
H
301a
301b
301c
301d
301e
301f
301g
301h
302a
302b
302c
302d
303a
303b
303c
X
Si(OEt)3
Si(OnOct)3
Si(OiPr)3
Si(OMenth)3
Si(OtBu)3
Si(OtBu)2(OEt)
Si(OtBu)2(OAc)
Si(OtBu)2(OPiv)
X
Si(OEt)3
Si(OnOct)3
Si(OiPr)3
Si(OMenth)3
X
H
H
H
Y
H
H
H
H
H
H
H
H
Y
Si(OEt)3
Si(OnOct)3
Si(OiPr)3
Si(OMenth)3
Y
Si(OEt)3
Si(OnOct)3
Si(OiPr)3
PTX  (Paclitaxel)
2'H
1
X
Y
7
301       2'-mono-silicate esters
302         2',7-bis-silicate esters
303          7-mono-silicate esters
i)
ii)
iii)
iv)
O
HO OH
OH
O
OAc
OBz
O
O
OH
Ph
BocHN
2'
7
O
HO OH
OH
O
OAc
OBz
O
O
O
Ph
BocHN
H
304a
304b
304c
304d
304e
X
Si(OEt)3
Si(OnOct)3
Si(OiPr)3
Si(OMenth)3
Si(OtBu)2(OEt)
DTX  (Docetaxel)
2'H
1
X
304    2'-mono-silicate esters
v)
ii)
10
ClSi(OR)3
305a
305b
305c
305d
305e
R
ethyl
n-octyl
i-propyl
menthyl
t-butyl
Cl2Si(OtBu)2
1-octanol
2-propanol
(-)–menthol
vii)
SiCl4
ROH
vi)
305
306
a b
c
Part I: Anticancer Drug Delivery  Chapter 3 | 
 
 
61 
61 
3.4 Synthesis of “Specialty” Prodrugs of PTX and DTX 
Several more-exotic silicate constructs were also synthesized to address 
new questions.  These prodrugs were used to probe different aspects of the 
silicate prodrug strategy and/or to provide a proof of concept.  Triethylsilylether 
308a was used to test the importance of a silicate ester moiety for cytotoxicity.  
The hydrogen-silane 313 was synthesized to determine the stability of PTX-
silanes through hydrolysis.  Extreme hydrophobicity present in the phytol derived 
silicate 319, was explored to determine the effecton particle size and 
subsequently release. Lastly, the DTX bis-silicate 320a was used as a control to 
verify the cytotoxicity of the analogous PTX bis-silicates. 
Following the functionalization procedure of PTX with the requisite 
chlorosilane as shown in Scheme 3.1, the synthesis of the PTX-2’-TES (308a) 
went smoothly when PTX was reacted with triethylsilylchloride (TES-Cl) in the 
presence of pyridine base (Scheme 3.2). The reaction proceeded more slowly 
than the analogous reaction with triethoxychlorosilane (305a), showing only 50% 
conversion after 12 hours at room temperature.  The heating of the reaction to 45 
˚C for 3 hours resulted in > 90% conversion as determined by LC-MS.  Following 
purification by MPLC, a 45% yield of the product was obtained. 
Scheme 3.2 | Synthesis of 2’-triethylsilyl protected paclitaxel PTX (308a). 
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SiR3].  As discussed in detail below the half-life for hydrolysis of the silylether 
308a was observed to be 15 times slower than that of the corresponding silicate 
301a (Table 3.2).  The cytotoxicity of 308a was also compared to that of the 
silicate 301a; it showed a 25-fold decrease in potency (Table 3.4).  Also upon 
hydrolysis the trialkylsilyl moiety is converted to the trialkylsilanol which raise a 
separate set of toxicity issues.130 These studies show the importance of using a 
silicate as a prodrug construct over alkyl-silane chemistry. 
Since the trialkylsilane based prodrug 308a showed poor cytotoxicity, a 
slower rate of hydrolysis, and degrades into the silanol, the hydrogen-based 
silanes were explored. Trichlorosilane (310) was reacted with 2.2 equivalents of 
n-octanol to afford the monochlorosilane 311 (Scheme 3.3).  Since a slight 
excess of the alcohol was used, the corresponding trioctyloxysilane (312) was 
observed by GC-MS. The reaction mixture containing 80% of the 
monochlorosilane was used without purification and reacted with PTX in the 
presence of N,N-dimethylbutylamine base.  The hydrogen-based silane, PTX-2’-
Si(H)(OnOCt)2 313, was obtained in a 59 % yield as shown in scheme 3.3. 
  
                                            
130 Showell, G. A.; Mills, J. S. Chemistry Challenges in Lead Optimization: Silicon Isosteres in 
Drug Discovery. Drug Discov. Today 2003, 8, 551–556. 
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Scheme 3.3 | Synthesis of PTX-2’-dioctyloxysilane (313). 
 
The hydrolysis rate of (313) was compared to the relative rate of the 
analogous silicate PTX-2’-Si(OnOct)3 (301b) (Table 3.2). Silane 313 is 1.5 times 
slower than 301b. This indicates that the use of hydrogen for the replacement of 
a primary alkoxy group does not increase lability.  Although the hydrolysis data is 
encouraging, no biological experiments were performed on the compound.  
Interestingly, the use of the silane allows for the reduction in the molecular weight 
of the prodrug while maintaining the hydrolytic stability. 
Instead of exploring more of the hydrogen based silanes rate of hydrolysis, 
we turned our attention to drastically alter the hydrophobicity of silicate based 
prodrugs.  We envisioned creating a hydrophobic prodrug that was so lipophilic 
that the release from a nanoparticle would not occur unless the silicate 
hydrolyzed.  To meet this goal, we turned to dihydrophytol (DHP) as the lipophilic 
side chain.  
Phytol (314) was hydrogenated by hydrogen at 40 psi in the presence of 
water and sodiumbicarbonate over a powdered bed of platinum(II)oxide (scheme 
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3.4).131  Dihydrophytol 315 was purified by flash chromatography, to provide the 
primary alcohol.  The removal of the alkene was done to mitigate any problems 
that may arise from silylation of an allyl alcohol.  The addition of DHP to silicon 
tetrachloride required the use of pyridine and THF to facilitate the formation of the 
tridihydrophytolchlorosilane (316) as well as the fully substituted silicate (317).  
Attempts were made without the presence of base, however only the mono- and 
di- adduct were observed.  The mixture containing the monochlorosilane was 
added to PTX dissolved in THF and allowed to react for > 96 hours.  Periodically, 
an aliquot of the reaction was removed and analyzed by NMR spectroscopy.  
Once downfield shifts were observed on the C2’ and C7 methine protons the 
reaction was purified by MPLC.  We were pleased when the crude 1H-NMR 
indicated functionalization to the product, because previous attempts to generate 
the product with varied sources of the chlorosilane 316 and the different bases in 
THF had failed. 
  
                                            
131 Burns, C. J.; Field, L. D.; Hashimoto, K.; Petteys, B. J.; Ridley, D. D.; Rose, M. Synthesis of 
Stereoisomerically Pure Monoether Lipids. Aust. J. Chem. 1999, 52, 387–394. 
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Scheme 3.4 | Synthesis of PTX-7-Si(DHP)3 (303p) from phytol (314). 
 
 
After three sequential purifications by MPLC, the C7 functionalized 
prodrug (303p) was isolated and characterized by NMR.  We hypothesize that 
the bis-adduct (302p) was formed, but during all of the handling the C2’ silicate 
cleaved.   Although the C2’ prodrug was not isolated, the C7 prodrug (303p) 
analogous to 303b provided a stable sample that was used to probe the effect of 
hydrophobicity.  Due to the recovery of a small amount of a material the reaction 
was optimized in hopes to obtain the C2’-silicate 301p. 
Initial attempts at optimizing the reaction included: i.) heating the reaction 
mixture (PTX, py, 316, and THF) up to 45 ˚C, ii.) changing the source of 
chlorosilane to a more pure starting material 316, iii.) changing the base to N,N-
dimethylbutylamine, and iv.) changing the solvent to CDCl3 or CH2Cl2.  
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everything was homogenous throughout the reaction (pyridinium chloride salt 
was fully soluble in CDCl3) the reaction proceeded smoothly.  The CDCl3 solvent 
system was chosen to easily monitor the reaction by 1H-NMR.  The C2’-silicate 
was isolated by MPLC along with a minor amount of bis-functionalized material.  
The stability of 301p was probed through hydrolysis and is compared in chapter 
3.5.  I was thrilled to synthesize this compound as it has the highest 
hydrophobicity to date with a clogP of 8.50, and yet a reasonable rate of 
hydrolysis (t1/2 = 130 mins). 
Scheme 3.5 | Synthesis of PTX-2’-Si(DHP)3 (301p) 
 
 
We were very interested in determining the size of the particles generated 
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followed the bis-functionalization procedure shown in Scheme 3.6, however the 
functionalization had to be monitored due to the use an excess of the silyating 
agent (305a) and the ability to derivatize the C10 hydroxyl in DTX (scheme 3.6).  
Upon full conversion of the reaction the bis-silicate ester (318a) was isolated after 
column chromatography.  As expected the derivatization increased the IC50 
compared to the mono-functionalized 304a and the parent DTX (Table 3.4).  This 
trend followed the decrease in potency as seen in the PTX series of silicates. 
Although reactions with an excess of 305a and 305c showed the formation 
of tris-adducts in which the C10 hydroxyl is also functionalized by LC-MS, we 
chose refrain from isolating these compounds.  Ultimately, the C10 hydroxyl 
could serve as another handle to modify hydrophobicity and hydrolytic lability. 
Scheme 3.6 | Synthesis of bis-silicate ester of DTX (318a). 
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3.5 Hydrophobicities and Hydrolytic Lability of Taxane Prodrugs 
 
3.5.1 Hydrophobicity Indicators for Taxane Prodrugs 
The relative hydrophobicities of the silicate esters was assessed in several 
ways. Qualitatively, we observed the expected trend that the silicates with 
greasier alkyl groups traveled faster on silica gel during thin layer and preparative 
chromatographic experiments.  A more quantitative measure of this same trend 
was observed from measurement of the retention times on a reversed-phase 
HPLC column (Table 3.1, column 4). In addition, two empirical indicators of 
hydrophobicity show similar trends: i.) calculated octanol:water partition 
coefficients (cLogP values, Table 3.1, column 5)132 and ii.) calculated aqueous 
solubilities (Table 3.1, column 6). 133   It has been noted that calculated 
hydrophobicities can vary tremendously depending on the weights assigned for 
each functional group in the empirical equations.134 
Additional calculated values of the octanol:water partition coefficients from 
a variety of programs is shown in the supporting information (SI, Table S3.1).  
The calculated water solubility gives a sense of the highly hydrophobic nature of 
these prodrugs (SI, Table S3.2).  Lastly, empirical calculations of the structure 
are shown in SI Table S3.3.  The calculated volume, total number of non 
hydrogen atoms/number of oxygen and nitrogen atoms/number of O-H and N-H 
bonds [natoms/nON/nOHNH], number of rotable bonds [nrotbonds], and 
Molecular Polar Surface Area [TPSA], serve as guidelines to determine how 
“drug like” the prodrugs are.  Although none of these calculated values solely 
                                            
132 Tetko, I. V.; Gasteiger, J.; Todeschini, R.; Mauri, A.; Livingstone, D.; Ertl, P.; Palyulin, V. A.; 
Radchenko, E. V.; Zefirov, N. S.; Makarenko, A. S.; Tanchuk, V. Y.; Prokopenko, V. V. Virtual 
computational chemistry laboratory—design and description. J. Comput. Aid. Mol. Des. 2005, 19, 
453–463. 
133 Tetko, I. V.; Tanchuk, V. Y.; Kasheva, T. N.; Villa, A. E. Estimation of aqueous solubility of 
chemical compounds using E-state indices. J. Chem. Inf. Comput. Sci. 2001, 41, 1488–1493. 
134 Eros, D.; Kovesdi, I.; Orfi, L.; Takacs-Novak, K.; Acsady, G.; Keri, G. Reliability of logP 
predictions based on calculated molecular descriptors: a critical review. Curr. Med. Chem. 2002, 
9, 1819–1829. 
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defines the drugs, collectively they are indicative of molecular structure and show 
the breath of this silicate prodrug strategy for nanoparticle formulations.  
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Table 3.1 | Hydrophobicity indicators for the silicate esters 301–313. 
     retention time calcd octanol:water calculated 
 Sub- 2' 7 tR (min)a partition coefficient aqueous solubility  
 strate alkyl alkyl  C18 (ODS) (cLogP)b (cLogS133 mg/L) 
  PTX - - 10.5   3.20  5.56 
  301a Et - 13.8   4.96  2.66 
  301b nOct - 22.1   7.74  0.24 
  301c iPr -  15.4   5.60  1.57 
  301d menthyl -  24.5   7.37  0.25 
  301f (tBu)2/Et -  16.1   5.81  0.94 
  301g (tBu)2/Ac -  – c    5.32  0.98 
  301h (tBu)2/Piv -  16.2d  5.83  0.66 
  301p  DHP  - – e    8.50  0.028 
 
  302a Et Et  16.6   6.31  1.70 
  302b nOct nOct  – e    8.59  0.13 
  302c iPr iPr 18.9   6.84  0.87 
  302d menthyl menthyl – e    8.06  0.090 
  302p DHP DHP – c    7.88  0.021 
 
  303a - Et  14.6   5.05  2.33 
  303b - nOct 24.6   7.84  0.22 
  303c - iPr 16.4   5.64  1.44 
  303p  -  DHP – e    8.52  0.025 
 
 308a (PTX-SiEt3) -  15.4   5.40  1.06 
  313  (nOct)2/H -  23.2   7.07  0.27   
  DTX - - 10.9   2.83  12.72 
  304a Et - 14.1   4.05  6.84 
  304b nOct - 22.4   7.34  0.32 
  304c iPr - 15.9   4.99  3.78 
  304d menthyl -  26.1   7.02  0.29 
  304e (tBu)2/Et - 16.4   5.29  2.58 
 
  318a Et Et  13.9f  5.81  3.92 
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a Each retention time was determined by gradient elution‡ from LC-MS on an (octadecyl)silyl 
(ODS, C18) column [5 µm, 4.6 (i.d.) x 150 mm] using a flow rate of 1 mL/min. ‡56/44% 
methanol/water to 98/2% methanol/water (15 mM NH4OAc) over 15 min followed by an 
appropriate final hold time.  
b aLogP132 data shown here; see SI (Table S3.1) for the values from these additional empirical 
predictors of cLogP: AC logP, KOWWIN, miLogP, XLOGP3; the trends among the values from 
any of these methods are very similar for all of the predictors.  
c Not determined. 
d retention time was determined by gradient elution‡ from LC-MS on an (octadecyl)silyl (ODS, 
C18) column [5 µm, 4.6 (i.d.) x 150 mm] using a flow rate of 1 mL/min. ‡28/72% methanol/water 
to 98/2% methanol/water (15 mM NH4OAc) over 30 min followed by an appropriate final hold 
time. The pivilate hydrolysis product silanol had a Rt of 13.8 min. 
e Not observed; elution time >60 min. 
f retention time was determined by gradient elution‡ from LC-MS on an (octadecyl)silyl (ODS, 
C18) column [5 µm, 4.6 (i.d.) x 150 mm] using a flow rate of 1 mL/min. ‡75/25% methanol/water 
to 98/2% methanol/water (15 mM NH4OAc) over 15 min followed by an appropriate final hold 
time.  
 
As anticipated the “specialty silicates” derived from the 18-carbon 
isoprenoid phytol gave the greatest hydrophobicities.  Interestingly, the aLogP 
program begins to top off at a value of 8.5, as the 302p prodrug showed a lower 
clogP than either of the mono-silicates (301p, 303p).  This further validates the 
need to use multiple clogP values to give a feel of hydrophobicity. 
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3.5.2 Hydrolytic Lability of Taxane Prodrugs 
We anticipated that these silicates would also differ in their hydrolytic 
lability given the differences in steric bulk at the silicon atom of the silicate esters 
across the series. We explored this question by devising a 1H NMR 
spectroscopy-based method 135  to establish the relative rates of chemical 
hydrolysis of the derivatives (Table 3.2). By design, these silicate esters were 
sufficiently highly hydrophobic to render them only marginally soluble in buffered 
aqueous solutions. To get meaningful fundamental understanding of the 
hydrolytic lability under acidic conditions, we deemed it essential to identify a 
common set of conditions under which each of the silicates would be fully 
soluble—that is, homogeneity is paramount. We determined that a 10:1 (vol:vol) 
ratio of acetone:water would solubilize all of these silicates at concentrations 
suitable for NMR analysis. We then established that use of 1% TFA in this 
solvent mixture (measured pH = 0.8) at ambient temperature led to rates of 
silicate ester cleavage that could be conveniently monitored spectroscopically. 
The change in intensity over time of the chemical shifts of H2', H3', H7, and/or 
the OCH resonances in the R groups as the silicates were cleaved to release 
PTX and ROH was monitored. For all silicates not containing a menthyloxy or t-
butoxy moiety (Table 3.2, footnote b), we saw no evidence for partially 
hydrolyzed silanol intermediates [i.e., (RO)nSi(OH)4-n]. This suggests that the 
initial hydrolysis event (i.e., cleavage of the first Si–OR bond) is the rate-limiting 
step and that the initially formed monohydroxysilane then degrades, sequentially 
but faster, to release all of its alcohol moieties, including the free drug. 
The relative rates of hydrolysis (krel) of 301-304, normalized to the least 
reactive silicate, the PTX-menthyloxysilicate 301d, are shown in Table 3.2. As 
anticipated, increase in steric bulk of the silicate near the silicon center slows its 
                                            
135 Turner, C. W.; Franklin, K. J. Studies of the hydrolysis and condensation of 
tetraethylorthosilicate by multinuclear (1H 17O 29Si) NMR spectroscopy. J. Non-Cryst. Solids 1986, 
91, 402–415. 
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hydrolysis rate. The krel values differ by >2000 between the extremes of the 
triethyl PTX-silicate 301a vs. the hindered trimenthyl silicate ester 301d. The 
hydrolysis rates for the triethyl vs. trioctyl silicates 301a vs. 301b (for PTX) or 
304a vs. 304b were similar (difference in krel of ca. 3), which shows that the 
hydrophobicity of the silicate can be significantly altered with only a small 
accompanying change in the relative hydrolysis rate. PTX-silicates at the more 
hindered C7-position hydrolyzed ca. 7-15 times more slowly than those at C2’. 
Moreover, (i) the rate difference for cleavage of silicates at these two sites 
increased slightly as the bulk of the alkyl groups increased in the series of ethyl 
to n-octyl to iso-propyl, and (ii) the trends were the same whether comparing the 
differences at C7 vs. C2' for both the mono-silicates (301a vs. 303a, 301b vs. 
303b, and 301c vs. 303c) as well as those same sites within each of the bis-
silicates 302a-c. 
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Table 3.2 | The relative rates of hydrolysisa of the PTX (301-303, 308, 313) or 
DTX (304) silicates. The krel values are benchmarked relative to that of the PTX-
trimenthyloxy derivative 301d, the PTX-silicate having the slowest observed rate 
of hydrolysis. 
Sili- at C2’  at C7 
cate ___________________________________
 __________________________ 
 2'-silicate t1/2  kobs  ca. krel 7-silicate t1/2  kobs ca. krel 
 alkyl (min)  (10-6 s-1)  alkyl (min) (10-6 s-1)   
301a Et 3.7 3100 ±900 18,000 –  
301b nOct 12  960  ±40 5,600 –  
301c iPr 120  97  ±6 570 –  
301db menthyl 69,000  0.17  ±0.002 1.0 –  
301fb (tBu)2/Et 12,000  0.96 ±0.1 5.6  –  
301gb(tBu)2/Acc 35  330 ±20 1,900  –  
301p DHP 130  89 ±2 530  –   
302a Et 4.6  2500 ±100 15,000 Et 33 350 ±20 2100 
302b nOct 18  640 ±10 3,800 nOct 200  58 ±4 340 
302c iPr 130  89  ± 5 520 iPr 1500 7.8 ±2 46  
303a –     Et 30. 380 ±10 2200 
303b –     nOct 150 77 ±5 450 
303c –     iPr 1700 6.7 ±2 39  
308a (PTX-SiEt3) 56  210  ±2 1,200 – 
313  (nOct)2/H 19 610  ±6 3,600 –  
304a Et 11  1100  ±100 6,500 – 
304b nOct 26  440  ±40 2,600 – 
304c iPr 260 45  ±5 260 – 
304db menthyl 78,900  0.15  ±0.02 0.88 – 
304eb (tBu)2/Et 13,600 0.85  ±0.09 5.0 – 
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a Each silicate in a solution of acetone-d6/D2O/CF3CO2H (90/9/1) at a concentration of ca. 0.01 M 
was kept at ca. 22 °C and the reaction progress monitored periodically and continuously by 1H 
NMR spectroscopy.   b NMR analysis suggested the presence of steady-state levels (typically 
≤10%) of intermediate, partially cleaved silicates [i.e., (RO)4-nSi(OH)n, where n = 1-3], which 
underwent further clean conversion of the fully hydrolyzed alcohols, including the taxane.  c Acetyl 
(CH3CO), which is part of an acetoxy substituent on the silicate oxygen atom. 
 
Control over the hydrolysis is required to give a slow release over time and 
to avoid a burst of drug and by-products.  The rate and the mechanism of 
hydrolysis of the prodrugs resemble that of model studies of tetramethyl 
orthosilicate (TMOS) and tetraethylorthosilicate (TEOS).  The rate of hydrolysis is 
pseudo-first order by way of an SN2 mechanism (assuming the hydrolysis 
mechanism is similar to the TMOS and TEOS silicates). This kinetic data requires 
an excess of water and is solvent-dependant.  Systematic studies to further 
understand the hydrolysis of mixed orthosilicate prodrugs based upon their steric 
and electronic features have been performed and a manuscript describing these 
results is in preparation. 
The rate can be easily tuned by the use of different alcohols used to 
create the silicate.  Both steric and electronic effects can be tuned to give optimal 
hydrolysis and release from nanoparticles.  Even though the longer aliphatic 
alcohol 315 yielded an extremely more hydrophobic silicate 301p compared to 
301d, the rate of hydrolysis was 530 times faster than 301d and similar to the 
less hydrophobic isopropyl derived silicate 301c. 
We were interested in the difference in hydrolysis rate as a function of pH.  
A 1:100 D3PO4:D2O stock solution was made.  The pD was adjusted by adding in 
an appropriate volume of a K3PO4 : D2O stock solution. Five values of pD were 
made using the procedure above as well as a control in which the only D2O was 
used for the 1H-NMR analysis.  The pD was calculated by measuring the pH and 
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adding 0.4 and the values are presented in Table 3.3 below.136,137,138 From the 
five ranges of pH, two were taken on to determine the hydrolysis rate as a 
comparison to the TFA standard conditions. 
Table 3.3 | The relative rate of hydrolysis as a function of pH for 301b. 
    Stock Organic Calculated  
 Acid/  D2O Volume Volume  Half-life  
 D2O pD (vol%)a (µL) (µL) (min) Krelc 
  d-TFA 1.2 90% 100  900b  12 720 
  D3PO4 2.4 99% 700  300c  6,900 1.3 
 CD3CO2D 2.8 90% 50   450b  210 42.0 
 CD3CO2D 2.8 90% 50   450c  2100 4.1 
  D3PO4 4.5 99% –   –    – – 
  D3PO4 5.4 99% 700  300c  8,600 1.0 
  D3PO4 6.4 99%  –   –    – – 
  D2O 7.5 100%  700  300c  8,600 1.0 
  D3PO4 8.0 99% –   –    – – 
 
a Volume % (vol%) of D2O present in the Acid/D2O stock solution   b The PTX-Si(OnOct)3 301b 
(~2.0 mg) was dissolved in d6-Acetone and the aqueous solution was kept at ca. 22 °C and the 
reaction progress monitored periodically and continuously by 1H NMR spectroscopy. c The PTX-
Si(OnOct)3 301b (~2.0 mg) was dissolved in d4-Methanol and the aqueous solution was kept at 
ca. 22 °C and the reaction progress monitored periodically and continuously by 1H NMR 
spectroscopy. c Krel is the relative rate of hydrolysis when compared to the D2O control solution 
set at Krel = 1.0. 
As the acidity of the solution decreased a much slower hydrolysis rate was 
determined by integrating the conversion of the prodrug back to parent PTX and 
                                            
136 Glasoe, P. K.; Long, F. A.; Use of glass electrodes to measure acidities in deuterium oxide. J. 
Phys. Chem. 1960, 64, 188—189. 
137 Gary, R.; Bates, R. B.; Robinson, R. A. Second dissociation” constant of deuteriophosphoric 
acidin deuterium oxide from 5-50°. Standardization of a pD scale. J. Phys. Chem. 1964, 68, 6–9. 
138 Long, F. A.; Dahlgren, G. Relative hydrogen bonding of deuterium. I. Ionization constants of 
maleic and fumaric acids of their nonethyl esters in H2O and D2O. J. Am. Chem. Soc. 1960, 82, 
1303—1308. 
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the evolution of octanol during the course of the experiment.  We were surprised 
that the rate decreased dramatically. As expected, once the solution was around 
typical biological pH the rate of hydrolysis was ca. the same as the no acid 
control sample (D2O only).  This study shows that the silicate ester prodrugs are 
actually quite stable in aqueous environments.  Further analysis of the stability of 
the prodrugs in presented later in this chapter. 
 
3.6 In Vitro Cytotoxicity of PTX and DTX Prodrugs 
Cytotoxicity of the PTX-silicates (301-303, 308a) and DTX-silicates (304a-
304e, 318a) was examined against MDA-MB-231 cells (Table 3.4). We used this 
as a model cell line representing triple negative breast cancer, a malignancy for 
which taxanes are used as front-line agents. Silicates having faster rates of 
hydrolysis (Table 3.2) tend to show cytotoxicities similar to those of the parent 
taxane. This suggests that the silicate esters are hydrolyzed back to PTX or DTX 
either in the culture medium or inside the cell during the course of the assay. 
Experiments to determine the form of 302a inside and outside the cell are 
presented in Chapter 3.7.  The details of the experimental design to determine 
the IC50 values are shown in the supporting information for Chapter 3.  
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Table 3.4 | Cytotoxicity (IC50) of PTX, PTX-silicates (301-303), PTX-silane (308a) 
DTX, and DTX-silicates (304,318a) in MDA-MB-231 cells.a 
 PTX Compounds IC50 (nM)b DTX Compounds IC50 (nM)b 
 _______________ _________ _______________ _________ 
 PTX 5.6 DTX 1.0  
 301a 8.3 304a 2.5  
 301b 7.0 304b 9.7  
 301c 4.2 304c 0.2  
 301d 590 304d 720  
 301f 260 304e 430  
 302a 12 318a 6.5 
 302b 280  
 302c 1600  
 302d 240  
 303a 18  
 303b 290  
 303c 260  
PTX-2’-SiEt3 308a 220 
a Cell viability was measured after 72 h.  b The reported data are the median values for the 
distribution of IC50 values falling within the 95% confidence interval. 
 
We were interested in a possible increase in the in vitro cytotoxicity of the 
silicate prodrugs with the use of acidic medium for the cell assay.  It was 
envisioned that the increased acidity of the medium would more closely mimic 
the microenvironment of tumor tissue.  To accomplish this, stock solutions of 
acidic cell culture media (pH ~ 2.5) were further diluted in each well by adding 
100 µL of the acidic media to cells with 100 µL of regular growth media 
[(Minimum Essential Medium (MEM) with 10% Fetal Bovine Serum (FBS)] to 
obtain a pH = 5.75. The prodrugs were then added as a DMSO stock solution at 
different concentrations. The plate was then placed in a cell culture incubator at 
37 ˚C for 72 h.  An MTT assay was performed to determine the IC50 as done 
before (Supporting Information) and tabulated below.  The IC50 values of the 
regular growth media (RGM) are reproduced below (left side of columns 2 and 4 
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Table 3.5) to serve as a comparison with the acidic media treated cells.  The cells 
treated with media at pH = 5.75  show a slight increase in the potency. However, 
they did not show an equal potency in the IC50 when compared with the parent 
drug, PTX or DTX. The 303b prodrug did show an overall increase in potency, 
likely due to hydrolysis in the media.  The slow hydrolyzing prodrug 304d showed 
little to no cytotoxicity in RGM, but gave a more potent IC50 value when treated in 
acidic media.  Although improved cytotoxicities were shown by this experiment, 
we chose not to probe other compounds further in vitro.  We instead turned our 
attention toward in vivo experiments for the nanoparticle formulations (Chapter 
6). 
 
Table 3.5 | Cytotoxicity (IC50) of PTX, PTX-silicates (301-303), DTX, and DTX-
silicates (304) in MDA-MB-231 cells in: i.) regular growth media (RGM) Values in 
grey have been reproduced from Table 3.4 and included for reference, and ii.)  
acid growth media.   
 PTX Compounds IC50 (nM)a DTX Compounds IC50 (nM)a 
 _______________ _________ _______________ _________ 
 PTX 5.6 | 3.3 DTX   1.0 | 0.40  
 301b 7.0 | 4.6 304a 2.5 | 1.8  
 302b 280 | 230 304d 720 | 130  
 302d 240 | 220    
 303b 290 | 130    
a Cell viability was measured after 72 h in acidic media at pH = 5.75. The reported data are the 
median values for the distribution of IC50 values falling within the 95% confidence interval. 
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3.7 Prodrug Stability in Biologically Relevant Media 
Although the hydrolytic lability determined in situ by 1H-NMR is useful in 
determining trends of silicate prodrug stability, it did not provide conditions that 
the prodrugs would likely be subjected to during typical experiments.  We first 
examined the stability of the prodrugs to wet acetonitrile (ACN).  These 
conditions were explored to determine apparent stability for a long queue of 
samples for HPLC analysis after tissue extraction. 
To probe the stability and storage of 302a, a stock solution of 302a was 
made in ACN.  An aliquot containing 20 µg of 302a was diluted to in 1 mL of 
HPLC grade ACN that contained 5 µL of water in a septa capped HPLC vial and 
placed on the auto-sampler of an LC-MS.  Over the course of 22 days a 5 µL 
injection was analyzed for the amount of the bis-silicate 302a, mono-silicate 
303a, and PTX species present by calculating the integration values at 227 nm 
from a calibration curve (all samples were run in triplicate).  The percentage of 
each species was plotted as a function of time as shown in Figure 3.3 below.  
The raw integral value at 227 nm for each species and the calibration curve is 
shown in the supporting information (SI, Figures S3.5–S3.7). 
The bis-functionalized 302a is reasonably stabile in ACN for ca. a week, at 
which point there is 50% of the mono-silicate 303a.  After another week sitting in 
the HPLC vial at room temperature, essentially all of the 302a prodrug has 
cleaved at the 2’-position to give 303a and yet no free PTX can be quantified.  
This stability study offers the suggestion that prodrug stock solutions in ACN are 
not entirely stable, the apparent half-life (t1/2) of 302a in wet acetonitrile is one 
week, and that the 303a prodrug is very stable in ACN. 
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Figure 3.3 | The 302a prodrug stability in wet acetonitrile over the course of 22 
days plotted as a percentage of the total mixture vs. time. 
 
We were interested in the fate of the silicate prodrugs when subjected to 
phosphate buffered saline (PBS).  By performing the same procedure described 
above in an aqueous system, we could compare the rate of degradation iwith 
other aqueous conditions such as: the NMR hydrolysis, cell uptake, and later 
release data collected by Jing Han.139  In this experiment 20 µg of 302a was 
dissolved in 0.5 mL of ACN, and 0.5 mL PBS, pH 7.4.  The ACN was used to 
ensure homogeneity of the very hydrophobic prodrug. The samples were then 
allowed to sit capped at room temperature in the LC-MS auto-samper.  Over the 
course of 22 days, the amount of compounds 302a, 303a, and PTX were 
calculated by the integration values at 227 nm, as described before. 
In an aqueous buffer system, 302a is completely converted to the mono-
silicate 303a in only three days, and further hydrolysis of the mono silicate 
prodrug to free PTX ensues (Figure 3.4).  The apparent half-life of 302a was on 
                                            
139 Han, J. Diblock copolymer stabilized nanoparticles for drug delivery via flash nanoprecipitation. 
Ph.D. Dissertation, University of Minnesota, Minneapolis, 2014. 
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the order of hours, which implies that the unprotected silicate prodrug is 
extremely labile in aqueous buffers.  Not shown, are the results of an acid study 
in which a formic acid buffer (pH 4.5) system was used as the co-solvent with 
ACN. The experiment with an acidic solvent system showed very fast hydrolysis 
of 302a completely to give PTX in less than 1 day and 303a was not observed.  
These studies demonstrate the importance of the polymer to protect the labile 
prodrug. 
 
Figure 3.4 | The 302a prodrug stability in a 1:1 mixture of acetonitrile to PBS (pH 
=7.4) over the course of 22 days plotted as a percentage of the total mixture vs. 
time. 
To probe the stability in a more biologically relevant system, Gibco® 
Minimum Essential Medium (MEM) with 10 % fetal bovine serum (FBS) was used 
as the matrix.  Stock solutions of PTX-2’-Si(OnOct)3 (301b), PTX-7-Si(OnOct)3 
(303b), PTX-2’-Si(OiPr)3 (301c), were prepared at 1 mg/mL in ACN.  A 40 µL 
aliquot of each was placed into six separate HPLC vials which corresponded to 
20 µg of each prodrug.  To each sample 10 µL of a 1 mg/mL DTX stock solution 
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was added to serve as an internal standard (I.S.).  The resulting 50 µL of ACN 
containing the prodrugs and DTX was diluted with 950 µL of MEM 10% FBS 
media.  The samples were then placed on the auto-sampler and held at room 
temperature over the course of 150 hours.  At predetermined time points 5 µL 
injections were analyzed by LC-MS.  We were pleased to find that the media did 
not interfere with the chromatography or the mass spectrometry, which showed 
small amount of matrix components eluting well before the compounds on a C-18 
Ace® column.  The integral values at 227 nm were analyzed against a calibration 
curve of the ratio of PTX/DTX or (301b/DTX, 303b/DTX, 301c/DTX) respectively.  
From the raw integral values the percentage of PTX to prodrug was plotted as a 
function of time to determine the stability of each toward media hydrolysis.   
The most labile of the prodrugs 301b (t1/2 = 12 mins NMR) analyzed by 
this method showed immediate hydrolysis in the media, only 4% of the prodrug 
remained after 4 hours (Figure 3.5).  This suggests that for the in vitro cytotoxicity 
assay the cells are treated predominately with the parent drug and accounts for 
the equal potency of 301b. 
 
Figure 3.5 | The 301b prodrug stability in MEM with 10% FBS PBS (pH =7.4) 
over the course of 150 hours plotted as a percentage of the total mixture vs. time. 
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The slower hydrolyzing prodrug 303b (t1/2 = 150 mins, NMR) that has a 
similar hydrophobicity was analyzed in a similar fashion.  This compound showed 
complete stability toward the media catalyzed hydrolysis even up to 288 hours; 
only ca. 2% of PTX was observed (Figure 3.6).  We speculate that this increase 
in media stability is due the formation of micelles in aqueous environment (when 
compared to 301c).  The lack of reversion back to the parent drug correlates with 
the 50-fold decrease in potency in the in vitro cytotoxicity of 303b.   
 
Figure 3.6 | The 303b prodrug stability in MEM with 10% FBS PBS (pH =7.4) 
over the course of 300 hours plotted as a percentage of the total mixture vs. time. 
 
Guided by the apparent enhanced cytotoxicity of 301c with an IC50 of 4.2 
nM compared to 5.6 nM of PTX, we wished to determine the form of the prodrug 
in the MEM media.  Interestingly, we found that only 20% of 301c reverts back to 
PTX over the course of 72 hours (Figure 3.7).  Although the hydrolysis rate (t1/2 = 
120 mins, NMR), is close to that of 303b, the lower hydrophobicity diminishes the 
propensity for micelle formation.  We hypothesize that 301c can serve as both a 
prodrug to reveal PTX overtime and that it is perhaps a new bioactive compound 
that binds to microtubules as well.  A quick examination of a crystal structure of 
PTX bound to a microtubule suggests there is room in the hydrophobic pocket for 
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the silicate.140,,141  I modified the 7-position of DTX to estimate the silicate 304c, 
and is included in the appendices (Figure S3.4) to provide a very crude idea of 
the possible binding.  Further docking experiments and ultimately a crystal 
structure are needed to confirm this hypothesis.  
 
Figure 3.7 | The 301c prodrug stability in MEM with 10% FBS PBS (pH =7.4) 
over the course of 150 hours plotted as a percentage of the total mixture vs. time. 
 
Encouraged by the LC-MS quantification results of the prodrugs treated 
with media, we wanted to determine the fate of 302a during an MDA-MB-231 
breast cancer cell assay.  The form of the prodrug both inside and outside of the 
cells was examined, as well as the total amount taken up into the cells, and the 
amount remaining in the media.  Due to the presence of cellular debris, an 
extraction procedure was developed which gave reliable quantitation during LC-
MS analysis. 
                                            
140 Li, H.; DeRosier, D. J.; Nicholson, W. V.; Nogales, E.; Downing, K. H. Microtubule Structure at 
8 Å Resolution. Structure 2002, 10, 1317–1328. 
141 Amos, L. A.; Löwe, J. How Taxol Stabilises Microtubule Structure. Chem. Biol. 1999, 6, R65–
R69. 
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50,000 MDA-MB-231 cells were seated in each well of a 24 well plate and 
allowed to grow for one day in the presence of growth media at 37 ˚C provided by 
a cell incubator.  To begin the experiment, we removed the media and replaced it 
with 0.5 mL of media containing the drug at a concentration of 10 µM or 100 µM 
and 1% FBS or 10% FBS, the experimental design is shown in Figure 3.8 below.  
At 24 h and 48 h the media was removed, extracted, and analyzed by extracting 
the ions in the mass spectrum of an LC-MS run.  The remaining cells were also 
removed from the plate with trypsin, lysed with acetonitrile, extracted and 
analyzed by LC-MS.  The amount of 302a, 303a, and PTX were quantified from a 
calibration curve in which DTX was used as the I.S. and found in the 
supplementary information (S3.5).  Media samples that did not contain cells 
served as controls to obtain an extraction efficiency of 81% recovery. 
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Figure 3.8 | The cell uptake experimental design, extraction procedure, and 
depiction of LC-MS chromatogram. 
 
The form of the prodrug 302a, 303a, and PTX in the media was plotted as 
a percentage of the total taxane present in the mixture shown in Figure 3.9.  The 
prodrug hydrolyzed to the mono-functionalized silicate after the first 24 hours 
which shows an enhancement when compared to the 1:1 ACN:PBS summary 
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from above.  The results from both 1% and 10% FBS were combined as we 
assumed the amount of protein present would not effect the rate of hydrolysis of 
the prodrug.  Interestingly, after 48 hours the bis-silicate 302a could not be 
detected in the cell media.  The analysis of the prodrug form was not performed 
on the 10 µM treated media. 
 
Figure 3.9 | The form of the prodrug in the 1% and 10% FBS media from the 
MDA-MB-231 cell uptake assay observed at 24 h and 48 h. *not detected. 
 
We then analyzed the form of the prodrug contained inside the cells after 
24 h and 48 h for all cells treated at 10 µM and 100 µM 302a.  Unfortunately like 
the media study, the results from the 10 µM concentration could not be 
quantified.  Unlike the in the bulk media, 302a was present as the dominate form 
even after 48 hours.  Also both time points show similar ratios (302a:303a:PTX) 
in the form of the prodrug with 302a being the dominate form.  This indicated that 
the hydrolysis is generally slower in the cell compared to the bulk media.  The 
increase in hydrophobicity of 302a compared with that of 303a and free PTX 
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suggests a second benefit of enhanced lipophilicity for the prodrug strategy.  The 
molecules an improved lipophilicity and leads to a more facile uptake into the 
cells determined from the cell uptake study.  This is very encouraging for our 
future nanoparticle formulations as it suggests more of the prodrug accumulation 
into tumor cells. 
 
Figure 3.10 | The form of the prodrug up-taken into the MDA-MB-231 cells 
observed at 24 h and 48 h after being treated at 100 µM 302a in both 1% and 
10% FBS media. *not detected. 
 
The difference in the total amount of PTX present in the cells at 24 h and 
48 h was determined based on the percentage of FBS in the media.  We 
hypothesized that the media containing a higher amount of protein would restrict 
the uptake of the prodrug into the cells.  By quantifying the total amount taxane 
(302a, 303a, and PTX), we quickly saw a validation of the hypothesis.  Cells 
treated at 100 µM of the prodrug in 10% FBS media showed significantly less 
drug present in the cells.  Due to the small volume of the cells in comparison to 
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the 0.5 mL of media, far less of the drug was present in the cells.  The plot 
comparing the two is shown in Figure 3.12. 
 
Figure 3.11 | The total amount of taxane (302a, 303a, and PTX) present inside 
the MDA-MB-231 cells after 24 h and 48 h.  
 
The total amount of drug quantified both inside and outside the cells is 
presented in Figure 3.12.  From these values the mass balance and validation of 
the extraction procedure is determined.  Each well was treated at 100 µM of 302a 
using 0.5 mL of the media corresponds to 58.9 µg of 302a.  Taking in account the 
molecular weight of the prodrug (1178 µg/µmol) to that of PTX (854 µg/µmol), the 
available taxane to quantify was 42.7 µg.  Overall, 75% of the PTX components 
were retained in the media and 1% was up-taken into the cells.  This mass 
balance of 76% is slightly lower than the extraction efficiency for the protocol 
described in the Figure 3.11 above, which was 81% for media controls (without 
cell treatment).  Similar efficiency (64%) was quantified from the 10 µM treated 
media and is lower due to the 10-fold decrease in concentration of the prodrug.  
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tight binding to proteins present in the media and lost during the extraction 
procedure.   
The total amount of protein present in the cell assay was determined by a 
Bradford assay.  The total amount of drug was normalized as a ratio to the total 
protein and plotting in the SI Figure S3.8.  This further confirms that the higher 
10% FBS content reduces the quantifiable amount of drug by the protocol shown 
in Figure 3.12.  
 
Figure 3.12 | The total amount of taxane (302a, 303a, and PTX) quantified both 
inside the MDA-MB-231 cells and retained in the media after 24 h and 48 h.  
 
To further understand the stability of the prodrug over time and probe the 
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stability studies will focus on more biologically relevant media with the 
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mice and split into a series of aliquots i.) prodrugs free in solution ii.) prodrugs 
free in solution solubilized via Cremophor EL®  and iii.) prodrugs in a 5k-10k 
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extracted through the solid phase extraction (SPE) technique presented above to 
determine the ratios of free drug to prodrug.  Standards will be run to verify good 
recovery and ensure that the prodrug hydrolysis does not occur by way of the 
SPE protocol.  This experiment will give insight to the stability of the prodrug 
when circulating in vivo.  Further studies of stability and total drug amounts in 
tissue homogenates are presented in Chapter 5. 
 
3.8 Chapter 3 Conclusions 
A new class of prodrug–silicate esters has been shown in this thesis 
chapter.  The strategy provides the ability to control both the hydrophobicity and 
the hydrolysis rate of these drug derivatives. Each of these features provides a 
mechanism through which i.) drug encapsulation into nanoparticles and ii.) 
release properties from nanoparticles can be tuned. We have determined relative 
rates of hydrolysis of these silicates via 1H NMR spectroscopic analysis. 
Cytotoxicity studies were performed against the MDA-MB-231 cell line. Silicates 
301a-c, 302a, 303a, and 304a-c all showed IC50 values similar to that of their 
parent taxane, suggesting hydrolysis in the culture medium and/or inside the cell. 
The IC50 values spanned a range of ca. 103 for each of the PTX and DTX family 
of taxanes. Certain of these silicates are further evaluated in subsequent 
chapters for their ability to form small, stable, block copolymer-based 
nanoparticles as potential drug-delivery constructs. 
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4.1 Biocompatible Polymers 
4.1.1 Synthesis of PEG-b-PLGA  
In tandem with the development of FNP techniques, biocompatible block 
copolymers have been developed to effectively solubilize and protect prodrugs 
without being biologically active or toxic.  This section will discuss previous 
techniques to synthesize a variety of block co-polymers and the techniques 
employed to create functionalized polymers for coupling with tumor-targeting 
ligands for medical applications. 142  Specifically, polyesters synthesized from 
lactide or glycolide (among many monomers) are of great interest due to the 
controllable rate of degradation in vivo via the citric acid cycle.143 The hydrolysis 
of ester bonds releases lactic acid and glycolic acid, both of which are naturally 
found in the body.  PLGA has FDA approval in drug delivery polymers, sutures, 
and implants. 
To create polymers from lactide (Scheme 4.1, 401) and glycolide (Scheme 
4.1, 402), Ring-Opening Transesterification Polymerization (ROTEP) techniques 
have been utilized.73 It should be noted that this field contains a wealth of 
knowledge and innovation yet is only briefly discussed in this thesis and is 
specifically for drug delivery applications.  For ROTEP of 401 and 402 to occur, a 
variety of catalysts have been explored to give sufficient polymerization of the 
two monomers.  The two common organometallic catalysts used to convert the 
dilactones to the long, linear, aliphatic ester backbone of linear polyesters are 
                                            
142 Kim, S.; Cho, S.; Chu, L. Biotin-Conjugated Block Copolymeric Nanoparticles as Tumor-
Targeted Drug Delivery Systems. Macromol. Res. 2007, 15, 646-655. 
143 Dechy-Cabaret, O.; Martin-Vaca, B. Controlled Ring-opening Polymerization of Lactide and 
Glycolide. Chem. Rev. 2004, 104, 6147-76. 
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tin(II) octoate Sn(Oct)2, or aluminum(III) isopropoxide Al(Oi‐Pr)3. 144 , 145  Since 
these catalyst leave heavy metal contaminates in the product, they are not suited 
for the biological purposes and do not meet FDA guidelines unless stringent 
purification is performed. 
Scheme 4.1 | Co-Polymerization of rac-lactide [(±)-401] and glycolide (402) 
(adapted from ref 146)146  
 
Alternatively, organocatalysts have been developed to catalyze the 
polymerization without the need of the heavy metals. These catalysts perform 
these polymerizations efficiently and produce polymers with narrow polydispersity 
indices (PDIs), which indicate that all growing polymer chains are of similar 
                                            
144 Liggins, R. Polyether-polyester Diblock Copolymers for the Preparation of Paclitaxel Loaded 
Polymeric Micelle Formulations. Adv. Drug Deliver. Rev. 2002, 54, 191-202. 
145 Kowalski, A.; Duda, A.; Penczek, S. Kinetics and Mechanism of Cyclic Esters Polymerization 
Initiated with Tin(II) Octoate. 3. †Polymerization of l, l-Dilactide. Macromolecules 2000, 33, 7359–
7370. 
146 Qian, H.; Wohl, A. R.; Crow, J. T.; Macosko, C. W.; Hoye, T. R. A Strategy for Control of 
“Random” Copolymerization of Lactide and Glycolide: Application to Synthesis of PEG- b-PLGA 
Block Polymers Having Narrow Dispersity. Macromolecules 2011, 44, 7132—7140. 
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length or uniform.  The organocatalysts used in ROTEP of most relevance to this 
thesis include the amidines and guanidines such as those shown in Figure 4.1 
and compared in Table 4.1 with L-lactide as the monomer.147,148  
 
Figure 4.1 |  Guanidine and amidine organocatalysts used for ROTEP. 
 
Table 4.1 |  Comparison of the organocatalysts used for ROTEP of L-lactide 
(adapted from Ref. 148). 
 Catalyst cat. (%)a - Time conv. (%)b -  Mnc PDIc 
  {[M]0/[I]0} (h) solvent (g mol-1)  
 TBD 0.1 – {100} 20 s 99 – CH2Cl2 24 200 1.19 
  0.1 – {500} 1 min 95 – CH2Cl2 62 600 1.11 
 MTBD 1 – {100} 0.5 92 – CDCl3 17 900 1.05 
  0.5 – {500} 0.5 99 – CDCl3 55 300 1.10 
 DBU 1 – {100} 1 99 – CDCl3 21 000 1.05 
  1 – {500} 2 98 – CDCl3 85 000 1.08 
 a Percentage relative to monomer. 
 b Measured by 1H NMR. 
 c Measured by GPC in THF relative to PS standard. 
                                            
147 Kamber, N. E.; Jeong, W.; Waymouth, R. M.; Pratt, R. C.; Lohmeijer, B. G. G.; Hedrick, J. L. 
Organocatalytic Ring-Opening Polymerization. Chem. Rev. 2007, 107, 5813–5840. 
148 Lohmeijer, B. G. G.; Pratt, R. C.; Leibfarth, F.; Logan, J. W.; Long, D. A.; Dove, A. P.; 
Nederberg, F.; Choi, J.; Wade, C.; Waymouth, R. M.; Hedrick, J. L. Guanidine and amidine 
organocatalysts for ring-opening polymerization of cyclic esters. Macromolecules 2006, 39, 8574–
8583. 
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The organocatalysts 1,5,7-triazabicyclo[4.4.0]dec-5-ene (TBD) 406, 7-
methyl-1,5,7-triazabicyclo[4.4.0]dec-5-ene (MTBD) 407, and 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU) 404 have different reactivities toward L-
lactide.  The comparison in Table 4.1 serves as a good starting point for the 
development of PLGA polymers by systematically checking the reactivity of the 
catalyst toward lactide.  TBD is the most reactive organocatalyst, but produces 
the most variation of polymer molecular weights (broad PDIs) due to 
transesterification of growing polymer chains.  MTBD reacts quickly with suitable 
PDI values, however we opted to use the DBU catalyst is this research due to the 
slower reaction rate and tighter PDI values.148 Scheme 4.1 shows the 
polymerization of monomers 401 and 402 are initiated by a methoxy capped 
polyethylene oxide (MeO-PEO) [which is referred to in this thesis as a methoxy 
capped polyethylene glycol (mPEG)] to undergo ROTEP to form the random 
block copolymer mPEG-b-PLGA 405.  This is rather difficult since the glycolide 
402 reacts significantly faster than the lactide.  Since a rate is a rate constant 
times a concentration, the rate of lactide and glycolide can be matched if the 
concentration of 402 is reduced by slow infusion over time.  This offset in 
concentration of 402 in the reaction mixture allows for the rate of ROTEP for the 
two monomers to be equal and thus a random block copolymer can be 
created.146 We explored a variety of molecular weights of the random block co-
polymer, but ultimately settled on using a 5k-10k mPEG-PLGA for the 
subsequent FNP studies. 
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Table 4.2 |  A comparison of polymers made by DBU-catalyzed ROTEP. 
 Polymer  Mn(PEG) Mn(PLGA)a Ratio a,b PDI c  
 (targeted)    LA : GA  
 PEG 5-PL1G1A iii-16 5K 1.88K 75 : 25 1.03 
PEG 5- PL1.5G1.5A iii-26 5K 2.52K 63 : 37 1.05 
 PEG 5- PL4G1A iii-109 5K 4.12K 70 : 30 – 
 PEG 5-PL4G1A i-224 5K 4.44K 90 : 10 – 
 PEG 5- PL3G3A i-228 5K 7.11K 53 : 47 1.05 
 PEG 5-PL10A i-31 5K 9.65K 100 : 0 – 
 PEG 5-PL5G5A ii-26 5K 9.22K 59 : 41 1.05 
 PEG 5-PL5G5A ii-33 5K 9.26K 69 : 31 1.15 
 PEG 5-PL5G5A i-195 5K 10.59K 55 : 45 – 
 PEG 5-PL5G5A i-195 5K 11.34K 52 : 48 – 
 PEG 5-PL5G5Ad i-195 5K 12.77K 59 : 41 – 
 PEG 5-PL5G5A  iii-33 5K 13.86K 64 : 36 1.02 
 PEG 5-PL5G5A i-195 5K 15.38K 70 : 30 – 
 PEG 5-PL20A i-31 5K 17.85K 100 : 0 – 
PL5G2.5A-PEG5-PL5G2.5A 5K 17.60K 74 : 26 1.05 
 a Results based on NMR spectroscopy 
 b Mass ratio of the repeat units 
 c Results based on GPC (THF, 1 mL/min) measurements against a 
polystyrene standard 
 d dn/dc = 0.1850 (mL/g) from size exclusion chromatography multi-angle light 
scattering (SEC-MALS). 
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4.2 Nanoparticle Formulations of Model Compounds 
4.2.1 Drug Encapsulation and Model Compound Synthesis 
Flash nanoprecipitation (FNP) experiments were performed to create 
nanoparticles of uniform size, high drug loading by weight, and easy processing.  
An organic solvent of either THF or acetone was used to dissolve an amphiphilic 
block copolymer (mPEG-b-PLGA) and hydrophobic organic solute. This solvent 
is impinged against an equal amount of a miscible anti-solvent, usually water as 
discussed in Chapter 2.80  In the small mixing chamber, the polymer organizes as 
the hydrophobic block and hydrophobic organic solute in the core, while the 
hydrophilic block spans and solubilizes the particles on the outside.  The mixing 
is extremely fast, ca. 15 milliseconds, and requires very little organic solvent, 
making this process easily scalable.  The rapid mixing of the polymer and 
hydrophobic solute create kinetically trapped nanoparticles.  If the mixing occurs 
too slowly, the particles form thermodynamic micelles.  Due to this rapid 
encapsulation of FNP, the particles can contain a much higher weight percentage 
(wt%) of the organic solute.82  
In order to effectively study this methodology, model compounds were 
chosen that contained sufficient hydrophobicity, as well as being cost efficient by 
not containing expensive taxanes. β-Carotene is a reddish-orange hydrocarbon 
with a measured logP of 14.76 and is a precursor to vitamin A.149  We chose to 
conduct many of the nanoparticles with this compound due to its availability and 
lack of synthetic preparation.  To ensure that the FNP process is fully compatible 
with the silicate methodology the tetra-menthoxy silicate [short hand, (MenO)4Si  
(411)] was synthesized.  These compounds allowed for the exploration of loading 
levels, morphology, and stability of resulting nanoparticle formulations.  Lastly, a 
series of iodine containing compounds (413) were made to explore the final 
                                            
149 Mojaat, M.; Foucault, A.; Pruvost, J.; Legrand, J. Optimal Selection of Organic Solvents for 
Biocompatible Extraction of Beta-Carotene From Dunaliella Salina. J. Biotechnol. 2008, 133, 
433–441. 
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morphology of the nanoparticles by cryogenic-transmission electron microscopy 
(Cryo-TEM).  The heavy iodine was chosen to improve the contrast of the 
images. 
The initial attempts to synthesize 411 with an excess of (-)-menthol (409) 
in pentane showed the monochlorosilane 410 and starting material by GC-MS.  
Even allowing the reaction to continue overnight, did not push the reaction to 
completion. Addition of pyridine smoothly facilitated full conversion of 411, and a 
95 % yield was obtained following MPLC purification. 
An aliquot of 410 was reacted with triiodophenol (412) in pyridine and 
THF.  Following 2 hours of reaction, two sequential rounds of MPLC purified the 
crude mixture containing trimenthoxy-triiodophenol silicate (413) and 411. The 
appearance of 411 was attributed to excess 409 in the pentane solution used for 
the reaction. 
 
 
Figure 4.2 | Highly hydrophobic model compound (408) used for FNP studies. 
  
β-carotene
408
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Scheme 4.2 | Highly hydrophobic model compounds (411, 413) used for FNP 
studies. 
 
 
4.2.2 Effect of Loading on Nanoparticle Size and Stability 
One advantage of the FNP process to make BCP protected nanoparticles 
is the ability to make particles with a high loading of the cargo of interest.  The 
theoretical loading level is the ratio (w/w) of the mass of the drug to that of the 
drug plus the BCP that was introduced in the THF stream during FNP. To better 
understand how loading affects nanoparticle stability, particles were made with 
varying loadings of (MenO)4Si (411), while the total concentration of dissolved 
solute was kept constant.  The particle size was measured by DLS and the 
measurement repeated multiple times.  There was a tight distribution within the 
replicate measurements but considerable variability when different batches of 
particles were prepared.  Typically, particle size increased from about 75 nm with 
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no (MenO)4Si (411), to ca. 100 nm at 50% (MenO)4Si (411) loading, to ca. 200 
nm at 90% (MenO)4Si loading, as shown in Figure 4.3.  These results also show 
that varying the loading levels provides a means to control particle size. 
 
Figure 4.3 | Effect of loading level on nanoparticle size in FNP.  All particles were 
made using 5k-10k PEG-b-PLGA and (MenO)4Si.  The ratio of polymer to 
(MenO)4Si was varied while the total solute concentration was kept constant. 
 
We next compared the nanoparticle stability of the (MenO)4Si (411) solute 
with the nanoparticles filled with β-carotene (408) at the same two loading levels 
shown in Figure 4.4.  The intensity average diameter or z-average size and 
polydispersity (pdi) of the particles are shown in the bar graph in Figure 4.4.  The 
(MenO)4Si particles at either 50% or 90% loading were stable for a week and 
even up to a month in suspension! A 0.9 wt% NaCl was added to mimic the salt 
concentration in blood, to which the particles did not aggregate and remained 
below 200 nm in size. 
Particles made using β-carotene (408) at either 50% or 90% loading were 
stable for up to a week in suspension. However, they were unstable when either 
standing in solution for a month or by treatment with NaCl.  The large increase in 
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particle size to ca. 250 nm in the 90% loading is suggestive of nanoparticle 
aggregation.  While both molecules have similar calculated logP (clogP) values 
[9.72 for β-carotene (408), 9.19 for (MenO)4Si (411)] we hypothesized that they 
may differ in morphology inside the core of the nanoparticle, or the difference in 
stability could be due to the difference in zeta potential.150 
 
 
Figure 4.4 | Effect of loading level on nanoparticle size and stability for 
(MenO)4Si [blue] and β-carotene [orange].  DLS measurements were made i.) 
immediately following FNP, ii.) after 1 week in suspension, iii.) after 1 month in 
suspension, and iv.) after addition of salt and standing for 30 min.  All particles 
were made using 5k-10k PEG-b-PLGA and (MenO)4Si or β-carotene. 
Also we were interested in determining if the instability of the 90 wt% β-
carotene nanoparticles was a result of residual THF.  Particles were made using 
the same methods as before.  Acetone was chosen as an alternating solvent to 
                                            
150 Abdelwahed, W.; Degobert, G.; Stainmesse, S.; Fessi, H. Freeze-Drying of Nanoparticles: 
Formulation, Process and Storage Considerations. Adv. Drug Deliv. Rev. 2006, 58, 1688–1713. 
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probe the effect of the choice of water-miscible solvent may have on the FNP 
process and stability of the resulting nanoparticles.  Four batches of particles 
were made and adding in 0.9 wt% NaCl tested the nanoparticle stability.  The 
images of the suspensions themselves are shown in Figure 4.5 and the DLS 
measurements are shown in Figure 4.6. 
  
  
 
Figure 4.5 | Photos of 90 wt% solute nanoparticle suspensions prepared by FNP 
with a.) β-carotene in 10% v/v THF without salt (left) with salt (right), b.) 
(MenO)4Si in 10% v/v THF without salt (left) with salt (right), c.) β-carotene in 
10% v/v acetone without salt (left) with salt (right), d.) (MenO)4Si in 10% v/v 
acetone without salt (left) with salt (right). 
 
The images show major differences between THF and acetone for use in 
FNP to make β-carotene nanoparticles at 90% loading.  The nanoparticles have 
a diameter of ca. 150 nm in size (Figure 4.6) but begin to aggregate upon the 
addition of salt as shown in the image (Figure 4.5, panel a, right) and the 
increase in size to ca. 280 nm, bar graph Figure 4.6.  The (MenO)4Si loaded 
nanoparticles are stable in the THF suspension even with the addition of salt as 
a b 
c d 
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shown in the image (Figure 4.5, panel b, right) and do not increase in size (Figure 
4.6). 
We performed the FNP using acetone as the water-miscible organic 
solvent and observed a drastic difference in particle size between the β-carotene 
and the (MenO)4Si loaded at 90 wt% particles.  The β-carotene particles gave a 
dark red appearance (Figure 4.5, panel c, left), had a large particle diameter of 
2,500 nm and broad PDI of 1.0 shown in Figure 4.6. Treating these particles with 
salt at a 0.9 wt% concentration lead to rapid flocculation of β-carotene (Figure 
4.5, panel c, right).  Due to the large crystals of the solute out of solution, a DLS 
measurement could not be obtained.  These observations indicate that acetone is 
not a good solvent for FNP of β-carotene.  The (MenO)4Si particles gave a more 
transparent appearance when acetone was used instead of THF [compare 
(Figure 4.5, panel d, left) to (Figure 4.5, panel b, left)].  This more transparent hue 
is due to the smaller particle diameter of ca. 150 nm and narrow pdi of 0.15 as 
shown in Figure 4.6.  Unfortunately, treating these particles salt at a 0.9 wt% 
concentration lead to precipitation of (MenO)4Si  on the walls of the vial (Figure 
4.5, panel d, right).  Due to the (MenO)4Si dropping out of solution, a DLS 
measurement could not be obtained. These observations indicate that acetone is 
not a good solvent for FNP of (MenO)4Si when salt is added, but removal of 
acetone would be beneficial. 
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Figure 4.6 | Particle stability of nanoparticles loaded at 90% with and β-carotene 
[orange] or (MenO)4Si [blue] and mPEG-b-PLGA (5k-10k).  DLS measurements 
were made i.) immediately following FNP with THF, ii.) after 30 min incubation at 
0.9 wt% NaCl, iii.) immediately following FNP with acetone. 
 
4.2.3 Effect of Nanoparticle Zeta-Potential and Morphology on Stability 
We were very interested in the drastic difference in stability of 
nanoparticles loaded with either β-carotene and (MenO)4Si.  We measured the 
zeta-potential of the particles presented in Figures 4.4 and 4.5, because the zeta-
potential is an important indicator of stability. Below in Table 4.3 shows the 
values for the nanoparticles prepared using THF as the water-miscible organic 
solvent, the particles prepared with acetone were not measured due to the lack of 
stability. 
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Table 4.3 | The electrokinetic parameters of nanoparticles loaded at 90 wt% with 
either β-carotene or (MenO)4Si and mPEG-b-PLGA (5k-10k) block copolymer. 
 
Zeta-
Potential Mobility Conductivity 
Conditions (mV) (µmcm/Vs) (mS/cm) 
β-carotene NPs (THF) -10.50 ± 0.14 -0.83 ± 0.01 0.06 ± 0.00 
β-carotene NPs (0.9 wt% NaCl) -0.84 ± 0.32 -0.07 ± 0.03 16.15 ± 0.92 
(MenO)4Si NPs (THF) -29.05 ± 0.07 -2.28 ± 0.01 0.01 ± 0.00 
(MenO)4Si NPs (0.9 wt% NaCl) -0.73 ± 0.02 -0.06 ± 0.00 13.90 ± 0.99 
 
The zeta-potential for the nanoparticles made with (MenO)4Si (-29 mV) is 
three times that of the analogues β-carotene NPs (-10 mV).  This difference is 
enough to be classified differently in colloidal literature shown in Table 4.4.151  
The electrophoretic mobility of the particles correlates with the zeta-potential of 
each particle (Table 4.3 column 2). As expected when salt is added to the particle 
suspensions the zeta-potential drops to essentially zero (Table 4.3 column 1) for 
both sets of particles, but the (MenO)4Si particles do not aggregate. Also the 
conductivity of the solution is increased when the salt is added (Table 4.3 column 
3). 
Table 4.4 | The stability behavior of colloids as a function of zeta-potential.151 
Zeta-Potential (mV) Stability Behavior of the Colloid 
0 ± 5 Rapid coagulation or flocculation 
± 10 to ± 30 Incipient instability 
± 30 to ± 40 Moderate stability 
± 40 to ± 60 Good stability 
Greater than ± 60 Excellent stability 
 
Since the zeta-potentials both dropped with the addition of salt for the β-
carotene NPs as well as the (MenO)4Si NPs, we anticipated both to aggregate in 
solution.  To further probe this stark contrast in stability between particles loaded 
                                            
151 Greenwood, R. Review of the Measurement of Zeta Potentials in Concentrated Aqueous 
Suspensions Using Electroacoustics. Adv. Colloid Interfac. 2003, 106, 55–81. 
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with β-carotene or (MenO)4Si, we studied the solute morphology within the core 
of the nanoparticles.  X-ray diffraction shown in Figure 4.7, was used to 
determine the crystallinity of the small molecule encapsulated in nanoparticles. 
 
 
Figure 4.7 | X-ray powder diffraction (XRD) of a.) β-carotene and b.) 
tetramenthoxysilicate ((MenO)4Si) as the pure compound (red) vs. nanoparticles 
(5k-10k mPEG-b-PLGA BCP) loaded with 90 wt% (blue) and 50 wt% (green) 
(MenO)4Si. The inset with expanded scale clearly shows the (MenO)4Si remains 
crystalline in the 90 wt% and 50 wt% nanoparticles. 
The XRD pattern was collected on a PANalytical X′Pert Pro MPD 
diffractometer equipped with a cobalt anode (45 kV, 40 mA, λ = 1.790 Å) and an 
X-Celerator detector with the help of Yuqiang Qian. 
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Interestingly, the particles made with β-carotene are amorphous in the 
core at both 50 and 90 wt%, while those made with (MenO)4Si remain crystalline 
throughout the two loading levels.  This difference in morphology leads to the 
differences in stability of the two different compounds with nominally the same 
hydrophobicity.  While we have shown that FNP can be used to make 
nanoparticles from a variety of compounds provided they are of sufficiently high 
hydrophobicity,86 the internal structure of the particles is critical for understanding 
stability.  Although the cLogP values of compounds provides an initial guide for 
selecting organic solutes or drugs for the FNP process, the morphology inside 
the core and zeta-potential are crucial indicators for long term stability. 
Improved understanding of the nanoparticle structure is vital, because it 
affects the release of the organic solute or, more critical, drug release in terms of 
this project.  For example, a loaded drug may release from the particles more 
quickly if the particle has a loosely packed structure with some hydrophilic blocks 
incorporated into the core vs. a tightly packed core shell structure. 
Nanoparticles were made using hydrophobic compounds containing the 
heavy atom iodine.  Iodine was chosen in hopes to provide an improved contrast 
of images taken cryogenic transmission electron microscopy (cryo-TEM) taken by 
Han Seung Lee compared to particles loaded with β-carotene.86  Particles were 
initially formed by FNP of the commercially available iodohexadecane (414) with 
mPEG-b-PLGA (5k-10k) at 10 wt%.  Unfortunately these particles did not show a 
well-defined spherical particle and did not show a distinct core shell structure 
(Figure 4.8, panel b). 
We next attempted to fashion particles from triiodophenol (412) itself due 
to the presence of three heavy iodine atoms per molecule, however the 
hydrophobicity of the compound was insufficient and the particles were not 
stable.86 The utility of silicate ester chemistry was proven again, as particles 
made with the hydrophobic trimenthoxy-triiodophenol silicate (413) gave 
excellent particle shape (Figure 4.8, panel a) and an imoproved contrast in the 
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core shell nature of the particles. The particles for this study were fashioned at 50 
wt% 413 and with a mPEG-b-PLGA (5k-10k) polymer. 
   
Figure 4.8 | a) FNP prepared, Trimenthoxy(triiodophenol)Silicate (413) 
nanoparticles loaded at ca. 50 wt% with mPEG-PLGA (5k-10k) b) FNP prepared, 
iodohexadecane (C16H33I, 414) nanoparticles loaded at ca. 10 wt% with mPEG-
PLGA (5k-10k) 
 
These model drugs proved that high loading of hydrophobic compounds 
into nanoparticles is attainable with the FNP process. The marriage of silicate 
chemistry with the FNP concept was shown with the use of the tetramenthoxy 
silicate (411) and (413).  We next turned our attention to the hydrophobic 
prodrugs of PTX shown in Chapter 3. 
  
a b 
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4.3 Nanoparticle Formulations of PTX Silicates 
4.3.1 Introduction 
A number of barriers diminish the translational success of 
nanomedicine.152 A key challenge is the limited intra-tumoral distribution of drug 
delivery carriers, since their transport within the tumor is highly inefficient. Distal 
regions receiving lower drug exposure often harbor the more aggressive tumor 
cells. Thus, achieving therapeutic drug concentrations in these under-supplied 
regions would represent a significant advance. Many recent studies have shown 
that particles that are in the sub-100 nm size range demonstrate improved tumor 
accumulation and, more importantly, improved tumor penetration.153,154,155 While 
many techniques are available to fabricate nanocarriers in the ≤100 nm size 
range, it is extremely difficult to achieve reasonable drug loading in such small 
particles. Most colloidal carriers can be loaded to a mere ≤10 wt%. 
Flash nanoprecipitation (FNP), a technique pioneered by Prud’homme 
(Chapter 2),117 enables the synthesis of sub-100 nm nanoparticles with very high 
drug loading (Chapter 4.2).78,86,117, 156  FNP requires rapid turbulent mixing of 
organic solutes dissolved in a water-miscible organic solvent (e.g., 
tetrahydrofuran, acetone, acetonitrile) with the antisolvent, water, in a confined 
                                            
152 Tarr, B. D.; Yalkowsky, S. H. A new parenteral vehicle for the administration of some poorly 
water soluble anti-cancer drugs. J. Parenter. Sci. Technol. 1987, 41, 31–3. 
153 ABRAXANETM for Injectable Suspension (paclitaxel protein-bound particles for injectable 
suspension) (albumin-bound). 
http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021660lbl.pdf (accessed April 26, 
2015). 
154 Gradishar, W. J.; Tjulandin, S.; Davidson, N.; Shaw, H.; Desai, N.; Bhar, P.; Hawkins, M.; 
O'Shaughnessy, J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with 
polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 2005, 23, 
7794–803. 
155 Smith, J. Overview of breast cancer drug therapy. US PHARMACIST. 2005, 30, 9. 
156 Pustulka, K. M. Polymer stabilized nanosuspension via flash nanoprecipitation: particle 
formulation, structure and freeze drying. M.S. Dissertation, University of Minnesota, Minneapolis, 
2012. 
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space. When the solvent and antisolvent streams meet and mix, the solutes 
rapidly precipitate into nanoparticles due to supersaturation. The encapsulating 
agent used in FNP is typically an amphiphilic block copolymer (BCP), such as 
poly(ethylene glycol)-b-poly(lactic-co-glycolic acid) (PEG-b-PLGA). The 
hydrophobic block of BCP co-precipitates with the drug, while the hydrophilic 
block provides steric stabilization on the nanoparticle surface.  
In this chapter, we evaluated the use of FNP to fabricate nanoparticles of 
paclitaxel (PTX), a widely used anticancer agent. Studies have shown that FNP-
loaded, PEG-b-PLGA-based nanoparticles loaded with PTX alone are not 
stable;78,80,82,89 rapid Ostwald ripening of the freshly prepared nanoparticles leads 
to precipitation of PTX from the 90-95% aqueous dispersion in which the initial 
FNP formulations are produced (Chapter 2.2.2).80,86,89,156 This phenomenon is 
likely due to a sufficient water solubility and inherent crystallinity of PTX. It is 
paradoxical that although PTX is too hydrophobic a drug to be dissolved in 
aqueous medium and therapeutically administered, it is still too hydrophilic to be 
efficiently encapsulated and stabilized as a nanoparticle by FNP.  
To render PTX more hydrophobic, we have developed a series of PTX-
prodrugs containing silicate esters [i.e., PTX-O-Si(OR)3] (Chapter 3).118,120 The 
silicate moiety is hydrolytically labile and serves as a prodrug to release the 
parent compound in biological media. We have shown that both the 
hydrophobicity as well as the rate of hydrolysis of the prodrug can be tailored. 
The goal of the current study was to evaluate the use of the FNP technique 
coupled with the silicate ester prodrug technology to fabricate nanoparticles 
suitable for PTX delivery. Using in vitro and in vivo models, we have identified 
factors affecting the regeneration of PTX from PTX-silicate prodrug-loaded 
nanoparticles. 
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4.3.2 PTX-silicate prodrugs 
The paclitaxel silicate prodrugs studied (i.e., 301-303) are shown at the 
top of Table 4.5. Their molecular weight, calculated octanol/water partition 
coefficients (cLogP), and relative rates of chemical hydrolysis (in aqueous 
acetone containing trifluoroacetic acid) are given in Table 4.5.118 Collectively, 
these show that the hydrophobicity can be tuned based upon the nature of the 
alkyl group present in the silicate ester(s) moiety. Greater hydrophobicity of the 
prodrug allows for the formation of stable nanoparticle suspensions, a property 
not attainable with FNP-produced PEG-b-PLGA nanoparticles loaded with PTX 
alone.80,78,82,86,89,156 The size of the alkyl groups in the silicate also affects the 
relative hydrolysis rates of silicate cleavage. The hydrolytic stability of each 
prodrug plays a significant role in the overall rate of drug release, as discussed 
below. 
Table 4.5 | Structures and properties (hydrophobicity and hydrolytic lability) of the 
PTX-containing silicate prodrugs used in this study.118 
 
R1 R2
PTX
301a
301b
301c
301f
301d
303a
303b
302a
H
Si(OEt)3
Si(OnOct)3
Si(OiPr)3
Si(OtBu)2(OEt)
Si(Omenthyl)3
H
H
Si(OEt)3
H
H
H
H
H
H
Si(OEt)3
Si(OnOct)3
Si(OEt)3
O
AcO O
OH
O
OAc
OBz
O
O
O
Ph
BzHN
2'
7
H
R1
R2
shorthand descriptor
paclitaxel
PTX-2’-Si(OEt)3
PTX-2’-Si(OnOct)3
PTX-2’-Si(OiPr)3
PTX-2’-Si(OtBu)2(OEt)
PTX-2’-Si(Omenthyl)3
PTX-7-Si(OEt)3
PTX-7-Si(OnOct)3
PTX-2’,7-[Si(OEt)3]2
N/A
18,000
5,600
570
5.6
1.0
2,200
450
15,000 (R1)
2,100 (R2)
MW
854
1016
1269
1058
1072
1347
1016
1269
1178
cLogPa
3.2
5.0
7.7
5.6
5.8
7.4
5.1
7.8
6.3
N/A
3.7
12
120
12,000
69,000
30
150
4.6 (R1)
33 (R2)
hydro-
phobicity
krelb t1/2 (min)
hydrolytic
lability
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a aLogP values from ALOPS 2.1.132  b hydrolysis was performed in homogenous 
solutions of 90:9:1 volume ratio of acetone-d6:D2O:CF3CO2H and the krel values 
are benchmarked against the silicate 301d, which showed the slowest rate of 
silicate cleavage118 
 
4.3.2 Nanoparticle Preparation 
The nanoparticles were fabricated by flash nanoprecipitation (FNP)116 
using a CIJ-D mixer (Chapter 2.1).85 In brief, to achieve a ca. 50 equiv wt% of 
PTX, the molecular weight of the prodrug was factored into consideration by use 
of the following equation. 
 
Specifically, an amount of PTX-prodrug containing the equivalent of 25 mg 
of free PTX and 25 mg of PEG-b-PLGA were dissolved in 2.5 mL of THF and 
impinged against 2.5 mL of deionized water in a CIJ-D mixer and further diluted 
into 45 mL of water. Blank polymer nanoparticles (i.e., containing no PTX-silicate) 
were also prepared and used as a control group for in vitro and in vivo 
cytotoxicity studies. PEG-b-PLGA (25 mg) was dissolved in 2.5 mL of THF and 
impinged against 2.5 mL of deionized water and further diluted into 45 mL of 
water.  
The size of the freshly prepared nanoparticles was measured by dynamic 
light scattering (DLS) on a DelsaTM Nano C (Beckmann Coulter) instrument. 
Samples for DLS were prepared by diluting the nanoparticle suspension with 
water immediately after CIJ-D mixing. The intensity average size, dI, and 
polydispersity index PDI calculated (via the cumulants method) by the instrument 
were recorded.  Measurements were taken in triplicate.  
To remove unencapsulated prodrug and free polymer from the 
nanoparticle suspension, ultracentrifugation was performed on the initial FNP 
mass of prodrug to obtain 50 wt% PTX = mass polymer (mg)
MW Prodrug
MW PTX
x
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suspension at 50,000 rpm and 4 ºC for 30 min. After each round of centrifugation, 
the supernatant, which contained a considerably higher wt% of polymer than that 
used in the initial preparation (1H NMR, Figures S4.9-S4.10), was removed using 
a transfer pipet. The pellet was resuspended in 25 mL of water and the process 
repeated twice. After the third ultracentrifugation, the pellet was collected and 
lyophilized using a Freeze Dryer System (Labconco) at -45 ºC for 24 h to remove 
residual water. The overall mass recovery varied following the rounds of three 
centrifugations for different formulations; it typically ranged from 30–80%.  
The prodrug loading level of the lyophilized nanoparticles was further 
assessed by high performance liquid chromatography (HPLC, Model 508, 
Beckmann Coulter, CA) or 1H-NMR analysis. To determine loading by HPLC, 1 
mg of lyophilized nanoparticles was suspended in 1 mL of acetonitrile (ACN) and 
agitated for 24 h, during which time the organic materials (block copolymer and 
PTX-silicate derived components) were solubilized. An aliquot (30 µL) of the 
resulting suspension was injected onto a C-18 HPLC column (4.6 × 250 mm with 
5 µm packing). The mobile phase consisted of a mixture of acetonitrile and water 
(75:25) and was delivered at a flow rate of 1 mL/min. The amounts of PTX and 
the PTX-silicate prodrug were quantified by UV detection at 228 nm against a 
series of calibration curves for PTX and the appropriate PTX-silicate, created 
over a range of concentrations from 3.125 to 100 µg/mL. Alternatively the loading 
level and efficiency of prodrug incorporation was assessed from 1H-NMR 
integrations of various resonances in a solution of the final lyophilized, drug-
loaded nanoparticle pellet. A portion (ca. 3 mg) was dissolved in CDCl3 , a 
solvent in which all components of the loaded nanoparticles are readily soluble. 
Equations describing these quantification methods are given in the Supporting 
Information for Chapter 4 (SI, Figure S4.8). 
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4.3.4 Nanoparticle Characterization 
An initial set of loaded nanoparticles was prepared using the most easily 
synthesized silicates 301 and 302. The intensity average size (dI) and size 
distribution (PDI) for each preparation was measured in triplicate by dynamic light 
scattering (DLS); the results are given in Table 4.6. The suspensions of 
nanoparticles (as initially formulated in 5% THF/water) remained homogeneous 
and stable for 1 (for 301a) to several (for 301b) to >14 (for 301c, 301d, 301f) 
days before showing significant aggregation, as determined both by visual 
inspection and DLS measurements. As the hydrophobicity of the PTX-silicate 
prodrug increased (higher cLogP), the resulting loaded nanoparticles sizes 
tended to decrease.  
Preliminary release studies with some of these preparations showed 
"burst-release" behavior139 that is characteristic of samples containing both 
loaded nanoparticles as well as a portion of free (pro)drug that is not protected by 
the block copolymer. 157  We therefore implemented a protocol using 
ultracentrifugation to pelletize the loaded nanoparticles (3x) followed by final 
lyophilization to produce dry-powdered preparations of the loaded nanoparticles. 
This means of preparation largely removed the initial burst phase of the release 
profiles.  Redispersion of the lyophilized powder in water, aided by probe tip 
sonication, gave nanoparticles that showed evidence of aggregation as judged 
from the larger sizes revealed by DLS analysis (Table 4.6). Freeze-drying 
induced aggregation and resulted in an increase in particle size, as has been 
reported for other nanoparticle structures.86,156,158,159 
                                            
157 Huang, X.; Brazel, C.S. On the importance and mechanisms of burst release in matrix-
controlled drug delivery systems. J. Control. Release. 2001, 73, 121–136. 
158 Lee, M. K.; Kim, M. Y.; Kim, S.; Lee, J. Cryoprotectants for freeze drying of drug nano-
suspensions: effect of freezing rate. J. Pharm. Sci. 2009, 98, 4808–4817. 
159 Schuch, H.; Klingler, J.; Rossmanith, P.; Frechen, T.; Gerst, M.; Feldthusen, J.; Müller, A. H. 
E. Characterization of Micelles of Polyisobutylene- Block-Poly(Methacrylic Acid) in Aqueous 
Medium. Macromolecules 2000, 33, 1734–1740. 
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The levels of prodrug loaded into these final lyophilized nanoparticles are 
listed in Table 4.6. The nanoparticles contained ca. 50-75 wt% of PTX-silicate. 
Because the supernatant from the centrifugation contained a greater portion of 
polymer than PTX-derived material (NMR analysis), the final PTX-silicate loading 
levels of the nanoparticle formulations were typically greater than the wt% of 
silicate charged in the initial FNP procedure. The very high load level that can be 
achieved using FNP formulation in combination with hydrophobic prodrugs of 
PTX is one of the main advantages of this nanoparticle formulation and 
approach. 
Evidence for high encapsulation was also demonstrated for a silicate 
derivative loaded particle. PTX-2',7-[Si(OEt)3]2 (302a) particles were flash 
precipitated with an equal mass of PEG-b-PLGA (5k-10k). Control particles were 
made without using any stabilizing PEG-b-PLGA. The particles were freeze-dried 
following FNP and then redispersed in water. Diethyl ether, a good solvent for the 
silicate but not for PEG or the BCP, was then used to extract each of these two 
aqueous dispersions.  The content of the ether extract was analyzed by 1H NMR 
spectroscopy. Without block copolymer protection >85% of the silicate derivative 
was recovered, while with PEG-b-PLGA protection the particles only lost 7% of 
their silicate  content even after multiple extractive washings with ether. This 
result also demonstrates that > 90% of the silicate was encapsulated in the 
nanoparticle core. 
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Table 4.6 | Size, prodrug loading levels, and cytotoxicities of nanoparticles 
loaded with PTX-silicates. 
a PTX-silicate prodrug loading is the wt% of encapsulated silicate derivative in the 
loaded nanoparticles following centrifugation; b PTX loading is the wt% of PTX 
that can be regenerated from silicate derivative in the loading nanoparticles 
following centrifugation. It is calculated using PTX-silicate loading and the MW of 
PTX and silicate derivatives.   
 
Cryo-transmission electron microscopy was used to examine various 
features of the loaded nanoparticle preparations. Selected cryo-TEM images are 
shown in Figure 4.6. The image in panel A shows the spherical nature of the 
freshly prepared loaded nanoparticles. In addition, a core-shell morphology is 
clearly evident. The core is rich in PTX-silicate, which is more electron dense 
than PLGA.   
Nanoparticles were examined following centrifugation, lyophilization, and 
redispersion into PBS. These were loaded with PTX-2’-Si(OEt)3 (301a), the most 
hydrolytically labile silicate. When examined immediately after redispersion, the 
 
Before 
centrifugation 
After centrifugation, lyophilization, and 
resuspension 
Pro-
drug dI (nm) PDI dI (nm) PDI 
PTX-
silicate 
loading 
(wt%)a 
PTX 
loading 
(wt%)b 
IC50 (nM) 
PTX - - - - - - 77 
301a 140 0.10 420 0.25 63.0 53.0 71 
301b 83 0.16 210 0.23 65.0 43.7 220 
301c 140 0.17 200 0.34 58.0 46.8 14 
301f 86 0.09 240 0.36 73.5 58.6 1000 
301d 95 0.08 200 0.31 73.5 46.6 650 
302a 120 0.13 310 0.65 60.4 43.8 80 
Part I: Anticancer Drug Delivery  Chapter 4 | 
 
 
118 
118 
core-shell structure was still intact (Figure 4.9, B). However, the particle size had 
grown due to aggregation as represented by the chain of particles in the right 
side of Figure 4.9, B and Figure S4.12. This is consistent with the increased dI 
measured by DLS (Table 4.6). After 24 h in suspension, another sample of these 
nanoparticles was imaged. The size had diminished and the cores disappeared 
(Figure 4.9, C), suggesting that hydrolysis and/or release of PTX and/or the PTX-
silicate was occurring during that aging period. Similar results were observed for 
particles made from PTX-2´7,-[Si(OEt)3]2 (302a), which hydrolyzed rapidly, lost 
their cores and appear to shrink while PTX-2’Si(OtBu)2(OEt) (301f), with very 
slow hydrolysis, did not change with 24 h aging (see Figure S4.11). 
 
 
Figure 4.9 | Cryo-TEM images of nanoparticles loaded with PTX-2’-Si(OEt)3 
(301a). A) freshly prepared (i.e., prior to centrifugation), B) lyophilized, 
immediately following redispersion into PBS after centrifugation, and C)  
lyophilized following redispersion into PBS and aging for 24 h in a dialysis 
cassette suspended in PBS (pH 7.4). 
The structure and morphology of nanoparticles (freeze-dried, 5k-10k PEG-
b-PLGA nanoparticles made using the CIJ-D mixer) was also evaluated using 
DSC. Typically, DSC studies of polymers utilize the “second run” of the trace so 
that the measured properties are independent of the polymer’s thermal history.  
In the case of the FNP-produced polymers, however, data from the “first run” are 
instructive. The “first run” DSC trace of unloaded PEG-b-PLGA nanoparticles 
exhibited a strong Tm of the crystalline PEG block at ca. 50 °C as shown in Figure 
A B C
100 nm100 nm100 nm
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4.10.  This is a depressed melting transition temperature relative to the pure PEG 
homopolymer (which exhibited a Tm of ca. 60 °C in a control experiment).  This 
observation is consistent with incomplete phase segregation.  The Tg from the 
PLGA block was not obvious in the trace, but it is conceivable that there is a 
weak, broad glass transition at ca. 20 °C whereas the Tg of pure PLGA is 39 
°C.86 This observation is consistent with some polyether/polyester mixing.160 
Recrystallization of the PEG did not occur upon cooling and the “second 
run” DSC trace exhibited a single Tg.  This result was reproduced when the 
polymer was cooled at an exceedingly slow rate (1 °C•sec-1), consistent with a 
thermodynamically stable, phase-mixed system.  Based on these results, a 
reasonable conclusion is that the polymer blocks are largely, but not exclusively, 
phase-segregated following FNP and lyophilization.  This further supports the 
core-shell structure of these nanoparticles.  
 
Figure 4.10 | The DSC trace of the FNP-precipitated and freeze dried 5k-10k 
PEG-b-PLGA BCP (405) shows a strong PEG Tm on the “first run” (blue ) 
indicative of significant phase segregation of the kinetically trapped nanoparticle. 
A single Tg on the “second run” (green) is characteristic of a phase mixed state at 
equilibrium. 
                                            
160 Kulinski, Z.; Piorkowska, E.; Gadzinowska, K.; Stasiak, M. Plasticization of poly(L-lactide) with 
Poly(propylene Glycol). Biomacromolecules 2006, 7, 2128–35. 
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With a basic understanding of the DSC behavior of the precipitated 
polymer, we turned our attention to the analysis of a paclitaxel silicate, PTX-2´7,-
[Si(OEt)3]2 (302a), loaded nanoparticle.  Particles were made using an equal 
mass of BCP and the silicate in the CIJ-D mixer and were lyophilized immediately 
after nanoprecipitation.  Again, a strong, depressed PEG Tm at ~50 °C was 
evident (Figure 4.11).  Additionally, there was a broad melting point centered at 
~105 °C.  This endothermic peak occurs at a lower temperature and is broader 
than that for the pure PTX silicate (red curve in Figure 4.11) indicating an impure, 
crystalline melting transition of the PTX silicate.  After cooling, a single Tg was 
again noted during the second heating cycle, a feature consistent with a well-
mixed, silicate-loaded polymer film (rather than nanoparticles). 
 
Figure 4.11 | The DSC trace of the FNP-precipitated and freeze-dried 
nanoparticle composed of equal mass of 2’,7-bis(triethoxy)-PTX-Si and 5k-10k 
PEG-b-PLGA BCP shows a strong PEG Tm and a broad melting point attributed 
to a depressed melting of the PTX silicate on the “first run” (blue) and a single Tg 
associated with a phase mixed film in the “second run” (green).  The pure 2’,7-
bis(triethoxy)-PTX-Si (red) is overlaid on the DSC trace showing a higher Tm and 
sharper melting transition. 
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We also performed powder x-ray diffraction as done with the model 
systems (c.f. Figure 4.7).  The prodrugs were predominately amorphous in the 
core of the nanoparticles, which is advantageous for the future release profiles. 
The powder XRD profiles of the nanoparticles made with 301b and 302a are 
shown (SI, Figures S4.1 and S4.2).  Nanoparticles made with 301a, 301c, 301d, 
and 301f were also made and showed similar results and are not shown in this 
thesis. 
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4.3.5 In Vitro Drug Release Profiles 
PTX and PTX-silicate release studies were performed by Jing Han on 
selected PTX-silicate-loaded nanoparticles using dialysis mini capsules with a 
semipermeable membrane. Control experiments showed that diffusion of the 
drug or prodrug alone through the membrane occurred readily. An aqueous 
suspension of either PTX or PTX-2’,7-[Si(OEt)3]2 (302a) was placed in the 
capsule, which was then immersed in buffer (pH = 7.4). Departure of each 
compound from the capsule was monitored over time. Both compounds were 
absent after 3 hours (SI, Figure S4.3). This showed that diffusion of PTX or a 
PTX-silicate could be expected to occur rapidly once each was no longer inside a 
nanoparticle.  
We next studied the release of PTX and the PTX-silicate from several of 
the prodrug-loaded nanoparticle preparations. These studies were conducted at 
37 ˚C and representative plots for release of PTX-2’-Si(OnOct)3 (301b) from the 
loaded nanoparticles are shown in Figure 4.12. The release and retention plots 
for nanoparticles loaded with 301a or with 301b at pH 7.4 and pH 5.0 are 
provided in the SI (Figures S4.4-S4.7). The amount of total drug/prodrug was 
measured both inside and outside the dialysis capsules. The amounts released 
and retained 12, 24, and 48 h are given in Table 4.7 (for 301a and 301b at pH = 
7.4) and Table 4.8  [for 301(a-d,f)] at pH = 5.0). These measurements indicated 
good overall mass-balance. In general, the release rates were faster at the lower 
pH. 
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Figure 4.12 | Release profiles for nanoparticles loaded with PTX-2’-Si(OnOct)3 
(301b). A. Appearance of 301b and free PTX to the exterior of the dialysis 
cassette at pH = 7.4. B. Appearance of 301b and free PTX to the exterior of the 
dialysis cassette at pH = 5.0. C. Amount of 301b and PTX remaining inside the 
dialysis cassette at pH = 7.4. 
 
Table 4.7 | Release profiles over time of the percent of PTX plus PTX-silicate 
prodrug released into PBS at pH = 7.4. 
Time (h) 
301a [PTX-2'-
Si(OEt)3] 301b [PTX-2'-Si(O
nOct)3] 
%Releaseda %Retaineda %Releaseda %Retaineda 
12 39±6 51±5 33±8 57±3 
24 52±6 50±6 41±8 49±9 
48 63±8 34±5 56±13 – 
a Total amount of the PTX-silicate plus free PTX, as measured by HPLC analysis. 
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Table 4.8 | Release profiles over time of the percent of PTX plus PTX-silicate 
prodrug released into acetate buffered saline at pH = 5.0.   
Time 
(h) 
301a  [PTX-2'-Si(OEt)3] 301b  [PTX-2'-Si(OnOct)3] 301c  [PTX-2'-Si(O
iPr)3] 
% 
Releaseda 
% 
Retaineda 
% 
Releaseda 
% 
Retaineda 
% 
Releaseda 
% 
Retaineda 
12 76±11 25±12 45±5 46±6 36±5 65±4 
24 99±6 0.4±1.3 58±7 36±17 42±8 55±11 
≥48 -- -- 74±10 27±20 50±15 37±7 
  
301f  [PTX-2'- 
Si(OtBu)2(OEt)] 
301d  [PTX-2'-
Si(Omenthyl)3] 
 Time (h) % Releaseda 
% 
Retaineda 
% 
Releaseda 
% 
Retaineda 
 12 32±4 69±10 35±7 65±8 
 24 40±5 60±13 49±9 50±14 
 ≥48 53±11b 46±13b 89±17c 10±9c 
a Total amount of the PTX-silicate plus free PTX, as measured by HPLC analysis.  
 b 216 hr . c168 hr. 
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4.3.6 In vitro cytotoxicity of PTX-silicate prodrug-loaded PEG-b-PLGA 
nanoparticles (uncentrifuged) against the aggressive 4T1 breast cancer 
cell line 
To probe the efficacy of 302a and nanoparticles loaded with 50 wt% of 
302a, a cyctotoxicity assay was performed on an aggressive breast cancer cell 
line (4T1).  The 4T1 cells divide rapidly and were chosen as a challenge for our 
highly loaded nanoparticle formulation. 
To perform these studies, the 4T1 cells were incubated at 37 ˚C, and non-
viable cells were removed from the cell culture media by vacuum and washing 
with Dulbecco's modified eagle medium (DMEM).  The viable cells remained 
adhered to the bottom of the culture flask.  To free the cells, trypsin (5 mL) was 
added and the culture was incubated for 5 minutes at which time an equal 
amount of DMEM neutralized the enzyme.  The cells were centrifuged, 
resuspended in new media (12 mL), counted, diluted to 10,000 cells per 100 μL 
and recounted, and finally plated.  The cells retained in different wells of the plate 
were treated with one of the following drug formulations dissolved in DEM media: 
i.) PTX, ii.) 302a, iii.) uncentrifuged nanoparticles consisting of 302a (ca. 50 wt%) 
and a 5k-10k mPEG-b-PLGA (405), and iv.) empty unloaded nanoparticles 5k-
10k mPEG-b-PLGA (405) only at concentrations ranging from 100 nM to 1 µM of 
PTX equivalent and incubated for 72 h at 37 ˚C. 
The cells were treated with MTS to give a blue color that can be detected 
by UV-Vis absorption, and the concentration of viable cells compared to 
untreated cells can be determined.  The percentage of viable cells is plotted 
against the concentration to show the efficacy of the treatments against 4T1 
cells.  As shown in Figure 4.13, the prodrug 302a is as viable as the parent drug 
at concentrations of 500 nM or greater.  Although the assay shows only 50% cell 
death, the drugs are considered a success, due to the aggressive nature of the 
4T1 cell line.  It is likely that the breast cancer cells have some resistance to the 
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PTX based treatments due to the relatively high concentrations required to inhibit 
cell growth. 
 
Figure 4.13 | Cytotoxicity Assay against 4T1 Aggressive Breast Cancer Cell 
Line. 
 
4.3.7 In vitro cytotoxicity of PTX-silicate prodrug-loaded PEG-b-PLGA 
nanoparticles (centrifuged) 
We have previously reported the cytotoxicity of prodrugs 301-303 alone 
toward the MDA-MB-231 human breast cancer cell line,118 which has been 
shown to be less aggressive.161 As we described there, "silicates having faster 
rates of hydrolysis [cf. Table 3.4] tend to show cytotoxicities similar to those of 
the parent taxane. This suggests that the silicate esters are hydrolyzed back to 
                                            
161 Larive, R. M.; Moriggi, G.; Menacho-Márquez, M.; Cañamero, M.; de Álava, E.; Alarcón, B.; 
Dosil, M.; Bustelo, X. R. Contribution of the R-Ras2 GTP-Binding Protein to Primary Breast 
Tumorigenesis and Late-Stage Metastatic Disease. Nat. Commun. 2014, 5, 3881. 
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PTX … either in the culture medium or inside the cell during the course of the 
assay." We have now examined the cytotoxicities of the prodrug-loaded 
nanoparticles. 
Cytotoxicity of nanoparticle formulations loaded with six different prodrugs 
[301(a-d,f) and 302a] was evaluated in the MDA-MB-231 cells and the IC50 data 
are shown in Table 4.6. The ethyl-containing silicate prodrugs of PTX 301a and 
302a show a cytotoxicity profile similar to that of free PTX.  The cytotoxicity of the 
PTX-2’-Si(OnOct)3 (301b) nanoparticles was considerably lower, consistent with 
the fact that only a small portion of 301b had been observed to hydrolyze to free 
PTX in the PBS release experiments at pH = 7.4. The nanoparticle formulation 
containing 301c is more potent than that loaded with 301a, which, interestingly, 
mirrors the relative IC50 values of 301c not in nanoparticles and PTX.118 Finally, 
the formulations containing the hindered and, therefore, hydrolytically stable 
PTX-silicates 301f and 301d showed very low cytotoxicity, which is consistent 
with our early observations made with these silicates.118 The in vitro cytotoxicities 
of the PTX-silicate loaded nanoparticle formulations are provided in Figure 4.14. 
 
Figure 4.14 | In vitro cytotoxicity of nanoparticle formulations of 301(a-d,f) and 
302a. 
Free PTX
301a, PTX-2'-Si(OEt)3
301b, PTX-2'-Si(OnOct)3
301c, PTX-2'-Si(OiPr)3
301f, PTX-2'-Si(OtBu)2OEt
301d, PTX-2'-Si(Omenthyl)3
302a, PTX-2',7-[Si(OEt)3]2
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4.4 Nanoparticle Design Future Outlook 
4.4.1 End Group Functionalization 
Alternatively, the copolymerization can be achieved with a benzyl-
protected PEG macro-initiator (BnO-PEG-OH), 415 to allow for further 
modification of the polymer.  This is useful for the covalent attachment a targeting 
ligand to the hydrophilic portion of the polymer.  The hydrophilic functionalization 
allows for the ligand to be exposed and presented to the cell for tumor targeting.  
The benzyl-protected PEG 415 can be synthesized by benzyloxyethanol 415 
initiated anionic polymerization of ethylene oxide shown in Scheme 4.3.162 Upon 
ROTEP, the BnO-PEG-b-PLGA is synthesized and subsequently acetylated.  
Finally, the benzyl group is deprotected through hydrogenolysis to yield the very 
useful precursor polymer 416.  The exposed alcohol of the PEG in 416 can be 
oxidized via Swern conditions to the aldehyde163 417a or to carboxylic acid 418a 
by Jones conditions.164 The aldehyde 417a can also undergo Lindgren oxidation 
to yield 418a. The precursor 416 can also undergo a Mitsunobu reaction to 
create a maleimido derivative 419a165,166 or undergo reaction with sodium azide 
to produce a terminal azide 420a suitable for click chemistry with an alkyne linked 
peptide to form 1,2,3-triazoles.165 The elimination of the Tosyl-PEG can be 
accomplished with ammonium hydroxide to yield 421a.  Alternatively, the amine 
                                            
162 Reed, N. N.; Janda, K. D. A One-step Synthesis of Monoprotected Polyethylene glycol Ethers. 
J. Org. Chem. 2000, 65, 5843–5845. 
163 Wirth, P. Chemical Modification of Horseradish Peroxidase with Ethanal-methoxypolyethylene 
glycol: Solubility in Organic Solvents, Activity, and Properties. Bioorg. Chem. 1991, 19, 133–142. 
164 Kulkarni, M. Single Step Room Temperature Oxidation of Poly(ethylene glycol) to 
Poly(oxyethylene)-dicarboxylic acid. J. Appl. Polym. Sci. 1998, 70, 883-890. 
165 Gill, H. S.; Tinianow, J. N.; Ogasawara, A.; Flores, J. E.; Vanderbilt, A. N.; Raab, H.; Scheer, J. 
M.; Vandlen, R.; Williams, S.-P.; Marik, J. A Modular Platform for the Rapid Site-specific 
Radiolabeling of Proteins with 18F Exemplified by Quantitative Positron Emission Tomography of 
Human Epidermal Growth Factor Receptor 2. J. Med. Chem. 2009, 52, 5816–5825. 
166 Ji, S.; Zhu, Z.; Hoye, T. R.; Macosko, C. W. Maleimide Functionalized Poly(ε-caprolactone)-b-
poly(ethylene glycol) (PCL-PEG-MAL): Synthesis, Nanoparticle Formation, and Thiol Conjugation. 
Macromol. Chem. Phys. 2009, 210, 823. 
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can be synthesized by reduction with hydrogen gas and palladium on carbon 
[Pd/(C)] or by a Staudinger reduction.  To ensure the chemistries work with the 
precious block copolymer 416 the model commercial MeO-PEG-OH (403) can be 
used to obtain 417b, 418b, 419b, 420b, and 421b. 
 
Scheme 4.3.  End functionalization of the free hydroxyl of the PEG terminus. 
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The functionalization at the PEG terminus of the block copolymer serves as 
an important tool to couple tumor targeting peptides to the surface of the 
nanoparticles.  The two oxidized polymers 417a-b and 418a-b can form amide 
bonds with the terminal amines via reductive amination and amide bond 
formation respectively.167 The maleimide 419a-b can undergo addition with a 
sulfur containing ligand to achieve the macromolecular coupling.168 The azido 
polymers 420a-b can undergo click chemistry.  Lastly, the amino polymers 421a-
b can form amide bonds with targeting molecules that contain carboxylic acids. 
Previous research has showed the utility inclusion of tumor targeting 
peptides on the surface of the nanoparticle to direct the accumulation of 
nanoparticles to the tumor tissues and away from metabolic pathways. 169 
Progress towards the functionalization of PEG is presented here as well as 
efforts to modify the end groups of block-copolymers.170 
Model studies with MeO-PEG-OH (403) were designed to mimic the 
chemical reactivity of the HO-PEG terminus in HO-PEG-PLGA-OAc.  The 
methoxy protected 5 kDa polymer (mPEG) 403, as summarized in Scheme 4.3 
was used for the optimization and exploration to install an amine at the terminus.  
First, tosylation of the terminal alcohol in 403 gave MeO-PEG-OTs (422b, not 
shown).  Displacement by sodium azide (NaN3) gave the azido polymer 420b, 
which can undergo click chemistry (Scheme 4.5 and 4.6).  Alternatively, the azide 
420b was reduced to the amine through hydrogenation to give the primary amine 
421b, which can be directly coupled to peptides. 
                                            
167 Chae, S. Y.; Kim, T. H.; Park, K.; Jin, C.-H.; Son, S.; Lee, S.; Youn, Y. S.; Kim, K.; Jo, D.-G.; 
Kwon, I. C.; Chen, X.; Lee, K. C. Improved Antitumor Activity and Tumor Targeting of NH(2)-
terminal-specific PEGylated Tumor Necrosis Factor-Related Apoptosis-inducing Ligand. Mol. 
Cancer Ther. 2010, 9, 1719–1729. 
168 Song, S.; Liu, D.; Peng, J.; Sun, Y.; Li, Z.; Gu, J. Peptide Ligand-mediated Liposome 
Distribution and Targeting to EGFR Expressing Tumor in vivo. Int. J. Pharm. 2008, 363, 155-161. 
169 Wang, M.; Thanou, M. Targeting Nanoparticles to Cancer. Pharmacol. Res. 2010, 62, 90–99. 
170 Tong, R.; Tang, L.; Ma, L.; Tu, C.; Baumgartner, R.; Cheng, J. Chem. Soc. Rev. 2014, 43, 
6982–7012. 
Part I: Anticancer Drug Delivery  Chapter 4 | 
 
 
131 
131 
The azido-PEG is particularly useful due to the orthogonal reactivity with 
an alkyne to give a triazole via click chemistry.  This chemistry is useful when 
linking functionalizing macromolecules covalently.171  To achieve this, we first 
synthesized a small linker molecule to bind to a peptide or tumor targeting agent 
e.g. biotin, and also to introduce the alkyne functionality.  The synthesis of the 
amino alkyne linker is presented in Scheme 4.4. The 2-[2-(2-
chloroethoxy)ethoxy]ethanol 423 was used as the starting material to create the 
small linker that underwent azide substitution to give compound 424.  This azido 
alcohol was reacted with propargyl bromide 425 to yield the azide alkyne 426.  A 
Staudinger reaction successfully reduced the azide to amine 428 in the presence 
of the alkyne, however the purification by flash chromatography after each step 
was problematic. Therefore, an alternative route was explored. In this route, the 
propargylation of 423 to give compound 427 occurred under the previously 
described reaction conditions.172,173 Treatment with ammonia in methanol also 
gave the linker 428 in a shorter synthetic reaction sequence. 
  
                                            
171 Zhang, S.; Chan, K. H.; Prud'homme, R. K.; Link, A. J. Synthesis and Evaluation of Clickable 
Block Copolymers for Targeted Nanoparticle Drug Delivery. Mol. Pharm. 2012, 9, 2228–2236. 
172 Polito, L.; Monti, D.; Caneva, E.; Delnevo, E.; Russo, G.; Prosperi, D. One-step Bioengineering 
of Magnetic Nanoparticles via a Surface Diazo Transfer/Azide-Alkyne Click Reaction Sequence. 
Chem. Comm. 2008, 5, 621–623. 
173 Natarajan, A.; Du, W.; Xiong, C.; DeNardo, G. Construction of Di-scFv through a Trivalent 
Alkyne–azide 1, 3-dipolar Cycloaddition. Chem. Comm. 2007, 7, 695-697. 
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Scheme 4.4 | Synthesis of a small linker for macromolecule conjugation.173 
 
 
4.2.2 Polymer Conjugation 
The amino alkyne linker 428 serves as a dual coupling reagent.  It can first 
couple to a peptide (or another biological molecule such as biotin 429 or folic 
acid) to form a peptide bond, as shown in Scheme 4.6.167 Following this coupling, 
click chemistry of 430 can conjugate the targeting agent to polymer 420a or 420b 
to give the biologically active polymer 431a and 431b.165 The polymer 430a, 
when R is PLGA, can then be impingement mixed with mPEG-b-PLGA and the 
silicate prodrug to produce nanoparticles suitable for targeting tumor tissues.  
Biotin is proposed here since antibody conjugates of biotin have been shown to 
target tumor tissues. 
We first probed the click reaction conditions with a model system to 
determine if the azido-polymer (420b) would be tractable throughout, shown in 
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Scheme 4.5.  The initial set of conditions used a strong base (DBU) to serve as a 
ligand for the copper and a simple alkyne (ethynyltrimethylsilane) to form the 
triazole.  We were pleased that the reaction occurred (SI, Figure S14) and the 
resulting polymer was recovered after precipitation. Our attention turned to the 
click chemistry of the biotin-linker 430 and the PEG-N3 (420b) as well as the 
block polymer 420a120. 
Scheme 4.5 | Click coupling chemistry with a model system 
 
 
Scheme 4.6 | Coupling chemistry with tumor targeting agent biotin. 
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Unfortunately, the click chemistry has proved to be problematic; 
unfortunately the use of an exotic ligand was required for the simple click 
chemistry with a different substrate (not shown).  Although obtainable, we chose 
to explore nanoparticle formulations without the use of a targeting agent.  There 
is still a lot of work to be done with the optimization presented in Scheme 4.3.  
The coupling of different targeting agents (antibodies or polypeptides) to 
functionalized polymers 417, 418, 419, 420, and 421 provides many opportunities 
to develop and synthesize unique functionalized polymers, designed for the 
targeting of tumor tissues to improve drug distribution in vivo while utilizing a 
variety of chemical transformations.  More specifically the conjugation of 417a, 
418a, 419a, and 421, to unique peptides/antibodies through amide or sulfur 
bonds are of great interest for future studies.  These targeting ligands have been 
shown to target and destroy tumor cells through apoptotic pathways, but will not 
be discussed further in this thesis. 
  
Part I: Anticancer Drug Delivery  Chapter 4 | 
 
 
135 
135 
4.4.2 Polymer Backbone Functionalization 
We were also interested in the functionalization of the hydrophobic 
backbone of our block copolymer mPEG-b-PLGA (405).  A series of monomers 
were synthesized for this purpose some of which are shown in Scheme 4.7 
below. 174,175,176  The (S)-4-((benzyloxy)methyl)-1,3-dioxolan-2-one (437) or the 
benzyl protected lactide (438) can undergo polymerization with the macroinitiator 
mPEG-OH (403), as described before, to yield a functionalized block copolymer.  
After the hydrogenation of the benzyl protecting group a free hydroxyl is 
revealed.  We envisioned that this hydroxyl could be captured with either a 
fluorescent tag or even a silicate prodrug.  Both of these goals to capture the free 
hydroxyls about the polymer backbone are quite lofty, so we pursued making the 
polymers first and foremost. 
The benzyl (Bn) and tert-Butyl carbamate (Boc) protected serine (434) is 
commercially available, so we entered the synthesis with this reagent. The Boc 
group was easily removed by TFA in methylene chloride to give the free amide 
(435).  Sodium nitrite and sulfuric acid converted the amide to the valuable 
common intermediate (436). Following the work of Pasquato,174 the reaction with 
triphosgene over activated charcoal afforded the (S)-4-((benzyloxy)methyl)-1,3-
dioxolan-2-one (437) in reasonable yield.  Alternatively, a dimerization reaction 
with p-toluenesulfonic acid to evolve water can be performed, though dilute 
conditions and a long reaction time is required.175 With the monomers in hand we 
                                            
174 Tang, L.; Deng, L. Dynamic Kinetic Resolution via Dual-Function Catalysis of Modified 
Cinchona Alkaloids: Asymmetric Synthesis of Alpha-Hydroxy Carboxylic Acids. J. Am. Chem. 
Soc. 2002, 124, 2870–2871. 
175 Leemhuis, M.; van Nostrum, C. F.; Kruijtzer, J. A. W.; Zhong, Z. Y.; Breteler, ten, M. R.; 
Dijkstra, P. J.; Feijen, J.; Hennink, W. E. Functionalized Poly(Α-Hydroxy Acid)S via Ring-Opening 
Polymerization:  Toward Hydrophilic Polyesters with Pendant Hydroxyl Groups. Macromolecules 
2006, 39, 3500–3508. 
176 Pounder, R. J.; Dove, A. P. Synthesis and Organocatalytic Ring-Opening Polymerization of 
Cyclic Esters Derived From L-Malic Acid. Biomacromolecules 2010, 11, 1930–1939. 
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next explored the co polymerization with rac-lactide (401) and the subsequent 
deprotection. 
Scheme 4.7 | Synthesis of benzyl-protected monomers 
 
 
An initial  set of three 1H-NMR experiments with the benzyl protected 
lactide (438), rac-lactide (401), mPEG-OH (403) initiator, and DBU (404) were 
performed to observe the different rate of polymerization between the two 
monomers.  Molar ratios of each experiment were: (438:401:401:404) i.) 
1.2:0.9:1:0.24, ii.) 1.7:0:1:0.31, and iii.) 0.7:3.6:1:0.27. Although, kinetic rates 
were not determined the benzyl protected lactide (438) was observed to undergo 
polymeriztion much faster than the rac-lactide (401). We were excited to make 
polymers with this monomer and determine the feasibility of the deprotection. 
The polymerization of the benzyl protected lactide (438) was iniated with 
mPEG-OH (403), and DBU (404) as the catalyst. The reaction was monitored by 
removing alloquots ca. every 15 mins over the course of an hour.  The 
polymerization was quenched with benzoic acid and percipitaed into ice cold 
ether to yield the desired benzyl protected block copolymer 438 shown in 
Scheme 4.8. The polymer was then dried in a vaccuum oven overnight. 
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Scheme 4.8 | Synthesis of benzyl-protected block copolymer 438. 
 
A set of random block copolymers from the benzyl protected lactide (438) 
and rac-lactide (401) were synthesized as shown in Scheme 4.9 below. A short 
summary of the different molecular weights achieved is also shown in Table 4.9. 
Unfortunately, the extent of random incorporation was not determined as more 
detailed 13C-NMR studies and kinetics data are required. 
 
Scheme 4.9 | Synthesis of random poly(ethylene glycol)-b-poly(benzyl-lactide-
co-lactide) block copolymers 438. 
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Table 4.9 |  A comparison of polymers made by DBU-catalyzed ROTEP 
 Polymer  Mn(PEG) Mn[PL(Bn/Me)A]a Ratio a,b PDI c  
 (targeted)    LABn : LAMe  
PEG 5-PL(Bn)A iii-16 5K 11.2K 100 : 0 – 
PEG 5-PL(Bn6/Me10)Aiii-16 5K 16.3K 37 : 63 – 
PEG 5-PL(Bn9/Me8)A iii-16 5K 16.6K 53 : 47 1.08 
PEG 5-PL(Bn9/Me9)A iii-16 5K 18K 50 : 50 – 
 a Results based on NMR spectroscopy 
 b Mass ratio of the repeat units 
 c Results based on GPC (CHCl3, 1 mL/min) measurements against a 
polystyrene standard 
 
We conducted a trial reaction for the deprotection of the benzyl group 
under hydrogen with palladium on carbon. The hydrogenolysis was monitored by 
the evolution of toluene by 1H-NMR.  After two days of reaction the polymer was 
ca. 14% deprotected. While this result provided a proof of concept, the reaction 
was not explored further.  We instead focuced on new developements of the 
project toward novel silicate deravatives presented in Chapter 7 of this thesis. 
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5.1 In Vivo efficiency of Nanoparticle Formulations 
5.1.1 Efficacy of PTX-silicate prodrug-loaded PEG-b-PLGA nanoparticles 
(uncentrifuged) against the aggressive 4T1 breast cancer tumors via tail 
vein injection 
With the efficacy of the prodrug established against the 4T1 cells in vitro, 
animal testing was performed to determine the degree of tumor reduction over 
time, and also the distribution of the drug throughout the mouse. Not only will 
these studies show the efficiency of the chemotherapy formulations, they will also 
give insight into the form of the drug over time.  By understanding distribution of 
the nanoparticles in the mice models, the nanoparticle prodrug formulation can 
be improved upon. 
C57/B16 wild type mice were purchased from Charles River Labs and 
seeded with approximately 1 million 4T1 cells in the fat pad of the mice.  The 
tumor grows quickly and the cells metastasize to the lungs, liver, bone, and brain 
in 3-6 weeks.   The resulting tumors were allowed to grow to a volume of 
approximately 150 mm3.  Once the tumors grew to the suitable size (1 week) the 
mice were randomized and treated with one of the following formulations at a 
single dosage of 40 mg equivalent PTX per kg of mouse: i.) Taxol® ii.) PTX-2',7-
[Si(OEt)3]2 (302a) in Cremophor EL®  iii.) (302a) nanoparticles iv.) untreated v.) 
saline only vi) Cremophor EL®.  Since there were only 30 mice available, the 
number of mice to receive each treatment was i.) n=4 ii.) n=8 iii.) n=8 iv.) n=2 v.) 
n=4 vi.) n=4.  Since the saline treated mice also served as a control a small 
number of mice were used for the untreated control group.  The tumor size was 
monitored over the course of 2 weeks via caliper measurements every day.  
These sizes were compared to the initial tumor volume and plotted against time 
and presented in Figure 5.1. 
Chapter 5. In Vivo  Evaulation of Nanoparticles
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Although the control mice did not survive the 2-week period due to cancer 
tumor growth, the drug formulations could still be compared. Once tumors grow 
to a size greater than ca. 10 times their original size, the mice must be 
euthanized. The experimental formulations are as effective as Taxol® in vivo 
during the time course (14 days) of the study.  Much like the cytoxicity assay, the 
tumor cells are so aggressive that they do not fully regress over the course of the 
experiment, but continue to grow even after treatment.  The rate of tumor growth 
is clearly inhibited by paclitaxel in mice treated with some formulation containing 
paclitaxel.  The study also showed that the nanoparticle formulation is essentially 
the same as Taxol®, which is very significant.  And as expected, the nanoparticle 
formulation reduced hypersensitivity in the tail vein of the mice. 
 
Figure 5.1 | Tumor inhibition study against C57/B16 Wild Type Mice bearing 4T1 
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5.1.2 Efficacy of PTX-silicate prodrug-loaded PEG-b-PLGA nanoparticles 
(uncentrifuged) against the MDA-MB-231 breast cancer tumors via tail vein 
injection120 
The samples of NPs prepared from the PTX-2',7-[Si(OEt)3]2 (302a) that we 
used for in vivo studies performed by Stephen Kalscheuer were uncentrifuged 
particles prior to being administered. As described in Chapter 4, we now know 
this to be a suboptimal choice. Despite the significant burst release 
characteristics of these particles,139 we observed therapeutic efficacy that was 
comparable to commercial formulations. We anticipated that formulations 
prepared using centrifugation (unencapsulated free drug/prodrug removed), 
which show more sustained drug regeneration behavior will enable significant 
improvement in efficacy. 
The in vivo efficacy of 302a uncentrifuged-nanoparticles (NPs) was 
evaluated in mice xenografted with orthotopic MDA-MB-231 tumors. This cell line 
was stably transfected with luciferase to enable quantitative bioluminescence 
imaging of tumor growth. Three active PTX-based drug formulations were 
administered (≥5 animals for each group): 302a nanoparticles, Taxol®, and 
Abraxane® at equimolar quantities of PTX (50 µmol kg-1). Non-drug loaded CrEL® 
and blank PEG-b-PLGA NP control groups were also included. The PTX 
treatment showed significant inhibition of tumor growth relative to the controls 
and that all three formulations (302a nanoparticles, Taxol®, and Abraxane®) were 
statistically comparable in their protective capacity (Figure 5.2). Upon completion 
of the study, the toxicological profile was determined for each of the three 
treatment groups. Qualitatively, tail tissue near the injection site in the mice 
treated with CrEL® alone or Taxol® were necrotic, suggesting significant 
inflammation from the CrEL® excipient56 while those treated with the NPs showed 
no visible necrosis. Notably, in four of five Abraxane®-treated mice, aspartate 
transaminase (AST) levels were significantly above the “expected” levels for 
Balb/c nude mice (not shown).120 Additionally, in three of five mice in the 
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Abraxane® group, measured alanine transaminase (ALT) levels were significantly 
higher than expected. Taken together, these results suggest potential liver 
damage. Lymphocytopenia (low white blood cell level) was noted in all three mice 
examined in the Taxol® group, in two out of three mice in the Abraxane® group, 
and in one of three in the 302a-treated mice. Less pronounced blood and liver 
toxicity would be consistent with the hypothesis that 302a provides lower levels of 
toxic agent over a longer duration by virtue of slow release of PTX from NPs. 
 
 
Figure 5.2 | Relative antitumor efficacy of 302a-NPs, Taxol®, and Abraxane® as 
determined by photon flux from the primary tumor site via bioluminescence 
imaging. Luciferin was administered at 150 mg•kg-1 by i.p. injection on an every 8 
day schedule. Photon intensity from the primary tumor site was determined for ≥4 
mice at each time point. CrEL® and blank NP groups are shown up to the time 
point preceding euthanasia or death, “x”, of a majority of the group 
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5.1.3 Efficacy of PTX-silicate prodrug-loaded PEG-b-PLGA nanoparticles 
(centrifuged) against the MDA-MB-231 breast cancer tumors via 
intratumoral injection 
Labile prodrugs that showed significant stability as well as cytotoxicity, 
either alone118 or in the nanoparticle formulation (i.e., 301b, 301c, 303a, 303b, 
302a) were chosen for an intratumoral injection study in a xenograft mouse 
model. The ratio of the prodrug to polymer in the initial FNP feeds, the total mass 
of loaded nanoparticles recovered following ultracentrifugation (3x) and 
lyophilization, the DLS-measured size and size distribution, and the load levels of 
PTX-silicate (expressed as equivalent wt% of PTX) are presented in the SI 
(Table S5.1). This study showed (Figure 5.3) that all nanoparticles slowed tumor 
growth rates relative to a control using blank nanoparticles. Particles containing 
PTX-silicates having faster hydrolysis rates [e.g., PTX-2’-Si(OnOct)3 (301b) and 
PTX-7-Si(OEt)3 (303a), see Table 3.2] were the most effective in inhibiting tumor 
growth. These studies also show that even a single dose of these silicate prodrug 
nanoparticles is capable of inhibiting tumor growth over a prolonged period, 
pointing to their ability to sustain PTX levels in the tumor tissue. 
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Figure 5.3 | Intratumoral injection of nanoparticles loaded with PTX-2’-Si(OnOct)3 
(301b), PTX-2’-Si(OiPr)3 (301c), PTX-7-Si(OEt)3 (303a), PTX-7-Si(OnOct)3 
(303b), and PTX-2’,7-[Si(OEt)3]2 (302a) at equivalent dose (i.e., the same amount 
of PTX if all prodrug has reverted back to PTX and is no longer in the 
nanoparticles) in comparison to a control with empty nanoparticles. 
 
5.1.4 In Vivo efficacy conclusions  
The combination of FNP and silicate prodrug strategy enabled the 
fabrication of nanoparticles in a size range desirable for tumor drug delivery, with 
high PTX loading levels, and sustained drug-release properties. Particle size, 
drug loading, and drug release rates were a function of the hydrophobicity of the 
prodrug. The in vitro and in vivo anticancer activities correlated with the 
hydrolysis rates of the prodrug. Future studies will examine the in vivo efficacy of 
these formulations following intravenous administration. Overall, the FNP/silicate 
prodrug strategy is a promising approach for delivering PTX while avoiding the 
side effects associated with the use of large quantities of nanoparticle excipients. 
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5.2 Maximum Tolerated Dose (MTD) Studies 
5.2.1 In Vivo MTD Study via Tail Vein injection 
A cohort of C57BL/6 mice were purchased from The Jackson Laboratory 
for the maximum tolerated dose (MTD) study.  The 19 mice (n) were randomly 
divided into one of five different groups: i.) untreated control (n=3), ii.) low dose 
301b in CrEL® (n=4), iii.) low dose 301b in centrifuged nanoparticle formulation 
(n=4), iv.) high dose 301b in CrEL® (n=4), and v.) high dose 301b in centrifuged 
nanoparticle formulation (n=4).  Each group of treated mice received either a low 
dose of 40 mg/kg or a high dose of 80 mg/kg PTX equivalent at the outset via tail 
vein injection followed by a second dose of the same concentration one week 
later.  All animals were sacrificed on the 3rd week following treatment and the 
essential tissues and blood were harvested for further analysis.  Liver, kidneys, 
lungs, and spleen were removed and placed into a -80 ºC freezer until analysis.  
Liver samples were extracted and results are presented in Chapter 5.3.  A 
cardiac puncture of the heart of each sacrificed mouse allowed for the removal of 
the whole plasma. 
The whole mouse blood plasma was sent to IDEXX Bioresearch for 
analysis.  The hematology and liver function biomarkers were determined to see 
if any adverse side effects from the formulations were present in the mice. The 
values were compared to the untreated control mice as well as the normal range 
for the mouse model used.  The white blood cell count (WBC) shows that mice 
given any of the prodrug formulations of 301b fell within the normal range and 
was equivalent with the untreated control (Figure 5.4). Generally, this parameter 
shows that the formulations do not cause neutropenia in the animal models. 
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Figure 5.4 | Absolute number of white blood cells (WBC) counted in the whole 
mouse plasma of mice treated with formulations of PTX-7-Si(OnOct)3 (303b). 
[normal range 5.0-13.7 x 103/µL] 
 
The other hematology results: segmented neutrophils percentage (Figure 
S5.1), the absolute number of segmented neutrophils (Figure S5.2), lymphocytes 
percentage (Figure S5.3), the absolute number of lymphocytes (Figure S5.4), 
monocytes percentage (Figure S5.5), the absolute number of monocytes (Figure 
S5.6), eosinophils percentage (Figure S5.7), the absolute number of eosinophils 
(Figure S5.8), basophils percentage (Figure S5.9), the absolute number of 
basophils (Figure S5.10), red blood cell (RBC) count (Figure S5.11), the amount 
of hemoglobin (Figure S5.12), the percentage of red blood cells present (HCT) 
(Figure S5.13), the mean cell volume (MVC) of red blood cells (Figure S5.14), the 
mean cell hemoglobin (MCH) (Figure S5.15), the mean corpuscular oglobin 
concentration (MCHC) (Figure S5.16), number of platelets (S5.17), and the 
number of reticulocytes (Figure S5.18) are presented in the supporting 
information appendix of Chapter 5 at the end of this thesis. 
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The whole mouse plasma was also tested from various proteins present in 
the blood that are biomarkers for liver, kidney, and pancreatic damage.  The two 
most indicative markers (alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST)) are shown in Figures 5.5 and 5.6 below.  High levels of 
ALT and AST when compared to the untreated control animals indicate liver 
damage. Interestingly, none of the treated animals showed a statistical significant 
increase in either ALT or AST levels, which suggests that liver function is normal 
in treated animals. 
The other biomarkers to determine liver, kidney, and pancreatic function 
are shown in the supporting information of Chapter 5 of the appendix as: the 
concentration of albumin (ALB) (Figure S5.19), the concentration of globulins 
(GLOB) (Figure S5.20), the ratio of albumin to globulins (ALB/GLOB) (Figure 
S5.21), the amount of alkaline phosphatase (ALKP) (Figure S5.22), the amount 
of gamma glutamyl transpeptidase (GGT) (Figure S5.23), and the total protein 
(TP) (Figure S5.24). 
 
 
Figure 5.5 | Amount of alanine aminotransferase (ALT) measured in mouse 
plasma as activity units per liter (U/L). 
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Figure 5.6 | Amount of aspartate aminotransferase (AST) measured in mouse 
plasma as activity units per liter (U/L). 
 
5.2.2 In Vivo MTD Conclusions  
We were very pleased with the results of the MTD study, in that all of the 
treated mice with the prodrug formulation of 301b in either CrEl® or nanoparticles 
showed essentially the same toxicity to the animals.  Even at the highest 
concentration of 80 mg/kg PTX equivalent with prodrugs did not diminish the total 
white blood cell count, red blood cell count, or platelets found in the plasma. Also 
the ALT and AST levels did not rise in comparison to the untreated control, 
suggesting that no liver damage has occurred. In addition, no substantial dip in 
animal body weight occurred over the course of the study.  All these results show 
that the MTD for 301b is much greater than that of Taxol® (20 mg/kg) or 
Genexol® (60 mg/kg).177 Further studies are required to determine the MTD of our 
nanoparticle silicate prodrug formulation. 
                                            
177  Kim, S. C.; Kim, D. W.; Shim, Y. H.; Bang, J. S.; Oh, H. S.; Wan Kim, S.; Seo, M. H. In Vivo 
Evaluation of Polymeric Micellar Paclitaxel Formulation: Toxicity and Efficacy. J. Control. Release 
2001, 72, 191–202. 
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5.3 Drug Distribution and Extraction 
More can be learned from the in vivio experiments if the drug and/or 
prodrug can be isolated from the tissues of the mice.  Drug disposition typically 
occurs in less than 24 hours after administration, and in most cases 8 hours is 
suitable for the drug to disperse throughout the body.  Since the drug distribution 
is so fast, mice were sacrificed shortly after the administration of the drug for our 
initial experiments.  Also weights of each mouse can be compared to determine 
toxicity effects of the formulations. 
5.3.1 Extraction Techniques for Paclitaxel 
To determine the drug distribution in vivo, minute concentrations must be 
recovered, analyzed, and quantified from within various tissues, while removing 
various impurities from the biological matrix analyzed. Accomplishing the difficult 
task of recovering small amounts of drugs in complex mixtures requires a variety 
of complementary extraction techniques and chromatographic parameters, which 
we have been developing. Pretreatment of tissue samples by solid-phase 
extraction (SPE) or liquid-liquid extraction (LLE) is required to remove interfering 
proteins and other bio-molecules. SPE uses preparatory columns packed with 
hydrocarbon capped silica to hold hydrophobic molecules while impurities are 
removed through a series of wash steps. LLE achieves this through precipitation 
of proteins, centrifugation, and removal of the supernate.  Many improvements in 
these two pretreatment techniques can be made to increase the speed, recovery 
of the analyte (efficiency), and removal of contaminates. 
High performance liquid chromatography (HPLC) with UV detection at 227 
nm is the most common method for analysis of paclitaxel, but is limited by the 
detection threshold as shown in Table 5.1.  Liquid chromatography in tandem 
with mass spectrometry (LC-MS) increases sensitivity by detection of the ionizing 
molecules through electrospray and analyzing their respective masses.  This 
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technique can be expanded upon, to achieve analyte quantification at even lower 
concentration, by selection of the ions in the first mass spectrometer and further 
analysis of their masses with a second mass detector.  This technique is known 
as liquid chromatography tandem mass spectrometry (LC-MS-MS).  Different 
approaches used to extract paclitaxel from a variety of matrices and the tools 
used to analyze them are summarized in Table 5.1.  This information serves as a 
starting place to develop extraction and analysis methods of highly hydrophobic 
and labile silicate prodrugs of paclitaxel. 
Table 5.1 |  Extraction techniques to recover paclitaxel from different tissues. 
Research Group, Matrix Technique Efficie- Detectiona LOQb 
 Date abv.b abv.c ncy(%) Method (ng/mL) 
Beijen, 1995178 Hp & Mt SPE CN 89% C8 / HPLC 10 
Bannister, 2002179 Dp LLE (MTBE 2.5x)d NA C18 / LC-MS 0.1 
Beijen, 2004180 Hp, Htu, Mb LLE (MTBE 5x)d 72% C18 / LC-MS-MS 0.1 
Chi, 2005181 Mt LLE (EA 100x)d >95% C18 / HPLC 10 
Peterson, 2006182 Hp SPE CN NA C12 / LC-MS-MS 0.5 
Matsubara, 2007183 Hp SPE C18 >90% C18 / HPLC 3 
                                            
178 Huizing, M. T.; Sparreboom, A.; Rosing, H.; van Tellingen, O.; Pinedo, H. M.; Beijnen, J. H. 
Quantification of Paclitaxel Metabolites in Human Plasma by High-Performance Liquid 
Chromatography. J. Chromatogr. B 1995, 674, 261–268. 
179 McChesney, J.; Zygmunt, J.; Bannister, S. Measurement of paclitaxel in biological matrices: 
high-throughput liquid chromatographic-tandem mass spectrometric quantification of paclitaxel 
and metabolites in human and dog plasma J. Chromatogr. B 2003, 785, 253-261. 
180 Rosing, H.; Beijnen, J. A Simple and Sensitive Assay for the Quantitative Analysis of Paclitaxel 
in Human and Mouse Plasma and Brain Tumor Tissue using Coupled Liquid Chromatography 
and Tandem Mass Spetrometry. J. Mass Spectrom. 2004, 39, 1506-1512. 
181 Kim, S. C.; Yu, J.; Lee, J. W.; Park, E.-S.; Chi, S.-C. Sensitive HPLC Method for Quantitation 
of Paclitaxel (Genexol in Biological Samples with Application to Preclinical Pharmacokinetics and 
Biodistribution. J. Pharmaceut. Biomed. 2005, 39, 170–176. 
182 Gréen, H.; Vretenbrant, K.; Norlander, B.; Peterson, C. Measurement of Paclitaxel and its 
Metabolites in Human Plasma using Liquid Chromatography/Ion Trap Mass Spectrometry with a 
Sonic Spray Ionization Interface. Rapid Commun. Mass Sp. 2006, 20, 2183–2189. 
183 Suno, M.; Ono, T.; Iida, S.; Umetsu, N.; Ohtaki, K.-I.; Yamada, T.; Awaya, T.; Satomi, M.; 
Tasaki, Y.; Shimizu, K.; Matsubara, K. Improved High-performance Liquid Chromatographic 
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a Column used / Detection Method (HPLC only = UV-vis), C18 = octadecyl-silica, C12 = dodecyl-
silica, C8 = octyl-silica, CN = cyano-silica 
b Limit of Quantification (LOQ) based on less than 20% variation from calibration curve. All 
calibration curves were formed from ratios to an appropriate internal standard (I.S.). 
c Abbreviations- Dog Plasma (Dp), Human Plasma (Hp), Human Tumor (Htu), Mouse Brain (Mb), 
Mouse Tissues (Mt). 
d Abbreviations- Solid-Phase Extraction (SPE), Liquid-Liquid Extraction (LLE), Methyl tert- butyl 
ether (MTBE), Ethyl acetate (EA). 
e Example (EA 100x vol) signifies an extraction volume of EA 100 times the volumes of tissue 
homogenate or blood sample. 
 
5.3.2 Extraction protocol of PTX from various tissues 
A group of C57/B16 wild type mice (n=32) was seeded with 1 million 4T1 
tumor cells and allowed to grow to a volume of approximately 150 mm3.  Eight 
mice each were put into four groups and injected in the tail vein with one of the 
following formulations at a dose of 40 mg equivalent of PTX per kg of mouse i.) 
Taxol®, ii.) PTX-2’,7-[Si(OEt)3]2 (302a) in Cremophor EL®, iii.) 302a loaded 
nanoparticles (50 wt%, PEG-b-PLGA, 5k-10k), iv.) untreated (control).  After 2 
hours of treatment, 4 mice from each group were euthanized.  The other 16 mice 
(4 per group) were euthanized after 8 hours.  The euthanized mice were 
dissected to harvest 7 important tissue samples: brain, lungs, heart, liver, spleen, 
kidneys, and tumor.  Since the drug was administered intravenously, there was 
little need to collect any part of the gastrointestinal tract or excrement due to a 
low rate of back adsorption.184,185 Each tissue was collected, weighed as a wet 
mass (some residual blood), and stored in a -80 ºC freezer until extraction and 
analysis. 
                                                                                                                                  
Detection of Paclitaxel in Patient's Plasma using Solid-Phase Extraction, and Semi-micro-bore 
C18 Separation and UV detection. J. Chromatogr. B 2007, 860, 141–144. 
184 Martinez, M. A Mechanistic Approach to Understanding the Factors Affecting Drug Absorption: 
a Review of Fundamentals. J. Clin. Pharmacol. 2002, 42, 620-643. 
185 Varma, M.; Sateesh, K. Functional Role of P-glycoprotein in Limiting Intestinal Absorption of 
Drugs: Contribution of Passive Permeability to P-glycoprotein Mediated Efflux Transport. Mol. 
Pharm. 2005, 2, 12-21. 
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Before the tissues could be analyzed, and the drug/prodrug quantified, a 
series of controls was needed to validate the extraction methods and ensure that 
acceptable recovery was possible. By spiking in known concentrations of 
paclitaxel or prodrug along with docetaxel (as an internal standard) into untreated 
tissues, it was possible to determine extraction efficiencies.  Two different 
approaches, LLE and SPE, were explored to extract the compounds cleanly and 
prepare the samples for analysis by both HPLC and LC-MS. 
Paclitaxel and DTX are very similar in structure (cf. Figure 3.2), while the 
prodrug is highly hydrophobic, making separation quite difficult.  A slow gradient 
method followed by a 100% organic method was developed.  Mobile phase A 
was a 95:5 H2O:MeOH mixture buffered with 15 mM ammonium acetate 
(NH4OAc) and mobile phase B was 98:2 MeOH:H2O buffered with 15 mM 
(NH4OAc). The tissue matrix from which the analytes are extracted further 
complicates this task.  (Small peptides and phosphates typically survive the 
preparatory step.)  A gradient method was developed on an analytical Agilent 
XDB-C18 4.6 mm x 50 mm column with particle size of 1.8 µm.  A constant flow 
rate of 0.5 mL was maintained throughout the analysis.  The percentage of 
mobile phase B compared to A (%B) started at 55% and increased to 80% over 
the course of 10 minutes to separate PTX and DTX, the %B then ramped to 
100% in 5 minutes, and remained there for another 5 minutes to elute the 
relatively nonpolar analyte 302a.  The %B returned to 55% in 3 minutes to allow 
the column to re-equilibrate at this mobile phase ratio until the next 10 µL 
injection.  The characteristic mass spectrum of each compound can be clearly 
seen in the “negative ion” mode, and their corresponding integrals in the UV 
chromatogram are observed at 227 nm for quantification against a calibration 
curve. 
A LLE method was developed due to the lower cost associated with the 
procedure and less sample handling during the single extraction on the tissues 
would reduce losses as well.  The seven samples of different tissue types were 
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homogenized in 4 mL of de-ionized water to create a slurry of the solid tissues.  
The samples were then frozen at -80º C for 5 hours, after which they were 
lyophilized for 24-48 hours to remove the water.  The dried weights were 
recorded and known concentrations of PTX or 302a were spiked in along with 
DTX as the internal standard (I.S.).  Each sample was extracted with 3 mL of 
ethyl acetate overnight.  The samples were centrifuged at 16,000 rpm and a 2 mL 
aliquot of the supernate was transferred and concentrated by a stream of 
nitrogen (N2).  The samples were re-dissolved in 1 mL of acetonitrile (ACN) and 
analyzed by HPLC.  Initial attempts with one extraction showed poor efficiency 
and recovery of the drugs out of the tissues (Column 2, Table 5.2).  Multiple 
extractions (3 times of 3 mL of ethyl acetate each) were performed on the tissue 
samples, which increased the extraction efficiency.  However, the amount of time 
for sample preparation also increased.  Also, multiple extractions overnight can 
lead to the hydrolysis of 302a to give PTX as shown in mixed solvent system 
stability of 302a (Chapter 3, Figure 3.4).  An average of 60% recovery was noted 
by comparing the concentrations measured to a standard curve. 
A series of seven SPE cartridges were screened to determine the 
recovery from known concentrations of PTX, 302a, and the I.S. DTX in methanol 
and PBS without tissue present.  The SPE cartridges were first conditioned with 
methanol to wet the silica and remove any residual manufacturing impurities.  
They were then equilibrated with PBS buffer and the sample was loaded.  The 
load eluent was analyzed by HPLC to confirm that the column retained the 
analytes.  A second wash of 50:50 methanol:PBS washed the samples to remove 
the majority of the impurities that may be present.  Again, this eluent was 
analyzed by HPLC to test retention during this step.  Finally the compounds were 
eluted off of the adsorbant with 2.5 mL of ACN.  The eluate was concentrated by 
drying under a nitrogen stream and reconstituted in the HPLC mobile phase.  
Excellent recovery was observed in most cartridges.  Interestingly, cyano bond 
material (CN) did not retain PTX well but gave 95% recovery of 302a.  The C18 
gave optimal recovery of ≥ 90% for all 3 compounds (PTX, 302a, DTX). 
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Table 5.2 | Comparison of extraction efficiencies of each technique.  
 Technique LLEa LLEa LLEb SPEa SPEb 
 Tissue 1x3mL EA  3x3mL EA 3x3mL EA C18 C18 
 Brain 8 ± 0% 55 ± 10% 64 ± 2% – – 
 Heart 30 ± 26% 59 ± 12% 57 ± 13% 85 ± 3% 98 ± 10% 
 Lungs 16 ± 0% 56 ± 13% 52 ± 5% – – 
 Liver 69 ± 7% 66 ± 12% 48 ± 1% 41 ± 1% 34 ± 5% 
 Spleen 54 ± 18% 84 ± 41% 33 ± 16% – – 
 Kidneys 43 ± 3% 60 ± 12% 48 ± 9% 68 ± 3% 90 ± 9% 
 Tumor 33 ± 4% 83 ± 31% 52 ± 10% 79 ± 16% – 
 a Extraction efficiency of PTX. 
 b Extraction efficiency of prodrug 302a. 
 
To extract drugs out of the animal tissues, the solid phase extraction 
method with C18 adsorbent was employed due to the high recovery of spiked 
samples and good extraction efficiencies established in the control experiments.  
Although there are many stages to prepare the samples for analysis, the 
extraction can be accomplished in 1 day as opposed to LLE.  Also there is no 
need to lyophilize or extract overnight due to the highly hydrophobic nature of the 
C18 adsorbent. 
 
5.3.3 Bio-distribution study of PTX-silicate prodrug-loaded PEG-b-PLGA 
nanoparticles (uncentrifuged) against the aggressive 4T1 breast cancer 
tumors via tail vein injection 
Liver tissue samples from the prodrug distribution experiment were 
homogenized in 3 mL of PBS buffer for every gram of wet tissue weight.  The 
homogenate was then split into equal volumes for duplicate or triplicate analysis.  
To each sample, 5 µg of DTX was added along with an aliquot of methanol that 
was half the volume of the tissue sample.  Adding the internal standard at this 
point allows the ratio of drug to I.S. to be quantified without the errors associated 
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with quantitative transfer of small volumes.  The addition of methanol also 
precipitates many of the proteins, which are removed upon centrifugation at 
16,000 rpm.  By precipitating the proteins, the samples are effectively washed 
once, thereby increasing column lifetime and affinity of the adsorbent for the 
analytes.  After the columns were conditioned with methanol and equilibrated 
with PBS buffer, the supernate of the ~30% methanol/PBS homogenate 
containing the analytes and I.S. was loaded onto the cartridge.  The sample was 
then washed with a 50:50 MeOH:PBS solution, which after elution was analyzed 
to ensure drug retention as done in control experiments.  The analytes were 
finally eluted with 2.5 mL of ACN and concentrated over nitrogen.  The samples 
were re-dissolved in 1 mL of ACN and analyzed by the LC-MS method described 
above in Section 3.3.  The AUC in the UV region of PTX and 302a were 
calculated and divided with the integral of I.S. DTX to produce a ratio.  This ratio 
could be evaluated against a linear calibration curve of integration ratios 
(PTX/DTX) or (302a/DTX) vs. known concentrations of PTX or 302a.  Back-
calculation of dilutions from the tissue and efficiency of extraction allow the total 
amount of drug to be calculated as a ratio of the initial wet mass of the tissue.  
Figure 5.7 shows the concentrations calculated for each formulation performed in 
triplicates. 
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Figure 5.7 | Bar graph depicting the amount of drugs in the liver 8 Hours.  Each 
measurement is from 3 different measurements (sample split in 3 and extracted) 
of liver homogenates and repeated with another liver from a different mouse. 
(Prodrug = 302a) 
 
After 2 hours, there is approximately 120 µg of PTX per gram of liver 
tissue in all 3 treatments.  This reveals there is no significant difference between 
each formulation accumulation in the liver over the course of 2 hours.  
Interestingly, the prodrug is observed in the case of the silicate prodrug 
nanoparticle treatment at 2 hours.  This shows the ability of the polymer 
nanoparticle to protect the labile prodrug from immediate hydrolysis.  
Approximately 0.01% of the liver tissue homogenate is PTX at 2 hours.  Over the 
course of 8 hours, the drug concentrations in the liver are significantly lower, as 
expected.  The Taxol® formulation is the lowest.  This suggests that the drug is 
readily cleared from the liver while the prodrug formulations take longer for 
clearance of the drug.   
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Another study was conducted on tumor tissue, but concentrations were 
not detectable except for 302a administered in CrEL®, which had a concentration 
of 2.9 ± 0.9 µg of PTX per gram of tumor tissue.  Finding little or no drug in the 
tumor tissue is surprising since the extraction efficiency was high for the tumor 
tissue (Table 5.2).  It is possible that the concentrations are below the limit of 
quantification (LOQ), which is 100 ng/mL due to the presence of soluble proteins 
that can suppress the signal, or an absolute limit of detection (LOD) of 1.0 ng of 
PTX, and, thus, it is difficult to draw conclusions regarding the drug localization in 
the tumors. 
 
5.3.3 Bio-distribution study of PTX-silicate prodrug-loaded PEG-b-PLGA 
nanoparticles (centrifuged) in C57BL/6 mice via tail vein injection 
Liver samples were removed from the -80 ºC freezer and allowed to thaw 
to room temperature at which point 10 µg of DTX was added from a 1 mg/mL 
stock solution to the liver to serve as the I.S.  Quality controls were made from 
the untreated control group livers by adding in a known concentration of 1mg/mL 
stock solution of PTX (50.7 µg, 101.5 µg, 203 µg) for mouse liver 1 (M1), M2, M3 
respectively. The livers were wetted with 2 mL of saline and homogenized. The 
samples were loaded onto an equilibrated SPE cartridge by adding 1 mL of ACN 
and eluting the solvent mixture. LC-MS-MS revealed no PTX, DTX, or 301b in the 
load step. The analytes were eluted with 3 mL of methanol, concentrated on the 
rotary evaporator, dissolved in 1 mL of methanol, filtered through a 0.2 µm 
syringe filter, and injected (5 µL) as triplicates on the LC-MS-MS.  Samples and 
quality controls were quantified by a calibration curve of the ratio of PTX/DTX and 
tabulated in Figure 5.8 below. 
Unfortunately the quality controls showed a matrix effect with the liver 
tissue and gave an observed value greater than that of the known concentration 
especially at higher concentrations of PTX. Nevertheless, the graph provides an 
estimate for the amount of drug retained after the 3 week MTD study. 
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Figure 5.8 | Amount of PTX quantified by LC-MS-MS in each mouse model (M1-
M19) for each treatment group in the MTD study. 
 
In either low dose treatment group at the (40mg/kg) the liver retained ca. 
200 µg of PTX which accounts for ca. 12% of the total dose injected into the 
animals.  The high dose treatment group of 80 mg/kg PTX equivalent 301b in 
CrEL® dosed twice could not be quantified.  However, the high dose treatment 
with 80 mg/kg PTX equivalent 301b in our nanoparticle formulation dosed twice 
showed an average of ca. 660 µg of PTX in each liver sample which accounts for 
ca. 21% of the entire dose injected into the tail vein of the mice. The animals 
receiving nanoparticle formulations tolerated the 2x 100 µL dosing much better 
than those treated with CrEL® formulations as expected. 
The total amount of PTX quantified was divided by the total wet mass of 
the liver and tabulated in Figure 5.9 below.  From this graph the low dose 
formulations show significantly less PTX per mg of liver.  While the mice tolerated 
the high dose treatments for the MTD studies (Chapter 5.2) the extraction data 
suggest that multiple doses at 40 mg/kg are beneficial as less drug is retained by 
the liver. For the current efficacy study underway presented in the future outlook 
0
200
400
600
800
1000
1200
1400
1600
M1 M2 M3 M4 M5 M6 M7 M8 M9 M10M11 M12M13M14M15 M16M17M18M19
µg
 P
TX
 /L
iv
er
Sample
Quality Controls
40 mg/kg
301b + CrEL®
40 mg/kg 
301b NPs
80 mg/kg
301b + CrEL®
80 mg/kg 
301b NPs
Ex
pe
cte
d
Ob
se
rv
ed
Ex
pe
cte
d
Ob
se
rv
ed
Ex
pe
cte
d
Ob
se
rv
ed
Part I: Anticancer Drug Delivery  Chapter 5 | 
 
 
159 
159 
Chapter 5.4 we opted to dose at 40 mg/kg of two prodrugs namely 301a and 
301b. 
 
Figure 5.9 | Amount of PTX quantified by LC-MS-MS per mg liver sample for 
each treatment group. 
 
5.4 Future Outlook 
Further research is required to finish a complete distribution study of 
centrifuged nanoparticles.  The future outlook of the project is very promising. 
The nanoparticle formulation will continue to be optimized through the 
conjugation of polymers to tumor targeting peptides and antibodies. The 
effectiveness of these modifications can be analyzed through in vitro studies, and 
efficacy and tissue distribution studies in vivo. 
Lastly a cohort of 40 Balb/c Nu/Nu mice were purchased from Jackson 
Labs. Mice were transfected with MDA-MB-231-Luc+ cancer cells and tumors 
allowed to grow to 100 mm3. The nude mice six each were randomly divided into 
one of six groups: i.) untreated saline control ii.) Taxol®, iii.) PTX-2’-Si(OEt)3 
(301a) in CrEL®, iv.) 301a formulated in nanoparticles (centrifuged), v.) PTX-2’-
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Si(OnOct)3 (301b) in CrEL®, or vi.) 301b formulated in nanoparticles (centrifuged).  
Tail vein injections at 40 mg/kg dosing will allow for a comparison of the efficacy 
of the two different prodrugs. This study is currently underway, however we are 
optimistic in the outcome of our silicate prodrug loaded nanoparticle formulations. 
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6.1 Introduction 
Silicate esters [also known as orthosilicate esters or tetraalkoxysilanes, 
Si(OR)4]186 comprise a class of organic compounds that has been known for well 
over 150 years.103 More generally, silicate esters (and other organosilicon 
species187,188) have been widely studied primarily due to applications in sol-gel 
forming processes. Recently, we have a growing interest in the potential 
application of silicate derivatives as prodrugs, a setting in which hydrolytic 
cleavage of the (RO)3Si—XDrug (X = O, N) bond is essential for release of the 
parent drug molecule. 112,118 
Hydrolysis rates have been reported for the two simplest members of the 
silicate ester family, tetramethyl and tetraethyl orthosilicate (TMOS and TEOS, 
respectively), driven primarily by their wide use in sol-gel-forming processes.189 
The techniques used to monitor the hydrolysis of these silicate esters include gas 
chromatography,190  Raman spectroscopy,191  and nuclear magnetic resonance 
(NMR) spectroscopy.135,192 Acid-catalyzed hydrolysis in mixed aqueous-organic 
                                            
186 Most generally, names for compounds containing silicon are named from the simplest silane, 
SiH4. However, compounds that consist of four Si-O bonds are commonly named as a derivative 
of orthosilicic acid rather than as a silane derivative. 
187 Bassindale, A. R.; Taylor, P. G. Reaction Mechanisms of Nucleophilic Attack at Silicon. In The 
Chemistry of Organic Silicon Comounds. Patai, S.; Rappoport, Z., eds. John Wiley & Sons, Inc: 
New York, 1989, 839-892 and references therein. 
188 Holmes, R. R. The Stereochemistry of Nucleophilic Substitution at Tetracoordinated Silicon. 
Chem. Rev. 1990, 90, 17-31 and references therein. 
189 Aelion, R.; Loebel, A.; Eirich, F. Hydrolysis of Ethyl Silicate. J. Am. Chem. Soc. 1950. 69, 61-
75. 
190 Ro, J. C.; Chung, I. J.  Sol-Gel Kinetics of Tetraethylorthosilicate (TEOS) in Acid Catalyst. J. 
Non-Cryst. Solids 1989, 110, 26-32.   
191 Zerda, T. W.; Hoang, G. Effects of Solvents on the Hydrolysis Reaction of Tetramethyl 
Orthosilicate. Chem. Mater. 1990, 2, 372-376. 
192 Assink, R. A.; Kay, B. D.; Study of Sol-Gel Chemical Reaction Kinetics by NMR Annu. Rev. 
Mater. Sci. 1991, 21, 491-513. 
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media has been interpreted to occur via an SN2 mechanism in a process that is 
pseudo first-order in water and with a rate that is solvent dependent.193 TMOS 
and TEOS are hydrolytically labile under both acidic and basic conditions. 
Occasional qualitative inferences have been drawn about the relative 
hydrolytic lability of silicates. For instance, gelation times, used as a proxy for 
hydrolysis, of tetramethyl, tetraethyl, and tetra-n-butyl orthosilicates were found to 
be approximately two days, 10 days, and 25 days, respectively, when the 
compounds were stored without “special precautions.” 194  While not entirely 
satisfying from the perspective of quantified information, observations such as 
these give a hint of the subtle steric alterations that influence the rate of 
hydrolysis of silicate esters. In more recent studies, sterically hindered silicate 
esters have been synthesized and reported to hydrolyze very slowly, but these 
studies also were not quantitative.127,195  
We have been able to locate only a single study designed to quantify the 
hydrolysis rates of several silicate esters.196 This involved a comparison of four 
different compounds; all symmetrical tetraalkoxysilanes: ethoxy, n-butoxy, n-
hexyloxy, and 2,3-dimethylbutoxy. These experiments demonstrated an 
approximately six-fold slower hydrolysis rate with increasing aliphatic chain 
length (from ethyl to n-hexyl) and an approximately 17-fold slower hydrolysis rate 
with a branched side chain.196 However, these studies are slightly compromised 
by the analytical method used to measure the rates. Karl Fisher titration is now 
                                            
193 Zerda, T. W.; Hoang, G.  Effects of Solvents on the Hydrolysis Reaction of Tetramethyl 
Orthosilicate.  Chem. Mater. 1990, 2, 372-376. 
194 Arkles, B. Silicon Esters. In Kirk-Othmer Encyclopedia of Chemical Technology, Fourth 
Edition, Volume 22; Kroschwitz, J. I.; Howe-Grant, M., ed. John Wiley & Sons, Inc: New York, 
1997, 69-81. 
195 Clausen, R. P.; Bols, M. The First Tri- and Tetraalkoxysilanes with Four Different Substituents. 
J. Org. Chem. 1997, 62, 4457-4464. 
196 Brinker, C. J. Hydrolysis and Condensation of Silicates: Effects on Structure. J .Non-Cryst. 
Solids 1988, 100, 31-50. 
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known to consume both water and silanols, so the absolute rate constants 
measured are considered to be not entirely reliable.197  
We describe here experiments that establish broader trends in the relative 
hydrolytic lability of more extensive series of structurally related silicate esters as 
well as some analogs thereof. These results provide guidance on how to further 
capitalize on the applications of silicate derivatives194 in various settings. 
 
6.2 Hydrolytic Lability of Model Silicates 
 
The relative hydrolysis rates of several sets of silicates, as well as a few 
related silanols and silane derivatives, were studied by 1H NMR spectroscopy. 
Typically, experiments were performed in a 10:1 volume ratio of acetone-d6:D2O 
containing 1% (by volume) of one of trifluoroacetic acid (TFA), acetic acid 
(AcOH), or, for the case of TEOS, triethylamine (TEA) as a hydrolysis catalyst.   
Principally three types of silicates were studied (601-603). The synthesis 
strategies used to prepare each class are summarized in Figure 6.1. Many of the 
tetra-alkyl (and the tetra-phenyl) silicates 601 are commercially available. Others 
were prepared by reaction of tetrachlorosilane (SiCl4) with excess alcohol (ROH), 
sometimes in pentane alone (with evolution of HCl) or, for hindered ROH 
reactants, in the presence of a non-nucleophilic amine base like pyridine. 
Likewise, some trialkoxychlorosilanes can be purchased; others were made by 
reaction of SiCl4 with three equivalents of alcohol. Subsequent reaction with a 
different alcohol, a phenol, a carboxylic acid provided 602 or with an amine or 
amide gave 603.  
                                            
197 Brinker, C. J.; Scherer, G. W. Hydrolysis and Condensation II: Silicates. In Sol-Gel Science: 
The Physics and Chemistry of Sol-Gel Processing. Academic Press, Inc: San Diego, CA, 1990, 
97-233. 
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Figure 6.1 | General approaches used for the synthesis of each of the three 
classes of silicates (601–603) whose hydrolysis rates are compared. 
As a representative example that shows the protocol we used for 
determining hydrolysis half-lives (rates), we show in Figure 6.2 the case of 
tetraisopropyl orthosilicate (601e). Its hydrolysis in acetone-d6:D2O:TFA-d 
(90:9:1) was monitored by 1H NMR spectroscopy over time. The integration 
values corresponding to the resonances for the isopropyl methine protons of 
silicate 601e were compared with those of the released i-PrOH. This substrate is 
typical in that no resonances for any intermediate silanols [e.g., (iPrO)3SiOH] (or 
their anhydro-dimers) were detected during the course of reaction. This suggests 
that hydrolytic cleavage of the first alkoxy is the slowest compared with all of the 
remaining three events that lead, ultimately, to silicic acid [Si(OH)4] (and its 
oligomers198) and four equivalents of released i-PrOH. 
                                            
198 Belton, D. J.; Deschaume, O.; Perry, C. C. An overview of the fundamentals of the chemistry 
of silica with relevance to biosilicification and technological advances. FEBS J. 2012, 279 1710–
1720. 
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Figure 6.2 | NMR monitoring of the hydrolysis of 601e in 90:9:1 acetone-
d6:D2O:TFA-OD at 22 °C. 
 
Using this methodology, we determined the half-lives for hydrolysis of the 
six tetra-alkoxy (601a-f) and two tetra-aryloxy (601g-h) silanes shown in Table 
6.1. The first four of these all contain four primary alkoxy groups. Their rates of 
hydrolytic cleavage slowly decrease as the alkyls grow longer, but only over a 
span of <7 in relative rates. In fact one can discern a plateauing effect; the 
incremental decrease diminishes for each additional two carbons present in the 
termini of each chain. The krel values for the first three entries (ethyl, butyl, and 
hexyl silcates 601a-c) are entirely in accord with the relative reactivities reported 
by Brinker.196 The (tetra-isopropyl)silicate (601e, cf. Figure 6.2), which contains 
branched secondary alkyl groups, has a yet slower rate [25.9 times slower than 
TEOS (601a) and ca. 4 times slower than the octylsilicate 601d]. Tetramenthyl 
silicate (601f), also having four secondary alkoxy groups but, of course, of much 
greater "long-range" (or "outer sphere") steric bulk, has a dramatically increased 
stability toward hydrolysis. 
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Table 6.1 | Hydrolytic lability of symmetrical silicates 601a-h. 
601 (RO)4Si R TFA AcOH 
t1/2 (min) krel t1/2 (min) 
601a (EtO)4Si ethyl 3.1 ± 0.1 1 2,300 
601b (n-BuO)4Sia n-butyl 12.0 ± 1.0 3.8  
601c (n-HexO)4Si n-hexyl 17.5 ± 0.3 5.6  
601d (n-OctO)4Sia n-octyl 21.0 ± 1.0 6.7  
601e (i-PrO)4Si i-propyl 81.3 ± 2.6 25.9 >40 days 
601f (menthylO)4Sib menthyl >16 days   
601g (4-MePhO)4Sic 4-methylphenyl 6 1.9  
601h (MesO)4Sia 2,4,6-trimethylphenyl 
64 20.4 1,300 
a Measured by Dr. Adam Wohl. 
b This highly hydrophobic silicate was only partially soluble in the 10% aqueous acetone medium 
used for the other hydrolyses in this table. Its cleavage was studied, instead, under homogenous 
conditions using a 98:1:1 volume ratio of acetone:D2O:TFA. For comparison, TEOS (601a) 
measured in this less polar reaction medium showed a reduced rate of hydrolysis (t1/2 = 33 ± 1.0 
min). 
c Measured by Dr. Yutaka Miura. 
 
The mechanism for acid catalyzed hydrolysis is shown in Figure 6.3 
below, a menthol containing silicate has been chosen to clearly show the effect of 
steric bulk on the rate of hydrolysis. Starting in the top left of the figure, one of the 
alcohols becomes protonated by the acidic environment. Subsequently the 
association of water occurs and a geometry change is induced from tetrahedron 
(where all of the bulky alkoxy groups are ca. 109.5º from one another) to trigonal 
bipyamidal. The silicon center becomes five coordinate and adopts a trigonal 
bipyramidal geometry in which one of the bulky groups is placed 90º from the 
other three. This steric strain of the close alkoxy groups reduces the propensity to 
hydrolyze due to the energy requirement to achieve this conformation. Once in 
this conformation the bulky sterically congested alcohol must leave from the axial 
position relative to the incoming water (top right).  
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Figure 6.3 | The mechanism for acid catalyzed hydrolysis. 
Following the loss of a proton, the conformation reverts back to 
tetrahedral, forms the stable silanol, and the process repeats. However, in the 
case of very bulky silanols like 602f and 602h placing the bulky alkyl group in the 
axial position of the trigonal bipyramidal intermediate is disfavored in comparison 
to the hydroxyl group in the axial position. In essense, since the leaving group 
must be in the axial position, the silanol in the axial position of the incoming water 
is degenerate. Only when the bulky group is axial (bottom middle) to the 
incoming water can the reaction proceed to completion (bottom left). This 
suggests why bulky silanols are stable and have a considerably slower rate of 
hydrolysis compared to less bulky silicates. 
The rate of hydrolysis was measured as described above for mixed 
silicates 602a-j (Table 6.2). A clear trend can be seen with the increase in steric 
bulk around the silicon center from 602a to 602d with krel values ranging from 1.0 
to 12.4. When the steric bulk around the silicon center is great (602e, 602f, 602h, 
602i), the rate of hydrolysis slows considerably. Having an aryloxy instead of a 
bulky alkoxy group (compare 602a to 602g) increases the rate of hydrolysis.  
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Table 6.2 | Hydrolytic lability of silicates (602a-e, 602g, 602i), silanols (602f, 
602h), and silane (602j). 
602 (R1O)3SiOR2 R1 R2 
TFA AcOH 
t1/2 (min) krel t1/2 (min) 
602a (EtO)3Si(Omenthyl)a ethyl menthyl 17 ± 1 1.0 – 
602b (n-BuO)3Si(Omenthyl)a n-butyl menthyl 49 ± 2 2.9 – 
602c (n-OctO)3Si(Omenthyl)a n-octyl menthyl 79 ± 5 4.6 – 
602d (i-PrO)3Si(Omenthyl)a i-propyl menthyl 210 ± 10 12.4 – 
602e (menthylO)3Si(OEt)a,b menthyl ethyl 13,000 ± 1,000 764.7 – 
602f (menthylO)3Si(OH) menthyl hydroxyl 7,600 ± 250 445.2 – 
602g (EtO)3Si(Op-Tol)a ethyl 
4-methyl 
phenyl 
9.1 0.54 7,100 
602h (t-BuO)3Si(OH) t-butyl hydroxyl 602 ± 68 35.4 – 
602i 
(t-BuO)3Si 
(OCOCH=CHPh) 
t-butyl cinnamoyl 7,900 ± 740 462.1 
> 14,400 
(10 days) 
602j 
(t-Bu)2(Me)Si 
(OCOCH=CHPh) 
TBS cinnamoyl 2.60 ± 0.18 0.15 30.8 ± 3.2 
a Measured by Dr. Adam Wohl. 
b This highly hydrophobic silicate was only partially soluble in the 10% aqueous acetone medium 
used for the other hydrolyses in this table. Its hydrolysis was studied, instead, in a 98:1:1 volume 
ratio of acetone:D2O:TFA. 
 
Lastly, the hydrolytic lability of the cinnamoyl-silicate (602i) and cinnamoyl-
silane (602j) were compared (synthesis can be found in the experimental section 
for this chapter). We were surprised that the rate of hydrolysis of the silane was 
much faster (t1/2 = 2.60 min) than that of the silicate (t1/2 = 7,900 min). This is due 
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to the drastic difference in steric bulk between the two, as a silicon alkoxy bond is 
weaker than a silicon alkyl bond. 
We then tested the hydrolytic lability of amino- and amido- silicates or 
silanes 603a-e (Table 6.3). The synthesis for these compounds can be found in 
the experimental section of this chapter at the end of this thesis. The hydrolysis 
was measured in less acidic conditions (AcOH), because a rate could not be 
obtained in the TFA conditions as before due to the extremely weak nitrogen-
silicon bond (N-Si). The rates of hydrolysis of the amido-silanes (603a and 603b) 
are similar and are only slightly faster than amido-silicate 603c due to the steric 
bulk present in 603c. The same tend is observed for the amino-silane (603d) vs. 
the amino-silicate (603e). These silicates hydrolyze approximately twice as 
slowly as the corresponding silanes. 
 
Table 6.3 | Hydrolytic lability of amino-silicate (603e), amido-silicate (603c), 
amino-silane (603d), and amido-silanes (603a, 603b). 
603 (R1O)3SiOR2 R1 R2 
AcOH 
t1/2 (min) krel 
603a (t-Bu)2(Me)Si(benzamido) t-butyl2methyl benzamido 6.5 ± 0.3 1.4 
603b (i-Pr)3Si(benzamido) i-propyl benzamido 4.5 ± 0.6 1.0 
603c (t-BuO)3Si(benzamido) t-butyl benzamido 8.8 ± 0.5 2.0 
603d (t-Bu)2(Me)Si(morpholino) t-butyl2methyl morpholino 7.5 ± 0.9 1.7 
603e (t-BuO)3Si(morpholino) t-butyl morpholino 15.0 ± 0.9 3.3 
 
6.3 Nanoparticle Formulations of Model Silicate Prodrugs 
Nanoparticles were made by FNP as presented before in Chapters 2 and 
4. We chose to examine two silicates having new functionality compared to those 
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we have studied earlier (cinnamic-silicate 602i and  morpholine-silicate 603e). 
Either silicate (602i or 603e) and the mPEG-b-PLGA block copolymer (5k-10k) 
were dissolved in 4.0 mL of THF. The THF solution was impingement mixed 
against 4.0 mL of H2O in the CIJ-D FNP mixer. The resulting nanoparticles were 
diluted into 42 mL of water. From this suspension an aliquot of 20 µL was taken 
and diluted to 1 mL in a DLS cuvette. 
The mass of each prodrug model compound and mass of polymer used 
are presented in Table 6.4 (columns 3 and 4). The intensity average size (di) and 
the PDI of the resulting nanoparticle formulations are also shown in Table 6.4 
(columns 5 and 6). The DLS plot for 602i nanoparticles can be found in the 
experimental section Figure S6.1. 
 
Table 6.4 | Nanoparticles loaded with ca. 50 wt% of silicate prodrug model 
compounds 602i and 603e. 
Compound 
Number 
Short Hand 
Descriptor 
Amounts DLS 
Prodrug 
(mg) 
Polymer 
(mg) di (nm) PDI 
602i Cinn-Si(OtBu)3 18.0 20.2 118.7 0.150 
603e  Morph-Si(OtBu)3 25.9 28.9 338.9 0.165 
 
We were very pleased with the DLS measurements of the freshly prepared 
nanoparticle suspensions. However, as expected, when the suspensions 
containing 10% THF were allowed to stand for 1 week the particles ca. doubled 
in size and the PDI broadened, likely due to aggregation. In the case of the 
morpholine-silicate the particle size actually shrunk, likely due to hydrolysis of the 
N-Si bond. We also froze and lyophilized the solutions after 1 week to determine 
if the prodrugs were still intact. 1H-NMR analysis in CDCl3 showed that: 602i had 
had not degraded at all (no free cinnamic acid resonances were detected) and 
the 603e had fully degraded to free morpholine. 
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These results are very encouraging for future silicate synthesis and 
nanoparticle formulation of novel drugs with different functionality. We quickly 
focused our attention on the synthesis of novel silicate prodrugs with differing 
functionality and nanoparticle formulations thereof. 
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7.1 Novel Silicate Prodrug Synthesis 
We next looked to expand on the prodrug scope to other known drugs. 
The drugs were chosen for the functionality present and not nessecarily their 
biological activity.  For each drug, monochlorosilanes with varying steric bulk 
were chosen to determine the feasibility of synthesis and purification. The cLogP 
and the calculated logS were determined for each silicate as done before.132 
After a sufficient quantity of each silicate prodrug was made, the hydrolytic 
degradation was measured. Either very acidic (TFA) or slightly acidic (AcOH) in 
situ 1H-NMR hydrolysis conditions mentioned previously were utilized with these 
novel silicate prodrugs. To probe the biological activity of the silicate prodrugs, 
we tested five of them in vivo against MDA-MB-231 breast cancer cells, even if 
the drugs chosen were not anti-cancer agents. 
 
7.1.1 Dexamethasone 
Dexamethasone (701) has a variety of uses due to its anti-inflammitory 
and immunosuppressant properties.199 This synthetic glucocorticoid has been 
used in the treatment of meconium aspiration syndrome, hyperinfection 
syndrome, retinal disease, and certain types of cancer. Although there is a wide 
biological interest in the drug, we were interested in the feasibility of the silicate 
prodrug strategy on the steroid. 
The steroid dexamethasone was chosen mainly for its primary hydroxyl 
alpha to the C-20 ketone. Although there are other hydroxyls present in the 
                                            
199 Sauvage, A.; Levy, M. Dexamethasone: Therapeutic Uses, Mechanism of Action and Potential 
Side Effects; Nova Science Pub Incorporated; 2013. 
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molecule, only the most sterically accessible C-21 alcohol was functionalized with 
one of the monochlorosilanes (305) shown in Scheme 7.1. 
 
Scheme 7.1 | Synthesis of dexamethasone silicates (702a-c). 
 
 
For the synthesis of the triethoxydexamethasone silicate (702a), the 
standard pyridine (base) and the commercially available monochlorosilane (305a) 
in THF were utilized. The reaction went smoothly to the product, as determined 
by crude 1H-NMR and LC-MS analysis. The proper masses were found for the 
product when an aliquot of the reaction mixture was resolved on the LC-MS: 555 
[m+H]+ positive mode, and 613 [m+OAc]- negative mode. Unfortunately the 
product could not be purified by MPLC; a preponderance of starting material was 
recovered. 
We succeeded in the synthesis and isolation of the 
trioctyloxydexamethasone silicate (702b). Again the standard reaction conditions 
were employed to achieve the synthesis. Experimental details for the reaction 
and the full characterization can be found in the experimental section for chapter 
7 at the end of this thesis. 
Lastly, the bulky triisopropoxydexamethasone silicate (702c) was made 
under the same conditions. Proton NMR showed that the product was only 70% 
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pure after MPLC purification. The cLogP and the cLogS were calculated and 
tabulated in Table 7.1 (Chapter 7.2). Instead of pursuing these silicates further, 
we chose to explore the silicate prodrug strategy on different drugs presented 
later in this chapter. 
 
7.1.2 Ibuprofen 
Ibuprofen (703) was chosen to show that the starting drug does not need 
to be entirely pure before functionalization. It also serves as another carboxylic 
acid example, like the cinnamic acid, shown in Chapter 6. The nonsteroidal anti-
inflammatory drug is commonly used for pain relief and fever reduction. Lastly, 
ibuprofen is an over the counter medication and tablets are very cheap. 
Tablets of ibuprofen were crushed and ground into a fine powder in a 
motor and pestle. The resulting powered was extracted with ethyl acetate and the 
slurry was passed through a short plug of Celite®. This extraction protocol 
provided the starting material with > 95% purity and minimal handling only 
provided a 77% recovery of the ibuprofen. Since the drug is not expensive an 
optimized extraction procedure was not developed. 
The standard set of conditions (pyridine as the base and THF as the 
solvent) was utilized to synthesize the tri-tertbutoxyibuprofen silicate 704 from the 
extracted ibuprofen and the commercially available tri-tertbutoxychlorosilane 
(305e). Unfortunately multiple purifications were required to separate the starting 
305e from the final product 704 so a poor yield was obtained.  Further 
optimization of the purification would be required if there was more interest in the 
prodrug. The cLogP and the cLogS of the parent ibuprofen and the silicate are 
shown in Table 7.1. Also the hydrolytic lability is shown in Table 7.2 (Chapter 
7.2). by using the acid in situ NMR conditions presented in Chapters 3 and 6. 
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Scheme 7.2 | Synthesis of ibuprofen silicate 704 from extracted ibuprofen 703.  
 
 
7.1.3 Salinomycin 
Salinomycin (705) is a polyether ionophore that binds sodium or 
potassium and restricts the movement across cell membranes. Due to its 
mechanism of action, salinomycin is an effective antibacterial agent even against 
problematic bacteria. The drug is produced by the Streptomyces albus, strain 
ATCC 21838 and harvested in an impure form for use as a coccidiostat (anti-
parasitic) in the poultry industry as a feed additive.200 Salinomycin has been 
shown to selectively target cancer initiating or cancer stem cells, the problematic 
cells that are responsible for cancer recurrence after remission.201  
Not only is salinomycin interesting with regards to its biological activity, the 
chemical structure is also quite intriguing.  It contains 18 stereocenters with three 
hydroxyls at C-9, C-20, and C-28. All of these have the possibility of being 
functionalized with the silicate methodology. The C-1 carboxylic acid can also be 
functionalized, 202  and proved to be the most reactive toward the silicate 
                                            
200 Paulus, E. F.; Kurz, M.; Matter, H. Solid-State and Solution Structure of the Salinomycin-
Sodium Complex: Stabilization of Different Conformers for an Ionophore in Different 
Environments. J. Am. Chem. Soc. 1998, 120, 8209-8221. 
201 Borgström, B.; Huang, X.; Pošta, M.; Hegardt, C.; Oredsson, S.; Strand, D. Synthetic 
Modification of Salinomycin: Selective O-Acylation and Biological Evaluation. Chem. Comm. 
2013, 49, 9944–9946. 
202 Huczyński, A.; Janczak, J.; Stefańska, J.; Antoszczak, M.; Brzezinski, B. Synthesis and 
Antimicrobial Activity of Amide Derivatives of Polyether Antibiotic-Salinomycin. Bioorg. Med. 
Chem. Lett. 2012, 22, 4697–4702. 
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chemistry. Purification is difficult in part because the polyacetal ring system 
isomerizes when stored in aqueous media. 203 The mechanism suggests that 
slightly acidic media (e.g. silica gel) would enhance the rate of isomerization of 
the polyacetal to a furan.203 
Chicken fodder that contains ca. 12% salinomycin (705) by weight was 
graciously donated for the subsequent synthesis of silicate prodrugs of the drug.  
A total of 114 g of the feed additive was suspended into 500 mL of chloroform 
and allowed to stir overnight. The resulting slurry was filtered through Celite® and 
washed with CH2Cl2. A column of 200 g of silica gel was used to purify the crude 
salinomycin. It was eluted with 400 mL of ethyl acetate. A yellow solid was 
obtained (7.29 g, ca. 90% purity). The salinomycin could be further purified by 
reverse-phase MPLC (95% methanol: 5% H2O) to obtain white crystalline 
salinomycin with a purity of > 95%. 
For the synthesis of the salinomycin silicates, the yellow solid with ca. 
90% purity was used. For the synthesis of the least hindered silicate of 
salinomycin, 706a, triethylamine was used as the base and triethoxychlorosilane 
(305a) was used as the silylating agent. With the addition of the 
monochlorosilane, the reaction turned cloudy right away. However LC-MS 
showed only a 50% conversion. The reaction mixture was allowed to stir at r.t. 
over the weekend, which showed full conversion of starting material to the 
product (ESI-APCI positive scan 930 [m+NH4]+, 935 [m+Na]+). We attempted to 
purify the product by reverse phase MPLC (C18, 90:10, MeOH:H2O), but could 
not isolate a product with sufficient purity as the bridged dimer (EtO)3Si-O-
Si(OEt)3 was present in the fractions. 
We next looked to increase the steric hindrance around the carboxylic acid 
with use of the triisopropoxychlorosilane (305c) and pyridine as the base. The 
                                            
203 Davis, A. L.; Harris, J. A.; Russell, C.; Wilkins, J. Investigations by HPLC-Electrospray Mass 
Spectrometry and NMR Spectroscopy Into the Isomerisation of Salinomycin. Analyst 1999, 124, 
251-256. 
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reaction went smoothly to the product as confirmed by LC-MS product (ESI-APCI 
positive scan 972 [m+NH4]+, 977 [m+Na]+). The product 705b was purified by 
normal phase MPLC and fully characterized, found in the experimental section 
for this chapter. 
To test the accessibility of the C-1 carboxylic acid, we used the sterically 
encumbered tri-tertbutoxychlorosilane (305e) and N,N-dimethylbutyl amine as the 
base. Unfortunately, the reaction did not go to completion even after heating to 
35 ºC and waiting for 1 week. The LC-MS showed only a 5% conversion to the 
product (ESI-APCI positive scan 1014 [m+NH4]+, 1019 [m+Na]+). from the 
starting material. 
 
Scheme 7.3 | Synthesis of salinomycin silicates (706a-c). 
 
 
Lastly, a silane was made of salinomycin to serve as a reference for the 
complicated NMR spectra of the silicates 706.  Salinomycin and N,N-
dimethylbutylamine were dissolved in THF and allowed to stir at r.t. for 5 mins. 
Triisopropylsiyl chloride (TIPS-Cl, 615) was added by Wiretrol® and the reaction 
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mixture instantly turned cloudy. The mixture was stirred for 48 h. The THF was 
removed the solid residue was triturated with a mixture of hexanes:EtOAc (1:1), 
and the resulting slurry was filtered through a short plug of Celite® to remove the 
pyridinium salt. The filtrate was concentrated under reduced pressure, and the 
residue was purified by MPLC to yield the SAL-TIPS (715, not shown) as a white, 
crystalline solid. The full characterization can be found in the experimental 
section of this chapter. 
With all the different silicates and silanes, we calculated the cLogP and 
cLogS shown in Table 7.1 (Chapter 7.2). We performed a cell viability assay with 
706b and the parent salinomycin. However, the concentrations tested were not 
sufficient to induce cell death (IC50 > 10 µM). Also the 706b silicate was 
formulated into nanoparticles, which is presented in Chapter 7.3, Table 7.3. 
 
7.1.4 5-Fluorouracil 
5-Fluorouracil (5-FU, 707) is a pyrimidine analog that is a suicide inhibitor 
of thymidylate synthase. The irreversible binding makes 5-FU an important 
antimetabolite class drug for the treatment of a variety of cancers.  5-Fluorouracil 
is used for the treatment of breast, liver, ovarian, gastrointestinal, colon, head, 
and neck cancers.204 The dose is typically given through I.V. like PTX, or a 
topical cream. We sought to apply the silicate prodrug technology to this drug in 
hopes of making nanoparticle formulations. 
The pyrimidine analogue has two reactive nitrogen atoms that have been 
modified previously.205,206 We looked to capitalize on this reactivity to make bis-
                                            
204 Chi, G.; Wang, X.; Chen, R. Synthesis of Novel N1‐(2‐Furanidyl)‐5‐Fluorouracil Derivatives of 
Α‐Hydroxy (Thio) Phosphonates. Heteroatom Chem. 2002, 13, 211—215. 
205 Pizzirani, D.; Pagliuca, C.; Realini, N.; Branduardi, D.; Bottegoni, G.; Mor, M.; Bertozzi, F.; 
Scarpelli, R.; Piomelli, D.; Bandiera, T. Discovery of a New Class of Highly Potent Inhibitors of 
Acid Ceramidase: Synthesis and Structure-Activity Relationship (SAR). J. Med. Chem. 2013, 56, 
3518–3530. 
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functionalized silicates that diminish the water solubility of the drug for further 
FNP formulation into nanoparticles. Since the parent compound is water soluble, 
the typical reaction conditions had to be modified. We simply used the base as 
the solvent to allow for homogenous conditions throughout the reaction, shown in 
Scheme 7.4. 
 
Scheme 7.4 | Synthesis of bis-functionalized 5-fluorouracil silicates (708a-c).  
 
 
Since the molecular weight for the 5-fluorouracil (707) starting material is 
low, we were pleased that it could be ionized and detected by GC-MS. 
Performing the gas phase analysis allowed us to observe the formation of 
products without the possibility of cleavage of the N-Si bond. The 708a product 
was synthesized with pyridine as the base and triethoxychlorosilane (305a) as 
the silylating agent. GC-MS [30 m x 0.25 mm ID, HP-5, 50 °C/1.5 min/10 °C min-
1/290 °C, (5029021)] with a retention time (tR) of 9.03 min showed a mass to 
charge ratio [m/z] 454 (M+•), 439 (M+• -CH3), and 409 (M+• -C2H5O) that matched 
the product. The 708b product was synthesized with pyridine as the base and 
triisopropoxychlorosilane (305c) as the silylating agent. GC-MS [30 m x 0.25 mm 
                                                                                                                                  
206 Benci, K.; Wittine, K.; Radan, M.; Cetina, M.; Sedić, M.; Kraljević Pavelić, S.; Pavelić, K.; 
Clercq, E. D.; Mintas, M. The Unsaturated Acyclic Nucleoside Analogues Bearing a Sterically 
Constrained (Z)-4“-Benzamido-2-”Butenyl Moiety: Synthesis, X-Ray Crystal Structure Study, 
Cytostatic and Antiviral Activity Evaluations. Bioorg. Med. Chem. 2010, 18, 6249–6257. 
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ID, HP-5, 50 °C/1.5 min/10 °C min-1/290 °C, (5029021)] with a retention time (tR) 
of 9.09 min showed a mass to charge ratio [m/z] 538 (M+•), and 479 (M+• -
C3H7O). Unfortunately, neither 708a nor 708b could be purified or isolated 
through silica gel chromatography. 
We were delighted with the synthesis of 708c, the tri-
tertbutoxychlorosilane (305e) and pyridine cleanly converted the starting 5-
fluorouracil to the product. The 708c product was stable to purification and fully 
characterized in the experimental section of this chapter. 
The calculated hydrophobicity and solubility for each silicate (708a-c) 
synthesized is tabulated in Table 7.1 (Chapter 7.2). Further studies were done 
with 708c. The hydrolytic lability in the standard acidic conditions and in less 
acidic conditions was determined. An in vitro cytotoxicity assay against MDA-MB-
231 was also performed. However, the dosing concentrations were too low to 
induce cell death. Lastly, the 708c prodrug was loaded into nanoparticles, using 
the FNP process. The particle sizes are shown in Table 7.3 (Chapter 7.3). We 
are encouraged by the change in hydrophobicity demonstrated with this prodrug. 
The parent drug is completely water-soluble and upon silylation with 305e, it 
becomes insoluble. 
 
7.1.5 Dacarbazine 
Dacarbazine (DTIC, 709) is an alkylating agent that destroys cells though 
the irreversible addition of an alkyl group to the cell’s DNA.207 Dacarbazine is 
bioactivated by the liver through an oxidation followed by a subsequent 
demethylation. This intermediate then degrades to diazomethane, which is the 
                                            
207 Amirmostofian, M.; Pourahmad Jaktaji, J.; Soleimani, Z.; Tabib, K.; Tanbakosazan, F.; Omrani, 
M.; Kobarfard, F. Synthesis and Molecular-Cellular Mechanistic Study of Pyridine Derivative of 
Dacarbazine. Iran J. Pharm. Res. 2013, 12, 255–265. 
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true alkylating agent.208 It is typically administered to cancer patients by I.V. 
under direct supervision of medical personal, and has been used in the treatment 
of Hodgkin lymphoma, sarcoma, pancreatic cancer, and malignant melanoma. 
Modification of dacarbazine (709) has been studied before.209 However, 
silylation has not been explored. We were interested in the biological activity and 
encouraged by the results of the benzamide and the 5-fluorouracil silicates. Due 
to the water solubility of 709, we changed the reaction conditions to a stronger 
base and DMF as solvent. 
Dacarbazine (709) and DBU were dissolved in DMF. The yellow reaction 
mixture was stirred for 5 mins and tri-tertbutoxychlorosilane (305e) was added by 
syringe, and the mixture turned completely clear after 30 mins. The DMF was 
removed by a high vacuum rotary evaporator and the residue was resuspended 
in a mixture of hexanes:EtOAc (2:1), filtered, and purified by normal phase 
chromatography to give the two different bis-functionalized silicates 710a and 
710b as white crystalline solids (Scheme 7.5). The full experimental procedure 
and characterization is presented in the experimental section. 
Scheme 7.5 | Synthesis of dacarbazine silicates 710a and 710b. 
 
                                            
208 Horton, J. K.; Stevens, M. F. A New Light on the Photo-Decomposition of the Antitumour Drug 
DTIC. J. Pharm. Pharmacol. 1981, 33, 808–811. 
209 Shealy, Y. F.; Krauth, C. A. Imidazoles. I. Coupling Reactions of 5-Diazoimidazole-4-
Carboxamide. J. Org. Chem. 1962, 27 (6), 2150-2154. 
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The calculated hydrophobicity (cLogP) and solubility (cLogS) for each 
silicate (710a and 710b) is tabulated in Table 7.1. Further studies were done with 
710a. The hydrolytic lability in the less acidic conditions was determined (Table 
7.2). An in vitro cytotoxicity assay against MDA-MB-231 was also performed 
however the dosing concentrations were too low to induce cell death. Lastly, the 
710a prodrug was loaded into nanoparticles, using the FNP process. The particle 
sizes are shown in Table 7.3. Again the drastic change in hydrophobicity 
demonstrated with this prodrug shows the power of the silicate prodrug strategy. 
 
7.1.6 Imiquimod 
Imiquimod (711) was discovered at the 3M pharmaceutical division as an 
immune response modifier. Although they were pursuing the drug and analogues 
for use as anti-viral for HSV-2 (herpes) and HIV prevention, imiquimod was 
shown to induce the production of cytokines, which in turn triggers an immune 
response to eradicate the foreign virus or cell. Due to its mechanism of action, 
711 has been approved for the treatment of genital warts, actinic keratosis, and 
basal cell carcinoma. 210 It is administered as a cream for the skin conditions 
described above. 
We were mainly interested in the free amine present in the molecule and 
whether it could be functionalized and the resulting derivatives purified. We were 
also interested in the topical cream, like 5-FU, application and envisioned that the 
increased hydrophobicity induced by the silicate prodrug methodology would 
increase the skin penetration when applied. We sought to apply the silicate 
methodology, to determine the in vitro cytotoxicity, and to test the stability of 
silicates made from 711. 
                                            
210 Gerster, J. F.; Lindstrom, K. J.; Miller, R. L.; Tomai, M. A.; Birmachu, W.; Bomersine, S. N.; 
Gibson, S. J.; Imbertson, L. M.; Jacobson, J. R.; Knafla, R. T.; et al. Synthesis and Structure-
Activity-Relationships of 1H-Imidazo[4,5-C]Quinolines That Induce Interferon Production. J. Med. 
Chem. 2005, 48, 3481–3491. 
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Scheme 7.6 | Synthesis of imiquimod silicate 712.  
 
 
Imiquimod 711 and DBU were dissolved in THF. The reaction mixture was 
stirred for 5 min and tri-tert-butoxychlorosilane (305e) was added by syringe and 
the mixture turned slightly cloudy. The mixture was heated to 45 ºC for 18 h and 
more precipitate formed as the reaction progressed. The THF was removed and 
the residue was resuspended in a mixture of hexanes:EtOAc (1:1), filtered, and 
purified by MPLC to yield the imiquimod-silicate (712) as a white crystalline solid. 
The calculated hydrophobicity (cLogP) and solubility (cLogS) for 711 and 
712 are tabulated in Table 7.1 (Chapter 7.2). The hydrolytic lability was not 
determined, because the product was not very stable. When 712 was dissolved 
in CDCl3, after two days ca. 50% had degraded back to the parent drug 711. An 
in vitro cytotoxicity assay against MDA-MB-231 was also performed. However, 
the dosing concentrations were too low to induce cell death.  
 
7.1.7 Ciprofloxacin 
Ciprofloxacin is a fluoroquinolone that is in its second generation of 
development. 211 The drug inhibits DNA gyrase, which prevents the unraveling of 
supercoiled DNA, required for cell division and multiplication. By inhibiting this 
                                            
211 Ward, T. R.; Turunen, B. J.; Haack, T.; Neuenswander, B.; Shadrick, W.; Georg, G. I. 
Synthesis of a Quinolone Library From Ynones. Tetrahedron Lett. 2009, 50, 6494–9497. 
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enzyme, ciprofloxacin has been used as a broad-spectrum antibiotic. The 
medication has excelltent skin penetration and can be formulated for oral or I.V. 
administration.212 It is the most widely used quinolone antibiotic, and has 12-FDA 
approvals for human use. It is also used in combination with other antibiotics in 
empirical treatment of infections where the bacterium hasn’t been fully identified. 
It is however not effective against antibiotic resistant strains of bacteria. 
Due to wide spread use, multiple ways of formulation, and structure we 
looked to employ the silicate prodrug methodology with this drug. Ciprofloxacin 
contains a piperazine ring, common to many pharmaceuticals. It also contains a 
carboxylic acid, which could also be functionalized.213 In Scheme 7.7 the different 
silicate made of ciprofloxacin are shown. 
Scheme 7.7 | Synthesis of ciprofloxacin silicates (714a-b).  
 
 
Ciprofloxacin (713) and DBU were dissolved in 4 mL of DMF. The green-
yellow reaction mixture was stirred for 5 mins and tri-tert-butoxychlorosilane 
(305e) was added. The reaction turned clear after 50 mins. The DMF was 
removed by a high vacuum rotary evaporator and the yellow oil residue was 
                                            
212 Varanda, F.; de Melo, M. P.; Caco, A. I. Solubility of Antibiotics in Different Solvents. 1. 
Hydrochloride Forms of Tetracycline, Moxifloxacin, and Ciprofloxacin. Ind. Eng. Chem. Res. 
2006, 45, 6368—6374. 
213 Zieba, A.; Maślankiewicz, A.; Sitkowski, J. 1H, 13C and 15N NMR Spectra of Ciprofloxacin. 
Magn. Reson. Chem. 2004, 42, 903–904. 
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resuspended in a mixture of hexanes:EtOAc, filtered, and purified by MPLC to 
yield 714 as a white crystalline solid. 
The cLogP and cLogS for the ciprofloxacin-silicate 714 and the parent 
drug 713 is tabulated in Table 7.1. The hydrolytic lability in both acidic conditions 
was determined by in situ NMR monitoring (Table 7.2). An in vitro cytotoxicity 
assay against MDA-MB-231 was also performed. However, the dosing 
concentrations were too low to induce cell death. Lastly, the 714 prodrug was 
loaded into nanoparticles, using the FNP process. The particle sizes are shown 
in Table 7.3 (Chapter 7.3).  
 
7.1.8 Erlotinib and Gefitinib 
Erlotinib (713) and gefitinib (not shown) are both epidermal growth factor 
receptor (EGFR) inhibitors. This inhibition blocks signaling in cancer cells that 
over express EGFR. Both are used for the treatment of non-small cell lung 
cancer as well as pancreatic cancer.214 They both contain a secondary amine 
positioned between two aromatic rings. 215  We envisioned that the silicate 
methodology could functionalize this amine. 
Unfortunately a stable silicate prodrug could not be made from either 
erlotinib or gefitinib. We exhaustively altered the reaction conditions to generate 
the product but all attempts failed. Briefly the monochlorosilanes (305a-e) were 
all tried with a variety of bases [pyridine, N,N-dimethylbutylamine, sodium 
hexamethyldisilazide (NaHMDS), sodium hydride (NaH), butyl lithium (n-BuLi), 
and diisopropylethyl amine (DIPEA)] at different temperatures [-78 ºC, r.t., and 
35-45 ºC] and different durations of reaction [4 h – 1 week]. We were successful 
                                            
214 Rocha-Lima, C. M.; Soares, H.P.; Raez, L. E.; Singal, R. EGFR Targeting of Solid Tumors. 
Cancer Control. 2007, 14, 295-304. 
215 Marzaro, G.; Guiotto, A.; Pastorini, G.; Chilin, A. A Novel Approach to Quinazolin-4(3H)-One 
via Quinazoline Oxidation: an Improved Synthesis of 4-Anilinoquinazolines. Tetrahedron 2010, 
66, 962–968. 
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when methyl iodide was used as the electrophile instead of a monochlorosilane, 
which shows that the secondary amine is moderately reactive. We were pleased 
when a more reactive silane, triisopropylsilyl trifluoromethanesulfonate (717), 
afforded the erlotinib silane 718. 
 
Scheme 7.8 | Synthesis of erlotinib silane 718. 
 
 
Erlotinib (716) and diisopropylethylamine (DIPEA) were dissolved in THF. 
The reaction mixture was stirred for 5 mins and triisopropylsilyl 
trifluoromethanesulfonate (717) was added by syringe and the mixture turned 
yellow. The mixture was stirred for 6 h and a white precipitate formed as the 
reaction progressed. The THF was removed and the residue was resuspended in 
a mixture of hexanes:EtOAc, filtered, and purified by MPLC to yield 718 as a 
white crystalline solid. 
Encouraged by this, we reacted triethoxychlorosilane (305a) or 
triisopropoxychlorosilane (305c) with triflic acid followed by a subsequent 
reaction of crude mixture with erlotinib. Even though color changes (red-green) 
were observed, only the starting material could be recovered. After many 
attempts we abandoned the pursuit of silicate prodrugs of erlotinib or gefitinib. 
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7.2 Hydrophobicity and Hydrolytic Lability of Novel Silicate 
Prodrugs 
 
7.2.1 Hydrophobicity Indicators for Novel Silicate Prodrugs 
The relative hydrophobicities of the silicate esters was assessed in several 
ways. Qualitatively, we observed the expected trend that the silicates with 
greasier alkyl groups traveled faster on silica gel during thin layer and preparative 
chromatographic experiments. In addition, two empirical indicators of 
hydrophobicity show similar trends: i.) calculated octanol:water partition 
coefficients (cLogP values, Table 7.1, column 3)132 and ii.) calculated aqueous 
solubilities (Table 3.1, column 4-5).133 Recall, It has been noted that calculated 
hydrophobicities can vary tremendously depending on the weights assigned for 
each functional group in the empirical equations. 
The power of the silicate prodrug strategy can be clearly seen in the case 
of the water soluble drugs (707, 709, 711, and 713) which all have calculated 
aqueous solubility above 50 mg/mL. Once functionalized as a silicate the water 
solubility drops to below to around 5 mg/mL ca. 10 times less soluble than the 
original drug. Although this non-traditional approach to prodrug fabrication 
appears to go in the opposite direction in terms of administration, the silicate 
prodrug affinity for the polyester core of a nanoparticle is drastically increased. 
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Table 7.1 | Hydrophobicity indicators for the drugs and silicate prodrugs 701–718. 
Compound 
Number 
Short Hand 
Descriptor 
calcd 
octanol:water 
partition coeffient 
(cLogP)132  
calcd water 
solubility 
coeffient 
(cLogS)132  
Calculated 
aqueous 
solubility133 
(mg/L) 
701  Dexamethasone 1.93 -3.89 20.5 
702a  Dex-Si(OEt)3 3.78 -4.72 8.92 
702b  Dex-Si(OnOct)3 8.28 -7.07 0.85 
702c  Dex-Si(OiPr)3 4.52 -5.31 4.94 
703  Ibuprofen 3.50 -3.48 30.8 
704  Ibu-Si(OtBu)3 7.46 -6.8 1.11 
705  Salinomycin 4.48 -5.4 4.52 
706a  Sal-Si(OEt)3 6.05 -5.61 3.66 
706b  Sal-Si(OiPr)3 6.52 -5.81 3.00 
706c  Sal-Si(OtBu)3 7.15 -6.26 1.91 
715  Sal-TIPS 7.20 -6.39 1.68 
707  5-Fluorouracil -0.58 -1.35 259 
708a  5-FU-[Si(OEt)3]2 3.61 -4.29 13.70 
708b  5-FU-[Si(OiPr)3]2 5.14 -5.33 4.84 
708c  5-FU-[Si(OtBu)3]2 6.92 -6.84 1.07 
709 Dacarbazine  -0.32 -2.13 119 
710a  Dacarb-[Si(OtBu)3]2 7.24 -5.32 4.89 
710b  Dacarb-N[Si(OtBu)3]2 6.77 -5.86 2.85 
711  Imiquimod 2.83 -2.99 50.3 
712  Imiq-Si(OtBu)3 7.17 -5.24 5.30 
713  Ciprofloxacin -0.57 -2.39 91.6 
714  Cipro-[Si(OtBu)3]2 8.18 -5.39 4.56 
716  Erlotinib 3.13 -4.64 9.66 
718  Erlot-TIPS 5.99 -5.42 4.43 
 
7.2.2 Hydrolytic Lability of Novel Silicate Prodrugs 
We anticipated that these silicates would also differ in their hydrolytic 
lability based upon the nature of the oxygen-silicon or nitrogen-silicon bond. Each 
silicate that was tested contained the bulkiest alkoxy moieties (-OtBu) around the 
silicon center. As before we explored the acid lability by a 1H NMR spectroscopy-
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based method118 to establish the relative rates of chemical hydrolysis of the 
derivatives (Table 7.2). By design, these silicate esters were sufficiently highly 
hydrophobic to render them only marginally soluble in buffered aqueous 
solutions. To get a meaningful fundamental understanding of the hydrolytic 
lability under acidic conditions, we deemed it essential to identify a common set 
of conditions under which each of the silicates would be fully soluble—that is, 
homogeneity is paramount. We determined that a 10:1 (vol:vol) ratio of 
acetone:water would solubilize all of these silicates at concentrations suitable for 
NMR analysis. We then established that use of 1% TFA in this solvent mixture 
(measured pH = 0.8–1.2) at ambient temperature led to rates of silicate ester 
cleavage that could be conveniently monitored spectroscopically. Alternatively 
the use of 1% acetic acid (AcOH) in this solvent mixture (measured pH = 2.8) at 
ambient temperature led to rates of silicate ester cleavage that could more 
conveniently be monitored when the use of TFA was too fast. 
The change in intensity over time of the chemical shifts of distint 
resonances of each silicate, and/or the -OC(CH3)3 resonances in the R groups as 
the silicates were cleaved to release the drug and t-butanol was monitored. The 
half-life of each silicate is indicated in Table 7.2 as well as the observed rate Kobs. 
Although no trend in steric bulk was tested for the silicates chosen as was done 
in the taxane case (Chapter 3), the general lability is clearly shown depending on 
the nature of silicate prodrug. 
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Table 7.2 | Hydrolytic lability of silicate prodrugs 704, 708c, 710a, and 714. 
 
Compound 
Number 
Short Hand 
Descriptor 
TFA AcOH 
t1/2 (min) Kobs (s-1) t1/2 (min) Kobs (s-1) 
704 Ibu-Si(OtBu)3 3,100 ± 580 3.8 x 10-6 – – 
708c 5-FU-[Si(OtBu)3]2 (Si-1), (Si-3) 2.6 4.5 x 10
-3 45,000 ± 6.900 2.6 x 10
-7 
710a Dacarb-[Si(OtBu)3]2 (Si-4) – – 7.4 ± 0.9 1.6 x 10
-3 
710a Dacarb-[Si(OtBu)3]2 (Si-2) – – 510 ± 14 2.3 x 10
-5 
714 Cipro-[Si(OtBu)3]2 (Si-2’) 3.8 3.0 x 10
-3 7.2 ± 2.0 1.7 x 10-3 
714 Cipro-[Si(OtBu)3]2 (Si-3) 21 5.5 x 10
-4 6,900 ± 870 1.7 x 10
-6 
 
The nitrogen-silicon bond is the most labile as shown with the amide-
silicate at Si-4 of the dacarbazine silicate prodrug 710a and in 714 at Si-2’. The 
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half-life for cleavage for either bond is 7 mins in the less acidic conditions.  This 
is a drastic difference for the 5-fluorouracil 708c, which is 45,000 mins. Also no 
intermediate mono-functionalized 5-Fluorouracil silicate was found in the 1H-NMR 
spectrum. Both of the silicates degrade at near the same rate or when the first 
falls off the other is quickly lost. We presume the much slower rate is due to the 
steric congestion around the drug by the close proximity of both silicate groups. 
This can be also seen in the imidazole silicon bond in 710a, as its half life is 510 
mins. Lastly, the two carboxylic acid silicates 704 and 714 show considerable 
differences in the rate of cleavage due to the nature of the rest of the drug. 
Although the hydrolysis rates show the inherit stability of the novel silicate 
prodrugs, we were excited to test them in our FNP process and determine if 
stable nanoparticles could be made. 
 
7.3 Nanoparticle Formulations of Novel Silicate Prodrugs 
Nanoparticles preparations were made as presented in Chapters 2, 4, and 
6. We were encouraged by the nanoparticle formulations loaded with the 
cinnamic-silicate and the morpholine-silicate. The 5-fluorouracil-silicate 708c (8.9 
mg) and a mPEG-b-PLGA block copolymer (5k-10k, 6.3 mg) were dissolved in 
1.5 mL of THF. The THF solution was impingement mixed against 1.5 mL of H2O 
in the FNP device. The resulting nanoparticles were diluted into 17 mL of water. 
From this suspension an aliquot of 20 µL was taken and diluted to 1 mL in a DLS 
cuvette.  
Following the same procedure to produce 0.1 percent solids nanoparticle 
suspensions loaded at 50 wt% as above, three other novel silicate prodrugs 
(706b, 710a, and 714) were chosen to test the FNP conditions. The mass of 
each prodrug and mass of polymer used are presented in Table 7.3 (columns 3 
and 4). The intensity average size (di) and the PDI of the resulting nanoparticle 
formulations are also shown in Table 7.3 (columns 5 and 6). The DLS plot for 
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706b nanoparticles can be found in the experimental section (Figure S7.1). 
Lastly, it was observed that particles above 500 nm were not very stable and 
tended to aggregate overtime. 
 
Table 7.3 | Nanoparticles loaded with ca. 50 wt% of silicate prodrugs 704, 708c, 
710a, and 714 and drug 707. 
Compound 
Number 
Short Hand 
Descriptor 
Amounts DLS 
Prodrug 
(mg) 
Polymer 
(mg) di (nm) PDI 
706b Sal-Si(OiPr)3 5.8 7.0 132.0 0.081 
707  5-Fluorouracil 6.4 5.2 513.7 0.240 
708c 5-FU-[Si(OtBu)3]2 8.9 6.3 103.2 0.150 
710a Dacarb-[Si(OtBu)3]2  5.5 8.4 54 µm – 
714 Cipro-[Si(OtBu)3]2 6.4 6.3 159.6 0.227 
 
We were very pleased with the DLS measurements of the freshly prepared 
nanoparticle suspensions. However as expected, when the suspensions 
containing 10% THF were allowed to stand for 1 week the particles ca. doubled 
in size and the PDI broadened, likely due to aggregation. We also froze and 
lyophilized the solutions after 1 week to determine if the prodrugs were still intact. 
1H-NMR analysis in CDCl3 showed that: 706b had degraded ca. 50%, 710a had 
fully degraded (no resonances detected for the drug due to solubility in CDCl3), 
and 714 had completely lost the silicate at the piperazine ring (Si-2’) and 25% of 
the Si-3 carboxylic acid silicate had cleaved. A proton spectrum was not taken for 
the 706b nanoparticles after 1 week in solution. Although the particles grew and 
degraded in suspension after 1 week, this was expected and enforces the 
prodrug strategy in that the silicates are cleaved within a week of aqueous 
treatment.  
Only a handful of drugs were studied, we are very thrilled with the novel 
silicate prodrugs synthesized and formulated and have shown that the utility of 
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marrying the FNP process with the silicate methodology. We anticipate the use of 
this technology on new and old drug candidates that need to be packaged 
appropriately for subsequent administration. Many exciting new drug candidates 
fall through the pipeline due to undesirable properties that could be mitigated 
through nanoparticle formulation. Likewise, many old drugs have been 
discontinued due to side effects. The use of this technology has the potential to 
mitigate them and effectively deliver the drug to the proper site. We eagerly await 
the next chapter in the silicate prodrug loaded nanoparticle drug delivery. 
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1H, 13C, and 19F NMR spectra were taken on Varian Inova 500 (500 MHz), 
and Bruker Avance 500 (500 MHz, 400 MHz) spectrometers. 1H NMR chemical 
shifts in CDCl3 are referenced to TMS (0.00 ppm). Intractable multiplets resulting 
from overlap of one or more peaks are labeled as “m” and denoted with a range 
of ppm. 13C NMR chemical shifts in CDCl3 are referenced to chloroform (77.23 
ppm). The following format is used to report resonances: chemical shift in ppm 
[multiplicity, coupling constant(s) in Hz, integral, and assignment]. 1H NMR 
assignments are indicated by structure environment, e.g., CHaHb or numbering of 
the molecule. Some complex structures are numbered in order to simplify proton 
assignment numbering and naming. Coupling constant analysis was guided by 
methods we have described by Hoye and coworkers.216,217  
Infrared spectra were recorded on a Midac Corporation Prospect 4000 FT-
IR spectrometer. The most intense peaks are reported, and all spectra were 
collected in attenuated total reflectance (ATR) mode as thin films on a 
germanium window. High-resolution mass spectrometry (HRMS) measurements 
were performed on a Bruker BioTOF II (ESI-TOF) instrument using PEG as an 
internal standard/calibrant. Samples were introduced as solutions in CH2Cl2, 
methanol, or acetonitrile with sodium formate to assist in the ionization. LC-MS 
refers to liquid chromatography mass spectrometry, with different methods and 
columns which are described before diagnostic mass to charges are presented. 
Differential scanning calorimetry (DSC) was conducted on a TA Instruments 
                                            
216 Hoye, T. R.; Hanson, P. R.; Vyvyan, J. R. A practical guide to first-order multiplet analysis in 
1H NMR spectroscopy. J. Org. Chem. 1994, 59, 4096–4103. 
217 Hoye, T. R.; Zhao, H. A method for easily determining coupling constant values:  An 
addendum to “A practical guide to first-order multiplet analysis in 1H NMR spectroscopy.” J. Org. 
Chem. 2002, 67, 4014–4016. 
General Experimental for Chapters 2–7
 Experimental 197 
 
 
197 
Discovery DSC (New Castle, DE). The instrument was calibrated using an indium 
standard. All samples were prepared using T-Zero hermetic pans (ca. 5 mg).  
MPLC refers to medium pressure liquid chromatography (25-200 psi) 
using hand-packed columns of Silasorb silica gel (18-32 μm, 60 Å pore size) or 
Teledyne RediSep Gold Silica (20-40 μm, 60 Å pore size), a Waters 510 HPLC 
pump, a Waters R401 differential refractive index detector, and a Gilson 112 UV 
detector. Flash chromatography was performed using E. Merck silica gel (230-
400 mesh). Thin layer chromatography was performed on glass or plastic backed 
plates of silica gel and visualized by UV detection and/or a solution of ceric 
ammonium molybdate, anisaldehyde, potassium permanganate, or 
phosphomolybdic acid. 
Reactions requiring anhydrous conditions were performed under an 
atmosphere of nitrogen or argon in flame or oven dried glassware. Anhydrous 
THF, Et2O, toluene, and CH2Cl2 were taken immediately prior to use after being 
passed through a column of activated alumina. Reported (external) reaction 
temperatures are the temperature of the heating bath. Those reactions carried 
out in deuterated solvents were performed directly in a capped 5 mm NMR 
sample tube. 
 
 
Triethylamine and pyridine were purified by distillation over CaH2. N,N-
Dimethyl-n-butylamine was stored over 3 Å molecular sieves. The known tri-n-
octyloxychlorosilane, tri-i-propoxychlorosilane, trimenthyloxychlorosilane, and di-
t-butoxydichlorosilane were synthesized from silicon tetrachloride and n-octanol, 
i-propanol, (–)-menthol, and t-butanol (the liquids, each dried over activated 3Å 
molecular sieves overnight), respectively. Tetrahydrofuran was dried by being 
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passed through an activated alumina column. Ethanol (anhydrous) was further 
dried by storing overnight over activated 3Å molecular sieves. Ethyl acetate 
(EtOAc, ACS grade) and hexanes (ACS grade) were used as received. The d6-
acetone and d-chloroform were dried over activated 3Å molecular sieves 
overnight. D2O was used as received. 
 
All thin layer chromatography (TLC) data were collected on glass- or 
plastic-backed plates coated with F-254 indicator. Visualization was done by UV-
light and/or staining with phosphomolybdic acid (PMA). Medium pressure liquid 
chromatography (MPLC) purifications were performed using columns dry-packed 
with ca. 25-35 µm silica gel. The MPLC apparatus was pressurized with a dual 
piston HPLC pump. Compound detection was performed by using a UV 
absorbance detector at 254 nm and a differential refractometer in series. Each 
silicate ester was purified by MPLC, under conditions that achieved effective 
separation of starting taxane, monosilicate, and bis-silicate esters, shortly before 
being used in the cytotoxicity study. Each compound whose cytotoxicity is 
reported in Table 3.4 was purified in this fashion, at which point it was shown to 
be of >95% purity by HPLC analysis in a C18- or C8-reversed phase column. 
1H NMR spectra were taken on a 500 MHz (1H) instrument. All 1H 
characterization spectra were taken in CDCl3 and chemical shifts (δ) are 
referenced to tetramethylsilane at δ = 0.00. All 13C NMR characterization spectra 
were taken in CDCl3 on either a 125 MHz (13C) or a 75 MHz (13C) instrument and 
referenced to CHCl3 at δ = 77.23. The following abbreviations are used to 
describe the NMR signals: s (singlet), d (doublet), t (triplet), q (quartet), sept 
(septet), m (multiplet), br (broad), and app (apparent). Coupling constants (J) are 
reported in Hz. High resolution mass spectra were collected on an ESI-TOF 
instrument using poly(ethylene glycol) (PEG) or poly(propylene glycol) (PPG) as 
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an internal standard. Infrared spectra were recorded using an FT-IR instrument. 
All samples were collected in attenuated total reflectance (ATR) mode as thin 
films on a germanium window. Melting point data were collected on a hot stage 
and are uncorrected.  
 
Silicate Ester Hydrolysis Rate Studies: 
The PTX-silicate (ca. 10 mg) was dissolved in 900 µL of d6-acetone. To 
this homogenous solution, 100 µL of a 9:1 v/v solution of D2O:TFA was added, 
and the solution was vigorously mixed.  As instrumentation became more 
sensitive, the solvents were cut in half for the remainder of the hydrolysis 
experiments. 1H NMR spectra were taken (16 or 32 transients) at 500 MHz at 
multiple time points (8-30) over the course of more than three half-lives for all but 
the slowest reacting silicates. The study was conducted at room temperature (rt = 
22 °C ± 1.0 °C). The relative integration values were used to determine the extent 
of hydrolysis. Typically, resonances for the 2’- and/or 7-methine protons for the 
starting taxane silicate and the product free taxane (PTX or DTX) vs. that of H5 
(a remote proton whose chemical shift was invariant for the two species) were 
integrated in a baseline-corrected spectrum using MestRe-C® or iNMR© software. 
Data were plotted as growth or decay curves as ln[species observed] vs. time. 
The slope of each linear correlation gave the reported kobs value.  The indicated 
errors are the observed standard deviation from three replications of the 
experiment. The t1/2 values were calculated under the assumption that the 
process was pseudo-first order.   The krel data presented in Table 3.2 are the 
ratios of kobs for each silicate divided by that for the most slowly hydrolyzed 
silicate (301d).  
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In vitro Studies: 
Cell Culture Cytotoxicity (IC50 Determination) Studies. MDA-MB-231 and 
MDA-MB-231 luciferase positive cells218 were maintained independently in 
minimum essential medium (MEM) supplemented with 1% pen/strep and 10% 
fetal bovine serum (FBS) at 37 °C in a humidified incubator. MDA-MB-231 cells 
were obtained from the American Type Culture Collection. MDA-MB-231 Luc+ 
cells were obtained from Caliper Life Sciences. For cytotoxicity studies, MDA-
MB-231 cells were seeded at 8,000 cells/well in a 96 well plate in 100µL MEM 
with 5% FBS. Taxane and taxane silicate stock solutions (10 mM) were prepared 
in DMSO. Each stock solution was serially diluted in MEM with 5% FBS and 100 
µL of the solutions were pipetted into the 96 well plate. Concentration ranges 
were from 1–10,000 nM for PTX-silicates and 0.1–1000 for DTX-silicates. After 
72 hours 30 µL of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) 
bromide reagent was added to each well. Absorbance at 490 nm was monitored 
on a 96 well plate UV/Vis detector at 60 minutes. Viable cells reduce the 
tetrazolium compound and the absorbance (and the concentration) of the product 
correlates to the number of viable cells. IC50 values were determined by nonlinear 
regression analysis of log concentration vs. response data obtained from the 
MTT assay. The IC50 was interpolated from the resulting curves using Graphpad 
Prism v5.1.  
 
 
                                            
218 Shahani, K.; Swaminathan, S. K.; Freeman, D.; Blum, A.; Ma, L.; Panyam, J. Injectable 
sustained release microparticles of curcumin: A new concept for cancer chemoprevention. 
Cancer Res. 2010 70, 4443–4452. 
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β-Carotene (≥97%), betulin (≥98%), curcumin (≥80%), triethylamine (TEA; 
≥99.5%), octanoic acid (≥98%), silicon tetrachloride (99%), water (H2O; HPLC 
grade), methanol (HPLC grade), dichloromethane (anhydrous; ≥99.8%), and 
tetrahydrofuran (THF; HPLC grade) were purchased from Aldrich. 
Triethoxychlorosilane (95%) was purchased from Gelest Incorporated. Acetone 
was purchased as ACS grade from Fischer chemical. Acetone-d6 (D, 99.9%) and 
D2O (D, 99.9%) were purchased from Cambridge Isotope Laboratories 
Incorporated. Paclitaxel was obtained from Phytogen Life Sciences. 2,4,6-
Triiodophenol was obtained from Alfa Aesar (98% purity). Hydrocortisone was 
obtained from MP Biomedical (99.6% by HPLC, USP).  PS(10k)-b-PEG(5k) 
(Mw/Mn = 1.05) was purchased from Polymer Source. (D,L)-Lactide [or (rac)-
lactide] was purchased from Altasorb and purified by recrystallization from 
toluene; glycolide was purchased from Altasorb and was purified by 
recrystallization from THF. Monomethoxy PEG (Mn = 2000 and 5000 g·mol−1, 
denoted mPEG(2k or 5k)-OH), PEG-diol (HO-PEG(5k)-OH), monomethoxy 
diethylene glycol, ε- caprolactone 97%, (1R)-(−)-10-camphorsulfonic acid (98%), 
and 1,8-diazabicyclo[5.4.0]undec-7-ene were purchased from Aldrich, and 
mPEG(10k)-OH was purchased from JenKem Technology. Prior to its use in 
synthesizing mPEG-containing BCPs, mPEG-OH was dried by azeotropic 
distillation from toluene or by dissolution in dry dichloromethane and storage 
overnight on oven-dried molecular sieves in an airtight culture tube.  
The polymer PEG-b-PLGA (MW: 5k-10kDa) and suite of PTX-silicate 
prodrugs were synthesized as previously reported (Chapter 3). Paclitaxel was 
obtained from Phytogen Life Sciences. Water (H2O, HPLC grade), 
tetrahydrofuran (THF, HPLC grade), and acetonitrile (ACN, HPLC grade) were 
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purchased from Sigma-Aldrich and used as received. CDCl3 was purchased from 
Cambridge Isotope Laboratories, Inc. Ethanol (anhydrous) was purchased from 
Decon Labs, Inc. Monosodium phosphate and disodium phosphate were 
purchased from Fisher Scientific. Phosphate buffered saline was prepared by 
dissolving 3.12 g of monosodium phosphate, 20.74 g of disodium phosphate, and 
9 g of sodium chloride in 1 L of water to achieve a pH = 7.4. The 10 mM acetate 
buffer was prepared by dissolving 0.21 g of glacial acetic acid, 0.52 g of 
anhydrous sodium acetate, and 9 g of sodium chloride in 1 L of water to achieve 
a pH of 5.0. Slide-A-Lyzer dialysis mini capsules (MWCO: 10 kDa, 0.5-1 mL) 
were purchased from Thermo Scientific. 
 
 
4.3.3 Nanoparticle Morphology 
The morphology of the nanoparticles was observed by cryo-TEM and the 
procedure was explained in detail previously.219 Samples were prepared from 
either the nanoparticle suspension or the dried nanoparticle powder. A lacey 
carbon Cu grid (01881, 200-mesh, Ted Pella, Ltd., Redding, CA) was glow 
discharged in a vacuum evaporator at 70 mTorr (DV-502A, Denton Vacuum 
Moorestown, NJ) for 30 seconds to create a hydrophilic surface on the carbon 
coated side of the grid. A 2−3 µL volume of the fresh nanoparticle suspension 
was pipetted onto the carbon side at 22 °C in a Mark III Vitrobot chamber (FEI 
Company, Hillsboro, OR) with a relative humidity of ~100 %. The excess sample 
was blotted with grade 595 blotting paper (Ted Pella, Ltd., Redding, CA) once or 
twice with an ~1.5 mm offset parameter for 5 seconds to form a thin liquid film. 
                                            
219 Lee, H. S.; Morrison, E. D.; Frethem, C. D.; Zasadzinski, J. A.; McCormick, A. V.; Cryogenic 
electron microscopy study of nanoemulsion formation from microemulsions. Langmuir 2014, 30, 
10826-10833. 
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Three seconds after blotting, the sample was plunged into liquid ethane cooled 
by liquid nitrogen. 
The resulting vitrified sample was transferred to a Gatan 626 cryo-
transfer unit (Gatan, Pleasanton, CA) at -194 °C and then characterized at -
178 °C in the microscope. A 120 kV FEI Tecnai Spirit BioTWIN was used; images 
were taken digitally with an Eagle™ 2k CCD camera (FEI Company, Hillsboro, 
OR) in low-dose mode. The images were processed with the TEM Imaging and 
Analysis software package (version 4.2 SP1, build 816, FEI Company, Hillsboro, 
OR). To enhance the phase contrast, the images were deliberately under-
focused to 2-4 µm with an objective lens. The degree of under-focus was 
controlled intentionally both to create Fresnel fringes (white rings on the 
boundary of nanoparticle structure) and to enhance the contrast between the 
core and shell regions in nanoparticles. Occasionally, beam damage was used to 
differentiate the polymer versus drug particles. In these instances, the diblock 
copolymer PEG-b-PLGA was susceptible to selective damage by the electron 
beam, producing bubbles. 
 
4.3.4 Silicate Release Measurements 
Lyophilized nanoparticles (15 mg) were redispersed in 15 mL of PBS 
buffer using micro-tip (1/8”) sonication (Misonix Sonicator 3000, NY) in pulse 
mode for 5 minutes, with an increasing power of 3 to 9 volt within 1 minute. After 
every 1 minute of sonication, the tube containing nanoparticles was immersed in 
an ice/water bath to dissipate the heat generated by sonication. After 5 minutes, 
500 μL aliquots of the nanoparticle suspension were placed into mini dialysis 
capsules (MW cutoff size: 10,000 Da, Pierce Biotech, Rockford, IL, US). A total of 
30 capsules were immersed, 3 each, in ten 1L solutions of PBS buffer at pH 7.4 
and, separately, pH 5.0. The beakers were held at 37 °C and agitated at 100 rpm 
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on an incubated orbital shaker.  At predetermined time intervals (0, 1, 2, 4, 8, 12, 
24, 48, 72, 96 h), three capsules were removed and frozen at -80 ºC. To assay 
the amount of PTX-silicate and PTX remaining inside particles at each time point, 
the contents of each frozen capsule were lyophilized for 24 h. Acetonitrile (1 mL) 
was added to each capsule of dried particles and buffer salts, and the resulting 
suspension was transferred to a 2 mL glass vial. The vial was capped, sealed 
with Parafilm M® to prevent evaporative loss, and allowed to stand overnight. 
Undissolved buffer salts remained at the bottom of the vials. An aliquot of the 
supernatant was analyzed by HPLC and the amounts of PTX and PTX-silicate 
were quantified against calibration curves. To assay the amount of released PTX-
silicate and PTX, each 1 L external buffer solution was lyophilized in twenty-one 
60 mL centrifuge tubes.  The powdered contents of three sets of seven tubes 
were consolidated into three separate vials. Each was leached overnight with the 
same volume of acetonitrile and the supernatant assayed by HPLC as above. 
Release studies in pH 5.0 buffer were conducted using the same protocols. 
 
4.3.6 In vitro Cell Growth Inhibition  
Cytotoxicity studies were conducted using, MDA-MB-231 Luc+ breast 
cancer cells (Caliper Life Sciences, Hopkinton, MA). Cells were maintained in 
minimum essential medium (MEM) supplemented with 10% fetal bovine serum 
(FBS) and 1% penicillin/streptomycin in a humidified incubator held at 37 °C. For 
the cytotoxicity studies, MDA-MB-231 cells were seeded at 5,000 cells/well in a 
96 well plate containing 100 µL of MEM supplemented with 5% FBS. Following 
attachment, cells were treated with free PTX or PTX-silicate prodrug-loaded 
nanoparticles. For free PTX, a stock solution was prepared in DMSO (10 mM) 
and then diluted in regular growth media. Cells were incubated with the PTX 
control or each of the loaded nanoparticle formulations for 4 hours, then washed 
with fresh medium and finally incubated with fresh medium for an additional 72 
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hours. Cell viability was determined at the end of the study using the MTT assay. 
Untreated cells and cells treated with empty nanoparticles were used as controls. 
The IC50 was interpolated from the resulting curves using Graphpad Prism (v5.1, 
Graphpad Software Inc. La Jolla CA, USA). 
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In vivo Tumor Injection: 
The entire animal studies were performed in accordance to the policies 
approved by the University of Minnesota’s IACUC. Female Balb/c nu/nu 
immunocompromised mice were purchased from Charles River Labs (Wilmington 
MA, USA). For xenograft studies, 7.5 x 105 MDA-MB-231 Luc+ cells were 
suspended in 100 µL of Dulbecco’s phosphate buffered saline (DPBS) and mixed 
with an equal volume of Matrigel®. Subcutaneous injection into mammary pad #9, 
located near the left flank, was performed with a 26-gauge needle attached to a 
0.5 cc syringe. 
Based on the prodrug loading levels (Table S5.1), each nanoparticle 
formulation was weighed and resuspended in buffered saline such that a 10 
microliter volume of the resulting nanoparticle suspension contained 40 
micrograms of PTX-equivalent dose. Resuspension of the nanoparticles involved 
initial vortexing (ca. 1 min) followed by five cycles of probe sonication. Each cycle 
involved sonication for 1 minute at 5W, followed by 30 seconds of off time. 
Following probe sonication, 10 microliters of nanoparticle suspension was 
manually injected directly into tumors (average tumor volume ~100 mm). The 
mice were anaesthetized using isoflurane during nanoparticle administration. 
Tumor volume measurements were taken with an electronic caliper. Tumor 
volumes were calculated from the formula: Volume= (L2 x W)/2. The day when 
treatments were administered was considered Day 0. 
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2’-O-[(Triethoxy)silyl]paclitaxel (301a).  
 
Paclitaxel (55.3 mg, 0.0648 mmol, 1.0 equiv) was dissolved in dry THF (1.0 mL) 
in an oven-dried culture tube fitted with a Teflon-lined cap and magnetic stir bar. 
Triethylamine (20 µL, 0.130 mmol, 2.0 equiv) was added by Wiretrol®. 
Triethoxychlorosilane (305a) (25 µL, 0.0127 mmol, 2.0 equiv) was then added, 
and a white precipitate was immediately observed. The culture tube was sealed 
and the suspension was allowed to stir for 1 hour at room temperature. The 
reaction slurry was diluted with a mixture of hexanes:EtOAc (1:1) and filtered 
through a short plug of Celite® to remove the triethylammonium salt. The filtrate 
was concentrated under reduced pressure, and the residue was redissolved in a 
mixture of hexanes:EtOAc (1:1). Chromatography (SiO2, 1:1 hexanes:EtOAc) via 
MPLC yielded the title compound as a white, crystalline solid (59.6 mg, 0.0587 
mmol, 90.6%).  
1H NMR (500 MHz, CDCl3): δ 8.12 (dd, J = 8.5, 1.4 Hz, 2H, C2O2C-o-Ph), 7.78 
(dd, J = 8.5, 1.3 Hz, 2H, C3’NHCO-o-Ph), 7.62 (tt, J = 7.5, 1.2 Hz, 1H, C2O2C-
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p-Ph), 7.56-7.46 (m, 3H, C2O2C-m-Ph and C3’NHCO-p-Ph), 7.43-7.36 (m, 6H, 
C3’-o-Ph, C3’-m-Ph and C3’NHCO-m-Ph), 7.29 (tt, J = 6.5, 2.2 Hz, 1H, C3’-p-
Ph), 7.19 (d, J = 8.6 Hz, 1H, C3’NH), 6.28 (s, 1H, H10), 6.24 (br dd, J = 9, 9 
Hz, 1H, H13), 5.72 (dd, J = 8.5, 3.2 Hz, 1H, H3’), 5.68 (d, J = 7.1 Hz, 1H, H2), 
4.97 (dd, J = 9.4, 2.0 Hz, 1H, H5), 4.96 (d, J = 3.3 Hz, 1H, H2’), 4.43 (ddd, J = 
10.9, 6.4, 4.5 Hz, 1H, H7), 4.32 (d, J = 8.5 Hz, 1H, H20α), 4.20 (d, J = 8.5 Hz, 
1H, H20β), 3.80 (d, J = 7.2 Hz, 1H, H3), 3.71 [q, J = 7.0 Hz, 6H, 
C2’OSi(OCH2CH3)3], 2.56 (ddd, J = 14.7, 9.6, 6.5 Hz, 1H, H6α), 2.45 (s, 3H, 
C4OAc), 2.44 (br s, 1H, C7OH), 2.32 (dd, J = 15.4, 9.4, Hz, 1H, H14α), 2.24 
(s, 3H, C10OAc), 2.08 (dd, J = 15.2, 8.8 Hz, 1H, H14β), 1.90 (d, J = 1.2 Hz, 
3H, C18H3), 1.89 (ddd, J = 14.5, 11.0, 2.4 Hz, 1H, H6β), 1.68 (s, 3H, C19H3), 
1.64 (br s, 1H, C1OH), 1.24 (s, 3H, C17H3), 1.15 [t, J = 7.0 Hz, 9H, 
C2’OSi(OCH2CH3)3], and 1.13 (s, 3H, C16H3).  
13C NMR (75 MHz, CDCl3): δ 204.0, 171.6, 171.0, 170.1, 167.3, 167.2, 143.0, 
138.2, 134.2, 133.9, 132.9, 132.0, 130.4, 129.3, 128.9 (x2), 128.8, 128.2, 
127.3, 126.8, 84.6, 81.2, 79.3, 76.7, 75.8, 75.3, 75.1, 72.3, 71.5, 59.7, 58.7, 
55.6, 45.7, 43.4, 35.7, 35.6, 27.0, 23.0, 22.4, 21.1, 18.2, 14.9, and 9.8.   
HRMS (ESI) Calc’d for C53H65NNaO17Si [M + Na]+ 1038.3914, found 1038.3942.  
IR (thin film) 3500 (br), 2977, 2898, 1744, 1730, 1636, 1580, 1540, 1487, 1452, 
1371, 1314, 1268, 1240, 1170, 1145, 1078, 1025, 978, 908, 854, 797, and 710 
cm-1.  
mp = 131-134 °C. TLC Rf (1:1 hexanes:EtOAc) = 0.45.  
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2-O-[(Tri-n-octyloxy)silyl]paclitaxel (301b). 
 
Paclitaxel (76.0 mg, 0.0890 mmol, 1.0 equiv) was dissolved in dry THF (1.5 mL) 
in an oven-dried culture tube fitted with a Teflon-lined cap and magnetic stir bar. 
Triethylamine (60 µL, 0.430 mmol, 4.8 equiv) was added by Wiretrol®. A 1.67:1 
mixture of tri-n-octyloxychlorosilane (305b):tetra-n-octyloxysilane (0.200 mg, 
0.257 mmol, 2.9 equiv of tri-n-octyloxychlorosilane) was added and a white 
precipitate was immediately observed. The culture tube was capped and the 
suspension was allowed to stir for 22 h at room temperature. The reaction slurry 
was diluted with a mixture of hexanes:EtOAc (1:1), the slurry filtered through a 
short plug of Celite® to remove the triethylammonium salt, the filtrate 
concentrated under reduced pressure, and the residue redissolved in a mixture of 
hexanes:EtOAc (2:1). Chromatography (SiO2, 2:1 hexanes:EtOAc) via MPLC 
yielded the title compound as a white, crystalline solid (91.5 mg, 0.0721 mmol, 
81.0%).  
1H NMR (500 MHz, CDCl3): δ 8.13 (dd, J = 8.5, 1.5 Hz, 2H, C2O2C-o-Ph), 7.77 
(dd, J = 8.5, 1.4 Hz, 2H, C3’NHCO-o-Ph), 7.62 (tt, J = 7.4, 1.3 Hz, 1H, C2O2C-
p-Ph), 7.55-7.46 (m, 3H, C2O2C-m-Ph and C3’NHCO-p-Ph), 7.43-7.35 (m, 6H, 
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C3’-o-Ph, C3’-m-Ph and C3’NHCO-m-Ph), 7.28 (tt, J = 6.9, 1.7 Hz, 1H, C3’-p-
Ph), 7.19 (d, J = 8.6 Hz, 1H, C3’NH), 6.28 (s, 1H, H10), 6.25 (br dd, J = 9, 9 
Hz, 1H, H13), 5.72 (dd, J = 8.6, 3.2 Hz, 1H, H3’), 5.68 (d, J = 7.1 Hz, 1H, H2), 
4.97 (dd, J = 9.8, 2.1 Hz, 1H, H5), 4.96 (d, J = 3.2 Hz, 1H, H2’), 4.44 (ddd, J = 
10.9, 6.7, 4.2 Hz, 1H, H7), 4.31 (d, J = 8.4 Hz, 1H, H20α), 4.20 (d, J = 8.3 Hz, 
1H, H20β), 3.80 (d, J = 7.1 Hz, 1H, H3), 3.61 {t, J = 6.8 Hz, 6H, 
C2’OSi[OCH2(CH2)6CH3]3}, 2.56 (ddd, J = 14.8, 9.6, 6.6 Hz, 1H, H6α), 2.47 (d, 
J = 4.1 Hz, 1H, C7OH), 2.44 (s, 3H, C4OAc), 2.32 (dd, J = 15.4, 9.4 Hz, 1H, 
H14α), 2.24 (s, 3H, C10OAc), 2.07 (dd, J = 15.4, 8.8 Hz, 1H, H14β), 1.89 (d, J 
= 1.4 Hz, 3H, C18H3), 1.89 (m, 1H, H6β), 1.68 (s, 3H, C19H3), 1.65 (br s, 1H, 
C1OH), 1.48 [tt, J = 6.9, 6.9 Hz, 6H, C2’OSi(OCH2CH2(CH2)5CH3)3], 1.32-1.22 
{m, 33H, C2’OSi[OCH2CH2(CH2)5CH3]3 and C17H3}, 1.13 (s, 3H, C16H3), and 
0.88 {t, J = 6.9 Hz, 9H, C2’OSi[OCH2CH2(CH2)5CH3]3}.  
13C NMR (75 MHz, CDCl3): δ 204.0, 171.5, 170.9, 170.1, 167.2, 167.2, 143.0, 
138.3, 134.3, 133.9, 132.9, 132.0, 130.4, 129.3, 128.9 (x2), 128.8, 128.1, 
127.3, 126.8, 84.7, 81.2, 79.3, 76.6, 75.8, 75.3, 74.9, 72.4, 71.4, 64.1, 58.7, 
55.5, 45.7, 43.4, 35.8, 35.7, 32.4, 32.0, 29.54, 29.52, 27.0, 25.8, 23.0, 22.9, 
22.4, 21.1, 14.9, 14.3, and 9.8.  
HRMS (ESI) Calc’d for C71H101NNaO17Si [M + Na]+ 1290.6731; found 1290.6749.  
IR (thin film) 2926, 2855, 1730, 1665, 1643, 1602, 1581, 1518, 1484, 1453, 1371, 
1312, 1271, 1240, 1174, 1094, 1025, 985, 926, 907, 851, 801, 777, and 711 
cm-1.  
mp = 60–63 °C. TLC Rf (3:1 hexanes:EtOAc) = 0.15. 
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2’-O-[(Tri-i-propoxy)silyl]paclitaxel (301c).  
 
Paclitaxel (38.8 mg, 0.0454 mmol, 1.0 equiv) was dissolved in dry THF (1.0 mL) 
in an oven-dried culture tube fitted with a Teflon-lined cap and magnetic stir bar. 
Triethylamine (25 µL, 0.179 mmol, 3.9 equiv) was added by Wiretrol®. A 2.9:1 
mixture of tri-i-propoxychlorosilane (305c) : tetra-i-propoxysilane (0.155 mg, 
0.132 mmol, 2.9 equiv of tri-i-propoxychlorosilane) was added. The culture tube 
was capped and a white precipitate was observed within minutes. The 
suspension was stirred at room temperature for 48 hours and the cloudy, 
heterogeneous reaction mixture was noted to be slightly yellowed. The 
suspension was diluted with a mixture of hexanes:EtOAc (1:1), the slurry filtered 
through a short plug of Celite® to remove the triethylammonium salt, the filtrate 
concentrated under reduced pressure, and the residue redissolved in a mixture of 
hexanes:EtOAc (1:1). Chromatography (SiO2, 1:1 hexanes:ethyl acetate) via 
MPLC yielded the title compound as a white, crystalline solid (31.1 mg, 0.0294 
mmol, 64.7%).  
1H NMR (500 MHz, CDCl3): δ 8.11 (dd, J = 8.5, 1.4 Hz, 2H, C2O2C-o-Ph), 7.79 
(dd, J = 8.4, 1.3 Hz, 2H, C3’NHCO-o-Ph), 7.62 (tt, J = 7.6, 1.3 Hz, 1H, C2O2C-
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p-Ph, 1H), 7.55-7.47 (m, 3H, C2O2C-m-Ph and C3’NHCO-p-Ph), 7.44-7.35 (m, 
6H, C3’-o-Ph, C3’-m-Ph and C3’NHCO-m-Ph), 7.27 (tt, J = 7.0, 1.7 Hz, 1H, 
C3’-p-Ph), 7.17 (d, J = 8.5 Hz, 1H, C3’NH), 6.28 (s, 1H, H10), 6.19 (br dd, J = 
9, 9 Hz, 1H, H13), 5.69 (dd, J = 8.5, 3.6 Hz, 1H, H3’), 5.68 (d, J = 6.7 Hz, 1H, 
H2), 4.98 (d, J = 3.6 Hz, 1H, H2’), 4.96 (dd, J = 9.7, 2.4 Hz, 1H, H5), 4.44 
(ddd, J = 10.9, 6.6, 4.1 Hz, 1H, H7), 4.31 (d, J = 8.4 Hz, 1H, H20α), 4.20 (d, J 
= 8.4 Hz, 1H, H20β), 4.13 {sept, J = 6.1 Hz, 3H, C2’OSi[OCH(CH3)2]3}, 3.80 (d, 
J = 7.1 Hz, 1H, H3), 2.56 (ddd, J = 14.8, 9.8, 6.6 Hz, 1H, H6α), 2.47 (d, J = 4.1 
Hz, 1H, C7OH), 2.42 (s, 3H, C4OAc), 2.29 (dd, J = 15.4, 9.4 Hz, 1H, H14α), 
2.24 (s, 3H, C10OAc), 2.06 (dd, J = 15.4, 8.9 Hz, 1H, H14β), 1.91 (d, J = 1.4 
Hz, 3H, C18H3), 1.88 (ddd, J = 14.3, 11.0, 2.4 Hz, 1H, H6β), 1.76 (br s, 1H, 
C1OH), 1.68 (s, 3H, C19H3), 1.23 (s, 3H, C17H3), 1.15 {d, J = 6.1 Hz, 9H, 
C2’OSi[OCH(CH3)a(CH3)b]3}, 1.12 {d, J = 6.1 Hz, 9H, 
C2’OSi[OCH(CH3)a(CH3)b]3}, and 1.12 (s, 3H, C16H3).  
13C NMR (125 MHz, CDCl3): δ 204.1, 171.5, 171.1, 170.1, 167.3, 167.2, 143.1, 
138.3, 134.4, 133.9, 132.9, 131.9, 130.4, 129.4, 128.9 (x2), 128.8, 128.1, 
127.3, 127.0, 84.7, 81.2, 79.3, 76.7, 75.9, 75.3, 74.9, 72.3, 71.5, 66.7, 58.7, 
55.8, 45.7, 43.4, 35.8, 35.7, 27.0, 25.44, 25.42, 23.0, 22.4, 21.1, 15.2, and 9.8.  
HRMS (ESI) Calc’d for C56H71NNaO17Si [M + Na]+ 1080.4383; found 1080.4380.  
IR (thin film) 3500 (br), 2974, 2934, 1729, 1666, 1603, 1583, 1515, 1485, 1452, 
1371, 1313, 1269, 1241, 1174, 1114, 1052, 985, 897, 850, 800, 773, and 712 
cm-1.  
mp = 126–129 °C. TLC Rf (1:1 hexanes:EtOAc) = 0.45. 
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2’-[(Trimenthyloxy)silyl]paclitaxel (301d).   
 
Paclitaxel (95.0 mg, 0.111 mmol, 1.0 equiv) was dissolved in dry THF (8.0 mL) in 
an oven-dried culture tube fitted with a Teflon-lined cap and magnetic stir bar. 
Pyridine (100 µL, 1.24 mmol, 11.2 equiv) was added by Wiretrol®. 
Trimenthyloxychlorosilane (305d, judged to contain 90% of the chlorosilane 
(579.1 mg, 0.986 mmol, 8.9 equiv) by 1H NMR analysis, was added by Wiretrol®. 
The culture tube was capped and the suspension was allowed to stir for 12 h at 
45 ºC. The THF was removed by evaporation under reduced pressure, the solid 
residue was triturated with a mixture of hexanes:EtOAc (3:1), and the resulting 
slurry was filtered through a short plug of Celite® to remove the pyridinium salt. 
The filtrate was concentrated under reduced pressure, and the residue was 
purified by MPLC (SiO2, 3:1 hexanes:EtOAc) to yield the title compound as a 
white, crystalline solid (94.2 mg, 0.069 mmol, 62%).  
1H NMR (500 MHz, CDCl3): δ 8.11 (dd, J = 8.3, 1.3 Hz 2H, O2C-o-Ph, 7.77 (dd, J 
= 8.1, 1.0 Hz, 2H, C3’NHCO-o-Ph), 7.60 (tt, J = 7.4, 1.3 Hz, 1H, C2O2C-p-Ph), 
7.53-7.47 (m, 3H, C2O2C-m-Ph and C3’NHCO-p-Ph), 7.43-7.36 (m, 6H, C3’-o-
Ph, C3’-m-Ph and C3’NHCO-m-Ph), 7.30 (tt, J = 7.0, 1.6 Hz, 1H, C3’-p-Ph), 
7.11 (d, J = 8.5 Hz, 1H, C3’NH), 6.28 (s, 1H, H10), 6.22 (ddq, J = 10.3, 9.3, 
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1.4 Hz, 1H, H13), 5.72 (dd, J = 8.5, 3.5 Hz, 1H, H3’), 5.68 (d, J = 7.1 Hz, 1H, 
H2), 5.10 (d, J = 3.5 Hz, 1H, H2’), 4.97 (dd, J = 9.6, 2.3 Hz, 1H, H5), 4.45 
(ddd, J = 10.8, 6.7, 4.1 Hz, 1H, H7), 4.30 (dd, J = 8.6, 0.9 Hz, 1H, H20α), 4.20 
(d, J = 8.5, 1.1 Hz, 1H, H20β), 3.80 (d, J = 7.1 Hz, 1H, H3), 3.64 (ddd, J = 
10.6, 10.6, 4.3 Hz, 3H, H1menth), 2.57 (ddd, J = 14.8, 9.8, 6.6 Hz, 1H, H6α), 
2.48 (d, J = 4.1 Hz, 1H, C7OH), 2.39 (s, 3H, C4OAc), 2.30 (dd, J = 15.3, 9.5 
Hz, 1H, H14α), 2.25 (s, 3H, C10OAc), 2.20 (dsep, J = 2.6, 7.0 Hz, 3H, 
H7menth), 2.12 (dd, J = 15.9, 9.0 Hz, 1H, H14β), 1.92-1.86 (m, 4H, H6eqmenth 
and H6β), 1.88 (d, J = 1.3 Hz, 3H, H18 =CCH3), 1.80 (s, 1H, C1OH), 1.68 (s, 
3H, H19 O=CCCH3), 1.61 (m, 3H, H4eqmenth), 1.58 (dddd, J = 13.0, 3.0, 3.0, 
3.0 Hz, H3eqmenth ), 1.28-1.24 (m, 6H, H5menth), 1.25 (s, 3H, C(Me)C16H3), 
1.16-1.10 (dddd, 3H, J = 11.2, 11.2, 2.8, 2.8 Hz H2menth), 1.14 [s, 3H, 
C(Me)C17H3], 0.92 (ddd, J = 12, 12, 12 Hz, 3H, H6axmenth), 0.91-0.85 (m, 3H, 
H3axmenth), 0.87 (d, 9H, J = 7.1 Hz, H8menth), 0.83 (d, J = 6.6 Hz, 9H, H10menth), 
0.83-0.77 (dddd, J = 12.3, 12.3, 12.3, 3.0 Hz, 3H, H4axmenth), and 0.74 (d, J = 
6.9 Hz, 9H, H9menth).  
13C NMR (125 MHz, CDCl3): δ  204.1, 171.6, 170.7, 170.0, 167.2, 167.1, 143.2, 
138.1, 134.2, 133.8, 132.6, 132.0, 130.4, 129.3, 129.0, 128.9, 128.8, 128.1, 
127.3, 126.9, 84.7, 81.1, 79.3, 76.7, 75.8, 75.3, 74.5, 74.2, 71.4 (C1menth), 
71.36, 58.7, 55.5, 49.7 (C2menth), 45.6, 45.0 (C7menth), 43.4, 35.9, 35.7, 34.5 
(C5menth), 31.7 (C6menth), 27.0, 25.4 (C3menth), 22.9 (C4menth), 22.7, 22.5 
(C8menth), 22.4, 21.4 (C9menth), 21.1, 15.8 (C10menth), 15.1, and 9.8.  
HRMS (ESI) Calc’d for C67H103NNaO17Si [M + Na]+ 1368.7206; found 1368.7275.  
IR (thin film) 3443, 2953, 2925, 2870, 1762, 1718, 1496, 1452, 1368, 1316, 1274, 
1245, 1162, 1108, 1083, 1070, 1052, 1026, 987, 890, 765, and 751 cm-1. 
 mp = 115–118.5 °C.  TLC Rf (9:1 hexanes:EtOAc) = 0.20. 
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2’-O-[(Tri-t-butoxy)silyl]paclitaxel (301e).a   
 
aCompound synthesized by Dr. Wohl and included here for reference. 
Paclitaxel (PTX, 49.8 mg, 0.0583 mmol, 1.0 equiv) was dissolved in dry THF (1.0 
mL) in an oven-dried culture tube with a Teflon-lined cap and magnetic stir bar. In 
a separate oven-dried culture tube fitted with a Teflon-lined cap, SiCl4 (0.40 mL, 
2.6 mmol), pyridine (0.84 mL, 10.4 mmol), t-butanol (0.73 mL, 7.6 mmol), and 
THF (ca. 10 mL) were combined and the mixture was stirred for 24 h. A 1 mL 
aliquot of this silylating reagent mixture was added to the tube containing PTX. 
The culture tube was capped and the solution was allowed to stir at room 
temperature overnight. To the resulting suspension, additional pyridine (50 µL, 
0.62 mmol, 13 equiv) and glacial acetic acid (50 µL, 0.87 mmol, 24 equiv) were 
added. The mixture was allowed to stir for an additional 48 hours at room 
temperature. The reaction suspension was diluted with EtOAc, the slurry was 
filtered through a short plug of Celite® to remove the pyridinium salt, the filtrate 
was concentrated under reduced pressure, and the residue was redissolved in a 
mixture of hexanes:EtOAc (2:1). Chromatography (SiO2, 2:1 hexanes:EtOAc) via 
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MPLC yielded 301e (11.2 mg, 0.0107 mmol, 18.4%). Material collected from two 
later eluting fractions gave mass spectral evidence for the chloride PTX-Si(O-
tBu)2Cl (23.0 mg, 0.0212 mmol, 36.3%) and the silanol PTX-Si(O-tBu)2OH (8.6 
mg, 0.0078 mmol, 13.4%).  
1H NMR (500 MHz, CDCl3): δ 8.11 (dd, J = 8.8, 1.7 Hz, 2H, C2O2C-o-Ph), 7.78 
(dd, J = 8.8, 1.8 Hz, 2H, C3’NHCO-o-Ph), 7.61 (tt, J = 7.3, 1.2 Hz, 1H, C2O2C-
p-Ph, 1H), 7.56-7.34 (m, 9H, C2O2C-m-Ph, C3’NHCO-p-Ph, C3’-o-Ph, C3’-m-
Ph, and C3’NHCO-m-Ph), 7.30-7.24 (m, 1H, C3’-p-Ph), 7.05 (d, J = 8.5 Hz, 
1H, C3’NH), 6.29 (s, 1H, H10), 6.17 (br dd, J = 9, 9 Hz, 1H, H13), 5.74-5.66 
(m, 2H, H2 and H3’), 5.16 (d, J = 2.9 Hz, 1H, H2’), 4.97 (dd, J = 9.2, 2.3 Hz, 
1H, H5), 4.45 (app br dd, J = 11, 6 Hz, 1H, H7), 4.31 (d, J = 8.4 Hz, 1H, 
H20α), 4.20 (d, J = 8.6 Hz, 1H, H20β), 3.80 (d, J = 7.0 Hz, 1H, H3), 2.57 (ddd, 
J = 15.2, 9.9, 6.7 Hz, 1H, H6α), 2.47 (br d, J = 4 Hz, 1H, C7OH), 2.42 (s, 3H, 
C4OAc), 2.32 (dd, J = 15.9, 9.6, Hz, 1H, H14α), 2.25 (s, 3H, C10OAc), 2.17 
(br dd, J = 14, 5 Hz, 1H, H14β), 1.93 (br d, J = 1 Hz, 3H, C18H3), 1.89 (br m, 
1H, H6β), 1.78 (br s, 1H, C1OH), 1.68 (s, 3H, C19H3), 1.24 {overlapping s, 
27H, C2’OSi[OC(CH3)3]3 and s, 3H, C17H3}, and 1.13 (s, 3H, C16H3).  
13C NMR (125 MHz, CDCl3): δ 204.1, 171.6, 171.1, 170.1, 167.4, 167.2, 143.2, 
138.3, 134.5, 133.9, 132.8, 131.9, 130.4, 129.4, 128.97, 128.95, 128.8, 128.0, 
127.3, 126.9, 84.7, 81.2, 79.3, 76.7, 75.9, 75.3, 74.2, 73.9, 72.4, 71.4, 58.7, 
55.5, 45.7, 43.4, 36.0, 35.7, 31.4, 27.0, 23.0, 22.4, 21.1, 15.3, and 9.8.  
IR (thin film) 3500 (br), 2973, 2929, 1729, 1670, 1511, 1483, 1452, 1389, 1367, 
1268, 1242, 1183, 1124, 1069, 1025, 985, 835, 800, 758, and 711 cm-1.  
HRMS (ESI) Calc’d for C59H77NNaO17Si [M + Na]+ 1122.4853; found 1122.4901.  
mp = 134–138 °C. 
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2’-O-[(Di-t-butoxy)(ethoxy)silyl]paclitaxel (301f). 
 
Paclitaxel (111.0 mg, 0.13 mmol, 1.0 equiv) was dissolved in dry THF (3.0 mL) in 
an oven-dried culture tube fitted with a Teflon-lined cap and magnetic stir bar. 
Pyridine (100 µL, 1.24 mmol, 9.5 equiv) was added by syringe. A distilled sample 
of di-t-butoxydichlorosilane (306) (304.1 mg, 1.24 mmol, 10 equiv) was added by 
Wiretrol®. The culture tube was sealed and the solution was allowed to stir at 
room temperature. A small amount of a white precipitate was observed after ca. 
30 minutes, and the reaction mixture was noted to be cloudy and heterogeneous 
after stirring for 6 hours. To this suspension, additional pyridine (100 µL, 1,24 
mmol, 10 equiv) and anhydrous ethanol (dried overnight over 3Å molecular 
sieves, 1.0 mL, 17.2 mmol, 132 equiv) were added. The mixture was allowed to 
stir for one additional hour at room temperature. The suspension was diluted with 
a mixture of hexanes:EtOAc (1:1), the slurry was filtered through a short plug of 
Celite® to remove the pyridinium salt, the filtrate was concentrated under reduced 
pressure, and the residue was redissolved in a mixture of hexanes:EtOAc (2:1). 
Chromatography (SiO2, 2:1 hexanes:EtOAc) via MPLC yielded the title 
compound as a white, crystalline solid (130.0 mg, 0.12 mmol, 93.3%).  
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1H NMR (500 MHz, CDCl3): δ 8.11 (dd, J = 8.5, 1.4 Hz, 2H, C2O2C-o-Ph), 7.79 
(dd, J = 8.4, 1.4 Hz, 2H, C3’NHCO-o-Ph), 7.62 (tt, J = 7.4, 1.3 Hz, 1H, C2O2C-
p-Ph, 1H), 7.56-7.46 (m, 3H, C2O2C-m-Ph and C3’NHCO-p-Ph), 7.45-7.33 (m, 
6H, C3’-o-Ph, C3’-m-Ph and C3’NHCO-m-Ph), 7.30-7.22 (m, 1H, C3’-p-Ph), 
7.15 (d, J = 8.4 Hz, 1H, C3’NH), 6.28 (s, 1H, H10), 6.18 (br dd, J = 9, 9 Hz, 
1H, H13), 5.68 (d, J = 7.2 Hz, 1H, H2), 5.66 (dd, J = 8.3, 3.6 Hz, 1H, H3’), 5.01 
(d, J = 3.6 Hz, 1H, H2’), 4.97 (dd, J = 9.7, 2.3 Hz, 1H, H5), 4.44 (ddd, J = 10.8, 
6.6, 4.1 Hz, 1H, H7), 4.31 (d, J = 8.4 Hz, 1H, H20α), 4.19 (d, J = 8.4 Hz, 1H, 
H20β), 3.79 (d, J = 7.0 Hz, 1H, H3), 3.64 (q, J = 7.0 Hz, 2H, C2’OSiOCH2CH3), 
2.56 (ddd, J = 14.8, 9.7, 6.6 Hz, 1H, H6α), 2.45 (d, J = 4.1 Hz, 1H, C7OH), 
2.41 (s, 3H, C4OAc), 2.28 (dd, J = 15.4, 9.4, Hz, 1H, H14α), 2.24 (s, 3H, 
C10OAc), 2.05 (dd, J = 15.3, 9.0 Hz, 1H, H14β), 1.90 (d, J = 1.4 Hz, 3H, 
C18H3), 1.88 (ddd, J = 14.4, 11.1, 2.5 Hz, 1H, H6β), 1.68 (s, 4H, C1OH and 
C19H3), 1.26 (s, 9H, C2’OSiOC(CH3)2], 1.25 (s, 9H, C2’OSiOC(CH3)2], 1.23 (s, 
3H, C17H3), and 1.13 (overlapping t, J = 7.0 Hz, 3H, C2’OSiCH2CH3 and s, 
3H, C16H3).  
13C NMR (125 MHz, CDCl3): δ 204.1, 171.5, 171.0, 170.0, 167.3, 167.2, 143.1, 
138.4, 134.4, 133.9, 132.8, 131.9, 130.4, 129.4, 128.90, 128.89, 128.8, 128.1, 
127.3, 127.0, 84.7, 81.2, 79.3, 76.6, 75.9, 75.3, 74.9, 73.99, 73.98, 72.3, 71.4, 
59.3, 58.7, 55.8, 45.7, 43.4, 35.8, 35.7, 31.41, 31.38, 27.0, 22.9, 22.3, 21.1, 
18.2, 15.1, and 9.8. IR (thin film) 3500 (br), 2976, 2936, 1726, 1665, 1603, 
1582, 1514, 1485, 1452, 1389, 1368, 1312, 1270, 1242, 1179, 1128, 1069, 
1025, 981, 909, 853, 821, 800, 775, 733, and 711 cm-1.  
HRMS (ESI) Calc’d for C57H73NNaO17Si [M + Na]+ 1094.4540; found 1094.4579.  
mp = 130–134 °C. TLC Rf (2:1 hexanes:EtOAc) = 0.2. 
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2’-O-(Di-t-butoxyacetoxysilyl)paclitaxel (301g).a 
 
aCompound synthesized by Dr. Wohl and included here for reference. 
Paclitaxel (33.5 mg, 0.0392 mmol, 1.0 equiv) was dissolved in THF (1.0 mL, dried 
by distillation from sodium/benzophenone) in an oven-dried culture tube with a 
Teflon-lined cap and magnetic stir bar. Pyridine (50 µL, 0.618 mmol, 16 equiv) 
was added by Wiretrol®. A distilled sample of di-t-butoxydichlorosilane (306) 
(0.0524 mg, 0.214 mmol, 5.5 equiv) was added by Wiretrol®. The culture tube 
was sealed and the solution was allowed to stir at room temperature for 24 hours. 
The reaction mixture was noted to be cloudy and heterogeneous after stirring 
overnight. To the suspension, pyridine was again added (50 µL, 0.618 mmol, 16 
equiv). Immediately afterward, glacial acetic acid (50 µL, 0.873 mmol, 22 equiv) 
was added. The mixture was allowed to stir for an additional 24 hours at room 
temperature. The reaction suspension was diluted with EtOAc, the slurry filtered 
through a short plug of Celite® to remove the pyridinium salt, the filtrate 
concentrated under reduced pressure, and the residue redissolved in a mixture of 
hexanes:EtOAc (2:1). Purification (SiO2, 2:1 hexanes:EtOAc) using MPLC 
yielded the title compound (28.0 mg, 0.0258 mmol, 65.8%).  
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1H NMR (500 MHz, CDCl3): δ 8.13 (dd, J = 8.5, 1.4 Hz, 2H, C2O2C-o-Ph), 7.81 
(dd, J = 8.5, 1.4 Hz, 2H, C3’NHCO-o-Ph), 7.63 (tt, J = 7.4, 1.3 Hz, 1H, C2O2C-
p-Ph), 7.54 (t, J = 7.9 Hz, 2H, C2O2C-m-Ph), 7.48 (tt, J = 7.4, 1.9 Hz, 1H, 
C3’NHCO-p-Ph), 7.43-7.34 (m, 6H, C3’-o-Ph, C3’-m-Ph, and C3’NHCO-m-Ph), 
7.30-7.21 (m, 2H, C3’-p-Ph and C3’NH), 6.28 (s, 1H, H10), 6.13 (br dd, J = 9, 
9 Hz, 1H, H13), 5.69 (dd, J = 8.5, 3.9 Hz, 1H, H3’), 5.66 (d, J = 7.2 Hz, 1H, 
H2), 5.19 (d, J = 4.0 Hz, 1H, H2’), 4.96 (dd, J = 9.6, 2.1 Hz, 1H, H5), 4.44 
(ddd, J = 10.8, 6.4, 4.3 Hz, 1H, H7), 4.31 (d, J = 8.4 Hz, 1H, H20α), 4.20 (d, J 
= 8.3 Hz, 1H, H20β), 3.79 (d, J = 7.0 Hz, 1H, H3), 2.56 (ddd, J = 14.9, 9.9, 6.6 
Hz, 1H, H6α), 2.45 (overlapping m, 1H, C7OH and s, 3H, C4OAc), 2.30-2.18 
(overlapping m, 1H, H14α and s, 3H, C10OAc), 1.97-1.84 (m, 8H, H14β, 
C18H3, SiOAc, and H6β), 1.67 (s, 3H, C19H3), 1.61 (s, 1H, C1OH), 1.30 (s, 
9H, C2’OSiOC(CH3)2], 1.26 (s, 9H, C2’OSiOC(CH3)2], 1.22 (s, 3H, C17H3), 
and 1.12 (s, 3H, C16H3).  
13C NMR (75 MHz, CDCl3): δ 204.1, 171.6, 170.9, 170.3, 170.2, 167.2, 167.1, 
143.2, 138.2, 134.4, 133.9, 132.7, 131.8, 130.4, 129.4, 128.92, 128.85, 128.7, 
128.1, 127.4, 127.1, 84.7, 81.1, 79.3, 76.6, 75.9, 75.4, 75.31, 75.27 (x2), 72.3, 
71.6, 58.7, 56.1, 45.7, 43.3, 35.70, 35.68, 31.34, 31.32, 26.9, 23.1, 22.9, 22.4, 
21.1, 15.2, and 9.8.  
HRMS (ESI) Calc’d for C57H71NNaO18Si [M + Na]+ 1108.4333; found 1108.4360. 
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2’-O-(Di-t-butoxypivaloxysilyl)paclitaxel (301g). 
 
Paclitaxel (81.0 mg, 0.0949 mmol, 1.0 equiv) was dissolved in THF (2.0 mL) in an 
oven-dried culture tube with a Teflon-lined cap and magnetic stir bar. Pyridine (10 
μL, 0.124 mmol, 1.3 equiv) was added by Wiretrol®. A distilled sample of di-t-
butoxydichlorosilane (0.46 mg, 0.189 mmol, 2 equiv) was added by Wiretrol®. 
The culture tube was sealed and the solution was allowed to stir at room 
temperature for 27 hours. Pyridine (50 μL, 0.62 mmol, 4.5 equiv) and pivalic acid 
(75.5 mg, 0.749 mmol, 7.8 equiv) were co-dissolved in dry THF (1 mL), and the 
solution was added in a single portion to the reaction vesicle., The mixture was 
allowed to stir for an additional 113 hours at room temperature. An aliquot of the 
reaction mixture was removed, concentrated to dryness under reduced pressure, 
and analyzed by crude LC-MS ([M+H]+, m/z = 1129). Analysis showed that ca. 
25% conversion to 301h. The remainder of the reaction slurry stirred for an 
additional 4 hours. A second aliquot of the reaction mixture was removed, 
concentrated to dryness under reduced pressure, and analyzed by crude 1H 
NMR spectroscopy. The remainder of the reaction suspension was diluted with 
EtOAc, the slurry filtered through a short plug of Celite® to remove the pyridinium 
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salt, the filtrate concentrated under reduced pressure, and the residue 
redissolved in a mixture of hexanes:EtOAc (2:1). Chromatography (SiO2, 2:1 
hexanes:EtOAc) via MPLC yielded the title compound as a mixture of ca. (30 mg, 
0.026 mmol, 28%). The mixture of products was further purified on a reversed-
phase an ACE 121-1520 C18 150 x 21.2 mm 5µM particle size semi-prep HPLC 
column with an isocratic elution solvent of MeOH:H2O (98%:2%) at 10.5 mL/min 
to yield PTX, PTX-2’-Si(OtBu)2OH, and a minor amount of 301h (12 mg, 0.011 
mmol, 1%).  The methanol:water was removed by rotary evaporation and the 
residual removed by storage under high vacuum for ≥ 24h.  
1H NMR (500 MHz, CDCl3)160: δ 8.12 (dd, J = 8.6, 1.4 Hz, 2H, C2O2C-o-Ph), 
7.80 (dd, J = 8.2, 1.1 Hz, 2H, C3’NHCO-o-Ph), 7.60 (br tt, J = 7, 1 Hz, 1H, 
C2O2C-p- Ph), 7.54-7.35 (m, 9H, C2O2C-m-Ph, C3’NHCO-p-Ph, C3’-o-Ph, 
C3’-m-Ph, and C3’NHCO-m-Ph), 7.31 (t, J = 7.0 Hz, 1H, C3’-p-Ph), 7.07 (d, J 
= 9.3 Hz, 1H, C3’NH), 6.28 (s, 1H, H10), 6.22 (br dd, J = 9, 8 Hz, 1H, H13), 
5.82 (dd, J = 9.0, 2.5 Hz, 1H, H3’), 5.68 (d, J = 7.5 Hz, 1H, H2), 5.20 (d, J = 
2.4 Hz, 1H, H2’), 4.96  (dd, J = 9.3, 2.2 Hz, 1H, H5), 4.44 (br m, 1H, H7), 4.30 
(d, J = 8.8 Hz, 1H, H20α), 4.20 (d, J = 8.6 Hz, 1H, H20β), 3.80 (d, J = 6.9 Hz, 
1H, H3), 2.56 (ddd, J = 14.4, 9.7, 6.3 Hz, 1H, H6α), 2.45 (overlapping m, 1H, 
C7OH and s, 3H, C4OAc), 2.37 (dd, J = 14.8, 8.5 Hz, 1H, H14α), 2.25 (s, 3H, 
C10OAc), 1.97-1.84 (overlapping m, 1H, H14β and s, 3H, C18H3), 1.68 
(overlapping m, 1H, H6β and s, 3H, C19H3), 1.59 (br s, 1H, C1OH), 1.33 [s, 
9H, C2’OSiOC(CH3)2], 1.32 [s, 9H, C2’OSiOC(O)C(CH3)3], 1.31 [s, 9H, 
C2’OSiOC(CH3)2],, 1.22 (s, 3H, C17H3), and 1.13 (s, 3H, C16H3). 
13C NMR (125 MHz, CDCl3): δ 202.5, 180.5 [C2’OSiOC(O)C(CH3)3],172.7, 170.3, 
169.0, 167.2, 167.1, 140.3, 138.2, 133.9, 133.8, 132.1, 130.4, 129.4, 129.3, 
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129.2, 128.9 (2x), 128.5, 127.3, 127.2, 84.5, 81.5, 78.8, 77.4, 76.8, 76.0, 74.9, 
73.3, 72.6, 66.3 (2x) [C2’OSiOC(CH3)2], 58.5, 55.0, 47.0, 43.4, 36.8 
[C2’OSiOC(O)C(CH3)3], 35.6, 35.5, 26.9, 25.5 (6x) [C2’OSiOC(CH3)2], 25.4 
(3x) [C2’OSiOC(O)C(CH3)3], 22.9, 21.1, 21.0, 14.7, and 10.4. 
 
Figure S3.1 | Reverse-phase HPLC purification chromatogram at 230 nm of 
PTX-2’-Si(OtBu)2(OPiv). Yielded PTX, PTX-2’-Si(OtBu)2OH, and the title 
compound. A = PTX, B = PTX-2’-Si(OtBu)2OH. C = PTX-2’-Si(OtBu)2(OPiv) 
  
A• B• • C Solvent/grease 
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2’-O-(Di-t-butoxypivaloxysilyl)paclitaxel (301p). 
 
Paclitaxel (92.3 mg, 0.1081 mmol, 1.0 equiv) was dissolved in dry CH2Cl2 (3 mL) 
in an oven-dried culture tube fitted with a Teflon-lined cap and magnetic stir bar. 
Pyridine (100 µL, 1.24 mmol, 11.5 equiv) was added by Wiretrol®. A 1:1.7 mixture 
based on moles (1H NMR) which corresponds to a 1:1.3 mixture based on mass 
(1H NMR) of the DHP-silicates tri-n-dihydrophytolchlorosilane (316):tetra-n- 
dihydrophytolchlorosilane (317) (300 µL, ca. 0.257 mmol based on an ca. density 
of 1.5, 1.6 equiv of tri-n- dihydrophytolchlorosilane) was added.  The culture tube 
was capped and the solution was allowed to stir for 3 h at room temperature. The 
reaction solvent was removed on a rotary evaporator replaced with a mixture of 
hexanes:EtOAc (5:1), the slurry filtered through a short plug of Celite® to remove 
the pyridinium salt, the filtrate concentrated under reduced pressure.  The 
residue redissolved in 2 mL of hexanes:EtOAc (5:1). Chromatography (SiO2, 5:1 
hexanes:EtOAc) via MPLC yielded the title compound as a clear, glassy solid 
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(98.5 mg, 0.055 mmol, 50.9%) and the bis-functionalized product 302p (16.6 mg, 
0.006 mmol, 5.7%). 
1H NMR (500 MHz, CDCl3): δ 8.13 (dd, J = 8.0, 1.5 Hz, 2H, C2O2C-o-Ph), 7.77 
(dd, J = 7.9, 1.4 Hz, 2H, C3’NHCO-o-Ph), 7.61 (tt, J = 8.3, 1.2 Hz, 1H, C2O2C-
p-Ph), 7.55-7.47 (m, 3H, C2O2C-m-Ph and C3’NHCO-p-Ph), 7.42-7.35 (m, 6H, 
C3’-o-Ph, C3’-m-Ph and C3’NHCO-m-Ph), 7.28 (tt, J = 6.2, 1.6 Hz, 1H, C3’-p-
Ph), 7.19 (d, J = 8.6 Hz, 1H, C3’NH), 6.28 (s, 1H, H10), 6.26 (br dd, J = 9, 9 
Hz, 1H, H13), 5.73 (dd, J = 8.6, 3.1 Hz, 1H, H3’), 5.68 (d, J = 7.1 Hz, 1H, H2), 
4.97 (dd, J = 9.6, 2.7 Hz, 1H, H5), 4.97 (overlapping d, J = 4.2 Hz, 1H, H2’), 
4.44 (ddd, J = 10.9, 6.5, 4.1 Hz, 1H, H7), 4.31 (d, J = 8.6 Hz, 1H, H20α), 4.20 
(d, J = 8.5 Hz, 1H, H20β), 3.80 (d, J = 7.1 Hz, 1H, H3), 3.71-3.60 {m, 6H, 
C2’OSi[OC1DHPH2]3}, 2.55 (ddd, J = 15.4, 9.5, 6.7 Hz, 1H, H6α), 2.46 (d, J = 
4.0 Hz, 1H, C7OH), 2.44 (s, 3H, C4OAc), 2.32 (dd, J = 15.4, 9.5 Hz, 1H, 
H14α), 2.24 (d, J = 1.0, 3H, C10OAc), 2.08 (dd, J = 15.3, 8.8 Hz, 1H, H14β), 
1.92-1.86 (m, 1H, H6β), 1.90 (overlapping br s, 3H, C18H3), 1.68 (s, 3H, 
C19H3), 1.66 (s, 1H, C1OH), 1.56-1.49 [br td, J = 6.7, 6.7 Hz, 6H, 
C2’OSi[OC2DHPH2]3], 1.48-1.31 {m, 12H, C2’OSi[OC3DHPH1]3, 
C2’OSi[OC7DHPH1]3, C2’OSi[OC11DHPH1]3, C2’OSi[OC15DHPH1]3}, 1.30-1.15 {m, 
30H, C2’OSi[OC4DHPH2]3, C2’OSi[OC5DHPH2]3, C2’OSi[OC6DHPH2]3, 
C2’OSi[OC8DHPH2]3}, C2’OSi[OC9DHPH2]3}, 1.24 (overlapping s, 3H, C17H3), 
1.14-0.99 {m, 30H, C2’OSi[OC10DHPH2]3, C2’OSi[OC12DHPH2]3, 
C2’OSi[OC13DHPH2]3, C2’OSi[OC14DHPH2]3}}, 1.13 (overlapping s, 3H, C16H3), 
0.86 {d, J = 6.6 Hz, 18H, C2’OSi[OC16DHPH3]3, and C2’OSi[OC17DHPH3]3}, and 
0.84 {br d, J = 6.5 Hz, 27H, C2’OSi[OC18DHPH3]3, C2’OSi[OC19DHPH3]3, and 
C2’OSi[OC20DHPH3]3}. 
13C	  NMR	  (125	  MHz,	  CDCl3):	  δ	  203.7,	  171.2,	  170.3,	  169.9,	  166.8,	  167.3,	  142.6, 138.6, 
133.9, 133.8, 132.8, 131.6, 130.5, 129.0, 128.8, 128.7, 128.4, 128.2, 127.5, 
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127.2, 84.3, 80.1, 78.8, 76.4, 75.5, 74.9, 74.4, 70.9, 72.0, {62.3, 62.3, 61.6, 
Cdhp1}, 58.4, 55.1, 45.3, 43.5, {40.3 (3x), Cdhp2}, {39.8 (2x), 39.7, Cdhp3}, {37.9 
(3x), Cdhp4}, {37.8 (3x), Cdhp14}, {37.7 (6x), Cdhp8 and Cdhp10 }, {37.6 (3x), 
Cdhp12}, 35.7, 35.6, {33.2, 33.1 (2x), Cdhp6}, {29.8 (2x), 29.7, Cdhp7}, {28.3 (3x), 
Cdhp11}, 27.1, {25.1 (3x), Cdhp15}, {24.8 (3x), Cdhp5}, {24.7 (3x), Cdhp13}, {23.0 
(3x), Cdhp9}, 23.0, {22.9 (3x), Cdhp16}, 22.9, 20.8, {20.1 (2x), 20.0, Cdhp17}, 
{20.0 (3x), Cdhp18}, {20.0, 19.9 (2x), Cdhp19}, {19.8 (2x), 19.7 Cdhp20},15.0, and 
9.9. 
HRMS (ESI) Calc’d for C107H173NNaO17Si [M + Na]+ 1795.2365; found 
1795.2383.  
IR (thin film) 3904, 3857, 3751, 3677, 3569, 2954, 2926, 2867, 2368, 2343, 1722, 
1657, 1641, 1480, 1463, 1375, 1271, 1241, 1093, 1024, 986, 907, 857, 805, 
and 771 cm-1.  
mp = 106–109 °C. TLC Rf (5:1 hexanes:EtOAc) = 0.41. 
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2’,7-Di-O-(Triethoxysilyl)paclitaxel (302a).  
 
Paclitaxel (58.0 mg, 0.0679 mmol, 1.0 equiv) was dissolved in dry THF (1.0 mL) 
in an oven-dried culture tube fitted with a Teflon-lined cap and a stir bar. Pyridine 
(25 µL, 0.309 mmol, 4.5 equiv) was added by Wiretrol®. Triethoxychlorosilane 
(305a) (50 µL, 0.255 mmol, 3.8 equiv) was added, and a white precipitate was 
immediately observed. The suspension was allowed to stir for 2 hours at room 
temperature and then diluted with hexanes:EtOAc (1:1). The slurry was filtered 
through a short plug of Celite® to remove the pyridinium salt, and the filtrate 
concentrated under reduced pressure. The residue was purified by MPLC (SiO2, 
2:1 hexanes:EtOAc) to yield 302a as a white crystalline solid (68.0 mg, 0.058 
mmol, 85%). If necessary, residual EtOAc was removed by storage under high 
vacuum for ≥ 24 h.  
1H NMR (500 MHz, CDCl3): δ 8.12 (dd, J = 8.5, 1.5 Hz, 2H, C2O2C-o-Ph), 7.78 
(dd, J = 8.5, 1.5 Hz, 2H, C3’NHCO-o-Ph), 7.62 (tt, J = 7.5, 1.0 Hz, 1H, C2O2C-
p-Ph, 1H), 7.54-7.46 (m, 3H, C2O2C-m-Ph and C3’NHCO-p-Ph), 7.44-7.36 (m, 
6H, C3’-o-Ph, C3’-m-Ph and C3’NHCO-m-Ph), 7.29 (tt, J = 7.0, 1.5 Hz, 1H, 
C3’-p-Ph), 7.20 (d, J = 8.5 Hz, 1H, C3’NH), 6.58 (s, 1H, H10), 6.18 (br dd, J = 
9, 9 Hz, 1H, H13), 5.72 (dd, J = 8.5, 3.0 Hz, 1H, H3’), 5.71 (d, J = 6.5 Hz, 1H, 
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H2), 4.98 (d, J = 3.0 Hz, 1H, 2’H), 4.96 (dd, J = 10.0, 2.0 Hz, 1H, H5), 4.62 
(dd, J = 10.5, 6.7 Hz, 1H, H7), 4.31 (d, J = 8.5 Hz, 1H, H20α), 4.20 (d, J = 8.5 
Hz, 1H, H20β), 3.85 (d, J = 7.0 Hz, 1H, H3), 3.76 [q, J = 7.0 Hz, 6H, 
C7OSi(OCH2CH3)3], 3.71 [q, J = 7.0 Hz, 6H, C2’OSi(OCH2CH3)3], 2.66 (ddd, J 
= 14.5, 9.5, 6.5 Hz, 1H, H6α), 2.45 (s, 3H, C4OAc), 2.33 (dd, J = 15.4, 9.4Hz, 
1H, H14α), 2.15 (s, 3H, C10OAc), 2.08 (d, J = 1.5 Hz, 3H, C18H3), 2.07 (dd, J 
= 15.1, 9.0 Hz, 1H, H14β), 1.96 (ddd, J = 14.5, 10.8, 2.2 Hz, 1H, H6β), 1.73 (s, 
3H, C19H3), 1.65 (br s, 1H, C1OH), 1.23 (s, 3H, C17H3), 1.19 [t, J = 7.0 Hz, 
9H, C7OSi(OCH2CH3)3], 1.17 (s, 3H, C16H3), and 1.15 [t, J = 7.0 Hz, 9H, 
C2’OSi(OCH2CH3)3].  
13C NMR (75 MHz, CDCl3): δ 202.6, 171.0, 169.8, 169.0, 167.3, 167.2, 141.0, 
138.2, 134.3, 133.9, 133.3, 132.0, 130.4, 129.4, 128.9, 128.8, 128.7, 128.1, 
127.3, 126.8, 84.5, 81.2, 78.9, 76.7, 75.9, 75.02, 74.99, 72.1, 71.6, 59.7, 59.5, 
58.3, 55.5, 46.9, 43.4, 36.5, 35.5, 26.7, 23.0, 21.4, 21.0, 18.0 (x2), 14.2, and 
10.4.  
HRMS (ESI) Calc’d for C59H79NNaO20Si2 [M + Na]+ 1200.4626, found 1200.4631.  
IR (thin film) 3500 (br), 2976, 2928, 2896, 1744, 1725, 1644, 1603, 1580, 1541, 
1486, 1451, 1370, 1314, 1268, 1238, 1169, 1098, 1080, 1027, 969, 891, 842, 
795, and 708 cm-1.  
mp = 121-123 °C.  TLC Rf (2:1 hexanes:EtOAc) = 0.4. 
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2’,7-Di-O-(Tri-n-octyloxysilyl)paclitaxel (302b).  
 
Paclitaxel (57.8 mg, 0.0677 mmol, 1.0 equiv) was dissolved in dry THF (1.5 mL) 
in an oven-dried culture tube fitted with a Teflon-lined cap and magnetic stir bar. 
Pyridine (25 µL, 0.309 mmol, 4.6 equiv) was added by Wiretrol®. A 1.67:1 mixture 
of tri-n-octyloxychlorosilane (305b):tetra-n-octyloxysilane (0.155 mg, 0.199 mmol, 
2.9 equiv of tri-n-octyloxychlorosilane) was added, and formation of a white 
precipitate was immediately observed. The culture tube was capped and the 
suspension was allowed to stir for 5 h at room temperature. The reaction mixture 
was diluted with a mixture of hexanes:EtOAc (1:1), and the slurry was filtered 
through a short plug of Celite® to remove the pyridinium salt. The filtrate was 
concentrated under reduced pressure, and the residue was purified by MPLC 
(SiO2, 9:1 hexanes:EtOAc) to yield 302b as a colorless viscous glass (88.1 mg, 
0.0523 mmol, 77.3%). Additional elution with hexanes:EtOAc (2:1) yielded 1b 
(1.7 mg, 0.0013 mmol, 2.0 %).  
1H NMR (500 MHz, CDCl3): δ 8.13 (dd, J = 8.6, 1.4 Hz, 2H, C2O2C-o-Ph), 7.78 
(dd, J = 8.6, 1.5 Hz, 2H, C3’NHCO-o-Ph), 7.60 (tt, J = 7.4, 1.2 Hz, 1H, C2O2C-
p-Ph, 1H), 7.54-7.46 (m, 3H, C2O2C-m-Ph and C3’NHCO-p-Ph), 7.44-7.35 (m, 
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6H, C3’-o-Ph, C3’-m-Ph and C3’NHCO-m-Ph), 7.28 (tt, J = 7.2, 1.3 Hz, 1H, 
C3’-p-Ph), 7.22 (d, J = 8.7 Hz, 1H, C3’NH), 6.55 (s, 1H, H10), 6.23 (br dd, J = 
10, 9 Hz, 1H, H13), 5.74 (dd, J = 8.6, 3.0 Hz, 1H, H3’), 5.70 (d, J = 7.1 Hz, 1H, 
H2), 4.99 (d, J = 3.0 Hz, 1H, 2’H), 4.94 (dd, J = 9.7, 1.9 Hz, 1H, H5), 4.61 (dd, 
J = 10.6, 6.8 Hz, 1H, H7), 4.31 (d, J = 8.4 Hz, 1H, H20α), 4.20 (d, J = 8.4 Hz, 
1H, H20β), 3.86 (d, J = 7.0 Hz, 1H, H3), 3.67 {t, J = 6.7 Hz, 6H, 
C7OSi[OCH2(CH2)6CH3]3}, 3.61 {t, J = 6.7 Hz, 6H, C2’OSi[OCH2(CH2)6CH3]3}, 
2.65 (ddd, J = 14.7, 9.7, 6.8 Hz, 1H, H6α), 2.45 (s, 3H, C4OAc), 2.33 (dd, J = 
15.3, 9.4 Hz, 1H, H14α) 2.13 (s, 3H, C10OAc), 2.06 (d, J = 1.2 Hz, 3H, 
C18H3), 2.09-2.02 (m, 1H, H14β), 1.96 (ddd, J = 14.5, 10.8, 2.2 Hz, 1H, H6β), 
1.73 (s, 3H, C19H3), 1.66 (br s, 1H, C1OH), 1.56-1.44 {m, 12H, 
C2’OSi[OCH2CH2(CH2)5CH3]3  and C7OSi[OCH2CH2(CH2)5CH3]3}, 1.34-1.21 
{m, 63H, C17H3, C2’OSi[OCH2CH2(CH2)5CH3]3, and 
C7OSi[OCH2CH2(CH2)5CH3]3}, 1.17 (s, 3H, C16H3), and 0.88 {overlapping t’s, 
J = 6.8 Hz, 18H, C2’OSi[OCH2CH2(CH2)5CH3]3 and 
C7OSi[OCH2CH2(CH2)5CH3]3}.  
13C NMR (75 MHz, CDCl3): δ 202.4, 170.9, 169.8, 168.7, 167.3, 167.2, 140.9, 
138.3, 134.3, 133.8, 133.3, 131.9, 130.4, 129.4, 128.91, 128.89, 128.8, 128.1, 
127.3, 126.8, 84.6, 81.2, 79.0, 76.8, 75.8, 75.1, 74.9, 72.0, 71.5, 64.1, 63.9, 
58.3, 55.5, 46.8, 43.5, 36.6, 35.6, 32.5, 32.4, 32.1, 32.0, 29.6, 29.63, 29.60, 
29.57, 26.7, 25.92, 25.89, 23.0, 22.91, 22.90, 21.6, 21.1, 14.3 (x2), 14.1, and 
10.4.  
HRMS (ESI) Calc’d for C95H151NNaO20Si2 [M + Na]+ 1705.0260; found 
1705.0228.  
IR (thin film) 3500 (br), 2927, 2856, 1741, 1728, 1634, 1580, 1545, 1456, 1371, 
1315, 1270, 1239, 1174, 1095, 1028, 989, 968, 924, 893, 843, 779, and 709 
cm-1.  
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TLC Rf (3:1 hexanes:EtOAc) = 0.55. 
 
Figure S3.2 | Image of 2’,7-Di-O-(Tri-n-octyloxysilyl)paclitaxel (302b) at 200 
times magnification shows a glassy solid, no mp. could be obtained. 
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2’,7-Di-O-(Tri-i-propoxysilyl)paclitaxel (302c).  
 
Paclitaxel (30.1 mg, 0.0352 mmol, 1.0 equiv) was dissolved in dry THF (1.0 mL) 
in an oven-dried culture tube fitted with a Teflon-lined cap and magnetic stir bar. 
Pyridine (15 µL, 0.185 mmol, 5.3 equiv) was added by Wiretrol®. A 3.5:1 mixture 
of tri-i-propoxychlorosilane (305c) :tetra-i-propoxysilane (0.0424 mg, 0.134 mmol, 
2.9 equiv of tri-i-propoxychlorosilane) was added. The culture tube was capped 
and a white precipitate was observed within minutes. The suspension was stirred 
at room temperature for 18 hours, and the mixture was filtered through a short 
plug of Celite® to remove the triethylammonium salt. The filtrate was 
concentrated under reduced pressure, and the residue was redissolved in a 
mixture of hexanes:EtOAc (2:1). Purification by MPLC (SiO2, 2:1 hexanes:ethyl 
acetate) yielded the title compound as a white, crystalline solid (29.8 mg, 0.0236 
mmol, 67.0%).  
1H NMR (500 MHz, CDCl3): δ 8.12 (dd, J = 8.5, 1.5 Hz, 2H, C2O2C-o-Ph), 7.80 
(dd, J = 8.4, 1.5 Hz, 2H, C3’NHCO-o-Ph), 7.62 (tt, J = 7.4, 1.7 Hz, 1H, C2O2C-
p-Ph, 1H), 7.55-7.46 (m, 3H, C2O2C-m-Ph and C3’NHCO-p-Ph), 7.43-7.34 (m, 
6H, C3’-o-Ph, C3’-m-Ph and C3’NHCO-m-Ph), 7.29-7.24 (m, 1H, C3’-p-Ph), 
7.17 (d, J = 8.4 Hz, 1H, C3’NH), 6.53 (s, 1H, H10), 6.14 (br dd, J = 9, 9 Hz, 
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1H, H13), 5.70 (d, J = 7.3 Hz, 1H, H2), 5.67 (dd, J = 8.4, 3.6 Hz, 1H, H3’), 5.00 
(d, J = 3.6 Hz, 1H, H2’), 4.96 (dd, J = 9.4, 2.0 Hz, 1H, H5), 4.61 (dd, J = 10.7, 
6.7, Hz, 1H, H7), 4.31 (d, J = 8.8 Hz, 1H, H20α), 4.19 (d, J = 8.6 Hz, 1H, 
H20β), 4.13 and 4.12 {overlapping septs, J = 6.2 Hz, 6H, C2’OSi[OCH(CH3)2]3 
and C7OSi[OCH(CH3)2]3}, 3.85 (d, J = 7.4 Hz, 1H, H3), 2.68 (ddd, J = 14.7, 
9.7, 6.8 Hz, 1H, H6α), 2.41 (s, 3H, C4OAc), 2.30 (dd, J = 15.1, 9.3 Hz, 1H, 
H14α), 2.14 (s, 3H, C10OAc), 2.10 (d, J = 1.2 Hz, 3H, C18H3), 2.03 (dd, J = 
15.7, 9.5 Hz, 1H, H14β), 1.95 (ddd, J = 14.6, 10.9, 2.2 Hz, 1H, H6β), 1.72 (s, 
3H, C19H3), 1.61 (br s, 1H, C1OH), 1.23 (m, 3H, C17H3), and 1.18-1.10 {m, 
39H, C2’OSi[OCH(CH3)a(CH3)b]3}, C2’OSi[OCH(CH3)a(CH3)b]3, 
C7OSi[OCH(CH3)a(CH3)b]3}, C7OSi[OCH(CH3)a(CH3)b]3, and C16H3}.  
13C NMR (125 MHz, CDCl3): δ 202.6, 171.1, 169.6, 168.9, 167.3, 167.2, 141.2, 
138.4, 134.4, 133.8, 133.3, 131.9, 130.4, 129.5, 128.9 (x2), 128.8, 128.1, 
127.3, 127.0, 84.6, 81.2, 80.0, 76.8, 75.9, 75.2, 74.9, 72.3, 71.7, 66.6, 66.2, 
58.3, 55.9, 46.8, 43.5, 36.7, 35.5, 26.8, 25.5, 25.42, 25.41, 25.38, 23.0, 21.5, 
21.1, 14.7, and 10.5.  
HRMS (ESI) Calc’d for C65H91NNaO20Si2 [M + Na]+ 1284.5565, found 1284.5563.  
IR (thin film) 3500 (br), 2973, 2933, 1725, 1671, 1603, 1582, 1512, 1484, 1452, 
1371, 1313, 1267, 1238, 1173, 1116, 1047, 989, 893, 839, 767, and 711.  
mp = 108–113 °C. TLC Rf (2:1 hexanes:EtOAc) = 0.55. 
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2’,7-Di-O-(Tri-menthyloxysilyl)paclitaxel (302d).  
 
Paclitaxel (85.0 mg, 0.100 mmol, 1.0 equiv) was dissolved in dry THF (8.0 mL) in 
an oven-dried culture tube fitted with a Teflon-lined cap and magnetic stir bar. 
Pyridine (100 µL, 1.24 mmol, 12.4 equiv) was added by Wiretrol®. 
Trimenthyloxychlorosilane (305d), judged to contain 90% of the chlorosilane 
(579.1 mg, 0.986 mmol, 9.9 equiv) by 1H NMR analysis, was added by Wiretrol®. 
The culture tube was capped and the suspension was allowed to stir for 12 h at 
45 ˚C. The THF was removed by evaporation under reduced pressure, the solid 
residue was triturated with a mixture of hexanes:EtOAc (3:1), and the resulting 
slurry was filtered through a short plug of Celite® to remove the pyridinium salt. 
The filtrate was concentrated under reduced pressure, and the residue was 
purified by MPLC (SiO2, 3:1 hexanes:EtOAc) to yield the title compound (302d) 
as a white, crystalline solid (64.9 mg, 0.0353 mmol, 35.3 %) and the mono-
silylated product 301d (78.2 mg, 0.0581 mmol, 58.1 %). 
1H NMR (500 MHz, CDCl3): δ 8.13 (dd, J = 8.5, 1.4 Hz 2H, O2C-o-Ph), 7.78 (dd, 
J = 8.5, 1.4 Hz, 2H, C3’NHCO-o-Ph), 7.59 (tt, J = 7.4, 1.3 Hz, 1H, C2O2C-p-
Ph), 7.54-7.45 (m, 3H, C2O2C-m-Ph and C3’NHCO-p-Ph), 7.43-7.35 (m, 6H, 
C3’-o-Ph, C3’-m-Ph and C3’NHCO-m-Ph), 7.30 (tt, J = 7.1, 2.1 Hz, 1H, C3’-p-
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Ph), 7.14 (d, J = 8.5 Hz, 1H, C3’NH), 6.38 (s, 1H, H10), 6.23 (ddq, J = 10.2, 
9.7, 1.5 Hz, 1H, H13), 5.73 (dd, J = 8.5, 3.4 Hz, 1H, H3’), 5.68 (d, J = 7.1 Hz, 
1H, H2), 5.08 (d, J = 3.5 Hz, 1H, H2’), 4.90 (dd, J = 9.7, 2.3 Hz, 1H, H5), 4.64 
(ddd, J = 10.0, 6.5 3.4 Hz, 1H, H7), 4.28 (bd, J = 8.2 Hz, 1H, H20α), 4.20 (d, J 
= 8.3, 0.9 Hz, 1H, H20β), 3.85 (d, J = 7.0 Hz, 1H, H3), 3.73-3.57 (m, 6H, 
H1menth), 2.75 (ddd, J = 14.8, 9.8, 6.67 Hz, 1H, H6α), 2.38 (s, 3H, C4OAc), 
2.30 (dd, J = 15.1, 9.7 Hz, 1H, H14α), 2.22 (s, 3H, C10OAc), 2.20-2.03 (m, 
7H, H14β and H7menth), 1.94 (bs, 3H, H18 =CCH3), 1.92-1.87 (m, 4H, 
H6eqmenth and H6β), 1.71 (s, 1H, C1OH), 1.70 (s, 3H, H19 O=CCCH3), 1.66-
1.53 (m, 18H, H4eqmenth, H6eqmenth, and H10menthyl), 1.45-1.36 (m, 3H, H5menth), 
1.28-1.10 (m, 9H, H3menth and H5menth), 1.23 (s, 3H, C(Me)C16H3)), 1.18 [s, 
3H, C(Me)C17H3]), 1.08-0.94 (m, 6H, H2menth), 0.93-0.90 [(d, J = 6.9, 9H, 
H10menthyl) and (m, 6H, H6axmenth)], 0.88-0.85 [(d, J = 6.9, 9H, H8menthyl) and 
(m, 6H, H3axmenth)], 0.84-0.81 [(d, J = 6.6, 9H, H8menthyl) and (m, 3H, 
H4axmenth)], and 0.80-0.73 [(m, 3H, H4axmenth), (d, J = 6.9, 9H, H9menthyl), and 
(d, J = 6.9, 9H, H9menthyl]. 
13C NMR (125 MHz, CDCl3): δ  201.5, 170.3 (2x), 169.4, 166.8, 166.4, 140.8, 
138.2, 133.9, 133.4, 133.0, 132.1, 130.2, 130.0, 129.1, 128.9, 128.5, 128.2, 
127.8, 127.6, 84.0, 81.0, 78.8, 77.1, 75.3, 74.9, 73.6, 72.7, 71.8, 71.4 
(C1menth), 71.0 (C1menth), 58.0, 53.6, 49.7 (C2menth), 49.3 (C2menth), 44.1 
(C7menth), 43.1(C7menth), 45.8, 43.2, 35.4, 34.1, 34.1 (C5menth), 33.7 (C5menth), 
31.5 (C6menth), 31.1 (C6menth), 26.3, 25.4 (C3menth), 25.0 (C3menth), 23.4(C4menth), 
22.7(C4menth), 22.4, 22.4 (C8menth), 22.1 (C8menth), 21.5, 21.4 (C9menth), 21.1 
(C9menth), 20.7, 15.6 (C10menth), 15.5 (C10menth), 14.2, and 9.8. 
HRMS (ESI) Calc’d for C107H163NNaO20Si2+ [M + Na]+ 1861.1199; found 
1861.1578.  
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IR (thin film) 3256, 3163, 2953, 2924, 2868, 2345, 1737, 1722, 1673, 1509, 1456, 
1373, 1246, 1180, 1155, 1084, 1072, 1055, 1001, 989, 950, 921, 894, 818, 
803, and 788 cm-1. 
 mp = 93–95 °C.  TLC Rf (9:1 hexanes:EtOAc) = 0.30. 
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7-O-(Triethoxysilyl)paclitaxel (303a).  
 
Bis(triethoxy)silicate ester 302a (99.5 mg, 0.0845 mmol, 1.0 equiv) was dissolved 
in d6-acetone (1.8 mL, dried over 3Å molecular sieves) in an NMR sample tube. 
A 9:1 mixture of D2O:TFA was added (200 µL) and the reaction progress was 
monitored by 1H NMR spectroscopy. After eight minutes at 21.4 °C, the mixture 
was transferred into saturated aqueous NaHCO3 (2 mL). This mixture was 
extracted with CH2Cl2 (3 x 5 mL). The combined organic extracts were dried over 
MgSO4, filtered, and concentrated under reduced pressure. The residue was 
purified by MPLC (SiO2, 2:1 hexanes:EtOAc) to provide recovered starting 
material 302a (27.3 mg, 0.0232 mmol, 27.4%). Additional elution in 1:1 
hexanes:EtOAc gave the title compound as a white, crystalline solid [56.9 mg, 
0.0560 mmol, 66.3% (91.4% brsm)].  
1H NMR (500 MHz, CDCl3): δ 8.12 (dd, J = 8.5, 1.3 Hz, 2H, C2O2C-o-Ph), 7.75 
(dd, J = 8.5, 1.4 Hz, 2H, C3’NHCO-o-Ph), 7.61 (tt, J = 7.5, 1.2 Hz, 1H, C2O2C-
p-Ph, 1H), 7.53-7.46 (m, 5H, C2O2C-m-Ph, C3’NHCO-p-Ph, and C3’-o-Ph,), 
7.43-7.37 (m, 4H, C3’-m-Ph and C3’NHCO-m-Ph), 7.34 (tt, J = 7.3, 1.2 Hz, 1H, 
C3’-p-Ph), 7.09 (d, J = 9.0 Hz, 1H, C3’NH), 6.56 (s, 1H, H10), 6.18 (br dd, J = 
9, 9 Hz, 1H, H13), 5.80 (dd, J = 6.9, 2.5 Hz, 1H, H3’), 5.69 (d, J = 6.9 Hz, 1H, 
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H2), 4.93 (dd, J = 9.6, 1.7 Hz, 1H, H5), 4.78 (dd, J = 4.9, 2.7 Hz, 1H, 2’H), 
4.57 (dd, J = 10.5, 6.9 Hz, 1H, H7), 4.30 (d, J = 8.4 Hz, 1H, H20α), 4.19 (dd, J 
= 8.3, 0.9 Hz, 1H, H20β), 3.83 (d, J = 6.9 Hz, 1H, H3), 3.76 [q, J = 7.0 Hz, 6H, 
C7OSi(OCH2CH3)3], 3.69 (br s, 1H, C2’OH), 2.65 (ddd, J = 14.7, 9.7, 6.9 Hz, 
1H, H6α), 2.37 (s, 3H, C4OAc), 2.35-2.25 (m, 2H, H14α and H14β), 2.15 (s, 
3H, C10OAc), 1.95 (ddd, J =14.6, 10.7, 2.1 Hz, 1H, H6β), 1.93 (d, J = 1.3 Hz, 
3H, C18H3), 1.76 (br s, 1H, C1OH), 1.73 (s, 3H, C19H3), 1.23 (s, 3H, C17H3), 
1.19 [t, J = 7.0 Hz, 9H, C7OSi(OCH2CH3)3], and 1.16 (s, 3H, C16H3).  
13C NMR (125 MHz, CDCl3): δ 202.4, 172.6, 170.4, 169.0, 167.2, 167.1, 140.1, 
138.2, 133.9, 133.8, 132.1, 130.3, 129.4, 129.1, 128.89, 128.87, 128.5, 127.3, 
127.24, 127.23, 84.4, 81.5, 78.8, 76.8, 76.1, 74.8, 73.4, 72.5, 72.1, 59.5, 58.6, 
55.0, 47.0, 43.4, 36.7, 35.6, 26.8, 22.9, 21.1, 21.0, 18.2, 14.5, and 10.3.  
HRMS (ESI) Calc’d for C53H65NNaO17Si [M + Na]+ 1038.3914, found 1038.3914.  
IR (thin film) 3500 (br), 2975, 2898, 1724, 1653, 1602, 1580, 1515, 1485, 1451, 
1394, 1370, 1314, 1266, 1240, 1172, 1079, 1025, 969, 913, 888, 839, 797, 
and 712 cm-1.  
mp = 141-146 °C. TLC Rf (1:1 hexanes:EtOAc) = 0.5. 
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7-O-(Tri-n-octyloxysilyl)paclitaxel (303b).  
 
Bis(trioctyloxy)silicate ester 302b (88.1 mg, 0.0523 mmol, 1.0 equiv) was 
dissolved in d6-acetone (1.8 mL, dried over 3Å molecular sieves) in an NMR tube. 
A 9:1 mixture of D2O:TFA was added (200 µL) and the solution became white 
and cloudy. Upon vigorous mixing for 30 seconds, the mixture became 
homogeneous and transparent. The hydrolysis progress was monitored by 1H 
NMR spectroscopy. After 30 minutes at room temperature, the solution was 
transferred into saturated aqueous NaHCO3 (2 mL). This mixture was extracted 
with CH2Cl2 (3 x 5 mL). The combined organic layers were dried over MgSO4 and 
concentrated under reduced pressure. The residue was purified by MPLC (SiO2, 
3:1 hexanes:EtOAc) to provide recovered 302b (12.9 mg, 0.0076 mmol, 27.4%). 
Additional elution in 2:1 hexanes:EtOAc gave the title compound as a crystalline 
solid [37.3 mg, 0.0294 mmol, 56.2% (65.7% brsm)].  
1H NMR (500 MHz, CDCl3): δ 8.12 (dd, J = 8.5, 1.3 Hz, 2H, C2O2C-o-Ph), 7.75 
(dd, J = 8.5, 1.4 Hz, 2H, C3’NHCO-o-Ph), 7.61 (tt, J = 7.4, 1.3 Hz, 1H, C2O2C-
p-Ph, 1H), 7.53-7.47 (m, 5H, C2O2C-m-Ph, C3’NHCO-p-Ph, and C3’-o-Ph,), 
7.43-7.38 (m, 4H, C3’-m-Ph and C3’NHCO-m-Ph), 7.34 (tt, J = 7.2, 1.3 Hz, 1H, 
C3’-p-Ph), 7.06 (d, J = 9.0 Hz, 1H, C3’NH), 6.53 (s, 1H, H10), 6.17 (br dd, J = 
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9, 9 Hz, 1H, H13), 5.81 (dd, J = 6.8, 2.4 Hz, 1H, H3’), 5.68 (d, J = 6.9 Hz, 1H, 
H2), 4.92 (dd, J = 9.6, 1.8 Hz, 1H, H5), 4.78 (dd, J = 4.8, 2.6 Hz, 1H, 2’H), 
4.56 (dd, J = 10.5, 6.7 Hz, 1H, H7), 4.29 (d, J = 8.3 Hz, 1H, H20α), 4.19 (d, J = 
8.5 Hz, 1H, H20β), 3.83 (d, J = 7.0 Hz, 1H, H3), 3.66 {t, J = 6.7 Hz, 6H, 
C7OSi[OCH2(CH2)6CH3]3}, 3.60 (d, J = 4.9 Hz, 1H, C2’OH), 2.64 (ddd, J = 
14.7, 9.7, 6.9 Hz, 1H, H6α), 2.37 (s, 3H, C4OAc), 2.34-2.27 (m, 2H, H14α and 
H14β), 2.14 (s, 3H, C10OAc), 1.97-1.90 (m, 4H, H6β and C18H3), 1.74-1.70 
(m, 4H, C1OH and C19H3), 1.52 {tt, J = 6.8, 6.8 Hz, 6H, 
C7OSi[OCH2CH2(CH2)5CH3]3}, 1.34-1.22 {m, 33H, C17H3 and 
C7OSi[OCH2CH2(CH2)5CH3]3}, 1.16 (s, 3H, C16H3), and 0.88 {t, J = 6.8 Hz, 
9H, C7OSi[OCH2CH2(CH2)5CH3]3}.  
13C NMR (125 MHz, CDCl3): δ 202.2, 172.7, 170.3, 168.8, 167.2, 167.0, 140.0, 
138.3, 133.93, 133.89, 132.1, 130.4, 129.4, 129.1, 128.9 (x3), 128.5, 127.3, 
127.2, 84.5, 81.5, 78.8, 76.8, 76.0, 74.9, 72.5, 72.3, 71.7, 63.9, 58.6, 54.9, 
47.0, 43.4, 36.6, 35.6, 32.5, 32.1, 29.62, 29.57, 26.8, 25.9, 22.91, 22.88, 21.1, 
21.0, 14.5, 14.3, and 10.3.  
HRMS (ESI) Calc’d for C71H101NNaO17Si [M + Na]+ 1290.6731; found 1290.6738.  
IR (thin film) 3500 (br), 2926, 2855, 1732, 1710, 1673, 1602, 1582, 1452, 1396, 
1370, 1317, 1281, 1269, 1241, 1179, 1093, 1025, 988, 968, 890, 844, 809, 
and 712 cm-1.  
mp = 69-73 °C. TLC Rf (2:1 hexanes:EtOAc) = 0.4. 
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7-O-(Tri-i-propoxysilyl)paclitaxel (303c).  
 
Bis-silicate ester 302c (102.3 mg, 0.081 mmol, 1.0 equiv) was dissolved in d6-
acetone (1.35 mL, dried over 3Å molecular sieves). A 9:1 mixture of D2O:TFA 
was added (150 µL) and the solution became white and cloudy. Upon being 
shaken for ca. 30 seconds, the mixture became homogeneous and transparent. 
The hydrolysis progress was monitored by 1H NMR spectroscopy. After 18 hours 
at room temperature, the solution was transferred into saturated aqueous 
NaHCO3 (3 mL). This mixture was extracted with CH2Cl2 (3 x 5 mL). The 
combined organic layers were dried over MgSO4 and concentrated. The residue 
was purified by MPLC (SiO2, 1:1 hexanes:EtOAc) to provide recovered 302c 
(35.8 mg, 0.028 mmol, 35%) and the title compound as a crystalline solid [43.3 
mg, 0.041 mmol, 50.5% (77% brsm)].   
1H NMR (500 MHz, CDCl3): δ 8.13 (dd, J = 8.4, 1.3 Hz, 2H, C2O2C-o-Ph), 7.75 
(dd, J = 8.5, 1.3 Hz, 2H, C3’NHCO-o-Ph), 7.62 (tt, J = 7.0, 1.3 Hz, 1H, C2O2C-
p-Ph, 1H), 7.53-7.49 (m, 5H, C2O2C-m-Ph, C3’NHCO-p-Ph, and C3’-o-Ph,), 
7.43-7.39 (m, 4H, C3’-m-Ph and C3’NHCO-m-Ph), 7.34 (tt, J = 7.3, 1.2 Hz, 1H, 
C3’-p-Ph), 7.05 (d, J = 9.0 Hz, 1H, C3’NH), 6.50 (s, 1H, H10), 6.19 (ddq, J = 
9.1, 9.1, 1.4 Hz, 1H, H13), 5.80 (dd, J = 9.0, 2.4 Hz, 1H, H3’), 5.68 (d, J = 7.0 
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Hz, 1H, H2), 4.94 (dd, J = 9.6, 1.9 Hz, 1H, H5), 4.81 (d, J = 2.6 Hz, 1H, H2’), 
4.57 (dd, J = 6.8, 10.5 Hz, 1H, H7), 4.30 (d, J = 8.4 Hz, 1H, H20α), 4.19 (d, J = 
8.5 Hz, 1H, H20β), 4.11 {sept, J = 6.1 Hz, 3H, C7OSi[OCH(CH3)2]3}, 3.83 (d, J 
= 7.0 Hz, 1H, H3), 3.60 (br s, 1H, C2’OH), 2.67 (ddd, J = 14.8, 9.8, 6.9 Hz, 1H, 
H6α), 2.37 (s, 3H, C4OAc), 2.36–2.25 (m, 2H, H14α and H14β), 2.14 (s, 3H, 
C10OAc), 1.96 (d, J = 1.5 Hz, C18H3), 1.95-1.91 (ddd, J 14.7, 10.6, 2.1 Hz, 
1H, H6β), 1.73 (s, 3H, C19H3), 1.65 (br s, 1H, C1OH), 1.24 (s, C17H3), 1.160 
(s, 3H, C16H3), 1.160, {d, J = 6.1, 9H, C7OSi[OCH(CH3)3]}, and 1.15 {d, J = 
6.1 Hz, 9H C7OSi[OCH(C'H3)3]}.  
13C NMR (125 MHz, CDCl3): δ 202.5, 172.7, 170.3, 168.9, 167.2, 167.1, 140.3, 
138.2, 133.92, 133.80, 132.1, 130.4, 129.4, 129.2 (2x), 128.9 (2x), 128.5, 
127.3, 127.2, 84.5, 81.5, 78.8, 76.8, 76.0, 74.9, 73.3, 72.6, 72.4, 66.3 
{SiOCH(CH3)2}, 58.5, 54.9, 47.0, 43.4, 36.8, 35.6, 26.9, 25.5 {SiOCH(CH3)2}, 
25.4 {SiOCH(C'H3)2}, 22.9, 21.1, 21.0, 14.8, and 10.4.  
HRMS (ESI) Calc’d for C56H71NNaO17Si [M + Na]+ 1080.4383 ; found 1080.4393.  
IR (thin film) (br) 3448, 3067, 3026, 2972, 2934, 2898, 1724, 1662, 1602, 1581, 
1485, 1452, 1370, 1315, 1289, 1269, 1239, 1174, 1136, 1113, 1048, 987, 969, 
949, 892, 838, 803, and 775 cm-1.  
mp = 134.5-136 °C. TLC Rf (1:1 hexanes:EtOAc) = 0.40. 
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7-O-(Tri-i-propoxysilyl)paclitaxel (303p).  
 
Paclitaxel (76.1 mg, 0.089 mmol, 1.0 equiv) was dissolved in dry THF (3 mL) in 
an oven-dried culture tube fitted with a Teflon-lined cap and magnetic stir bar. 
Pyridine (500 µL, 6.20 mmol, 69.7 equiv) was added by Wiretrol®. A 1:1.7 mixture 
based on moles (1H NMR) which corresponds to a 1:1.3 mixture based on mass 
(1H NMR) of the DHP-silicates tri-n-dihydrophytolchlorosilane (316):tetra-n- 
dihydrophytolchlorosilane (317) (500 µL, ca. 0.428 mmol based on an ca. density 
of 1.5, 1.6 equiv of tri-n- dihydrophytolchlorosilane) was added.  The culture tube 
was capped and the suspension was allowed to stir for 27 h at room temperature. 
The reaction solvent was removed on a rotary evaporator replaced with a mixture 
of hexanes:EtOAc (2:1), the slurry filtered through a short plug of Celite® to 
remove the pyridinium salt, the filtrate concentrated under reduced pressure.  
The residue redissolved in 2 mL of hexanes:EtOAc (2:1). Three sequential 
purifications by MPLC chromatography (SiO2, 2:1 hexanes:EtOAc), (SiO2, 3:1 
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hexanes:EtOAc), (SiO2, 5:1 hexanes:EtOAc), yielded the title compound as a 
clear, glassy solid (8.3 mg, 0.0046 mmol, 5.2%). 
1H NMR (500 MHz, CDCl3): δ 8.12 (dd, J = 7.4, 1.5 Hz, 2H, C2O2C-o-Ph), 7.75 
(dd, J = 7.4, 1.4 Hz, 2H, C3’NHCO-o-Ph), 7.61 (tt, J = 7.6, 1.2 Hz, 1H, C2O2C-
p-Ph), 7.52-7.48 (m, 5H, C2O2C-m-Ph, C3’-o-Ph, C3’NHCO-p-Ph), 7.43-7.39 
(m, 4H, C3’-m-Ph and C3’NHCO-m-Ph), 7.34 (tt, J = 7.4, 2.3 Hz, 1H, C3’-p-
Ph), 7.05 (overlapping s, 1H, H10), 7.04 (d, J = 8.7 Hz, 1H, C3’NH), 6.17 (br 
dd, J = 8.7, 8.7 Hz, 1H, H13), 5.80 (dd, J = 8.9, 2.2 Hz, 1H, H3’), 5.68 (d, J = 
6.9 Hz, 1H, H2), 4.92 (dd, J = 9.0, 1.0 Hz, 1H, H5), 4.79 (dd, J = 4.4, 2.6 Hz, 
1H, H2’), 4.55 (dd, J = 10.4, 7.0, Hz, 1H, H7), 4.29 (d, J = 8.4 Hz, 1H, H20α), 
4.19 (d, J = 8.4 Hz, 1H, H20β), 3.83 (d, J = 6.9 Hz, 1H, H3), 3.74-3.65 {m, 6H, 
C7OSi[OC1DHPH2]3}, 3.54 (d, 2.55, J = 4.4 Hz, 1H, C2’OH), 2.63 (ddd, J = 
15.0, 9.4, 7.2 Hz, 1H, H6α), 2.36 (s, 3H, C4OAc), 2.32 (dd, J = 10.3, 9.3 Hz, 
1H, H14α), 2.13 (s, 3H, C10OAc), 2.08 (dd, J = 14.8, 8.8 Hz, 1H, H14β), 1.98-
1.92 (m, 1H, H6β), 1.93 (overlapping br s, 3H, C18H3), 1.73 (s, 3H, C19H3), 
1.70 (s, 1H, C1OH),1.55-1.48 [br td, J = 6.6, 6.6 Hz, 6H, C7OSi[OC2DHPH2]3], 
1.42-1.30 {m, 12H, C7OSi[OC3DHPH1]3, C7OSi[OC7DHPH1]3, 
C7OSi[OC11DHPH1]3, C7OSi[OC15DHPH1]3}, 1.30-1.20 {m, 30H, 
C7OSi[OC4DHPH2]3, C7OSi[OC5DHPH2]3, C7OSi[OC6DHPH2]3, 
C7OSi[OC8DHPH2]3}, C7OSi[OC9DHPH2]3}, 1.16 (overlapping s, 3H, C17H3), 
1.16-1.02 {m, 33H, C7OSi[OC10DHPH2]3, C7OSi[OC12DHPH2]3, 
C7OSi[OC13DHPH2]3, C7OSi[OC14DHPH2]3, and C16H3), 0.86 {d, J = 6.5 Hz, 
27H, C7OSi[OC16DHPH3]3, and C7OSi[OC17DHPH3]3 C7OSi[OC18DHPH3]3, }, 
and 0.84 {br d, J = 6.5 Hz, 18H, C7OSi[OC19DHPH3]3, and 
C7OSi[OC20DHPH3]3}. 
13C NMR (125 MHz, CDCl3): δ 201.5, 174.2, 169.9, 168.6, 167.7, 166.8, 139.5, 
137.8,	  133.5, 133.0, 131.8, 130.2, 128.7 (2x), 128.6, 128.4 (2x), 127.9, 127.1, 
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126.9, 84.3, 78.3, 75.8, 76.5, 75.6, 74.6, 73.0, 72.2, 71.8, 57.5, {61.9 (3x), 
Cdhp1}, 54.6, 46.7, 42.0, {39.3 (9x), Cdhp2, Cdhp3, and Cdhp4}, {37.5 (6x), Cdhp14, 
and Cdhp8}, {37.4 (6x), Cdhp10, andCdhp12}, 36.6, 35.4, {32.9 (3x), Cdhp6}, {29.6, 
29.3, 28.0 Cdhp7}, 28.0, {27.9 (3x), Cdhp11},{24.6 (3x), Cdhp15}, {24.5 (6x), 
Cdhp5, and Cdhp13}, {23.7 (2x), 23.4 Cdhp9}, 23.2, {23.0 (3x), 22.6 (3x), Cdhp16, 
and Cdhp17}, 22.7, {21.7 (3x), Cdhp18}, 20.8, {20.5 (2x), 20.3, Cdhp19}, {20.0 
(2x), 19.7 Cdhp20}, 14.2, 10.0.  
TLC Rf (5:1 hexanes:EtOAc) = 0.38.  
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2’-O-(Triethoxysilyl)docetaxel (304a).   
 
Docetaxel (75.0 mg, 0.0930 mmol, 1.0 equiv) was dissolved in dry THF (2.0 mL) 
in an oven-dried culture tube fitted with a Teflon-lined cap and magnetic stir bar. 
N,N-Dimethylbutylamine (35 μL, 0.250 mmol, 2.7 equiv) was added by Wiretrol®. 
Triethoxychlorosilane (305a) (50 µL, 50.6 mg, 0.255 mmol, 2.7 equiv.) was 
added. The culture tube was sealed and the suspension was allowed to stir for 2 
h at room temperature. A white precipitate was observed immediately upon the 
addition of the chlorosilane to the reaction mixture. The THF was removed by 
evaporation under reduced pressure and the solid residue was triturated with a 
mixture of hexanes:EtOAc (1:1), and the resulting slurry was filtered through a 
short plug of Celite® to remove the ammonium salt. The filtrate was concentrated 
under reduced pressure, and the residue was purified by MPLC (SiO2, 1:1 
hexanes:EtOAc) to yield the title compound as a white, crystalline solid (58.1 mg, 
0.060 mmol, 64.5%).  
1H NMR (500 MHz, CDCl3, some resonances were broadened presumably due to 
the presence of NBoc rotamers): δ 8.10 (d, J = 7.9 Hz 2H, O2C-o-Ph), 7.60 (t, 
J = 7.2 Hz, 1H, O2C-p-Ph), 7.50 (t, J = 7.9 Hz, 2H, O2C-m-Ph), 7.36 (t, 2H, J = 
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8.0 Hz, C3’-m-Ph), 7.33 (d, 2H, J = 7.2 Hz, C3’-o-Ph), 7.25 (t, J = 6.5 Hz 1H, 
C3’-p-Ph), 6.27 (br m, 1H, H13), 5.67 (d, J = 7.3 Hz, 1H, H2), 5.62 (d, J = 8.9 
Hz, 1H, H3’), 5.28 (br s, 1H, NH), 5.21 (s, 1H, H10), 4.96 (dd, J = 9.9, 1.9 Hz, 
1H, H5), 4.81 (br s, 1H, H2’), 4.31 (d, J = 8.6 Hz, 1H, H20α), 4.25 (br dd, J = 
11.6, 7.2, Hz, 1H, H7), 4.22 (d, J = 1.5 Hz, 1H, C10OH), 4.19 (d, J = 8.6 Hz 
1H, H20β), 3.92 (d, J = 6.9 Hz, 1H, H3), 3.66 {br q, J = 6.7, 5.8 Hz, 6H, 
C2’OSi[OCH2CH3]3}, 2.58 (ddd, J = 14.0, 9.9, 6.4 Hz, 1H, H6α), 2.44 (s, 3H, 
C4OAc), 2.29 (br m, 1H, H14α), 2.11 (br m, 1H, H14β), 1.93 (s, 3H, =CCH3), 
1.85 (ddd, J = 14.6, 11.5, 2.8 Hz 1H, H6β), 1.74 (s, 3H, O=CCCH3), 1.71 (s, 
1H,  C1OH), 1.32 (br s, 9H, tBoc), 1.25 {s, C(Me)C16H3}, 1.12 [t, J = 7.0 Hz, 
9H, C2’OSi(OCH2CH3)3], and 1.11 (s, 3H, C(Me)C17H3).  
13C NMR (125 MHz, CDCl3): δ 211.6 (C9), 170.7 (C1'), 170.0 (C21), 167.1 (C2-
OCOBz), 155.4 (C3'-NHCO), 139.3 (C3'-ipso-Ph), 138.6 (C12), 135.4 (C11), 
133.7 (OBz-p), 130.2 (OBz-i), 129.2 (OBz-o), 128.7 (OBz-m), 128.5 (2x C3'-o-
Ph), 127.6 (C3'-m-Ph), 126.5 (C3'-p-Ph), 84.2 (C5), 80.9 (OCMe3), 79.9 (C1), 
79.0 (C4), 76.6 (C20), 75.2 (C2), 75.0 (C10), 74.5 (C2'), 71.9 (C13), 71.2 (C7), 
59.4 (3x C2’OSiOCH2CH3), 57.5 (C8), 56.3 (C3'), 46.4 (C3), 43.1 (C15), 36.9 
(C6), 35.6 (C14), 28.2 [C3'-NHCOC(CH3)], 26.4 (C16), 22.7 (C22), 21.0 (C17), 
18.0 (SiOCH2CH3), 14.1 (C18), and 9.9 (C19).  
HRMS (ESI) Calc’d for C49H67NNaO17Si [M + Na]+ 992.4070; found 992.4083.  
IR (thin film) 3443, 2977, 2930, 2897, 2368, 1756, 1712, 1495, 1453, 1392, 1367, 
1314, 1271, 1244, 1166, 1105, 1081, 1025, 983, 915, 88, 798, 786, and 758 
cm-1.  
mp = 117-119 °C.  TLC Rf (1:1 hexanes:EtOAc) = 0.42. 
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2’-O-(Tri-n-octyloxysilyl)docetaxel (304b).   
 
Docetaxel (36.4 mg, 0.0450 mmol, 1.0 equiv) was dissolved in dry THF (2.0 mL) 
in an oven-dried culture tube fitted with a Teflon-lined cap and magnetic stir bar. 
N,N-Dimethylbutylamine (35 μL, 0.250 mmol, 5.5 equiv) was added by Wiretrol®. 
Tri-n-octyloxychlorosilane (305b) (containing ca. 20% of tetra-n-octyloxysilane; 
50 µL, estimated to contain 32.0 mg, 0.071 mmol, 1.6 equiv of the tri-n-
octyloxychlorosilane) was added. The culture tube was sealed and the 
suspension was allowed to stir for 3 h at room temperature. A white precipitate 
was observed to grow over the first 30 min of the reaction period. The THF was 
removed by evaporation under reduced pressure and the solid residue was 
triturated with a mixture of hexanes:EtOAc (2:1), and the resulting slurry was 
filtered through a short plug of Celite® to remove the ammonium salt. The filtrate 
was concentrated under reduced pressure, and the residue was purified by 
MPLC (SiO2, 2:1 hexanes:EtOAc) to yield the title compound as a white, 
crystalline solid (35.1 mg, 0.0287 mmol, 63.7%).  
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1H NMR (500 MHz, CDCl3, some resonances were broadened presumably due to 
the presence of NBoc rotamers): δ 8.12 (d, J = 7.9 Hz 2H, O2C-o-Ph), 7.60 (t, 
J = 7.3 Hz, 1H, O2C-p-Ph), 7.50 (t, J = 7.8 Hz, 2H, O2C-m- Ph), 7.35 (t, 2H, J = 
7.9 Hz, C3’-m-Ph), 7.32 (d, 2H, J = 6.9 Hz, C3’-o-Ph), 7.25 (t, J = 6.8 Hz 1H, 
C3’-p-Ph), 6.28 (br dd, J = 9, 9 Hz, 1H, H13), 5.69 (d, J = 7.1 Hz, 1H, H2), 
5.62 (d, J = 9 Hz H3’), 5.28 (br s, 1H, NH), 5.20 (s, 1H, H10), 4.96 (dd, J = 9.6, 
1.8 Hz, 1H, H5), 4.81 (br s, 1H, H2’), 4.32 (d, J = 8.5 Hz, 1H, H20a), 4.25 (br 
dd, J = 10.2, 7.0, Hz, 1H, H7), 4.20 (d, J = 8.1 Hz, 1H, H20b), 4.19 (br s, 1H, 
C10OH), 3.93 (d, J = 7.1 Hz, 1H, H3), 3.56 {t, J = 6.5 Hz, 6H, C2’OSi[OCH2 
(CH2)6CH3]3}, 2.59 (ddd, J = 15.8, 9.5, 6.5 Hz, 1H, H6a), 2.43 (s, 3H, C4OAc), 
2.29 (br m, 1H, H14a), 2.12 (br m, 1H, H14b), 1.93 (s, 3H, =CCH3), 1.85 (ddd, 
J = 13.9, 11.6, 2.2 Hz 1H, H6b), 1.75 (s, 3H, O=CCCH3), 1.65 (d, 1H, J = 2.6, 
C1OH), 1.46 {br pent, J = 6.4 Hz, 6H, C2’OSi[OCH2CH2(CH2)5CH3]3}, 1.32 (br 
s, 9H, tBoc), 1.31-1.24 {m, 33H, C2’OSi[OCH2CH2(CH2)5CH3]3}, and 
C(Me)C16H3}, 1.12 (s, 3H, C(Me)C17H3), and 0.89 {t, J = 6.7 Hz, 9H, 
C2’OSi[OCH2CH2(CH2)5CH3]3}.  
13C NMR (125 MHz, CDCl3): δ 211.9, 170.8, 170.1, 167.3, 155.3, 139.6, 138.9, 
135.5, 133.8, 130.4, 129.4, 128.9 128.7, 127.8, 126.7, 84.4, 81.1, 80.0, 79.2, 
77.6, 76.8, 75.2, 74.7, 72.1, 71.3, 64.0, 57.7, 56.3, 46.6, 43.3, 37.2, 35.9, 32.4, 
32.1, 29.6, 29.5, 28.4, 26.5, 25.8, 22.93, 22.90, 21.2, 14.4, 14.3, and 10.2.  
HRMS (ESI) Calc’d for C67H103NNaO17Si [M + Na]+ 1244.6887; found 1244.6954.  
IR (thin film) 3454, 3382, 2926, 2855, 1755, 1737, 1713, 1699, 1495, 1454, 1367, 
1272, 1245, 1165, 1095, 1025, 987, 946, 943, 920, 888, 865, 824, 800, and 
778 cm-1.  
mp = 54-58 °C.  TLC Rf (3:1 hexanes:EtOAc) = 0.13. 
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2’-O-(Tri-i-propoxysilyl)docetaxel (304c).   
 
Docetaxel (40.0 mg, 0.0490 mmol, 1.0 equiv) was dissolved in dry THF (2.0 mL) 
in an oven-dried culture tube fitted with a Teflon-lined cap and magnetic stir bar. 
N,N-Dimethylbutylamine (50 μL, 0.357 mmol, 7.3 equiv) was added by Wiretrol®. 
Tri-i-propoxychlorosilane (305c) (containing ca. 80% of tri-i-propoxychlorosilane; 
50 µL, estimated to contain 42.0 mg, 0.175 mmol, 3.8 equiv of the tri-i-
propoxychlorosilane) was added. The culture tube was capped and the 
suspension was allowed to stir for 5 h at room temperature. A white precipitate 
was observed to grow over 3 hours of the reaction. The THF was removed by 
evaporation under reduced pressure and the solid residue was triturated with a 
mixture of hexanes:EtOAc (2.4:1). The resulting slurry was filtered through a 
short plug of Celite® to remove the ammonium salt. The filtrate was concentrated 
under reduced pressure, and the residue was purified by MPLC (SiO2, 2.4:1 
hexanes:EtOAc) to yield the title compound as a white, crystalline solid (31.2 mg, 
0.0308 mmol, 62.8%).  
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1H NMR (500 MHz, CDCl3, some resonances were broadened presumably due to 
the presence of NBoc rotamers): δ 8.10 (d, J = 7.6 Hz 2H, O2C-o-Ph), 7.62 (t, 
J = 7.4 Hz, 1H, O2C-p-Ph), 7.51 (t, J = 7.8 Hz, 2H, O2C-m-Ph), 7.35 (t, 2H, J = 
8.0 Hz, C3’-m-Ph), 7.32 (d, 2H, J = 6.9 Hz, C3’-o-Ph), 7.23 (t, J = 6.6 Hz 1H, 
C3’-p-Ph), 6.21 (br m, 1H, H13), 5.69 (d, J = 9 Hz, 1H, H3’), 5.68 (d, J = 7.0 
Hz, H2), 5.21 (br s, 1H, NH), 5.20 (s, 1H, H10), 4.96 (dd, J = 9.6, 2.1 Hz, 1H, 
H5), 4.81 (br s, 1H, H2’), 4.31 (d, J = 8.5 Hz, 1H, H20a), 4.25 (ddd, J = 11.3, 
8.0, 7.0 Hz, 1H, H7), 4.19 (br s, 1H, C10OH), 4.18 (d, J = 8.6 Hz, 1H, H20b), 
4.09 {br septet, J = 5.9 Hz, 3H, OSi[OCH (CH3)2]3}, 3.91 (d, J = 7.1 Hz, 1H, 
H3), 2.60 (ddd, J = 14.4, 9.7, 6.5 Hz, 1H, H6a), 2.40 (s, 3H, C4OAc), 2.22 (br 
m, 1H, H14a), 2.05 (br m, 1H, H14b), 1.93 (s, 3H, =CCH3), 1.84 (ddd, J = 14.1, 
11.3, 2.5 Hz 1H, H6b), 1.75 (s, 3H, O=CCC19H3), 1.60 (br s, 1H, C1OH), 1.46 
(d, 1H, J = 8.0 Hz, C7OH), 1.33 (br s, 9H, tBoc), 1.24 [s, 3H, C(Me)C16H3], 
and 1.14-1.10 {m, 21H, C(Me)C17H3 and OSi[OCH(CH3)2]3}  
13C NMR (125 MHz, CDCl3): δ 211.7, 170.7, 169.9, 167.1, 155.4, 139.5, 138.7, 
135.2, 133.7, 130.2, 129.2, 128.7, 128.5, 127.6, 126.6, 84.2, 80.9, 79.0, 76.6, 
75.1, 75.0, 74.5, 73.2, 71.9, 71.1, 66.3, 57.5, 56.7, 46.4, 43.1, 36.9, 35.6, 28.2, 
26.3, 25.2, 22.7, 21.0, 14.4, and 10.0.  
HRMS (ESI) Calc’d for C52H73NNaO17Si [M + Na]+ 1034.4540; found 1034.4545.  
IR (thin film) 3683, 2973, 2917, 2849, 2349, 1757, 1733, 1717, 1701, 1649, 1631, 
1547, 1494, 1461, 1452, 1369, 1271, 1244, 1167, 1114, 1051, 986, 892, 846, 
and 778 cm-1.  
mp = 118.5-121 °C.  TLC Rf (2.4:1 hexanes:EtOAc) = 0.10. 
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2’-(Trimenthyloxysilyloxy)docetaxel (304d).   
 
Docetaxel (50.5 mg, 0.063 mmol, 1.0 equiv) was dissolved in dry THF (1.0 mL) in 
an oven-dried culture tube fitted with a Teflon-lined cap and magnetic stir bar. 
Pyridine (35 μL, 0.45 mmol, 7.2 equiv) was added by Wiretrol®. 
Trimenthyloxychlorosilane (305d) (50 µL, 44 mg, 0.083 mmol, 1.3 equiv) was 
added. The culture tube was sealed and the suspension was allowed to stir for 
18 h at 45 ºC. The THF was removed by evaporation under reduced pressure, 
the solid residue was triturated with a mixture of hexanes:EtOAc (2:1), and the 
resulting slurry was filtered through a short plug of Celite® to remove the 
pyridinium salt. The filtrate was concentrated under reduced pressure, and the 
residue was purified by MPLC (SiO2, 2.3:1 hexanes:EtOAc) to yield the title 
compound as a white, crystalline solid (36.0 mg, 0.028 mmol, 44%).   
1H NMR (500 MHz, CDCl3, some resonances were broadened presumably due to 
the presence of NBoc rotamers): δ 8.11 (d, J = 7.5 Hz 2H, O2C-o-Ph, 7.59 (t, J 
= 7.2 Hz, 1H, O2C-p-Ph), 7.49 (t, J = 7.8 Hz, 2H, O2C-m-Ph), 7.36 (t, 2H, J = 
7.7 Hz, C3’-m-Ph), 7.33 (d, 2H, J = 7.2 Hz, C3’-o-Ph), 7.27 (t, J = 7.0 Hz 1H, 
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C3’-p-Ph), 6.23 (br dd, J = 8.3, 8.4 Hz, 1H, H13), 5.70 (d, J = 7.1 Hz, 1H, H2), 
5.50 (d, J = 9.3 Hz, 1H H3’), 5.24 (br d, J= 8.8 Hz 1H, NH), 5.22 (s, 1H, H10), 
4.95 (dd, J = 9.5, 1.5 Hz, 1H, H5), 4.90 (br s, 1H, H2’), 4.31 (d, J = 8.5 Hz, 1H, 
H20a), 4.26 (br dd, J = 11.0, 7.2, Hz, 1H, H7), 4.21 (d, J = 7.1 Hz, 1H, H20b), 
4.19 (br s, 1H, C10OH), 3.94 (dd, J = 7.6, 5.2 Hz, 1H, H3), 3.60 (dt, J = 10.2, 
3.8 Hz, 3H, H1menth), 2.60 (ddd, J = 14.5, 9.7, 6.6 Hz, 1H, H6a), 2.39 (s, 3H, 
C4OAc), 2.28 (br m, 1H, H14a), 2.21 (br m, 1H, H14b), 2.20 (dsep, J = 7.0, 
2.1 Hz, 3H, H7menth), 1.96 (s, 3H, H18 =CCH3), 1.85 (m, 1H, H6b), 1.84 (m, 
3H, H6menth), 1.75 (s, 3H, H19 O=CCCH3), 1.67 (s, 1H, C1OH), 1.58 (m, 6H, 
H3menth and H4menth), 1.33 (br s, 9H, tBoc), 1.26-1.24 [m, 6H, H5menth and 
C(Me)C16H3], 1.30 [s, 3H, C(Me)C17H3], 1.11 (m, 3H, H2menth), 0.93-0.86 (m, 
6H, H4menth and H6menth), 0.88 (br d, 9H, H8menth), 0.87 (br d, 9H, H9menth), 0.79 
(m, 3H, H3menth), and 0.73 (d, J = 6.9 Hz, 9H, H10menth).  
13C NMR (125 MHz, CDCl3): δ 212.1, 170.8, 169.9, 167.3, 155.7, 139.9, 139.1, 
135.3, 133.8, 130.4, 129.4, 128.9, 128.8, 127.7, 126.6, 84.4, 81.0, 79.9, 79.2, 
76.8, 75.2, 74.8, 74.7, 73.9, 72.2, 71.4 (C1menth),, 57.7, 56.5 (br), 49.7 
(C2menth), 46.5, 45.0 (C7menth), 43.3, 37.2, 36.0, 34.6 (C5menth), 31.7 (C6menth), 
28.4, 26.5, 25.3 (C3menth), 22.82, 22.78 (C4menth), 22.5 (C8menth), 21.5 (C9menth), 
21.3, 15.8 (C10menth), 14.7, and 10.2 ppm. (assignments of resonances of the 
menthyl moieties deduced from 13C NMR spectrum assignments of 
[(MenthO)3SiOH].  
HRMS (ESI) Calc’d for C67H103NNaO17Si [M + Na]+ 1322.7357; found 1322.7351.  
IR (thin film) 3445, 2953, 2927, 2872, 2360, 2340, 1762, 1717, 1496, 1454, 
1368, 1274, 1245, 1163, 1108, 1083, 1070, 1052, 986, and 889 cm-1. 
 mp = 119-121 °C.  TLC Rf (1.5:1 hexanes:EtOAc) = 0.30. 
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2’-(Di-t-butoxyethoxysilyl)docetaxel (304e).   
 
Docetaxel (40.0 mg, 0.049 mmol, 1.0 equiv) was dissolved in dry THF (2.0 mL) in 
an oven-dried culture tube fitted with a Teflon-lined cap and magnetic stir bar. 
Pyridine (50 μL, 0.63 mmol, 12.8 equiv) was added by Wiretrol®. Dichlorodi-t-
butoxysilane (406) solution consisting of ca. 90% of the dichlorosilane and ca. 
10% of the monochlorosilane (100 μL, 93 mg, 0.38 mmol, 7.8 equiv) was added. 
The culture tube was sealed and the suspension was allowed to stir for 12 h at 
30 ºC. Absolute ethanol dried over 4 Aº molecular sieves (50 μL, 0.85 mmol, 17.5 
equiv) was added and the reaction mixture continued to stir for another 3 h.  The 
THF was removed by evaporation under reduced pressure, the solid residue was 
triturated with a mixture of hexanes:EtOAc (2:1), and the resulting slurry was 
filtered through a short plug of Celite® to remove the pyridinium salt. The filtrate 
was concentrated under reduced pressure, and the residue was purified by 
MPLC (SiO2, 2:1 hexanes:EtOAc) to yield the title compound as a white, 
crystalline solid (30.2 mg, 0.029 mmol, 60%).  
1H NMR (500 MHz, CDCl3, some resonances were broadened presumably due to 
the presence of NBoc rotamers): δ 8.09 (d, J = 7.6 Hz 2H, O2C-o-Ph, 7.63 (t, J 
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= 6.8 Hz, 1H, O2C-p-Ph), 7.52 (t, J = 7.5 Hz, 2H, O2C-m-Ph), 7.43 (t, 2H, J = 
8.0 Hz, C3’-m-Ph), 7.33 (br d, 2H, C3’-o-Ph), 7.20 (br t, 1H, C3’-p-Ph), 6.15 (br 
m, 1H, H13), 5.81 (d, J = 7.2 Hz, 1H, H2), 5.66 (d, J = 6.9 Hz, 1H H3’), 5.18 (s, 
1H, H10), 5.14 (br s, 1H, NH), 4.94 (br dd, J = 9.5, 2.3 Hz, 1H, H5), 4.76 (br s, 
1H, H2’), 4.30 (d, J = 8.4 Hz, 1H, H20a), 4.24 (br dd, J = 10.7, 6.4, Hz, 1H, 
H7), 4.18 (d, 1H, J = 9.5 Hz, C7OH), 4.17 (d, J = 8.5 Hz, 1H, H20b), 3.89 (br 
d, J = 7 Hz, 1H, H3), 3.67 [br q, 2H, C2’OSi(OCH2CH3)], 2.58 (ddd, J = 14.7, 
9.7, 6.5 Hz, 1H, H6a), 2.43 (br d, 1H, C7OH), 2.35 (s, 3H, O=CCH3), 2.12 (br 
m, 1H, H14a), 1.94 (very br m, 1H, H14b, chemical shift deduced from the 
COSY spectrum), 1.91 (br s, 3H, H18 =CCH3), 1.83 (ddd, J = 13.8, 11.3, 2.0 
Hz, 1H, H6b), 1.73 (s, 3H, H19 O=CCCH3), 1.60 (br s, 2H C7OH and C1OH), 
1.35 (br s, 9H, tBoc), 1.29 (br s, 9H, C2’OSi[OC(CH3)], 1.26 (br s, 9H, 
C2’OSi[OC(CH3)'], 1.22 (s, 3H, C17H3), 1.15 (br t, J = 6.8 Hz, 3H, 
C2’OSi[OCH2CH3]), and 1.10 (br s, 3H, C16H3). 
 13C NMR (125 MHz, CDCl3): δ 211.9, 170.8, 170.1, 167.2, 155.7, 139.7, 139.0, 
135.4, 133.9, 130.4, 129.9, 129.5, 128.9, 128.7, 127.0, 84.4, 81.0, 79.9, 79.1, 
76.8, 75.2, 75.1, 74.7, 74.0, 72.1, 71.0, 57.7, 59.3, 57.4, 46.5, 43.2, 37.1, 35.7, 
31.41, 31.40, 28.4, 26.5, 22.9, 21.2, 18.2, 14.6, and 10.2 ppm.  
HRMS (ESI) Calc’d for C53H75NNaO17Si [M + Na]+ 1048.4696; found 1048.4695.  
IR (thin film) 3456, 2975, 2931, 1757, 1715, 1602, 1494, 1453, 1391, 1367, 
1315, 1286, 1270, 1243, 1166, 1070, 1026, 986, 949, 915, 889, 870, 834, 782, 
759, 730, and 650 cm-1.  
mp = 97-104 °C.  TLC Rf (2:1 hexanes:EtOAc) = 0.50. 
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2-O-[(Di-n-octyloxy)(hydrogen)silyl]paclitaxel (313).  
 
Paclitaxel (96.5 mg, 0.113 mmol, 1.0 equiv) was dissolved in dry THF (3 mL) in 
an oven-dried culture tube fitted with a Teflon-lined cap and magnetic stir bar. 
N,N-dimethylbutylamine (100 µL, 0.713 mmol, 6.3 equiv) was added by Wiretrol®. 
Since a slight excess of the alcohol was used, the corresponding trioctyloxysilane 
(312) was observed by GC-MS at longer retention time of 15.6 minutes 
compared to the monochlorosilane (13.2 minutes). An 80% mixture of di-n-
octyloxyhydrogen-chlorosilane (311): tri-n-octyloxyhydrogensilane (200 µL, 0.613 
mmol, 5.5 equiv of di-n-octyloxyhydrogen-chlorosilane) was added and a white 
precipitate was immediately observed. The culture tube was capped and the 
suspension was allowed to stir for 14 h at room temperature. An aliquot was 
taken out an analyzed by 1H-NMR which showed little to no conversion.  The 
THF was exchanged for CDCl3, another portion of 311 was added (100 µL, 0.31 
mmol, 2.7 equiv), and the reaction was allowed to stir at room temperature for 24 
h.  The reaction slurry was diluted with a mixture of hexanes:EtOAc (2:1), the 
slurry filtered through a plug of Celite® (2x) to remove the triethylammonium salt, 
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the filtrate concentrated under reduced pressure, and the residue redissolved in a 
mixture of hexanes:EtOAc (2:1). The resulting slurry was purified by flash 
Chromatography (SiO2, 2:1 hexanes:EtOAc) give pure 313 (14.8 mg, 0.0130 
mmol, 11.5%).  The impure fractions were combined and subjected to MPLC 
purification to yielded the title compound as a white, crystalline solid (60.7 mg, 
0.0532 mmol, 47.1%).  The combined purified yield was (58.6%). 
1H NMR (500 MHz, CDCl3): δ 8.13 (dd, J = 8.5, 1.4 Hz, 2H, C2O2C-o-Ph), 7.77 
(dd, J = 8.5, 1.4 Hz, 2H, C3’NHCO-o-Ph), 7.62 (tt, J = 7.4, 1.3 Hz, 1H, C2O2C-
p-Ph), 7.54-7.47 (m, 3H, C2O2C-m-Ph and C3’NHCO-p-Ph), 7.43-7.36 (m, 6H, 
C3’-o-Ph, C3’-m-Ph and C3’NHCO-m-Ph), 7.28 (tt, J = 6.7, 1.8 Hz, 1H, C3’-p-
Ph), 7.20 (d, J = 8.7 Hz, 1H, C3’NH), 6.28 (s, 1H, H10), 6.24 (br dd, J = 9.1, 9 
Hz, 1H, H13), 5.72 (dd, J = 8.6, 3.1 Hz, 1H, H3’), 5.68 (d, J = 7.1 Hz, 1H, H2), 
4.97 (dd, J = 8.7, 1.9 Hz, 1H, H5), 4.96 (d, J = 3.1 Hz, 1H, H2’), 4.44 (ddd, J = 
10.8, 6.6, 4.1 Hz, 1H, H7), 4.32 (d, J = 8.4 Hz, 1H, H20α), 4.20 (d, J = 8.2 Hz, 
1H, H20β), 3.80 (d, J = 7.0 Hz, 1H, H3), 3.61 {t, J = 6.8 Hz, 4H, 
C2’OSi(H)[OCH2(CH2)6CH3]2}, 2.56 (ddd, J = 14.9, 9.6, 6.6 Hz, 1H, H6α), 2.48 
(d, J = 4.0 Hz, 1H, C7OH), 2.44 (s, 3H, C4OAc), 2.32 (dd, J = 15.4, 9.4 Hz, 
1H, H14α), 2.24 (s, 3H, C10OAc), 2.08 (dd, J = 15.4, 8.8 Hz, 1H, H14β), 1.89 
(d, J = 1.3 Hz, 3H, C18H3), 1.89 (m, 1H, H6β), 1.77 {s, 1H, 
C2’OSi(H)[OCH2CH2(CH2)5CH3]2}1.68 (s, 3H, C19H3), 1.64 (br s, 1H, C1OH), 
1.48 {tt, J = 6.7, 6.7 Hz, 4H, C2’OSi(H)[OCH2CH2(CH2)5CH3]2}, 1.32-1.22 {m, 
23H, C2’OSi(H)[OCH2CH2(CH2)5CH3]2 and C17H3}, 1.13 (s, 3H, C16H3), and 
0.88 {t, J = 6.8 Hz, 6H, C2’OSi(H)[OCH2CH2(CH2)5CH3]2}.  
13C NMR (125 MHz, CDCl3): δ 204.0, 171.6, 170.9, 170.1, 167.3, 167.2, 143.0, 
138.2, 134.2, 133.9, 132.9, 132.0, 130.4, 129.3, 129.0, 128.9, 128.8, 128.2, 
127.3, 126.8, 84.7, 81.2, 79.3, 77.4, 75.8, 75.3, 74.9, 72.4, 71.5, 64.1 (C1oct), 
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58.7 , 55.5, 45.7, 43.4, 35.8, 35.7, 32.4 (C2oct), 32.1 (C3oct), 29.6 (C4oct), 29.5 
(C5oct), 27.0, 25.8 (C6oct), 23.0, 22.9 (C7oct), 22.4, 21.1, 14.9, 14.3 (C8oct), and 
9.8. 
HRMS (ESI) Calc’d for  C63H85NKO16Si [M + K]+ 1178.5290; found 1178.7726. 
IR (thin film) 2927, 2856, 2355 (Si-H), 2324,1731, 1717, 1698, 1669, 1648, 1555, 
1538, 1519, 1506, 1489, 1241, 1170, 1096, 1025, and 839 cm-1.  
mp = 72–75 °C. TLC Rf (2:1 hexanes:EtOAc) = 0.27. 
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2’,7-Di-O-(Triethoxysilyl)docetaxel (318a). 
 
Docetaxel (75.0 mg, 0.0930 mmol, 1.0 equiv) was dissolved in dry THF (2.0 mL) 
in an oven-dried culture tube fitted with a Teflon-lined cap and magnetic stir bar. 
Pyridine (35 μL, 0.250 mmol, 2.7 equiv) was added by Wiretrol®. 
Triethoxychlorosilane (305a) (50 µL, 50.6 mg, 0.255 mmol, 2.7 equiv.) was 
added. The culture tube was sealed and the suspension was allowed to stir for 2 
h at room temperature. A white precipitate was observed immediately upon the 
addition of the chlorosilane to the reaction mixture. The THF was removed by 
evaporation under reduced pressure and the solid residue was triturated with a 
mixture of hexanes:EtOAc (1:1), and the resulting slurry was filtered through a 
short plug of Celite® to remove the ammonium salt. The filtrate was concentrated 
under reduced pressure, and the residue was purified by MPLC (SiO2, 1:1 
hexanes:EtOAc) to yield 401a (58.1 mg, 0.060 mmol, 64.5%) and the title 
compound as a white, crystalline solid (20.7 mg, 0.018 mmol, 19.7%). 
1H NMR (500 MHz, CDCl3, some resonances were broadened presumably due to 
the presence of NBoc rotamers): δ 8.11 (d, J = 7.5 Hz 2H, O2C-o-Ph), 7.61 (t, 
J = 7.2 Hz, 1H, O2C-p-Ph), 7.50 (t, J = 7.8 Hz, 2H, O2C-m-Ph), 7.35 (t, 2H, J = 
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7.4 Hz, C3’-m-Ph), 7.33 (d, 2H, J = 7.1 Hz, C3’-o-Ph), 7.26 (t, J = 6.6 Hz 1H, 
C3’-p-Ph), 6.27 (br m, 1H, H13), 5.67 (d, J = 7.0 Hz, 1H, H2), 5.61 (d, J = 8.8 
Hz, 1H, H3’), 5.42 (s, 1H, H10), 5.28 (br s, 1H, NH), 4.95 (dd, J = 9.5, 1.8 Hz, 
1H, H5), 4.82 (br s, 1H, H2’), 4.54 (br dd, J = 10.6, 6.7, Hz, 1H, H7), 4.31 (d, J 
= 8.4 Hz, 1H, H20α), 4.20 (d, J = 8.5 Hz 1H, H20β), 4.16 (d, J = 1.8 Hz, 1H, 
C10OH), 3.91 (d, J = 7.0 Hz, 1H, H3), 3.79 {q, J = 7.9, 7.0, Hz, 6H, 
C7OSi[OCH2CH3]3}, 3.66 {br q, J = 5.9, 5.3 Hz, 6H, C2’OSi[OCH2CH3]3}, 2.60 
(ddd, J = 14.6, 9.7, 6.7 Hz, 1H, H6α), 2.44 (s, 3H, C4OAc), 2.30 (br m, 1H, 
H14α), 2.12 (br m, 1H, H14β), 1.97 (s, 3H, =CCH3), 1.85 (ddd, J = 14.4, 10.9, 
2.3 Hz 1H, H6β), 1.77 (s, 3H, O=CCCH3), 1.63 (s, 1H,  C1OH), 1.34 (br s, 9H, 
tBoc), 1.25 {s, C(Me)C16H3}, 1.22 [t, J = 7.1 Hz, 9H, C7OSi(OCH2CH3)3], 1.13 
[t, J = 7.0 Hz, 9H, C2’OSi(OCH2CH3)3], and 1.12 (s, 3H, C(Me)C17H3).  
13C NMR (125 MHz, CDCl3): δ 210.2 (C9), 169.9 (C1'), 169.4 (C21), 166.8 (C2-
OCOBz), 154.3 (C3'-NHCO), 138.6 (C3'-ipso-Ph), 135.6 (C12), 135.2 (C11), 
133.4 (OBz-p), 130.2 (OBz-i), 128.9 (OBz-o), 128.5 (OBz-m), 127.9 (2x C3'-o-
Ph), 127.2 (C3'-m-Ph), 126.6 (C3'-p-Ph), 84.2 (C5), 80.5 (OCMe3), 78.8 (C1), 
77.1 (C4), 76.4 (C20), 74.8 (C2), 74.2 (C10), 73.5 (C2'), 72.6 (C13), 72.2 (C7), 
59.3 (3x C2’OSiOCH2CH3), 56.4 (C8), 56.1 (C3'), 46.4 (C3), 43.2 (C15), 36.3 
(C6), 35.4 (C14), 28.2 [C3'-NHCOC(CH3)], 27.3 (C16), 22.7 (C22), 20.8 (C17), 
17.9 (SiOCH2CH3), 14.0 (C18), and 9.8 (C19). 
HRMS (ESI) Calc’d for C55H81NKO20Si2 [M + K]+ 1170.4522; found 1170.4535.  
IR (thin film) 3459, 2976, 2929, 2897, 2359, 1717, 1716, 1502, 1453, 1368, 1246, 
167, 1082, 973, 889, and 796 cm-1.  
mp = 95.6-97.5 °C.  TLC Rf (1:1 hexanes:EtOAc) = 0.53. 
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Table S3.1 | Additional calculated values of physical properties for the silicate 
esters 301–304, 308a, 313, 318a.  Calculated octanol:water partition coefficient 
are shown as: Actelion LogP [AC logP], atom fragment contribution LogP 
[KOWWIN], molinspiration [miLogP],and atom additive LogP [XLOGP3]. 
Sub- 2’ 7  AC logP KOWWIN miLogP XLOGP3 
strate alkyl alkyl     
PTX - - 3.64   3.31 4.945 2.49 
301a Et - 4.27   3.49 6.563 4.30 
301b nOct - 12.62   12.33 10.176 13.45 
301c iPr -  5.48   4.74 7.653 5.60 
301d menthyl -  11.28   14.05 10.241 13.63 
301f (tBu)2/Et -  5.38   5.23 8.167 5.53 
301g (tBu)2/Ac -  4.98   –  – 5.20 
301h (tBu)2/Piv -  6.30   –  – 6.61 
301p DHP -  27.84   –  – 30.03 
308a PTX-SiEt3 -  4.95   7.26 6.687 6.03 
313 (nOct)2/H -  –   –  – 9.65a 
302a Et Et  4.89   3.26 8.167 6.11 
302b nOct nOct  21.60   20.94 10.979 24.41 
302c iPr iPr 7.31   5.76 9.212 8.70 
302d menthyl menthyl 18.93   –  – 24.77 
302p DHP DHP 52.03   –  – 57.57 
303a - Et  4.27   3.49 6.563 4.30 
303b - nOct 12.62   12.33 10.176 13.45 
303c - iPr 5.48   4.74 7.653 5.60 
303p - DHP 27.84   –  – 30.03 
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Table S3.1 | Continued 
Sub- 2’ 7  AC logP KOWWIN miLogP XLOGP3 
strate alkyl alkyl     
DTX - - 2.92   2.83 4.243 1.65 
304a Et - 3.55   3.01 5.861 3.45 
304b nOct - 11.90   11.85 10.093 12.61 
304c iPr - 4.76   4.26 6.950 4.75 
304d menthyl -  10.57   13.23 10.163 12.79 
304e (tBu)2/Et - 4.66   4.75 7.480 4.69 
318a Et Et 4.18   –  – 5.26 
aXLOGP2 value provided when XLOGP3 value not found. 
 
Table S3.2 | Additional calculated values of physical and chemical properties for 
the silicate esters 301–304, 308a, 313, 318a.  Calculated water solubility. (AC = 
Acetion pharma company). 
Sub- 2’ 7  ALOGpS mg/L AC logS AC Aqueous 
strate alkyl alkyl    Solubility 
PTX - - -5.19   5.56 -6.29 0.44 mg/L 
301a Et - -5.58   2.66 -4.79 16.33 mg/L 
301b nOct - -6.72   0.24 -9.65 0.28 µg/L 
301c iPr -  -5.83   1.57 -5.93 1.25 mg/L 
301d menthyl -  -6.74   0.25 -10.86 18.38 ng/L 
301f (tBu)2/Et -  -6.06   0.94 -5.77 1.83 mg/L 
301g (tBu)2/Ac -  -6.04   0.98 -5.75 1.93 mg/L 
301h (tBu)2/Piv -  -6.24   0.66 -6.36 0.50 mg/L 
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Table S3.2 | Continued 
Sub- 2’ 7  ALOGpS mg/L AC logS AC Aqueous 
strate alkyl alkyl    Solubility  
301p DHP -  -7.79   0.03 -18.05 0 ng/L 
308a PTX-SiEt3 -  -5.96   1.06 -13.40 0.04 ng/L 
301f (nOct)2/H -  -6.62   0.27 – – 
 
302a Et Et  -5.84   1.70 -3.30 0.59 g/L 
302b nOct nOct  -7.12   0.13 -13.02 0.16 ng/L 
302c iPr iPr -6.16   0.87 -5.57 3.42 mg/L 
302d menthyl  menthyl -7.31   0.09 -15.44 0 ng/L 
302p DHP DHP -8.13   0.02 -29.82 0 ng/L 
 
303a - Et  -5.64   2.33 -4.79 16.37 mg/L 
303b - nOct -6.76   0.22 -9.65 0.28 µg/L 
303c - iPr -5.87   1.44 -5.93 1.25 mg/L 
303p - DHP -7.84   0.03 -18.05 0 ng/L 
 
DTX - - -4.80   12.72 -5.81 1.25 mg/L 
304a Et - -5.15   6.84 -4.32 46.87 mg/L 
304b nOct - -6.58   0.32 -9.18 0.82 µg/L 
304c iPr - -5.43   3.78 -5.45 3.59 mg/L 
304d menthyl -  -6.65   0.29 -10.39 53.24 ng/L 
304e (tBu)2/Et - -5.60   2.58 -5.29 5.26 mg/L 
318a Et Et -5.46   3.92 -2.82 1.71 g/L 
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Table S3.3 | Additional calculated values of chemical properties for the silicate 
esters 301–304.  Calculated volume, total number of non hydrogen 
atoms/number of oxygen and nitrogen atoms/number of O-H and N-H bonds 
[natoms/nON/nOHNH], number of rotable bonds [nrotbonds], and Molecular 
Polar Surface Area [TPSA]. 
Sub- 2’ 7 Volume natoms/ nrotbonds TPSA 
strate alkyl alkyl   nON/nOHNH  
PTX - - 756.598   62/15/4 14 221.307 
301a Et - 914.156   72/18/3 22 238.015 
301b nOct - 1216.588   90/18/3 40 238.015 
301c iPr -  963.917   75/18/3 22 238.015 
301d menthyl -  1283.74   96/18/3 25 238.015 
301f (tBu)2/Et -  979.803   76/18/3 22 238.015 
308a PTX-SiEt3 -  887.202   69/15/3 19 210.313 
302a Et Et  1071.714   82/21/2 30 254.723 
302b nOct nOct  1676.579   118/21/2 66 254.723 
302c iPr iPr 1171.235   88/21/2 30 254.723 
303a - Et  914.156   72/18/3 22 238.015 
303b - nOct 1216.588   90/18/3 40 238.015 
303c - iPr 963.917   75/18/3 22 238.015 
DTX - - 723.849   58/15/5 13 224.464 
304a Et - 881.407   68/18/4 21 241.172 
304b nOct - 1183.84   86/18/4 39 241.172 
304c iPr - 931.168   71/18/4 21 241.172 
304d menthyl -  1250.991   92/18/4 24 241.172 
304e (tBu)2/Et - 947.055   72/18/4 21 241.172 
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Figure S3.3 | 1H-NMR hydrolysis acid buffer study containing 301b in 300 µL 
MeOH, and 700 µL of D3PO4 in D2O plotted over time shows the cleavage of the 
silicate to return free PTX after > 1,156 mins. 
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Figure S3.4 | 7-position modification of DTX to estimate the silicate 304c, to 
provide a very crude idea of the possible binding of the silicate prodrugs to 
microtubules.220 
 
                                            
220 Meurer-Grob, P.; Kasparian, J.; Wade, R. H. Microtubule Structure at Improved Resolution. 
Biochemistry 2001, 40, 8000–8008. 
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Figure S3.5 | Calibration curve of the ratio of PTX/DTX used to quantify the 
amount of PTX present in during the stability and uptake studies.  (prodrug 
calibration curves not shown). 
 
 
Figure S3.6 | Raw integral intensity at 227 nm of 302a, 303a, PTX vs. time in wet 
ACN. 
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Figure S3.7 | Raw integral intensity at 227 nm of 302a, 303a, PTX vs. time in 1:1 
ACN:PBS. 
 
 
Figure S3.8 | Ratio of total taxane quantified to the total amount of protein 
present determined from a Bradford Assay. 
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Methoxy-capped poly(ethylene glycol)-block-poly[(lactic)-co-(glycolic) acid] 
(405) 
 
MeO-PEG-OH (403, 5K, 5.0 g) was dissolved in 10 mL of dry CH2Cl2 and stored 
over 3 Å molecular sieves. From this stock solution 403 (3.0 mL, 1.5 g, 0.3 mmol, 
1.0 equiv.) was added to the rac-lactide 401 (3.56 g, 24.7 mmol, 82.4 equiv.) in 
an oven-dried round-bottom flask containing a magnetic stir bar and 70 mL of 
CH2Cl2. The glycolide (402) (1.82 g, 15.7 mmol, 52.3 equiv.) was vigorously 
stirred in 20.0 mL of THF. The glycolide solution was fed into the reaction with a 
syringe pump running at 1.82 mL/min and started simultaneously upon the 
Experimental Section for Chapter 4
O
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O
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O
O O O
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x y n
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addition of the DBU catalyst 404 (100 µL, 0.67 mmol, 2.2 equiv.) was added to 
the reaction.  After 11 min of reaction solid benzoic acid (ca. 500 mg) was added 
to arrest the polymerization. The mPEG-b-PLGA (405) was purified by removing 
all of the CH2Cl2 by rotary evaporation, dissolving the crude polymer in a minimal 
amount of CHCl3, two sequential precipitations into 500 mL ice cold isopropanol, 
and drying at 50 °C under vacuum overnight yielding the desired product as a 
white solid (98% yield) with Mn [PLGA] = 13,860 g/mol, ca. 64:36 lactic:glycolic 
ratio by mass. 
1H NMR (500 MHz, CDCl3): δ 5.29-5.11 [m, 124H, PLA(-CHCH3)],  
4.91-4.62 [m, 170H, PGA(-CH2-)], 4.41-4.20 [m, 9H, mPEG-(-OCH2-PGA/PLA) 
and mPEG-PLGA-CH(CH3)-OH}) ], 3.79-3.49 [m, 455H, MeO-PEG(-
OCH2CH2O-)], 3.38 (s, 3H, MeO-PEG-), and 1.69-1.45 [m, 430H, PLA(-
CHCH3)]. 
SEC (Polystyrene standards) PDI = 1.02.  
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tetra-(-)-menthoxy silicate (MenO)4Si (411). 
 
Silicaon tetrachloride (SiCl4 0.36 mL, 3.14 mmol, 1.0 equiv) was dissolved in dry 
pentane (5.0 mL) in an oven-dried three neck round bottom flask fitted with a 
magnetic stir bar. (-)-Menthol (2.05 g, 13.12 mmol, 4.2 equiv) was dissolved in 
pentane and added dropwise by a liquid addition funnel to the round bottom flask.  
1H-NMR determined that the monochlorosilane (410) and excess starting 
material 409 remained even after 4 hours. Pyridine (1 mL, 7.14 mmol, 2.3 equiv) 
was added by syringe to the reaction mixture. A white precipitate was observed 
immediately upon the addition of the pyridine and 1H-NMR confirmed 411 as the 
dominant product. The pentane was removed by evaporation under reduced 
pressure and the solid residue was triturated with a mixture of hexanes:EtOAc 
(95:5), and the resulting slurry was filtered through a short plug of Celite® to 
remove the ammonium salt. The filtrate was concentrated under reduced 
pressure, and the residue was purified by flash chromatography (SiO2, 95:5 
OH
SiCl4 , pyridine
THF, 2h
SiCl4
pentane
 > 4 h
O Si Cl
3
4
py
10 min
410
O Si
4 411409
95 % yield
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hexanes:EtOAc) to yield the title compound 411 as a white, crystalline solid (1.94 
g, 2.98 mmol, 95%). 
1H NMR (500 MHz, CDCl3): δ 3.65 (dt, J = 10.5, 4.2 Hz, 4H, H1), 2.28 (dq, J =  
7.0, 2.5 Hz, 4H, H7), 2.09 (m, 4H, H6), 1.66-1.56 (m, 8H, H3 and H4), 1.33 (m, 
4H, H5), 1.18 (dt, J = 10.2, 5.9, 2.9 Hz, 4H, H2), 1.03 (dd, J = 12.1, 4H. H6), 
0.94 (dd, J = 12.5, 2.9, 4H. H3), 0.90 (d, J = 6.6, 12H, H8), 0.88 (d, J = 7.1, 
12H, H9), 0.82 (dd, J = 12.3, 2.9, 4H. H4), and 0.74 (d, J = 6.9, 12H, H10).  
13C NMR (125 MHz, CDCl3)127 δ 73.2 (C-1), 49.7 (C-2), 44.9 (C-6), 34.5 (C-4), 
31.7 (C-5), 25.1 (C-7), 22.7 (C-3), 22.3 (C-8), 21.3 (C-9), 15.6 (C-10).  
GC-MS tr (5031022H) = 13.66 min; m/z: 649. 
mp = 103-104 °C.  TLC Rf (95:5 hexanes:EtOAc) = 0.66. 
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tris((1R,2S,5R)-2-isopropyl-5-methylcyclohexyl) (2,4,6-triiodophenyl) 
silicate (413) 
 
Triiodophenol (206 mg, 0.44 mmol, 1.0 equiv.) was dissolved in dry THF (3.0 mL) 
in an oven-dried culture tube fitted with a Teflon-lined cap and magnetic stir bar. 
Pyridine (104 μL, 1.30 mmol, 3.0 equiv.) was added by Wiretrol®. 
Trimenthoxychlorosilane (305d) (690 mg, 1.30 mmol, 3.0 equiv.) was added by a 
syringe. The culture tube was sealed and the suspension was allowed to stir for 
24 h at 45 ºC. A white precipitate was observed to grow in upon the addition of 
the chlorosilane to the reaction mixture. The THF was removed by evaporation 
under reduced pressure and the solid residue was triturated with a mixture of 
hexanes:EtOAc (98:2), and the resulting slurry was filtered through a short plug 
of Celite® to remove the pyridinium salt. The filtrate was concentrated under 
reduced pressure, and the residue was purified by sequential MPLC (SiO2, 98:2, 
99:1, then 100:0 hexanes:EtOAc) to yield 413 the title compound as a white 413, 
crystalline solid (62.7 mg, 0.065 mmol, 15%) as well as monochlorosilane 410 
and 411. 
(MenO)3SiCl
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py, THF
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I
I
I
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123
4 5 6
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1H NMR (500 MHz, CDCl3): δ 8.03 (s, 2H, H11), 3.89 (dt, J = 10.5, 4.2 Hz, 3H, 
H1), 2.29 (dq, J =  7.0, 2.5 Hz, 3H, H7), 2.14 (m, 3H, H6), 1.65-1.56 (m, 6H, 
H3 and H4), 1.35 (m, 3H, H5), 1.18 (dt, J = 10.2, 5.7, 2.9 Hz, 3H, H2), 1.05 
(dd, J = 11.2, 3H. H6), 0.89 (m, 3H. H3), 0.84 (d, J = 6.9, 9H, H8), 0.75 (d, J = 
7.1, 9H, H9), 0.74 (m, 3H. H4), and 0.70 (d, J = 6.9, 9H, H10).  
GC-MS tr (5031022H) = 18.18 min; m/z: 964, 921, 879, 826, 688, 533, 471, 406, 
280, 137, 81 and 55. 
TLC Rf (100:0 hexanes:EtOAc) = 0.60 
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Figure S4.1 | X-ray powder diffraction (XRD) of PTX-2’-Si(OnOct)3 (301b) as the 
pure compound (red) vs. nanoparticles (5k-10k mPEG-b-PLGA BCP) loaded with 
65.0 wt% (blue). 
 
	  
Figure S4.2 | X-ray powder diffraction (XRD) of PTX-2’,7-[Si(OEt)3]2 (302a) as 
the pure compound (red) vs. nanoparticles (5k-10k mPEG-b-PLGA BCP) loaded 
with 60.4 wt% (blue).	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Figure S4.3 | Dialysis permeability control experiments. (A) Percentage of 
paclitaxel remaining inside dialysis capsules and diffusing out of the capsules 
into PBS over time. (B) Percentage of  PTX-2’,7-[Si(OEt)3]2 (8), intermediate 
PTX-7-Si(OEt)3 (6), and PTX remaining inside dialysis capsules over time. 
 
Release profiles at pH = 7.4. 
 
Figure S4.4 | Release profiles for nanoparticles loaded with PTX-2’-Si(OEt)3 
(301a) at pH 7.4. Amount of PTX-2’-Si(OEt)3 (301a) (A) appearing outside or (B) 
remaining inside dialysis capsules vs. time. 
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Figure S4.5 | Release profiles for nanoparticles loaded with PTX-2’-Si(OnOct)3 
(301b) at pH 7.4. Amount of PTX-2’-Si(OnOct)3 (301b) (A) appearing outside or 
(B) remaining inside dialysis capsules vs. time. 
 
 
Release profiles at pH=5.0 
 
Figure S4.6 | Release profiles for nanoparticles loaded with PTX-2’-Si(OEt)3 
(301a) at pH 5.0. Amount of PTX-2’-Si(OEt)3 (301a) (A) appearing outside or (B) 
remaining inside dialysis capsules vs. time. 
 
 
0 10 20 30 40 50
0
10
20
30
40
50
60
70
80
90
100
+tota l
+P T X
+(1b)+2 '7trioc tyl+S i+P T X
re
m
ai
ni
ng
%
time/hr
0 10 20 30 40 50
0
10
20
30
40
50
60
70
80
90
100
+tota l
+P T X
+1b42 '4tri+oc tyl+S i+P T X
re
le
as
e%
time/hr
0
100
90
80
70
60
50
40
30
20
10
0
0 10 20 30 40 50
Time (h)
Re
lea
se
 (%
)
A
Total
PTX
301b, PTX-2'-Si(OnOct)3
Total
PTX
30 , PTX-2'-Si(OnOct)3
100
90
80
70
60
50
40
30
20
10
0
10 20 30 40 50
Time (h)
B
Re
m
ain
ing
 (%
)
0 5 10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
+tota l
+P T X
+(1a )+2 '6trie thyl+S i+P T X
re
le
as
e%
time/hr
0 5 10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
+tota l
+P T X
+(1a )+2 '6trie thyl+S i+P T X
re
m
ai
ni
ng
%
time/hr
0
100
90
80
70
60
50
40
30
20
10
0
5 1 5
Time (h)
Re
lea
se
 (%
)
A 100
90
80
70
60
50
40
30
20
10
0
5 10 15 20 25
Time (h)
B
Re
m
ain
ing
 (%
)
Total
PTX
301a, PTX-2'-Si(OEt)3
T t l
PTX
301a, PTX-2'-Si(OEt)3
 Experimental 278 
 
 
278 
 
Figure S4.7 | Release profiles for nanoparticles loaded with PTX-2’-Si(OnOct)3 
(301b) at pH 5.0. Amount of PTX-2’-Si(OnOct)3 (301b) (A) appearing outside or 
(B) remaining inside dialysis capsules vs. time. 
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Figure S4.8 | Equations used to determine the wt% of PTX-silicate-loaded NP, 
the equivalent wt% of free PTX in the silicate-loaded NP, and the efficiency of 
prodrug incorporation by 1H-NMR spectroscopy. 
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Figure S4.9 | 1H-NMR of 303c nanoparticles throughout the ultracentrifugation 
process. All 1H-NMR intensity is normalized to H2. Each wash step removes 
more polymer than prodrug, resulting in a greater loading level of 303c in the final 
nanoparticle dry pellet (blue). 
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Figure S4.10 | The change in loading level (wt%) of prodrug nanoparticle 
formulations of 301b, 301c, 302a, 303a, 303b, and 303c after each 
ultracentrifugation step. The plot was generated by taking the final weight pellet 
at the end of the process and adding back in the masses of prodrug polymer lost 
in each wash step of the ultracentrifugation, back to the initial FNP experiment. 
The target loading is depicted on the left. 
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Figure S4.11 | Cryo-TEM images of nanoparticles loaded with A-C) PTX-2´7,-
[Si(OEt)3]2 (302a), D-F) PTX-2’Si(OtBu)2(OEt) (301f). A and D) freshly prepared 
(i.e., prior to centrifugation), B and E) lyophilized, immediately following 
redispersion into PBS, and C and F) lyophilized following redispersion into PBS 
and aging for 24 h in a dialysis cassette suspended in PBS (pH 7.4). Particles 
made from 302a, which hydrolyzed rapidly, lost their cores and appear to shrink 
while 301d, with very slow hydrolysis, did not change with 24 hr aging. 
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Figure S4.12 | Cryo-TEM images of PEG-b-PLGA (5k-10k) nanoparticles loaded 
with PTX-2’Si(OtBu)2(OEt) (301f) lyophilized, immediately following redispersion 
into PBS, in aqueous solution. The chain of fused particles clearly shows 
aggregation after freeze drying. 
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Figure S4.13 | Cryo-TEM images of PEG-b-PLGA block copolymer in aqueous 
solution. A) Low magnification of block copolymer particles B) high magnification 
of red box in A) white arrows may suggest PEO halos and black arrowheads are 
beam-damaged block copolymers. We observe such beam damage only for 
nanoparticles with no drug. The PEO halo may be observed in the very thin 
vitrified aqueous film in an underfocused mode (6 µm). 
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Methoxypolyethylene glycol tosylate (422b) 
 
In an oven dried culture tube, MeO-PEG-OH 403 (3.08 g, 0.60 mmol, 1.0 equiv.) 
was dissolved in 15 mL of CH2Cl2. p-Toluenesulfonyl chloride (Ts-Cl, 1.51 g, 6.0 
mmol, 10 equiv.) was added and the reaction mixture was stirred at rt for 5 mins. 
Pyridine (485 µL, 6.0 mmol, 10 equiv.) was added and the reaction was allowed 
to run overnight ca. 18 hours. The crude product was concentrated and . added 
dropwise into 50 mL of ice cold (0 ºC) ether, which precipitated the polymer. The 
ether was decanted and the polymer was dried over vacuum to yield the title 
polymer 422b as a white solid (1.90 g, 0.368 mmol, 61.4%). 
1H NMR (500 MHz, CDCl3): δ 7.80 (d, J =  8.4 Hz, 2H, H6), 7.34 (d, J =  7.9 Hz, 
2H, H7), 4.16 (m, 2H, H5), 3.79 (m,  2H, H4), 3.75-3.57 (m, 447H, backbone 
Hs), 3.55 (m, 2H, H3), 3.50 (m, 2H, H2), 3.38 (s, 3H, H1), and 2.45 (s, 3H, 
H8). 
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Methoxypolyethylene glycol mesylate (422c) 
 
MeO-PEG-OH 403 (5.00 g, 1.0 mmol, 1.0 equiv.) was dissolved in 10 mL of 
CH2Cl2 and 3 Å molecular sieves over night. The reaction mixture was then 
transferred to an oven-dried culture tube with stir bar and pyridine (240 µL, 3.0 
mmol, 3 equiv.) and methanesulfonyl chloride (230 µL, 3.0 mmol, 3 equiv.) were 
added. The culture tube was capped with a Teflon-lined cap and allowed to stir 
overnight.  The crude product was concentrated and . added dropwise into 50 mL 
of ice cold (0 ºC) ether, which precipitated the polymer. The ether was decanted 
and the polymer was dried over vacuum to yield the title polymer 422b as a white 
solid (3.66 g, 0.72 mmol, 72 %). 
1H NMR (500 MHz, CDCl3): δ 4.39 (t, J = 4.4 Hz, 2H, H5), 3.75-3.57 (m, 453H, 
H2, H3, H4, and backbone Hs), 3.38 (s, 3H, H1), and 3.09 (s, 3H, H6). 
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Methoxypolyethylene glycol azide (420b) 
 
In a 10 mL oven dried culture tube, MeO-PEG-OTs 422b (393 mg, 0.08 mmol 1.0 
equiv.) was dissolved in 5 mL of DMF dried over 3 Å molecular sieves. NaN3 (51 
mg, 0.8 mmol, 10 equiv.) was added and the reaction mixture was stirred at r.t. 
for 18 hours. The crude product was extracted 3 times with CH2Cl2 and washed 
with water, and brine. The organic extracts were concentrated and added 
dropwise into 50 mL of ice cold (0 ºC) ether, which precipitated the polymer. The 
ether was decanted and the polymer was dried over vacuum to yield the title 
polymer 420b as a white solid (320 mg, 80%). 
1H NMR (500 MHz, CDCl3): δ 3.79 (m, 2H, H4), 3.70-3.63 (m, 447H, backbone 
Hs), 3.55 (m, 2H, H3), 3.50 (m, 2H, H2), 3.40 (m, 2H, H5), and 3.38 (s, 3H, 
H1). 
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Methoxypolyethylene glycol amine (421b) 
 
In a 25 mL oven dried round bottom flask, MeO-PEG-N3 420b (79.5 mg, 0.0159 
mmol, 1.0 equiv.) was dissolved in 5 mL of CH2Cl2. Palladium on carbon [Pd/(C), 
15.7 mg was added to the reaction. The headspace was flushed with N2 followed 
by a H2 purge. Lastly, a hydrogen (H2) balloon was fixed to the septa of the flask 
and the reaction was allowed to stir at r.t. overnight.  The solution was passed 
through a plug of cealite and washed 2x 5 mL with CH2Cl2.  The crude product 
was concentrated added dropwise into 10 mL of ice cold (0 ºC) ether, which 
precipitated the polymer. The ether was decanted and the polymer was dried 
over vacuum to yield the title polymer 421b as a white solid (43.7 mg, 0.009 
mmol, 55%). 
1H NMR (500 MHz, CDCl3): δ 3.75-3.63 (m, 453H, H2, H3, H4, and backbone 
Hs), 3.55 (m, 2H, H3), 3.50 (m, 2H, H2), 3.40 (m, 2H, H5), and 3.38 (s, 3H, 
H1), 2.89 (t, J = 5.2 Hz, 2H, H5), and 1.9 (br s, 2H, -NH2). 
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Methoxypolyethylene glycol carbamate (421c) 
 
In a 10 mL oven dried culture tube, MeO-PEG-NH2 421b (48 mg, 0.0096 mmol, 
1.0 equiv.) was dissolved in 6 mL of THF. Di-tert-butyl dicarbonate (BOC2, 2.1 
mg, 0.0096 mmol, 1.0 equiv.) was added and the reaction was allowed to stir at 
r.t. for 24 hours. The crude product was concentrated to ca. 1 mL THF and added 
dropwise into 12 mL of ice cold (0 ºC) ether, which precipitated the polymer. The 
ether was decanted and the polymer was dried over vacuum to yield the title 
polymer 421c as a white solid (30.6 mg, 0.006 mmol, 63%). 
1H NMR (500 MHz, CDCl3): δ 4.32 (br m, 1H, -NHBOC), 3.79-3.50 (m, 455H, H2, 
H3, H4, H5, and backbone Hs), 3.38 (s, 3H, H1), and 1.25 (s, 9H, H6) 
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Methoxypolyethylene glycol amine (421b) 
 
In a 25 mL oven dried round bottom flask, MeO-PEG-N3 420b (79.5 mg, 0.0159 
mmol, 1.0 equiv.) was dissolved in 5 mL of CH2Cl2. Palladium on carbon [Pd/(C), 
15.7 mg was added to the reaction. The headspace was flushed with N2 followed 
by a H2 purge. Lastly, a hydrogen (H2) balloon was fixed to the septa of the flask 
and the reaction was allowed to stir at r.t. overnight.  The solution was passed 
through a plug of cealite and washed 2x 5 mL with CH2Cl2.  The crude product 
was concentrated added dropwise into 10 mL of ice cold (0 ºC) ether, which 
precipitated the polymer. The ether was decanted and the polymer was dried 
over vacuum to yield the title polymer 421b as a white solid (43.7 mg, 0.009 
mmol, 55%). 
1H NMR (500 MHz, CDCl3): δ 3.75-3.63 (m, 453H, H2, H3, H4, and backbone 
Hs), 3.55 (m, 2H, H3), 3.50 (m, 2H, H2), 3.40 (m, 2H, H5), and 3.38 (s, 3H, 
H1), 2.89 (t, J = 5.2 Hz, 2H, H5), and 1.9 (br s, 2H, -NH2). 
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2-(2-(2-azidoethoxy)ethoxy)ethan-1-ol (424) 
 
A 100 mL round bottom flask was charged with NaN3 (1.75 g, 27.2 mmol, 3.1 
equiv.) and tetrabutyl-ammonium iodide (TBAI, 331 mg, 0.90 mmol, 0.1 equiv.) 
and dissolved with 20 mL of THF. The reaction was allowed to stir for 20 mins at 
which point 423 (1.50 g, 8.90 mmol, 1 equiv.) was added dropwise over the 
course of 5 mins.  The reaction proceeded for 8 hours. The THF was removed by 
rotary evaporation and replaced with 20 mL of EtOAc, washed with brine, dried 
over MgSO4. The EtOAC was removed and the residue was purified via flash 
column chromotagraphy (hexane:EtOAc = 7:3; to yield the title compound 424 
(1.31 g, 7.48 mmol, 84%) as a light orange oil.  
1H NMR (500 MHz, CDCl3): δ 3.75 (br t, 1H, H7), 3.71-3.66 (m, 8H, H3–H6), 3.63 
(m, 2H, H2), and 3.41 (t, J = 5.0 Hz, 2H, H1). 
13C NMR (125 MHz, CDCl3): δ 72.5, 70.6, 70.3, 70.0, 61.6, and 50.6. 
GC- MS: [30 m x 0.25 mm ID, HP-5, 50 °C/1.5 min/10 °C min-1/290 °C, 
(5029021)] tR = 9.86 min [m/z] 175 (M+), 158 (M+• -OH), 100 (M+• -C3H7O2), 
and 56 (M+• -C5H11O3).  
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3-(2-(2-(2-Azidoethoxy)ethoxy)ethoxy)prop-1-yne (426) 
 
In a 100 mL round bottom flask, 424 (226 mg, 1.5 mmol, 1 equiv.) was dissolved 
in 10 mL of DMF. NaH (48 mg, 2.0 mmol, 1.3 equiv.) and propargyl bromide 425 
(330 µL, 3.0 mmol, 2.0 equiv.) were added slowly to the solution, which was then 
stirred at r.t. for 10 hours. The DMF was removed and the residue was purified 
via flash column chromotagraphy (hexane:EtOAc = 7:3; to yield the title 
compound 426 (217 mg, 1.02 mmol, 68%) as an orange oil.  
1H NMR (500 MHz, CDCl3): δ 4.15 (d, J= 2.5 Hz, 2H, H7), 3.60-3.68 (m, 10H, 
H2–H6), 3.34 (t, J = 5.0 Hz, 2H, H1), and 2.37 (t, J = 2.5 Hz, 1H, H8). 
13C NMR (125 MHz, CDCl3): δ 78.24, 74.53, 70.71, 70.69, 70.52, 70.07, 69.12, 
58.42, and 50.70. 
GC- MS: [30 m x 0.25 mm ID, HP-5, 50 °C/1.5 min/10 °C min-1/290 °C, 
(5029021)] tR = 9.3 min [m/z] 213 (80, M+), 126 (100, M+• -C2H4N3OH), and 54 
(99, M+• -C6H12N3O2H).  
TLC Rf (7:3 hexanes:EtOAc) = 0.4. 
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3-(2-(2-(2-Aminoethoxy)ethoxy)ethoxy)prop-1-yne (428) 
 
In a 25 mL culture tube, 426 (135 mg, 0.63 mmol, 1.0 equiv.) and 
triphenylphosphine (Ph3P, 332 mg, 1.27 mmol, 2.0 equiv.) were dissolved in 10 
mL of THF. The reaction mixture was stirred at r.t. for 4 hours, after which HPLC 
grade H2O (1 mL) was added. The reaction mixture was stirred for an additional 
48 hours, concentrated, and purified by flash column chromatography 
(CH2Cl2:MeOH:TEA = 80:20:1) to yield 428 as an oil (64 mg, 0.340 mmol, 54%). 
1H NMR (500 MHz, CDCl3): δ 4.21 (d, J = 2.5 Hz, 2H, H7), 3.68-3.70 (m, 8H, H3-
H6), 3.41 (t, J = 5.0 Hz, 2H, H2), 3.39 (t, J = 5.0 Hz, 2H, H1), 2.44 (t, J = 2.0 
Hz, 1H, H8), and 1.47 (br s, 2H, -NH2). 
13C NMR (125 MHz, CDCl3): δ 79.75, 74.92, 73.12, 70.51, 69.70, 69.44, 69.11, 
58.39, and 41.68. 
GC- MS: [30 m x 0.25 mm ID, HP-5, 50 °C/1.5 min/10 °C min-1/290 °C, 
(5029021)] tR = 6.5 min [m/z] 187 (4, M+), 127 (5, M+• -C2H6NO), 87 (100, M+• -
C5H7OH).  
LC-MS: Waters Symmetry-C8 3.9 x 150 mm particle size 5 µm; 1 mL/min 
Isocratic Method 100 % for 20 min (Solvent System of 98:2 MeOH:H2O,15 mM 
NH4OAc), MM-ES+APCI Positive Scan 2.4 min 188.2 (100, M+H)+. 
TLC Rf (CH2Cl2:MeOH:TEA = 80:20:1) = 0.38. 
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3-(2-(2-(2-chloroethoxy)ethoxy)ethoxy)prop-1-yne (427) 
 
In an oven-dried culture tube, 423 (554 mg, 3.28 mmol, 1.0 equiv.) was dissolved 
in 5 mL of DMF. NaH (77.7 mg, 3.29 mmol, 1.0 equiv.) and propargyl bromide 
425 (584.5 µL, 6.56 mmol, 2.0 equiv.) were added slowly to the solution, which 
was then stirred at r.t. for 18 hours. GC-MS determined 427 was the major 
compound.  The chloro-alkyne 427 was taken forward to the next step without 
purification.  
GC- MS: [30 m x 0.25 mm ID, HP-5, 50 °C/1.5 min/10 °C min-1/290 °C, 
(5029021)] tR = 10.097 min [m/z] 206 (M+), 151 (M+• -C3H3O), 133 (M+• -
C3H2Cl), 107 (M+• -C5H17O2), and 55 (M+• -C6H12ClO2).  
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3-(2-(2-(2-Aminoethoxy)ethoxy)ethoxy)prop-1-yne (428) 
 
In a culture tube, 427 (546.3 mg, 3.24 mmol, 1.0 equiv.) and ammonia in 
methanol (454.2 mg, 12.96 mmol, 4.0 equiv.) were dissolved in 10 mL of MeOH. 
The reaction mixture was stirred at r.t. for 72 hours. The crude reaction mixture 
was concentrated, and purified by flash column chromatography 
(CH2Cl2:MeOH:TEA = 80:20:1) to yield 428 as an oil (254 mg, 1.36 mmol, 42%). 
1H NMR (500 MHz, CDCl3): δ 4.21 (d, J = 2.5 Hz, 2H, H7), 3.68-3.70 (m, 8H, H3-
H6), 3.41 (t, J = 5.0 Hz, 2H, H2), 3.39 (t, J = 5.0 Hz, 2H, H1), 2.44 (t, J = 2.0 
Hz, 1H, H8), and 1.47 (br d, 2H, NH2). 
13C NMR (125 MHz, CDCl3): δ 79.75, 74.92, 73.12, 70.51, 69.70, 69.44, 69.11, 
58.39, and 41.68. 
GC- MS: [30 m x 0.25 mm ID, HP-5, 50 °C/1.5 min/10 °C min-1/290 °C, 
(5029021)] tR = 6.5 min [m/z] 187 (4, M+), 127 (5, M+• -C2H6NO), 87 (100, M+• -
C5H7OH).  
LC-MS: Waters Symmetry-C8 3.9 x 150 mm particle size 5 µm; 1 mL/min, 
Isocratic Method 100 % for 20 min (Solvent System of 98:2 MeOH:H2O,15 mM 
NH4OAc)     MM-ES+APCI Positive Scan 2.4 min 188.2 (100, M+H)+. 
TLC Rf (CH2Cl2:MeOH:TEA = 80:20:1) = 0.38. 
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 (+)-Biotin N-hydroxysuccinimide ester (429a) 
 
In an oven dried culture tube, biotin (429) (112 mg, 0.459 mmol, 1.0 equiv.), N-
hydroxysuccinimide (NHS, 40.6 mg, 0.459 mmol, 1.0 equiv.), and N,N’-
dicyclohexylcarodiimide (DCC, 141.9 mg, 0.69 mmol, 1.5 equiv.), were dissolved 
in 5 mL of DMF. The reaction mixture was stirred at r.t. for overnight.  The 
reaction mixture was concentrated, and the solid product 429a was placed on a 
Büchner funnel and washed with 10 mL ether 3x the resulting white solid 429a 
(156.5 mg, 0.459 mmol, quant.) was used without further purification. 
1H NMR (500 MHz, CDCl3): δ 5.65 (s, 1H, NHb), 5.58 (s, 1H, NHa), 4.49-4.47 (m, 
1H, Hb), 4.29 (ddd, J = 7.4, 4.9, 2.2 Hz, 1H, Ha), 3.16 (ddd, J = 8.2, 6.5, 4.6 
Hz, 1H, Hd), 2.90 (dt, J = 12.0, 5.7 Hz, 1H, Hc), 2.86 (s, 4H, Hi), 2.75 (d, J = 
12.7 Hz, 1H, Hc), 2.64 (dd, J = 7.2, 5.6 Hz, 2H, Hh), 1.90-1.62 (m, 4H, He and 
Hg), 1.58-1.52 (m, 2H, Hf). 
N
H
H
N
S O
HO2C
H
H
429 429a
NHS
DCC
DMF
r.t. 18 h
N
H
H
N
S O
H
H
O O N
O
O
quant. yield
a
b
c
d
e
f
g
h
i
i
 Experimental 297 
 
 
297 
13C NMR (CDCl3)221: δ 170.2, 168.4, 165.3, 62.2, 60.1, 56.7, 42.4, 31.8, 28.4, 
25.3, 24.1, 23.2.  
LC-MS: Waters Symmetry-C8 3.9 x 150 mm particle size 5 µm; 1 mL/min, 
Gradient Method 50% B to 100% B over 15 min, hold at 100% B for 10 min 
(Solvent System A, 5:95 MeOH:H2O,15 mM NH4OAc) (Solvent System B, 98:2 
MeOH:H2O,15 mM NH4OAc), MM-ES+APCI Positive Scan 10.3 min 359 
(M+NH4)+, 364 (M+Na)+; Negative Scan 10.3 min 400 (M+OAc)-, and 376 
(M+Cl)-. 
  
                                            
221 Ma, M.; Bong, D. Protein Assembly Directed by Synthetic Molecular Recognition Motifs. Org. 
Biomol. Chem. 2011, 9, 7296. 
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5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-N-(2-(2-(2-
(prop-2-yn-1-yloxy)ethoxy)ethoxy)ethyl)pentanamide (430) 
 
In an oven dried culture tube, biotin-NHS (429a) (23.97 mg, 0.072 mmol, 1.0 
equiv.), 3-(2-(2-(2-Aminoethoxy)ethoxy)ethoxy)prop-1-yne (428) (20.3 mg, 0.108 
mmol, 1.5 equiv.), and triethylamine (TEA, 20 µL, 0.144 mmol, 2.0 equiv.) were 
dissolved in 1.0 mL of dry DMF.  After 72 h of reaction the DMF from removed 
and an LC-MS of the crude orange oil determined the completeion of the coupling 
along with the urea by-products from the formation of 429a.  The biotin linker 430 
was purified by affinity chromatography.  A 1 mL affinity column was made with 
Pierce™ NeutrAvidin™ Agarose resin.  The oil was loaded onto the column with 
0.5 mL of DMSO and vortexed for 5 min. The DMSO and byproducts were eluted 
off of the column, leaving the desired 430 product on the column.  An additional 
600 µL of DMSO was added and the affinity column was heated to 85 ºC for 1 
min.  The product was eluted off the column.  The 1H-NMR and LC-MS 
determined the purity of the compound 430 (16.1 mg, 0.039 mmol, 54%). 
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1H NMR (500 MHz, CDCl3): δ 8.02 (s, 1H, NHi), 6.58 (t, J = 5.0 Hz, 1H, NHb), 
6.28 (s, 1H, NHa), 4.53 (dd, J = 7.4, 5.0 Hz, 1H, Hb), 4.34 (dd, J = 7.4, 4.4, 
1H, Ha), 4.20 (d, J = 2.3 Hz, 2H, Hp), 3.77-3.61 (m, 10H, Hk-Ho), 3.57 (t, J = 
5.0 Hz, 2H, Hj), 3.16 (td, J = 7.2, 4.6 Hz, 1H, Hd), 2.92 (dd, J = 12.9, 4.9 Hz, 
1H, Hc), 2.76 (d, J = 12.8 Hz, 1H, Hc), 2.47 (t, J = 2.3 Hz, 1H, Hq), 2.29-2.19 
(m, 2H, Hh), 1.94-1.59 (m, 4H, He and Hg), 1.46 (dt, J = 14.5, 7.3 Hz, 2H, Hf). 
LC-MS: Waters Symmetry-C8 3.9 x 150 mm particle size 5 µm; 1 mL/min, 
Gradient Method 50% B to 100% B over 10 min, hold at 100% B for 15 min 
(Solvent System A, 5:95 MeOH:H2O,15 mM NH4OAc) (Solvent System B, 98:2 
MeOH:H2O,15 mM NH4OAc), MM-ES+APCI Positive Scan 4.4 min 431 
(M+NH4)+, 414 (M+H)+; Negative Scan 4.4 min 472 (M+OAc)-, 448 (M+Cl)-, 
458 (M+O2CH)-, 491 (M+DMSO)-, and 412 (M-H)-. 
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Methoxypolyethylene glycol 4-(trimethylsilyl)-1H-1,2,3-triazole (432b) 
 
In an oven dried culture tube, MeO-PEG-N3 420b (195.6 mg, 0.0391 mmol, 1.0 
equiv.) was dissolved in 10 mL of Toluene. A catalytic amount of copper(I) iodide 
(CuI, 3,72 mg, 0.0196 mmol, 0.5 equiv.) and an excess amount of DBU (112.8 
mg, 0.782 mmol, 20.0 equiv.) was added. The reaction mixture was allowed to 
stir for 5 min at which point ethynyltrimethylsilane (38.4 mg, 0.391 mmol, 10.0 
equiv.) was added.  The culture tube was sealed with a Teflon lined cap and 
heated to 50 ºC for 16 hours. The solution was passed through a plug of silica < 
1 c.m and concentrated. The crude product with residual solvent was added 
dropwise into 10 mL of ice cold (0 ºC) ether, which precipitated the polymer. The 
ether was decanted and the polymer was dried over vacuum to yield the title 
polymer 432b as a dark solid (20.4 mg, 0.0040 mmol, 10.2%). 
1H NMR (500 MHz, CDCl3): δ 7.68 (s, 1H, Ha), 4.56 (t, J = 5.1 Hz, 2H, Hb), 3.87 
(t, J = 5.1 Hz, 2H, Hc), 3.79-3.57 (m, 451H, He), 3.38 (s, 3H, Hf), and 0.31 [s, 
9H, TMS(Hd)]. 
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Figure S4.14 | 1H-NMR of the polymer click reaction product after 1 precipitation 
into cold ether. 
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(S)-3-(benzyloxy)-2-hydroxypropanoic acid (436) 
 
In a 100 mL round bottom flask 434 (10.4 g, 35.2 mmol, 1.0 equiv.) and TFA 
(10.0 mL, 14.9 g, 130.6 mmol, 3.7 equiv.) were dissolved in 60 mL of CH2Cl2. 
The reaction mixture was stirred at r.t. for 3.5 hours. The crude reaction mixture 
was concentrated, and a crude 1H-NMR showed full conversion to 435, which 
matched literature. The waxy solid was taken forward to the next reaction without 
further purification. The amide 435 and NaNO2 (3.42 g, 69.0 mmol, 1.4 equiv.) 
were dissolved in 25 mL of deionized H2O. A second portion of TFA (4.0 mL, 
52.2 mmol, 1.5 equiv.) was added and the headspace was purged 3 times with 
N2. The reaction was allowed to stir at room temperature for overnight (~16 h). 
Solid NaCl was added to the reaction mixture. The aqueous solution was 
extracted with ethyl acetate. The combined organic layers were dried (MgSO4) 
and concentrated to give the compound 436 as a yellow oil (6.2 g, 31.7 mmol, 
90%). To remove residual amount of TFA, DCM was added to the mixture and 
evaporated under reduced pressure. This was repeated several times. The 
yellow oil obtained was used in the next reaction without further purification. The 
1H-NMR matched literature175 so no other characterization was performed. 
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1H NMR (500 MHz, CDCl3): δ 7.35-7.186 (m, 5H, -OCH2Ph), 4.49 (s, 2H, -
OCH2Ph), 4.31 (t, J = 4 Hz, 1H, -CHCH2O-), 3.76 (dd, J = 4 Hz, 1H, -
CHCH2OCH2Ph), and 3.69 (dd, J = 4 Hz, 1H, -CHCH2O-). 
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(3S,6S)-3,6-bis((benzyloxy)methyl)-1,4-dioxane-2,5-dione (438) 
 
In a round bottom flask, 436 (14.5 g, 73.9 mmol, 1.0 equiv.) and p-toluenesulfonic 
acid catalyst (p-TsOH, 800 mg, 4.7 mmol, 6 mol%) were dissolved in 1.5 L of 
toluene and brought to reflux. The reaction mixture was refluxed at 168 ºC for 7 
days and the water removed through azeotropic distillation into a Dean-Stark 
trap. The toluene was removed and replaced with 20 mL of water, and extracted 
3x 200 mL with diethyl ether. The organic layer was dried with MgSO4 and the 
ether removed to yield the desired monomer 438 (8.95 g, 25.1 mmol, 34%). 1H-
NMR matched literature175 so no other characterization was performed. 
1H NMR (500 MHz, CDCl3): δ 7.36-7.26 (m, 10H, -OCH2Ph), 5.13 (t, J = 4.0 Hz, 
2H, -CHCH2O-), 4.48 (d, J = 11.5 Hz, 2H, -CHCH2OCH2Ph), 4.44 (d, J = 11.5 
Hz, 2H, -CHCH2OCH2Ph), and 3.89 (d, J = 4.0 Hz, 4H, -CHCH2O-). 
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3-(2-(2-(2-Aminoethoxy)ethoxy)ethoxy)prop-1-yne (428) 
 
In a 50 mL oven dried round-bottom flask charged with a magnetic stir bar 436 
(2.50 g, 12.7 mmol, 1.0 equiv.), triphosgene (3.92 g, 13.2 mmol, 1.1 equiv.) were 
dissolved in 10 mL of dry THF. Activated charcoal (30 mg) was added added and 
the reaction mixture was stirred at r.t. for 8 hours. The crude reaction mixture was 
filtered through a plug of cealite, concentrated, and purified by three MPLC runs 
(SiO2, 1:1, hexanes:EtOAc) to yield the title compound 437 as a white solid (1.52 
g, 6.86 mmol, 54%). 
1H NMR (500 MHz, CDCl3): δ 7.40-7.25 (m, 5H, -OCH2Ph), 5.12 (t, J = 2.1 Hz, 
1H, -CHCH2O-), 4.61 (d, J = 12.6 Hz, 1H, -CHCH2OCH2Ph), 4.56 (d, J = 12.3 
Hz, 1H, -CHCH2OCH2Ph), and 3.89 (m, 2H, -CHCH2O-). 
13C NMR (125 MHz, CDCl3): δ 165.5, 148.4, 136.2, 128.7 (2x), 128.3, 127.7 (2x), 
79.6, 73.8, and 66.1. 
GC- MS: [30 m x 0.25 mm ID, HP-5, 35 °C/1.5 min/10 °C min-1/250 °C, 
(3525018)] tR = 7.20 min [m/z] 222 (M+), 208 (M+• -H2O), 107 (M+• -C4H3O4), 91 
(M+• -C4H3O5), and 91 (M+• -C5H5O5). 
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Methoxy-capped poly(ethylene glycol)-block-poly(benzyloxy lactic acid)  
(439) 
 
MeO-PEG-OH (403, 5K, 5.0 g) was dissolved in 10 mL of dry CH2Cl2 and stored 
over 3 Å molecular sieves. From this stock solution 403 (200 µL, 100 mg, 0.02 
mmol, 1.0 equiv.) was added to the benzyl-protected lactide 4.38 (205.8 mg, 0.58 
mmol, 28.9 equiv.) in an oven-dried round-bottom flask containing a magnetic stir 
bar and 2 mL of CH2Cl2. The DBU catalyst (25 µL, 0.17 mmol, 8.4 equiv.) was 
added to the reaction.  After 1 hour of reaction solid benzoic acid (ca. 15 mg) was 
added to arrest the polymerization. The mPEG-b-PLBnA (439) was purified by 
precipitation twice into ice cold isopropanol from CH2Cl2 and dried at 50 °C under 
vacuum overnight yielding the desired product as a white solid with Mn [PL(Bn)A] 
= 11,000 g/mol.  
1H NMR (500 MHz, CDCl3): δ 7.34-7.24 [m, 567H, PLBnA(-OCH2-o-Ph), PLBnA(-
OCH2-m-Ph), and PLBnA(-OCH2-p-Ph)], 5.53-5.35 [m, 35H, PLBnA(-CHCH2O-
)], 4.64-4.46 [m, 173H, PLBnA(-CHCH2O-)], 4.03-3.81 [m, 133H, PLBnA(-
OCH2Ph)], 3.79-3.49 [m, 455H, MeO-PEG(-OCH2CH2O-)], and 3.38 (s, 3H, 
MeO-PEG-). 
  
439 mPEG-b-PLBnA
mPEG O
O
O
O
O H
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**
xBnO
OBn
438
mPEG OH 403O
O
O
O
OBn
OBn
DBU 404
CH2Cl2
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Methoxy-capped poly(ethylene glycol)-block-poly[(benzyloxy lactic)-co-
(lactic) acid] (440) 
 
MeO-PEG-OH (403, 5K, 5.0 g) was dissolved in 10 mL of dry CH2Cl2 and stored 
over 3 Å molecular sieves. From this stock solution 403 (200 µL, 100 mg, 0.02 
mmol, 1.0 equiv.) was added to the benzyl-protected lactide 4.38 (122.5 mg, 0.34 
mmol, 17.2 equiv.) and rac-lactide 401 (122.8 mg, 0.85 mmol, 42.6 equiv.) in an 
oven-dried round-bottom flask containing a magnetic stir bar and 10 mL of 
CH2Cl2. The DBU catalyst (30 µL, 0.20 mmol, 10.2 equiv.) was added to the 
reaction.  After 1 hour of reaction solid benzoic acid (ca. 50 mg in 5 mL CH2Cl2) 
was added to arrest the polymerization. The mPEG-b-PL(Bn/Me)A (440) was 
purified by precipitation 50 mL into ice cold isopropanol from CH2Cl2, centrifuged 
O
O
O
O
O O
(R,R-401)
D-Lactide
(S,S-401)
L-Lactide
438
440 mPEG-b-PLBn/MeA
Me
Me
Me
Me
OO
+ + mPEG OH
DBU 404
CH2Cl2
50:50 mixture: D,L-lactide,
rac-lactide, (±)-lactide, (±)-401
mPEG O
O
O
O
O
O
O O
O
H
* or S,S
**
x y n
403
O
O
O
O
OBn
OBn
Me
Me
**
BnO
OBn
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at 5,000 rpm, and dried at 50 °C under vacuum overnight yielding the desired 
product as a white solid (53% yield) with Mn [PL(Bn/Me)A] = 16,600 g/mol, ca. 
53:47 lactic(Bn):lactic(Me) ratio by mass. 
1H NMR (500 MHz, CDCl3): δ 7.37-7.21 [m, 261H, PLBnA(-OCH2-o-Ph), PLBnA(-
OCH2-m-Ph), and PLBnA(-OCH2-p-Ph)], 5.53-5.33 [m, 42H, PLBnA(-CHCH2O-
)], 5.27-5.10 [m, 109H, PLMeA(-CHCH3)], 4.65-4.35 [m, 119H, PLBnA(-
CHCH2O-)], 4.11-3.77 [m, 93H, PLBnA(-OCH2Ph)], 3.73-3.49 [m, 455H, MeO-
PEG(-OCH2CH2O-)], 3.39 (s, 3H, MeO-PEG-), and 1.64-1.43 [m, 430H, 
PLMeA(-CHCH3)]. 
SEC (Polystyrene standards) PDI = 1.08.  
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Table S5.1 | Characterization data for loaded nanoparticles used for intra-
tumoral studies. 
Pro-
drug 
# 
Pro-
drug 
(mg) 
Poly-
mer 
(mg) 
Total 
Mass 
Recov
ered 
(mg) 
wt% 
Recovered 
following 
centrifugation 
and 
lyophilization 
 
dI (nm) 
of the 
initially 
prepared 
FNP 
NPs 
 
PDI 
of the 
initially 
prepared 
FNP 
NPs 
 
PTX 
equivalent 
Loading 
2 88.4 59.5 114.2 77% 130 0.15 43% 
3 70.2 56.6 85.5 67% 93 0.15 58% 
6 33.7 28.3 21.1 34% 110 0.22 56% 
7 12.1 8.1 15.8 78% 110 0.18 31% 
8 72.2 52.3 76.0 61% 120 0.16 53% 
 
 
Figure S5.1 | Differential percentage of segmented neutrophils from the total 
white blood cell count (WBC). [normal range 10-40 %] 
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Figure S5.2 | Absolute number of segmented neutrophils calculated from the 
differential % of the whole mouse plasma. [normal range 0.1-2.4 x103/µL] 
 
Figure S5.3 | Differential percentage of lymphocytes from the total white blood 
cell count (WBC). [normal range 55-95 %] 
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Figure S5.4 | Absolute number of lymphocytes calculated from the differential 
percentage of the whole mouse plasma. [normal range 0.9-9.3 x103/µL] 
 
 
Figure S5.5 | Differential percentage of monocytes from the total white blood cell 
count (WBC). [normal range 0.1-3.5 %] 
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Figure S5.6 | Absolute number of monocytes calculated from the differential 
percentage of the whole mouse plasma. [normal range 0-0.4 x103/µL] 
 
 
Figure S5.7 | Differential percentage of eosinophils from the total white blood cell 
count (WBC). [normal range 0-4 %] 
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Figure S5.8 | Absolute number of eosinophils calculated from the differential 
percentage of the whole mouse plasma. [normal range 0-0.2 x103/µL] 
 
 
Figure S5.9 | Differential percentage of basophils from the total white blood cell 
count (WBC). [normal range 0-2 %] 
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Figure S5.10 | Absolute number of basophils calculated from the differential 
percentage of the whole mouse plasma. [normal range 0-0.2 x103/µL] 
 
 
Figure S5.11 | Absolute number of red blood cells (RBC) counted at millions per 
micro-liter (M/µL). [normal range 6.36-9.42 M/µL] 
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Figure S5.12 | Amount of hemoglobin protein present in the red blood cells 
measured as grams per deciliter (g/dL). [normal range 11.0-15.1 g/dL] 
 
 
Figure S5.13 | The percentage of red blood cells present (HCT) in the mouse 
whole blood sample. [normal range 35.1-45.4 %] 
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Figure S5.14 | The volume of red blood cells in the sample presented as the 
mean cell volume (MCV) measured in femtoliters (fL). [normal range 45.4-60.3 fL] 
 
 
Figure S5.15 | The amount of hemoglobin contained by each red blood cell 
presented as mean cell hemoglobin (MCH) measured in picograms (pg). [normal 
range 14.1-19.3 pg] 
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Figure S5.16 | The mean corpuscular hemoglobin concentration (MCHC) shown 
in grams per deciliter (g/dL). [normal range 30.2-34.2 g/dL] 
 
 
Figure S5.17 | Absolute number of platelets found in the whole mouse plasma. 
[normal range 592-2972 x103/µL] 
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Figure S5.18 | Absolute number of reticulocytes counted at millions per micro-
liter (M/µL). 
 
 
Figure S5.19 | The concentration of albumin (ALB) found in the mouse plasma 
measured in grams per deciliters (g/dL). 
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Figure S5.20 | The concentration of globulins (GLOB) found in the mouse 
plasma measured in grams per deciliters (g/dL). 
 
 
Figure S5.21 | The ratio of albumin (ALB) to globulins (GLOB) found in the 
mouse plasma from the MTD study. 
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Figure S5.22 | The amount of alkaline phosphatase (ALKP) presented as units of 
activity per liter (U/L). 
 
 
Figure S5.23 | The amount of gamma glutamyl transpeptidase (GGT) presented 
as units of activity per liter (U/L). 
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Figure S5.24 | The concentration of total protein measured in the mouse plasma 
measured as grams per deciliter (g/dL). 
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(E)-cinnamic (triethyl silicic) anhydride (602k) 
 
In an oven dried culture tube fitted with a magnetic stir bar and Teflon lined cap, 
cinnamic acid 604 (133.5 mg, 0.90 mmol, 1.0 equiv.) and pyridine (py, 72 µL, 
0.90 mmol 1.0 equiv.) were dissolved in 3 mL of THF. The reaction was stirred 
for 5 mins and triethoxychlorosilane (305a) (176 µL, 0.90 mmol, 1.0 equiv.) was 
added by Wiretrol®. The mixture turned cloudy instantly upon the addition of the 
chlorosilane.  The reaction was allowed to stir overnight ca. 12 hours, and the 
mixture was filtered through a short plug of Celite® to remove the pyridinium salt. 
The filtrate was concentrated under reduced pressure, and the residue was 
redissolved in a mixture of hexanes:EtOAc (5:1). Purification by MPLC (SiO2, 5:1 
hexanes:ethyl acetate) yielded the title compound as a colorless oil (81.9 mg, 
0.26 mmol, 30% yield). 1H-NMR revealed a 1:2 mixture of the product to the 
starting materials. The TLC also showed considerable streaking on the plate, 
which suggests some column degradation of the compound, so no further 
purification was performed. 
Experimental Section for Chapter 6
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1H NMR (500 MHz, CDCl3): δ 7.72 (d, J = 15.9 Hz, 1H, PhCH=CHCO2-), 7.55-
7.51 (m, 2H, o-PhCH=CH-), 7.40-7.39 (m, 3H, m-PhCH=CH- and p-
PhCH=CH-), 6.45 (d, J = 15.9 Hz, 1H, PhCH=CHCO2-), 3.99 (q, J = 7.0 Hz, 
6H, -Si(OCH2CH3)3, and 1.29 (t, J = 7.0 Hz, 9H, -Si(OCH2CH3)3. 
GC- MS: [30 m x 0.25 mm ID, HP-5, 50 °C/1.5 min/10 °C min-1/310 °C, 
(5031022H)] tR = 9.05 min [m/z] 310 (M+), 265 (M+• -C2H5O), 237 (M+• -C4H9O), 
219 (M+• -C4H11O2), 163 (M+• -C9H7O2), 147 (M+• -C6H15O3Si), 131 (M+• -
C6H15O4Si), and 103 (M+• -C7H15O5Si). 
TLC Rf (5:1 hexanes:EtOAc) = 0.71. 
 
 (E)-cinnamic (triisopropyl silicic) anhydride (602l) 
 
In an oven dried culture tube fitted with a magnetic stir bar and Teflon lined cap, 
cinnamic acid 604 (139 mg, 0.94 mmol, 1.0 equiv.) and pyridine (py, 75 µL, 0.93 
mmol 1.0 equiv.) were dissolved in 3 mL of THF. The reaction was stirred for 5 
mins and triisopropoxychlorosilane (305c) (250 µL, 1.0 mmol, 1.1 equiv.) was 
added by Wiretrol®. The mixture turned cloudy instantly upon the addition of the 
chlorosilane.  The reaction was allowed to stir overnight ca. 12 hours, and the 
mixture was filtered through a short plug of Celite® to remove the pyridinium salt. 
602l604
Si(OiPr)3Cl (305c)
pyridine, THF
r.t., 12 h
OH
O
O
O
Si(OiPr)3
73% yield
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The filtrate was concentrated under reduced pressure, and the residue was 
redissolved in a mixture of hexanes:EtOAc (8:1). Purification by MPLC (SiO2, 8:1 
hexanes:ethyl acetate) yielded the title compound (602l) as a white waxy solid 
(242.5 mg, 0.69 mmol, 73% yield). 
1H NMR (500 MHz, CDCl3): δ 7.70 (d, J = 15.9 Hz, 1H, PhCH=CHCO2-), 7.53-
7.49 (m, 2H, o-PhCH=CH-), 7.38-7.37 (m, 3H, m-PhCH=CH- and p-
PhCH=CH-), 6.45 (d, J = 15.9 Hz, 1H, PhCH=CHCO2-), 4.42 (sept, J = 6.1 Hz, 
3H, -Si[OCH(CH3)2]3), and 1.27 (d, J = 6.2 Hz, 18H, -Si[OCH(CH3)2]3). 
13C NMR (125 MHz, CDCl3): δ 164.9, 146.2, 134.4, 130.5, 129.0 (2x), 128.3 (2x), 
119.2, 66.9 (3x), and 25.3 (6x). 
HRMS (ESI) Calc’d for C18H28NaO5Si+ [M + Na]+ 375.1598; found 375.1585.  
IR (thin film) 2974, 1706, 1633, 1466, 1451, 1382, 1371, 1315, 1282, 1173, 1118, 
1053, 984, 879, and 766 cm-1. 
GC- MS: [30 m x 0.25 mm ID, HP-5, 50 °C/1.5 min/10 °C min-1/290 °C, 
(5029021)] tR = 9.22 min [m/z] 352 (M+), 293 (M+• -C3H7O), 251 (M+• -C6H13O), 
209 (M+• -C9H19O), 147 (M+• -C9H21O3Si), 131 (M+• -C9H21O4Si), and 103 (M+• -
C10H21O5Si). 
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 (E)-(tri-tert-butyl silicic) cinnamic anhydride (602i) 
 
In an oven dried culture tube fitted with a magnetic stir bar and Teflon lined cap, 
cinnamic acid 604 (744.9 mg, 5.03 mmol, 1.0 equiv.) and pyridine (py, 600 µL, 
7.45 mmol 1.5 equiv.) were dissolved in 5 mL of THF. The reaction was stirred 
for 5 mins and tritertbutoxychlorosilane (305e) (1.68 mL, 7.54 mmol, 1.5 equiv.) 
was added by syringe, however the mixture remained clear upon addition of the 
chlorosilane. After 12 h of no reaction, DBU (1.0 mL, 6.69 mmol, 1.0 equiv.) was 
added and the reaction immediately turned cloudy. Several previous attempts at 
heating this reaction, suggested that the stronger base was required. The 
reaction was allowed to stir for an additional 12 hours, and the mixture was 
filtered through a short plug of Celite® to remove the salts. The filtrate was 
concentrated under reduced pressure, and the residue was redissolved in a 
mixture of hexanes:EtOAc (8:1). Purification by flash chromatography (SiO2, 8:1 
hexanes:ethyl acetate) yielded the title compound (602i) as a white solid (750.8 
mg, 1.90 mmol, 38% yield). 
1H NMR (500 MHz, CDCl3): δ 7.66 (d, J = 15.9 Hz, 1H, PhCH=CHCO2-), 7.54-
7.50 (m, 2H, o-PhCH=CH-), 7.40-7.35 (m, 3H, m-PhCH=CH- and p-
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PhCH=CH-), 6.44 (d, J = 15.9 Hz, 1H, PhCH=CHCO2-), and 1.37 (s, 27H, -
Si[OC(CH3)3]3). 
13C NMR (125 MHz, CDCl3): δ 164.4, 145.3, 134.7, 130.3, 129.0 (2x), 128.3 (2x), 
120.6, 74.2 (3x), and 31.5 (9x). 
HRMS (ESI) Calc’d for C21H34NaO5Si+ [M + Na]+ 417.2068; found 417.2073.  
IR (thin film) 2974, 1701, 1366, 1189, 1086, 977, and 769 cm-1. 
GC- MS: [30 m x 0.25 mm ID, HP-5, 50 °C/1.5 min/10 °C min-1/290 °C, 
(5029021)] tR = 9.77 min [m/z] 394 (M+), 321 (M+• -C4H9O), 265 (M+• -C8H17O), 
209 (M+• -C12H25O), 147 (M+• -C12H27O4Si), and 103 (M+• -C13H27O5Si). 
TLC Rf (8:1 hexanes:EtOAc) = 0.67. 
 
tert-butyldimethylsilyl cinnamate (602j) 
 
In an oven dried culture tube fitted with a magnetic stir bar and Teflon lined cap, 
cinnamic acid 604 (604 mg, 4.07 mmol, 1.0 equiv.) and triethylamine (TEA, 378 
µL, 2.69 mmol 0.7 equiv.) were dissolved in 10 mL of CH2Cl2. The reaction was 
stirred for 5 mins and tert-butyldimethylsiyl chloride (605) (TBS-Cl, 787 mg, 5.22 
mmol, 1.3 equiv.) was added to the reaction mixture. The reaction was allowed to 
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stir for overnight ca. 18 hours. The reaction mixture was concentrated under 
reduced pressure, and the residue was redissolved in a mixture of 
hexanes:EtOAc (8:1) and filtered through a short plug of Celite® to remove the 
salts. Purification by flash chromatography (SiO2, 8:1 hexanes:ethyl acetate) 
yielded the title compound (602j) as a white crystalline solid (595.5 mg, 2.27 
mmol, 56% yield). 
1H NMR (500 MHz, CDCl3): δ 7.62 (d, J = 15.9 Hz, 1H, PhCH=CHCO2-), 7.54-
7.51 (m, 2H, o-PhCH=CH-), 7.40-7.35 (m, 3H, m-PhCH=CH- and p-
PhCH=CH-), 6.41 (d, J = 15.9 Hz, 1H, PhCH=CHCO2-), 1.00 [s, 9H, -
Si(CH3)2C(CH3)3], and 0.34 [s, 6H, -Si(CH3)2C(CH3)3]. 
13C NMR (125 MHz, CDCl3): δ 167.0, 145.2, 134.6, 130.4, 129.0 (2x), 128.3 (2x), 
120.2, 25.9 (3x), 18.0, and -4.5 (2x). 
HRMS (ESI) Calc’d for C15H22NaO2Si+ [M + Na]+ 285.1281; found 285.1290.  
GC- MS: [30 m x 0.25 mm ID, HP-5, 50 °C/1.5 min/10 °C min-1/290 °C, 
(5029021)] tR = 8.52 min [m/z] 262 (M+), 247 (M+• -CH3), 205 (M+• -C4H9), 190 
(M+• -C5H12), 131 (M+• -C9H7O), 131 (M+• -C6H15OSi), 115 (M+• -C9H7O2), and 
103 (M+• -C7H15O2Si). 
TLC Rf (8:1 hexanes:EtOAc) = 0.38. 
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N-(tri-tert-butoxysilyl)benzamide (603c) 
 
In an oven dried culture tube fitted with a magnetic stir bar and Teflon lined cap, 
benzamide 606 (670 mg, 5.53 mmol, 1.0 equiv.) and pyridine (py, 445 µL, 5.53 
mmol 1.0 equiv.) were dissolved in 5 mL of THF. The reaction was stirred for 5 
mins and tritertbutoxychlorosilane (305e) (1.20 mL, 5.53 mmol, 1.0 equiv.) was 
added by syringe, the mixture remained clear upon addition of the chlorosilane. 
After 12 h of no reaction, DBU (400 µL, 3.02 mmol, 0.5 equiv.) was added and 
the reaction immediately turned cloudy. The reaction was allowed to stir for 
overnight ca. 10 hours. The suspension was concentrated under reduced 
pressure, and the residue was redissolved in a mixture of hexanes:EtOAc (2:1) 
and filtered through a short plug of Celite® to remove the salts. Purification by 
flash chromatography (SiO2, 2:1 hexanes:ethyl acetate) yielded the title 
compound (603c) as a white crystalline solid (1.23 g, 3.35 mmol, 60.5% yield). 
1H NMR (500 MHz, CDCl3): δ 7.84-7.77 (m, 2H, o-PhC=ONH-), 7.49 (tt, J = 7.3, 
6.2, 2.4, 1.2 Hz, 1H, p-PhC=ONH-), 7.44-7.40 (m, 2H, m-PhC=ONH-), 5.78 (s, 
1H, PhC=ONH-), and 1.38 (s, 27H, -Si[OC(CH3)3]3). 
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13C NMR (125 MHz, CDCl3): δ 171.3, 136.1, 131.5, 128.6 (2x), 127.4 (2x), 74.3 
(3x), and 31.7 (9x). 
HRMS (ESI) Calc’d for C19H33NNaO4Si+ [M + Na]+ 390.2071; found 390.2078.  
GC- MS: [30 m x 0.25 mm ID, HP-5, 50 °C/1.5 min/10 °C min-1/290 °C, 
(5029021)] tR = 8.95 min [m/z] 367 (M+), 352 (M+• -CH3), 311 (M+• -C4H8), and 
294 (M+• -C4H9O).  
mp = 45-52 °C. TLC Rf (2:1 hexanes:EtOAc) = 0.50. 
 
N-(tert-butyldimethylsilyl)benzamide (603a) 
 
In an oven dried round bottom flask fitted with a magnetic stir bar and septum, 
benzamide 606 (1.14 g, 4.07 mmol, 1.0 equiv.) and DBU (1.5 mL, 11.33 mmol 
1.2 equiv.) were dissolved in 20 mL of CH2Cl2. The reaction was stirred for 5 
mins and tert-butyldimethylsiyl chloride (605) (TBS-Cl, 2.76 g, 18.31 mmol, 1.9 
equiv.) was added to the reaction mixture. The reaction was allowed to stir for 
overnight 12 hours. The reaction mixture was concentrated under reduced 
pressure, and the residue was redissolved in a mixture of hexanes:EtOAc (3:1) 
and filtered through a short plug of Celite® to remove the salts. Purification by 
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flash chromatography (SiO2, 3:1 hexanes:ethyl acetate) followed by a silica plug 
(SiO2, 95:5 hexanes:ethyl acetate) yielded the title compound (603a) as a white 
crystalline solid (294.4 mg, 1.25 mmol, 31% yield). 
1H NMR (500 MHz, CDCl3): δ 7.79 (d, J = 7.7 Hz, 2H, o-PhC=ONH-), 7.48 (tt, J = 
7.3, 2.2 Hz, 1H, p-PhC=ONH-), 7.41 (dt, J = 7.7, 2.7 Hz, 2H, m-PhC=ONH-), 
5.72 (s, 1H, PhC=ONH-), 1.00 [s, 9H, -Si(CH3)2C(CH3)3], and 0.33 [s, 6H, -
Si(CH3)2C(CH3)3]. 
13C NMR (125 MHz, CDCl3): δ 172.5, 169.8, 135.5, 133.5, 132.2, 128.8, 127.5, 
25.9 (3x), 18.2, and -3.4 (2x). 
HRMS (ESI) Calc’d for C13H21NNaOSi+ [M + Na]+ 258.1285; found 258.1305.  
GC- MS: [30 m x 0.25 mm ID, HP-5, 50 °C/1.5 min/10 °C min-1/290 °C, 
(5029021)] tR = 7.80 min [m/z] 235 (M+), 220 (M+• -CH3), 178 (M+• -C4H9), 121 
(M+• -C6H14Si), and 104 (M+• -C6H17NSi). 
 
N-(triisopropylsilyl)benzamide (603b) 
 
In an oven dried culture tube fitted with a magnetic stir bar and Teflon lined cap, 
benzamide 606 (273.4 g, 2.26 mmol, 1.0 equiv.) and DBU (438 µL, 2.93 mmol 
1.3 equiv.) were dissolved in 5.0 mL of CH2Cl2. The reaction was stirred for 5 
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mins and triisopropylsiyl chloride (607) (TIPS-Cl, 628 µL, 2.93 mmol, 1.3 equiv.) 
was added to the reaction mixture. The slight yellow in color reaction was allowed 
to stir for 4 hours. An aliquot was analyzed by GC-MS and showed the desired 
product as the major component > 90%.  The reaction mixture was concentrated 
under reduced pressure, and the residue was redissolved in a mixture of 
hexanes:EtOAc (2:1) and filtered through a short plug of Celite® to remove the 
salts. Purification by flash chromatography (SiO2, 2:1 hexanes:ethyl acetate) 
yielded the title compound (603b) as a white crystalline solid (714.8 mg, 2.26 
mmol, 97% yield). 
1H NMR (500 MHz, CDCl3): δ 7.80 (dd, J = 7.6, 1.5 Hz, 2H, o-PhC=ONH-), 7.51 
(tt, J = 7.3, 1.7 Hz, 1H, p-PhC=ONH-), 7.46-7.43 (m, 2H, m-PhC=ONH-), 5.59 
(s, 1H, PhC=ONH-), 1.43 [sept, J = 7.5 Hz, 3H, -Si{CH(CH3)2}3], and 1.14 [d, J 
= 7.5 Hz, 18H, -Si{CH(CH3)2}3]. 
GC- MS: [30 m x 0.25 mm ID, HP-5, 50 °C/1.5 min/10 °C min-1/290 °C, 
(5029021)] tR = 9.31 min [m/z] 325 (M+), 262 (M+• -CH3), 234 (M+• -C3H7), 192 
(M+• -C6H13), 191 (M+• -C6H14), 148 (M+• -C9H21), and 104 (M+• -C9H23NSi). 
TLC Rf (2:1 hexanes:EtOAc) = 0.75. 
  
 Experimental 332 
 
 
332 
4-(tri-tert-butoxysilyl)morpholine (603e) 
 
In an oven dried culture tube fitted with a magnetic stir bar and Teflon lined cap, 
morpholine 608 (600 µL, 6.93 mmol, 1.0 equiv.) and pyridine (558 µL, 6.93 mmol 
1.0 equiv.) were dissolved in 7 mL of dry CH2Cl2. The reaction was stirred for 5 
mins and tritertbutoxychlorosilane (305e) (1.54 mL, 6.93 mmol, 1.0 equiv.) was 
added by syringe, the mixture turned cloudy within 5 mins. After 2 h of reaction, 
an aliquot was analyzed by GC-MS and showed the desired product as the major 
component > 90%. The reaction mixture was concentrated under reduced 
pressure, and the residue was redissolved in a mixture of hexanes:EtOAc (20:1) 
and filtered through a short plug of Celite® to remove the salts. Purification by two 
sequential MPLC runs (SiO2, 20:1, and 30:1 hexanes:ethyl acetate) yielded the 
title compound (603e) as a clear viscous oil (680.7 mg, 2.04 mmol, 29% yield). 
1H NMR (500 MHz, CDCl3): δ 3.57 (t, J = 4.6 Hz, 4H, -CH2CH2OCH2CH2-), 2.93 
(t, J = 4.7 Hz, 4H, -CH2N(Si[OC(CH3)3]3CH2-), and 1.30(s, 27H, -
CH2N(Si[OC(CH3)3]3CH2-). 
13C NMR (125 MHz, CDCl3): δ 72.6 (3x), 68.5 (2x), 45.5 (2x), and 31.8 (9x). 
HRMS (ESI) Calc’d for C16H36NO4Si+ [M + H]+ 334.2408; found 334.2402.  
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GC- MS: [30 m x 0.25 mm ID, HP-5, 50 °C/1.5 min/10 °C min-1/290 °C, 
(5029021)] tR = 7.08 min [m/z] 333 (M+), 318 (M+• -CH3), 302 (M+• -C2H7), 288 
(M+• -C2H5O), 276 (M+• -C4H9), 260 (M+• -C4H9O), 220 (M+• -C8H17), and 164 
(M+• -C12H25).  
TLC Rf (20:1 hexanes:EtOAc) = 0.47. 
 
4-(tert-butyldimethylsilyl)morpholine (603d) 
 
In an oven dried culture tube fitted with a magnetic stir bar and Teflon lined cap, 
morpholine 608 (863 µL, 10.0 mmol, 1.0 equiv.) and DBU (1.73 mL, 11.64 mmol 
1.1 equiv.) were dissolved in 8 mL of dry CH2Cl2. The reaction was stirred for 5 
mins and tert-butyldimethylsiyl chloride (605) (TBS-Cl, 174.6 mg, 11.64 mmol, 
1.1 equiv.) was added and allowed to stir overnight ca. 12 h. The reaction mixture 
was concentrated under reduced pressure, and the residue was redissolved in a 
mixture of hexanes:EtOAc (2:1) and filtered through a short plug of Celite® to 
remove the salts followed by a plug of silica (SiO2, 2:1, hexanes:ethyl acetate). 
An aliquot was analyzed by GC-MS and showed the desired product as the major 
component > 98% so no further purification was performed. The title compound 
603d608
TBS-Cl (605)
DBU, CH2Cl2
r.t., 12 h
N
H
O
N
O
TBS
67% yield
 Experimental 334 
 
 
334 
(603d) was obtained as clear viscous oil (1.35 g, 6.69 mmol, 67% yield).  Further 
characterization has been presented before. 222 
GC- MS: [30 m x 0.25 mm ID, HP-5, 50 °C/1.5 min/10 °C min-1/290 °C, 
(5029021)] tR = 5.07 min [m/z] 201 (M+), 186 (M+• -CH3), 144 (M+• -C4H9), 114 
(M+• -C6H15), 100 (M+• -C5H11NO), and 86 (M+• -C6H15Si).  
 
 
 
 
Figure S6.1 | Intensity distribution of freshly prepared Cinnamic-silicate 602i 
loaded mPEG-b-PLGA (5k-10k) based nanoparticles ca. 50 wt%. 
 
  
                                            
222 Millar, R. W.; Philbin, S. P. Clean Nitrations: Novel Syntheses of Nitramines and Nitrate Esters 
by Nitrodesilylation Reactions Using Dinitrogen Pentoxide (N2O5). Tetrahedron 1997, 53, 4371–
4386. 
 Experimental 335 
 
 
335 
 
2-((9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-10,13,16-
trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-
cyclopenta[a]phenanthren-17-yl)-2-oxoethyl trioctyl silicate (702b) 
 
In an oven dried culture tube fitted with a magnetic stir bar and Teflon lined cap, 
dexamethasone 701 (133.1 mg, 0.33 mmol, 1.0 equiv.) and pyridine (50 µL, 0.41 
mmol 1.2 equiv.) were dissolved in 2 mL of THF. The reaction was stirred for 5 
mins and Tri-n-octyloxychlorosilane (305b (200 mg, 0.41 mmol, 1.2 equiv.) was 
added by syringe the mixture turned cloudy instantaneously upon the addition of 
the chlorosilane. The reaction stirred overnight (18 h). The THF was removed by 
evaporation under reduced pressure, the solid residue was triturated with a 
mixture of hexanes:EtOAc (2:1), and the resulting slurry was filtered through a 
short plug of Celite® to remove the pyridinium salt. The filtrate was concentrated 
under reduced pressure, and the residue was purified by flash chromatography 
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(SiO2, 20:1 hexanes:EtOAc), followed by MPLC (SiO2, 2:1 hexanes:EtOAc) to 
yield the title compound as a white, crystalline solid (84.2 mg, 0.104 mmol, 32%).  
1H NMR (500 MHz, CDCl3): δ 7.21 (d, J = 10.1 Hz, 1H, H1), 6.32 (dd, J = 10.1, 
1.8 Hz, 1H, H2), 6.11 (s, 1H, H4), 4.79 (d, J = 18.4 Hz, 1H, H21α), 4.52 (d, J = 
18.4 Hz, 1H, H21β), 4.35 (br d, J = 9.8 Hz, 1H, H11), 3.79 (t, J = 6.7 Hz, 6H, -
Si[OCH2(CH2)6CH3]3), 3.07 (dqd, J = 10.9, 7.2, 3.8 Hz, 1H, H16), 2.67 (s, 1H, -
OH), 2.64-2.58 (m, 1H, H6β), 2.40-2.31 (m, 3H, H6α, H8, H12β), 2.18 (td, J =  
11.8, 8.3 Hz, 1H, H14), 2.03 (s, 1H -OH), 1.82 (dt, J = 12.1, 5.7 Hz, 1H, H7α), 
1.74 (q, J = 11.9 Hz, 1H, H15β), 1.61-1.52 (m, 6H, -Si[OCH2CH2(CH2)5CH3]3, 
1.54 (s, 3H, H19), 1.44 (dd, J = 14.3, 1.2 Hz, 1H, H12α), 1.36-1.22 (m, 32H, 
H7β, H15α, and -Si[OCH2CH2(CH2)5CH3]3), 1.06 (s, 3H, H18), 0.91 (d, J = 
7.26 Hz, 3H, H22), and 0.88 (t, J = 6.9 Hz, 9H, -Si[OCH2CH2(CH2)5CH3]3). 
13C NMR (125 MHz, CDCl3): δ 208.4, 186.8, 166.4, 152.3, 130.0, 125.2, 101.1, 
90.7, 72.5, 72.1, 68.7, 64.1 (3x), 48.6, 43.9, 37.1, 35.9, 34.5, 34.3, 32.5 (3x), 
32.0 (3x), 31.2, 29.6 (3x), 29.5 (3x), 27.5, 25.9 (3x), 23.2, 22.9 (3x), 17.3, 14.3 
(3x), and 14.2. 
HRMS (ESI) Calc’d for C46H79FNaO8Si+ [M + Na]+ 829.5420; found 829.5546. 
TLC Rf (2:1 hexanes:EtOAc) = 0.20. 
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 (tri-tert-butyl silicic) 2-(4-isobutylphenyl)propanoic anhydride (704) 
 
Ibuprofen pills (609.4 mg) were ground in a motor and pestle and suspended into 
10 mL of ethyl acetate in a round bottom flask. The mixture was stirred overnight 
ca. 12 hours, and filtered through a plug of Celite® to remove the filler from the 
ibuprofen tablet. 1H-NMR showed the ibuprofen (703) extracted (465.1 mg, 2.25 
mmol, 1.0 equiv.) was > 95% pure, and was used as the starting material for the 
subsequent reaction. In an oven dried culture tube fitted with a magnetic stir bar 
and Teflon lined cap, ibuprofen 703 and pyridine (1.0 mL, 12.42 mmol 5.5 equiv.) 
were dissolved in 10 mL of THF. The reaction was stirred for 5 mins and 
tritertbutoxychlorosilane (305e) (1.0 mL, 4.48 mmol, 2.0 equiv.) was added by 
syringe the mixture slowly turned cloudy upon addition of the chlorosilane. The 
reaction was allowed to stir for an additional 12 hours, the THF was removed 
under reduced pressure and then resuspended in a mixture of hexanes:EtOAc 
(2:1). The suspension was filtered through a short plug of Celite® to remove the 
salts. The filtrate was concentrated under reduced pressure, and the residue was 
redissolved in a mixture of hexanes:EtOAc (30:1). Purification by MPLC (SiO2, 
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30:1 hexanes:ethyl acetate) followed by a small silica plug eluting with 100% 
hexanes first followed by a mixture of hexanes:EtOAc (1:1) yielded the title 
compound (704) as a white solid (18.1 mg, 0.018 mmol, 1.8% yield). 
1H NMR (500 MHz, CDCl3): δ 7.19 (d, J = 8.0 Hz, 2H, H4), 7.06 (d, J = 8.0 Hz, 
2H, H5), 3.64 (q, J = 7.1 Hz, 1H, H2), 2.43 (d, J = 7.2 Hz, 2H, H7), 1.82 (dq, J 
= 7.2, 6.7 Hz, 1H, H8), 1.48 (d, J = 7.1 Hz, 3H, H10), 1.22 (s, 27H, -
Si[OC(CH3)3]3 H1c), and 0.86 (d, J = 6.6 Hz, 6H, H9). 
13C NMR (125 MHz, CDCl3): δ 185.9, 129.3, 127.7, 73.9, 31.5, and 31.3. 
GC-MS: [30 m x 0.25 mm ID, HP-5, 50 °C/1.5 min/10 °C min-1/290 °C, 
(5029021)] tR = 10.13 min [m/z] 452 (M+•), 437 (M+• -CH3), 379 (M+• -C4H9O), 
323 (M+• -C8H17O), 267 (M+• -C12H25O), 247 (M+• -C13H17O2), 161 (M+• -
C13H27O5Si), and 135 (M+• -C15H29O5Si). 
LC-MS: Waters Symmetry-C8 3.9 x 150 mm particle size 5 µm; 0.5 mL/min, 
Gradient Method 50% B to 100% B over 10 min, hold at 100% B for 10 min 
(Solvent System A, 5:95 MeOH:H2O,15 mM NH4OAc) (Solvent System B, 98:2 
MeOH:H2O,15 mM NH4OAc), MM-ES+APCI Positive Scan 18.48 min 475.3 
(M+Na)+. 
TLC Rf (30:1 hexanes:EtOAc) = 0.72. 	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(S)-2-((2R,5R,6R)-6-((2R,3S,4S,6R)-6-((2S,5S,7R,9S,10S,12R,15R)-2-
((2R,5R,6R)-5-ethyl-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)-15-
hydroxy-2,10,12-trimethyl-1,6,8-trioxadispiro[4.1.57.35]pentadec-13-en-9-yl)-
3-hydroxy-4-methyl-5-oxooctan-2-yl)-5-methyltetrahydro-2H-pyran-2-
yl)butanoic (triisopropyl silicic) anhydride (706b) 
 
In an oven dried culture tube fitted with a magnetic stir bar and Teflon lined cap, 
salinomycin 705 (173.2 mg, 0.23 mmol, 1.0 equiv.) and pyridine (6.0 mL, 2.24 
mmol 9.7 equiv.) were dissolved in 3 mL of THF and allowed to stir at r.t. for 5 
mins. Tri-i-propoxychlorosilane (305c) (containing ca. 80% of tri-i-
propoxychlorosilane; 500 µL, estimated to contain 420.0 mg, 1.75 mmol, 7.7 
equiv.) was added by syringe and the reaction instantly turned cloudy. The 
reaction stirred overnight (18 h). The THF was removed by evaporation under 
reduced pressure, the solid residue was triturated with a mixture of 
hexanes:EtOAc (2:1), and the resulting slurry was filtered through a short plug of 
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Celite® to remove the pyridinium salt. The filtrate was concentrated under 
reduced pressure, and the residue was purified by MPLC (SiO2, 2:1 
hexanes:EtOAc) to yield the title compound as a white, crystalline solid (50.6 mg, 
0.053 mmol, 23%).  
1H NMR (500 MHz, CDCl3): δ 6.04 (dd, J = 10.8, 2.5 Hz, 1H, H18), 5.95 (d, J = 
11.0 Hz, 1H, H19), 4.34 (br s, 1H, H20), 4.22 (q, J = 6.1 Hz, 3H, -
Si[OCH(CH3)2]3), 4.14 (s, 1H, -OH), 4.12 (q, J = 7.1 Hz, 1H, H29), 3.98 (dd, J = 
10.9, 5.7 Hz, 1H, H9), 3.88-3.84 (m, 1H, H3), 3.82 (d, J = 10.3 Hz, 1H, H13), 3.65 
(d, J = 9.6 Hz, 1H, H7), 3.47 (dd, J = 10.0, 2.8 Hz, 1H, H25), 2.89 (td, J = 10.9, 
3.5 Hz, 1H, H2), 2.79-2.7 (m, 1H, H10), 2.64 (dd, J = 10.7, 1.9 Hz, 1H, H12), 
2.35-2.27 (m, 2H, H22α and H23α), 2.05 (s, 1H, -OH), 2.04-1.85 (m, 6H, H4α, 
H5α, H6, H22β, H23β, and H36α), 1.83-1.78 (m, 2H, H15α and H16), 1.76-1.66 
(m, 3H, H27α H27β, and H14), 1.66-1.53 (m, 5H, H4β, H5β, H8, H26α, and 
H26β), 1.50 (s, 3H, H33), 1.47-1.29 (m, 5H, H31α, H31β, H36β, H41α, and 
H41β), 1.26 (dd, J = 7.1, 0.7 Hz, 3H, H30), 1.21 (ddd, J = 6.1, 1.1 Hz, 1H, H15β), 
1.19 (s, 1H, -OH), 1.17 (d, J = 6.2 Hz, 18H -Si[OCH(CH3)2]3), 0.95 (t, J = 7.1 Hz, 
3H, H42), 0.93 (t, J = 6.0 Hz, 3H, H32), 0.90 (overlapping d, J = 7.7 Hz, 6H, H35 
and H40), 0.81 (d, J = 7.4 Hz, 3H, H38), 0.78 (t, J = 7.4 Hz, 3H, H37), 0.72 (d, J 
= 7.2 Hz, 3H, H39), and 0.71 (d, J = 7.0 Hz, 3H, H34), 
13C NMR (125 MHz, CDCl3): δ 215.4, 178.1, 131.7, 122.3, 106.4, 99.8, 87.9, 
76.6, 75.5, 75.0, 72.8, 71.8, 71.6, 68.6, 68.4, 66.2 (3x), 56.1, 50.2, 49.4, 41.4, 
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39.3, 36.6, 34.5, 34.0, 33.2, 29.7, 29.2, 28.2, 26.5, 25.5 (6x), 23.0, 22.9, 21.0, 
20.1, 18.1, 17.3, 15.8, 14.4, 13.5, 13.0, 12.3, 11.2, 6.9, and 6.7. 
HRMS (ESI) Calc’d for C51H90NaO14Si+ [M + Na]+ 977.5992; found 977.6020. 
LC-MS: ACE ODS-C18 4.6 x 150 mm particle size 5 µm; 0.5 mL/min, Gradient 
Method 55% B to 100% B over 15 min, hold at 100% B for 15 min (Solvent 
System A, 5:95 MeOH:H2O,15 mM NH4OAc) (Solvent System B, 98:2 
MeOH:H2O,15 mM NH4OAc), MM-ES+APCI Positive Scan 19.70 min 955.2 
(M+H)+, 972.4 (M+NH4)+, and 977.2 (M+Na)+, Negative Scan 19.70 min 953.2 
(M-H)-. 
TLC Rf (2:1 hexanes:EtOAc) = 0.61. 	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5-fluoro-1,3-bis(tri-tert-butoxysilyl)pyrimidine-2,4(1H,3H)-dione (708c) 
 
In an oven dried culture tube fitted with a magnetic stir bar and Teflon lined cap, 
5-fluorouracil 707 (474.5 mg, 3.67 mmol, 1.0 equiv.) and pyridine (6.0 mL, 74.52 
mmol 20.3 equiv.)  were allowed to stir at r.t. for 5 mins. The 
tritertbutoxychlorosilane (305e) (2.45 mL, 11.03 mmol, 3.0 equiv.) was added by 
syringe and the reaction turned cloudy after 10 mins. The reaction stirred 
overnight (18 h). The pyridine was removed by a high vacuum rotary evaporator 
and the oil residue was filtered through a short plug of Celite® and the plug was 
washed with CH2Cl2. TheCH2Cl2 was removed and the crude reaction was 
redissolved in a mixture of hexanes:EtOAc (5:1), and purified by two sequential 
MPLC runs (SiO2, 3:1 and 20:1 hexanes:ethyl acetate), which yielded the title 
compound (708c) as a white crystalline solid (453.9 mg, 0.73 mmol, 19.8% 
yield). 
1H NMR (500 MHz, CDCl3): δ 8.12 (d, 3J(H4-F5) = 2.3 Hz, 1H, H4), 1.33 (s, 27H, 
-Si[OC(CH3)3]3 H1c), and 1.32 (s, 27H, -Si[OC(CH3)3]3 H3c). 
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13C NMR (125 MHz, CDCl3): δ 157.3 (d, 4J(C2-F5) = 3.5 Hz, C2), 157.0 (d, 2J(C6-
F5) = 11.9 Hz, C6), 144.9 (d, 2J(C4-F5) = 21.1 Hz, C4), 144.8 (d, 1J(C5-F5) = 
253.4 Hz, C5), 74.3 (C1b, 3x), 73.9 (C3b, 3x), 31.5 (C1c, 9x), and 31.4 (C3c, 
9x). 
HRMS (ESI) Calc’d for C28H55FN2NaO8Si2+ [M + Na]+ 645.3373; found 645.3548. 
GC-MS: [30 m x 0.25 mm ID, HP-5, 50 °C/1.5 min/10 °C min-1/290 °C, 
(5029021)] tR = 10.13 min [m/z] 549 (M+• -C4H9O), 493 (M+• -C8H17O), 437 (M+• 
-C12H25O), 381 (M+• -C16H33O), 325, 287, 269, 251, 155, and 57. 
LC-MS: Waters Symmetry-C8 3.9 x 150 mm particle size 5 µm; 1 mL/min, 
Gradient Method 50% B to 100% B over 10 min, hold at 100% B for 15 min 
(Solvent System A, 5:95 MeOH:H2O,15 mM NH4OAc) (Solvent System B, 98:2 
MeOH:H2O,15 mM NH4OAc), MM-ES+APCI Positive Scan 20.28 min 623.2 
(M+H)+. 
TLC Rf (5:1 hexanes:EtOAc) = 0.71. 	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(E)-5-(3,3-dimethyltriaz-1-en-1-yl)-N,1-bis(tri-tert-butoxysilyl)-1H-imidazole-
4-carboxamide (710a) 
 
In an oven dried culture tube fitted with a magnetic stir bar and Teflon lined cap, 
dacarbazine 709 (133.3 mg, 0.73 mmol, 1.0 equiv.) and DBU (339 µL, 2.27 mmol 
3.1 equiv.) were dissolved in 2 mL of DMF. The yellow reaction was stirred for 5 
mins and tritertbutoxychlorosilane (305e) (505 µL, 2.27 mmol, 3.1 equiv.) was 
added by syringe and the reaction turned completely clear after 30 mins. The 
DMF was removed by a high vacuum rotary evaporator and the residue was 
resuspended in a mixture of hexanes:EtOAc (2:1), filtered through a short plug of 
silica (SiO2, 2:1 hexanes:ethyl acetate) and purification by flash chromatography 
(SiO2, 98:2 hexanes:ethyl acetate) followed by MPLC (SiO2, 5:1 hexanes:ethyl 
acetate) yielded the title compound (710a) as a white crystalline solid (105.1 mg, 
0.16 mmol, 21.3% yield). 
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1H NMR (500 MHz, CDCl3): δ 7.58 (s, 1H, H2), 7.03 (s, 1H, -NH(Si[OC(CH3)3]3) 
3.52 (br s, 3H, -N=N-NCH3CH3), 3.21 (br s, 3H, -N=N-NCH3CH3), 1.36 (s, 27H, 
-NH(Si[OC(CH3)3]3), and 1.32 (s, 27H, N1-(Si[OC(CH3)3]3). 
13C NMR (125 MHz, CDCl3): δ 166.3, 150.1, 139.0, 135.5, 116.8 75.5 (3x), 74.2 
(3x), 73.0, 31.8 (9x), and 31.6 (9x). 
HRMS (ESI) Calc’d for C30H62N6NaO7Si2+ [M + Na]+ 697.4111; found 697.4119.  
TLC Rf (5:1 hexanes:EtOAc) = 0.37. 
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(E)-5-(3,3-dimethyltriaz-1-en-1-yl)-N,N-bis(tri-tert-butoxysilyl)-1H-imidazole-
4-carboxamide (710b) 
 
In an oven dried culture tube fitted with a magnetic stir bar and Teflon lined cap, 
dacarbazine 709 (114.1 mg, 0.62 mmol, 1.0 equiv.) and DBU (280 µL, 1.87 mmol 
3.0 equiv.) were dissolved in 5 mL of DMF. The yellow reaction was stirred for 5 
mins and tritertbutoxychlorosilane (305e) (415 µL, 1.87 mmol, 3.0 equiv.) was 
added by syringe and the mixture turned clear after 10 mins. The DMF was 
removed by a high vacuum rotary evaporator and the residue was resuspended 
in a mixture of hexanes:EtOAc (1:1), filtered through a short plug of Celite® to 
remove the salts, and purification by MPLC (SiO2, 1:1 hexanes:ethyl acetate) 
yielded the title compound (710b) as a white-yellow crystalline solid (52 mg, 
0.077 mmol, 12.4% yield). 
1H NMR (500 MHz, CDCl3): δ 7.91 (s, 1H, H2), 7.80 (s, 1H, H1), 3.61 (br s, 3H, -
N=N-NCH3CH3), 3.24 (br s, 3H, -N=N-NCH3CH3), 1.35 (s, 54H, -N 
{(Si[OC(CH3)3]3}2). 
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13C NMR (125 MHz, CDCl3): δ 162.5, 151.7, 145.2, 121.3, 75.2 (3x), 73.9 (3x), 
43.7, 37.0, 31.8 (9x), and 31.6 (9x). 
HRMS (ESI) Calc’d for C30H63N6O7Si2+ [M + H]+ 675.4291; found 675.6186.  
mp = 179-180.5 °C. TLC Rf (1:1 hexanes:EtOAc) = 0.33. 
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1-isobutyl-N-(tri-tert-butoxysilyl)-1H-imidazo[4,5-c]quinolin-4-amine) (712) 
 
In an oven dried culture tube fitted with a magnetic stir bar and Teflon lined cap, 
imiquimod 711 (94.9 mg, 0.39 mmol, 1.0 equiv.) and DBU (176 µL, 1.18 mmol 
3.0 equiv.) were dissolved in 3 mL of THF. The reaction was stirred for 5 mins 
and tritertbutoxychlorosilane (305e) (263 µL, 1.18 mmol, 3.0 equiv.) was added 
by syringe and the mixture turned slightly cloudy. The reaction was heated to 45 
ºC for 18 h and more precipitate formed as the reaction progressed. The THF 
was removed and the reaction was resuspended in a mixture of hexanes:EtOAc 
(1:1), filtered through a short plug of Celite® to remove the salts, and purified by 
MPLC (SiO2, 1:1 hexanes:ethyl acetate) which yielded the title compound (712) 
as a white crystalline solid (110.0 mg, 0.23 mmol, 58% yield). 
1H NMR (500 MHz, CDCl3): δ 7.89 (dd, J = 8.3, 0.8 Hz, 2H, H6 and H9), 7.72 (s, 
1H, H2), 7.48 (t, J = 7.8 Hz, 1H, H7), 7.29 (t, J = 7.5 Hz, 1H, H8), 5.61 (s, 1H, 
H4), 4.27 (d, J = 7.4 Hz, 2H, H10), 2.36 (dq, J = 13.7, 6.9 Hz, H11), 1.41 (s, 
27H, H14), and 1.02 (d, J = 6.6 Hz, 6H, H12). 
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HRMS (ESI) Calc’d for C26H43N4O3Si+ [M + H]+ 487.3099; found 487.3104.  
TLC Rf (2:1 hexanes:EtOAc) = 0.32. 	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(tri-tert-butyl silicic) 1-cyclopropyl-6-fluoro-4-oxo-7-(4-(tri-tert-
butoxysilyl)piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic anhydride 
(714) 
 
In an oven dried culture tube fitted with a magnetic stir bar and Teflon lined cap, 
ciprofloxacin 713 (133.8 mg, 0.40 mmol, 1.0 equiv.) and DBU (181 µL, 1.21 mmol 
3.0 equiv.) were dissolved in 4 mL of DMF. The green-yellow reaction was stirred 
for 5 mins and tritertbutoxychlorosilane (305e) (270 µL, 1.21 mmol, 3.0 equiv.) 
was added by syringe and the reaction turned clear after 50 mins. The DMF was 
removed by a high vacuum rotary evaporator and the yellow oil residue was 
resuspended in a mixture of hexanes:EtOAc (3:1), filtered through a short plug of 
Celite® to remove the salts, and purified by MPLC (SiO2, 3:1 hexanes:ethyl 
acetate), which yielded the title compound (714) as a white crystalline solid (112 
mg, 0.12 mmol, 30.6% yield). 
1H NMR (500 MHz, CDCl3): δ 8.58 (s, 1H, H2), 8.06 (d, 3J(H5-F6) = 13.5 Hz, 1H, 
H5), 7.22 (d, 4J(H8-F6) = 7.1 Hz, 1H, H8), 3.41 (tt, J = 7.1, 3.6, 1H, H1a), 3.17-
3.07 (m, 8H, H3’ and H4’), 1.38 (s, 27H, -Si[OC(CH3)3]3 H3c), 1.33 (s, 27H, -
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Si[OC(CH3)3]3 H2c’), 1.29 (dd, J = 12.7, 6.3 Hz, 2H, H1bα), and 1.11 (dd, J = 9.9, 
6.3 Hz, 2H H1bβ). 
13C NMR (125 MHz, CDCl3): δ 173.4 (C4) 161.2 (C3a), 154.3 (C6), 148.6 (C2), 
145.2 (C7), 137.8 (C9), 137.3 (C3), 122.6 (C10), 113.3 (C5), 104.3 (C8), 73.6 
(C3b, 3x), 72.3 (C2b', 3x), 51.5 (C3'), 51.2 (C3'), 44.7 (C4'), 44.5 (C4'), 34.1 
(C1a), 31.5 (C2c', 9x), 31.1 (C3c, 9x), 7.9 (C1b), and 7.6 (C1b). 
19F NMR (470 MHz, CDCl3): δ -123.9 (dd, 3J(H5-F6) = 13.4 and  4J(H8-F6) = 6.9 
Hz) 
HRMS (ESI) Calc’d for C41H70FN3NaO9Si2+ [M + Na]+ 846.4527; found 846.4557.  
TLC Rf (3:1 hexanes:EtOAc) = 0.61. 	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triisopropylsilyl (S)-2-((2R,5R,6R)-6-((2R,3S,4S,6R)-6-
((2S,5S,7R,9S,10S,12R,15R)-2-((2R,5R,6R)-5-ethyl-5-hydroxy-6-
methyltetrahydro-2H-pyran-2-yl)-15-hydroxy-2,10,12-trimethyl-1,6,8-
trioxadispiro[4.1.57.35]pentadec-13-en-9-yl)-3-hydroxy-4-methyl-5-oxooctan-
2-yl)-5-methyltetrahydro-2H-pyran-2-yl)butanoate (715) 
 
In an oven dried culture tube fitted with a magnetic stir bar and Teflon lined cap, 
salinomycin 705 (107.6 mg, 0.14 mmol, 1.0 equiv.) and N,N-dimethylbutylamine 
(98 µL, 0.70 mmol 5.0 equiv.) were dissolved in 2 mL of THF and allowed to stir 
at r.t. for 5 mins. Triisopropylsiyl chloride (607) (TIPS-Cl, 149 µL, 0.70 mmol, 5.0 
equiv.) was added by Wiretrol® and the reaction instantly turned cloudy. The 
reaction stirred for 48 h. The THF was removed by evaporation under reduced 
pressure, the solid residue was triturated with a mixture of hexanes:EtOAc (1:1), 
and the resulting slurry was filtered through a short plug of Celite® to remove the 
pyridinium salt. The filtrate was concentrated under reduced pressure, and the 
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residue was purified by MPLC (SiO2, 1:1 hexanes:EtOAc) to yield the title 
compound as a white, crystalline solid (80.3 mg, 0.089 mmol, 63%).  
1H NMR (500 MHz, CDCl3): δ 6.11 (dd, J = 10.8, 2.1 Hz, 1H, H18), 5.96 (d, J = 
11.0 Hz, 1H, H19), 4.01 (dd, J = 9.3, 5.3 Hz, 1H, H3), 4.04-3.98 (m, 2H, H9 and -
OH), 3.92 (d, J = 9.4 Hz, 1H, -OH), 3.83 (q, J = 6.9 Hz, 1H, H29), 3.76 (dd, J = 
9.7, 2.2 Hz, 1H, -OH), 3.66 (dd, J = 11.3, 2.9 Hz, 1H, H7), 3.60 (dd, J = 10.3, 3.5 
Hz, 1H, H13), 3.50 (d, J = 5.5 Hz, 1H, H25), 3.14 (dq, J = 10.0, 7.1 Hz, 1H, H10), 
3.02 (td, J = 10.8, 3.9 Hz, 1H, H2), 2.74 (dt, J = 9.0, 3.1 Hz, 1H, H12), 2.38 (dt, J 
= 12.5, 9.1 Hz, 1H, H22α) 2.21 (td, J = 10.8, 4.7 Hz, 1H, H23α), 2.08-2.02 (m, 
2H, H22β,), 1.95-1.69 (m, 8H, H4α, H5α, H6, H14, H15α, H16, H23β, and H36α), 
1.69-1.63 (m, 2H, H27α, and H27β), 1.57-1.45 (m, 8H, H4β, H5β, H8, H26α, 
H26β, and H33), 1.44-1.44-1.29 (m, 9H, H31α, H31β, H36β, H41α, H41β, H15β, 
and -Si[CH(CH3)2]3),  1.22 (d, J = 7.0 Hz, 3H, H30), 1.12 (dd, J = 7.5, 5.5 Hz, 18H 
-Si[CH(CH3)2]3), 0.97 (br t, 3H, H42), 0.89 (br t, 3H, H32), 0.92-0-86 (m, 6H, H35 
and H40), 0.79 (br t, J = 7.5 Hz, 9H, H37, H38, and H39), and 0.69 (d, J = 6.8 Hz, 
3H, H34). 
13C NMR (125 MHz, CDCl3): δ 214.0, 171.4, 132.9, 121.4, 106.4, 99.3, 87.7, 
79.7, 77.1, 75.3, 74.2, 71.6, 71.1, 69.7, 68.1, 57.8, 49.4, 47.5, 40.5, 39.5, 36.7, 
36.5, 34.1, 30.7, 30.5, 29.3, 28.5, 26.4, 25.8 (3x), 22.4, 22.2, 20.9, 20.4, 18.2, 
18.1 (6x), 17.7, 15.8, 14.7, 13.9, 12.6, 12.5, 12.0, 7.7, 6.5 
HRMS (ESI) Calc’d for C51H90NaO11Si+ [M + Na]+ 929.6145; found 929.6158 
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LC-MS: ACE ODS-C18 4.6 x 150 mm particle size 5 µm; 0.5 mL/min, Gradient 
Method 55% B to 100% B over 15 min, hold at 100% B for 15 min (Solvent 
System A, 5:95 MeOH:H2O,15 mM NH4OAc) (Solvent System B, 98:2 
MeOH:H2O,15 mM NH4OAc), MM-ES+APCI Positive Scan 27.00 min 924.7 
(M+NH4)+, and 977.2 (M+Na)+. 
TLC Rf (1:1 hexanes:EtOAc) = 0.35. 	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N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-N-
(triisopropylsilyl)quinazolin-4-amine (718) 
 
In an oven dried culture tube fitted with a magnetic stir bar and Teflon lined cap, 
erlotinib 716 (93.8 mg, 0.239 mmol, 1.0 equiv.) and diisopropylethylamine 
(DIPEA, 300 µL, 200 mg, 1.73 mmol 7.2 equiv.) were dissolved in 10 mL of THF. 
The reaction was stirred for 5 mins and triisopropylsilyl trifluoromethanesulfonate 
(717) (400 µL, 456 mg, 1.48 mmol, 6.2 equiv.) was added by syringe and the 
mixture turned yellow. The reaction was stirred for 6 h and a white precipitate 
formed as the reaction progressed. The THF was removed and the reaction was 
resuspended in a mixture of hexanes:EtOAc (1:1), filtered through a short plug of 
Celite® to remove the salts, and purified by MPLC (SiO2, 1:1 hexanes:ethyl 
acetate) which yielded the title compound (718) as a white crystalline solid (128.6 
mg, 0.23 mmol, 97.8% yield). 
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1H NMR (500 MHz, CDCl3): δ 8.52 (s, 1H, H2), 7.57-7.30 (m, 4H, H8, H4Ar, 
H5Ar, and H6Ar), 7.12 (s, 1H, H5), 6.17 (s, 1H, H2Ar), 4.21 (t, J = 4.8 Hz, 2H, 
H12), 3.80 (t, J = 4.8 Hz, 2H, H9), 3.60 (t, J = 4.6 Hz, 2H, H13),  3.50 (t, J = 
4.7 Hz, 2H, H10), 3.43 (s, 3H, H14), 3.41 (s, 3H, H11), 3.12 (s, 1H, -3Ar-CC-
H), 1.51 (sept., J = 7.4 Hz, 3H, -Si[CH(CH3)2]3), and 1.05 (d, J = 7.3 Hz, 18H, -
Si[CH(CH3)2]3). 
13C NMR (125 MHz, CDCl3): δ 171.3, 153.3, 146.8, 129.8, 123.7, 110.7, 108.7, 
82.7, 78.7, 70.6 (2x), 68.3, 67.8, 60.6, 59.5, 59.4, 21.3, 19.1 (6x), 18.2, 17.9, 
14.4, 13.9 (3x), 12.5, and 12.0. 
HRMS (ESI) Calc’d for C31H43N3NaO4Si+ [M + Na]+ 572.2915; found 572.2938 
LC-MS: Waters Symmetry-C8 3.9 x 150 mm particle size 5 µm; 0.5 mL/min, 
Gradient Method 50% B to 100% B over 10 min, hold at 100% B for 10 min 
(Solvent System A, 5:95 MeOH:H2O,15 mM NH4OAc) (Solvent System B, 98:2 
MeOH:H2O,15 mM NH4OAc), MM-ES+APCI Positive Scan 17.51 min 550.4 
(M+H)+. Negative Scan 17.51 min 392 (M+2OAc+HOAc)-2. 
TLC Rf (1:1 hexanes:EtOAc) = 0.26. 	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Figure S7.1 | Intensity distribution of freshly prepared Salinomycin-silicate 706b 
loaded mPEG-b-PLGA (5k-10k) based nanoparticles ca. 50 wt%. 
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